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ºC - Degree Celsius 
A-549 - “Human lung carcinoma cells 
AGS - Human Caucasian gastric adenocarcinoma cell 
AKT - Serine/threonine-specific protein kinase 
AMPK - Adenosine 5′-monophosphate-activated protein kinase 
B16 - Murine melanoma cell line 
Bcl-2 - Apoptosis regulators protein encoded by the Bcl 
BCRP - Breast cancer resistant protein 
BMS - Bristol-Myers Squibb 
Capan-2 - Human pancreas adenocarcinoma cells 
CC50 - Cytotoxic concentration at 50% 
c-FLIP - Cellular FLICE (FADD-like interleukine-1β-converting enzyme) inhibitory protein 
COX - Cyclooxygenase 
COX-1 - Cyclooxygenase-1 
COX-2 - Cyclooxygenase-2 
CVB3 - Coxsackievirus B3 enterovirus 
d - doublet 
dd - doublet of doublet 
ddd - doublet of doublet of doublet 
dddd - doublet of doublet of doublet of doublet 
DNA - Deoxyribonucleic acid 
DMEM - Dulbeco’s modified Eagle’s minimum essential medium 
DOX - Doxorubicin 
dq - doublet of quartet 
dt - doublet of triplet 
ED50 - Effective dose to produce effect in 50% of a population 
EDTA - Ethylenediaminetetraacetic acid 
eq - Equivalent 
G1 - Astrocytoma cell line 
G2/M - Cell cycle checkpoints in eukaryotes 
GMK - Green monkey kidney cell line 
GSTs - Glutathione-S-transferases 
HCT-116 - Human colon carcinoma cells 
HeLa - Human cervix cancer cell line 
HepG-2 - Liver hepatocellular carcinoma cell line 
HIV/AIDS - Human immunodeficiency virus /acquired immuno-deficiency syndrome 
HIV-1 - Human immunodeficiency virus type 1 
HL-60 - Human promyelocytic leukaemia cell line 
HPLC - High performance liquid chromatography 
HSV-1 - Herpes Simplex Virus type 1 
HT-29 - Human colon adenocarcinoma grade II cell line 
Hz - Hertz 
IC50 - Inhibitory concentration for 50% of viability 
IKK - IκB kinase 
IKKβ - IκB kinase β 
IL-2 - Interleukin 2;  
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iNOS - Inducible nitric oxide synthase 
IR - Infrared spectrometry 
JNK - c-jun terminal-NH2 kinase 
K652 - Human chronic myelogenous leukaemia cell-line 
KB - human nasopharyngeal carcinoma 
L6 - Rat skeletal myoblasts cell line;  
L929 - Murine aneuploid fibro-sarcoma cell line 
L929sA - Murine fibro-sarcoma cell line 
L-NAME - Nω-nitro-l-arginine methyl ester 
LOVO - Human colon adenocarcinoma cell line 
LPS - Lipopolysaccharides 
LTB4 - Leukotriene B4 
m - multiplet 
MBC - Minimum bactericidal concentrations 
MCF-7 - Breast cancer cell line 
McCoy - McCoy’s 5A modified medium 
MDA-MB-435 - Human breast adenocarcinoma cells 
MDCK - Madin-Darby canine kidney cell line 
MGC-803 - Human gastric carcinoma cell line 
MIC - Minimum inhibitory concentrations 
MMP-9 - Matrix metalloproteinase-9 
m.p. - Melting point 
mRNA - Messenger ribonucleic acid 
MRP-2 - Multi-drug resistance protein 2 
MRSA - Methicillin resistant Staphylococcus aureus 
MS - Mass spectrometry 
MSSA - Methicillin-sensitive Staphylococcus aureus 
MTT - 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide 
MTS -[3-(4,5-Dimethylthiazole-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium salt 
NCI - National Cancer Institute 
NF-κB - Nuclear factor kappa B 
NMR - Nuclear magnetic resonance 
NO - Nitric oxide 
Nrf2 - Nuclear factor 2-related factor 2 
NSCLC - Non-Small Lung Cancer 
OPN - Osteopontin 
p47phox - 47-kilodalton cytosolic subunit of the multi-protein complex known as NADPH 
oxidase 
PABA - Para-aminobenzoic acid 
PAF - Platelet-activating factor 
PBS - Phosphate buffered saline 
PC-3 - Human prostate cancer cell lines 
PDGF - Platelet-derived growth factor 
PGE2 - Prostaglandin E2 
p-gp - Permeability glycoprotein 
PI3K - Phosphatidylinositol 3-kinase 
PLA2 - Phospholipase A2 
PMNs - Polymorphonuclear leukocytes 
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PPARγ2 - Peroxisome proliferator-activated receptor γ 2 
ppm - Part per million 
QR - Quinone reductase 
RAW264     - Murine monocyte/macrophage line derived from ascitic tumour induced with 
Abelson leukaemia virus 
Rf - Retardation factor  
ROS - Reactive oxygen species 
RPR - Rapid Plasma Reagin 
SCF - Stem cell factor 
SGC-7901 - Gastric cancer cell line 
SiHa - Human cervix uteri cancer cell line 
SK-28 - Human melanoma cell line 
SOD - Superoxide dismutase 
sPLA2 - Secretory phospholipase A2 
STAT1 - Signal transducer and activator of transcription 1 
SW620 - Human colon carcinoma cell line 
Th2 - T helper cells type 2 
TLC - Thin layer chromatography 
TNFR1 - Tumour necrosis factor receptor 1 
TNF-α - Tumour necrosis factor-alpha 
Topo - Topoisomerase 
TPA - 12-O-Tetradecanoylphorbol-13-acetate 
TRAIL - TNF-related apoptosis-inducing ligand 
Tyrp1 - Tyrosinase-related protein 1 
U937 - Human monoblastic leukaemia cell line 
PARP  - poly ADP ribose polymerase 
CTLA  - Cytotoxic T lymphocytes A 
IgG - Immunoglobulin G 
PD-1 - programmed cell death ligand 1 






This study focused on isolation, synthesis, development and evaluation of novel antimicrobial and 
anticancer agents from natural product. Natural products have found lead applications in the 
pharmaceutical industry as sources of chemotherapeutics against cancers and infectious diseases. 
This investigation focussed on isolating sesquiterpene lactones from natural products, and 
synthesis of flavonoid based anticancer and antimicrobial agents from the flavonoid – chrysin 
because sesquiterpene lactones and flavonoids are potent anticancer and antimicrobial agents. 
In addition to the sesquiterpene lactones – alantolactone (D1) and isoalantolactone (D2), this is the 
first time costunolide (D3) has been isolated from Inula helenium. A series of 8-novel and 10 known 
Chrysin-derivatives were also synthesised via microwave-assisted O-alkylation of chrysin and other 
synthetic methods, and their antimicrobial and anticancer activities investigated. 
Twenty compounds were screened against eight bacteria and one fungus - Candida albicans using 
Gentamycin and Fluconazole as standard drugs for antibacterial and antifungal studies. 4-((5-
Hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)butyl acetate (C1), 7-((3,5-dimethylbenzyl)oxy)-5-
hydroxy-2-phenyl-4H-chromen-4-one (C2) and 7-(2,4-Dinitrophenoxy)-5-hydroxy-3-phenyl-4H-
chromen-4-one (C3) indicated bactericidal inhibition against a broad spectrum of bacteria and 
Candida albicans; Staphylococcus aureus, Escherichia coli, Bacillus cereus and Enterococcus 
faecalis were the most susceptible bacteria to inhibition by these compounds. MIC of C1 against 
these microorganisms was 25, 50, 50 and 50 µg / mL, C2: 50, 100, 100 and 100 µg / mL, C3: 12.5, 
12.5, 25.0 and 50 µg / mL. MIC values indicated by these compounds were better than those 
indicated by chrysin and were comparable to those showed by the standard drug – Gentamycin. 
C1 and C3 also inhibited the growth of the drug-resistant bacteria MRSA at doses of 65 and 100 
µg / mL respectively. Chrysin derivatives also inhibited the growth of extended spectrum beta 
lactamase (ESBL) bacteria – E. coli, K. pneumoniae and P. aeruginosa.  C1 and C3 also showed 
superior antifungal activity against the pathogenic fungus – Candida albicans at MIC values of 50 
µg / mL respectively compared to the standard antifungal drug – Fluconazole (MIC 125 µg / mL). 
7-O-bromochrysin and 7-O-alkylchrysin derivatives of chrysin showed weak antimicrobial activities 
(MIC ≥ 125 µg / mL) against all bacteria and fungus tested. D1, D2 and D3 also inhibited the growth 
of S. aureus and B. cereus at MIC values ≤ 125 µg / mL. The best antimicrobial agent synthesised 
were C1 and C3. The antiproliferative activities of D1, D2 and D3 were also investigated in hypoxia 
and normoxia (under hypoglycaemic and hyperglycaemic conditions). In hypoxia D1, D2 and D3 
elicited a 10 to 55-fold significant antiproliferative activity against leukaemia cell line (K562) in 
hypoglycaemic conditions with cytotoxicity (IC50 values) 0.58, 0.66 and 3.07 µM compared to the 
antiproliferative activity indicated in hyperglycaemic condition (IC50 values – 0.80, 1.18 and 4.77 
µM) respectively. In normoxia (normal oxygen concentration), the IC50 values in hypoglycaemia 
were 1.80, 1.90 and 6.72 µM for D1, D2 and D3. The IC50 values in hyperglycaemia were 2.60, 
3.29 and 7.15 µM for D1, D2 and D3 respectively. The antiproliferative activities indicated by D1, 
D2 and D3 under the conditions stated above were better than those indicated by the positive 
control – Chlorpromazine hydrochloride (CPZ) with IC50 values 32.88, 27.05, 9.36 and 16.21 µM 
respectively. D1, D2 and D3 were selectively cytotoxic against cancer cell lines but not the normal 
cell line – BEAS-2B. Anticancer activities against colorectal cancer cell lines (HCT 116 and Caco-
2) indicated by C1, C2 and C3 (IC50 ≤ 2.0 µM for HCT 116, and IC50 ≤ 6.0 µM for Caco-2 cell line), 
were better than those indicated by chrysin and the positive control drug – (CPZ) – IC50 4.07 and 
5.9 µM respectively, and IC50 4.84 µM (chrysin) and 5.17 µM (CPZ) for Caco-2 cell line. C1, C2 
and C3 also elicited better anticancer activities against leukaemia (K562) at concentrations of 7.27 
µM, 5.58 µM and 8.69 µM; and mesothelioma (Mero-14) cell lines at concentrations of 7.65 µM, 
26.31 µM and 8.71 µM respectively, compared to chrysin (IC50 13.13 µM for K562 cell line and 
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45.99 µM for Mero-14 cell line) and CPZ (IC50 7.38 µM for K562 cell line and 13.42 µM for Mero-14 
cell line). Similarly, C1 and C2 also elicited significant cytotoxic inhibition against the triple-negative 
breast cancer cell line – MDA-MB 468 at IC50 values 7.49 and 16.59 µM compared to chrysin. 
Anticancer activities elicited by long-chain 7-O-alkylchrysin derivatives (C10, C11 and C12) against 
HCT 116 cancer cells (IC50 16.4, 17.5 and 18.9 µM) was comparable to those indicated by chrysin 
and CPZ (IC50 5.9 µM).  C16 and C17 also elicited good to moderate cytotoxic inhibition against a 
broad spectrum of the ten cancer cell lines tested. Interestingly, C1, C2 and C3 were selectively 
cytotoxic against cancer cell lines but not the normal cell line – BEAS-2B. Chrysin was selectively 
cytotoxic but CPZ killed both cancer and normal cell lines. D1, D2 and D3 also indicated anticancer 
inhibition against K562 cell lines during hypoxia and normoxia, and during hyperglycaemia and 
normoglycaemia. Anticancer inhibition during hypoxia and low glucose for D1 and D2 (IC50 ≤ 0.66 
µM) was better than the anticancer inhibition elicited in normoxia and low glucose concentrations 
(IC50 ≤ 1.8 and 1.9 µM respectively). 
In this study, novel anticancer and antimicrobial agents which elicited better bioactivity and 
solubilities compared to standard antimicrobial agents (Gentamycin and Fluconazole), anticancer 
positive control agent (Doxorubicin) and chrysin (the parent compound) have been synthesised. 
Furthermore, hyperglycaemia in normoxic condition was associated with rapid cell proliferation in 
contrast to hypoxia in hypoglycaemic condition. Compounds isolated in this study were more 
cytotoxic under hypoxic conditions. Costunolide was isolated for the first time from Inula helenium. 
In-vivo cytotoxicity studies of costunolide against leukaemia cell line – K562 in mammalian models 
is necessary. Some modified chrysin-derivatives also indicated significant cytotoxicity in-vitro. In-
vivo cytotoxicity studies using mammalian model is also required. Synthesised chrysin derivatives 
were selectively cytotoxic against cancer cell lines but were not toxic against normal cell line at IC50 
≤ 100 µM. From the structure–activity point of view, nature and position of the electron withdrawing 
and electron donating functional groups on the chrysin core might have contributed to the observed 
antibacterial and anticancer action. 
The observed anticancer activity of alantolactone, isoalantolactone, costunolide, C1, C2, C3, C6, 
C8 and C10 and the antimicrobial activity of C1, C2 and C3 makes them an attractive drug 
candidate than chrysin and shows that substitution at the 7-OH position of chrysin could enhance 





Chapter 1    Introduction 
1.1    Cancer; an Overview 
1.1.1    What is cancer? 
 
Cancer is a group of multifaceted systems comprising hematopoietic cells (Jadav & Niper-
Ahmedabad, 2014; National Cancer Institute, 2014), mesenchymal stem cells, fibroblast, 
endothelial cells, infiltrating macrophages and heterogeneous cancer cells etc. (Catalano 
et al., 2013), which interacts individually or with other cells within a nested complex niche, 
giving rise to cancer. To understand what cancer is, it is important to understand the role 
of the cell cycle and apoptosis in cancer. 
 
1.1.1.1  The cell Cycle and Apoptosis 
 
In multicellular organisms, homeostasis is maintained as cells continuously proliferate 
and die. Many researchers have suggested that this regulation is achieved by coupling 
the cell cycle processes and apoptosis (programmed cell death), by controlling certain 
regulatory factors within the cell. Manipulation of the cell cycle could either induce or 
prevent an apoptotic response. This process (apoptotic response) has been recognised 
for tumour suppression genes such as cyclin-dependent kinases (Cdks), c-Myc, RB and 
p53 and their regulators (Pucci et al., 2000). These genes may also act to sensitize cells 
to apoptosis which if unregulated can result in pathological conditions such as neoplasia 
(Pucci et al., 2000). Apoptosis is a highly conserved mechanism by which eukaryotic cells 
commit suicide, enabling the organism to eliminate defective and unwanted cells via an 
ordered process of cellular disintegration which do not induce an inflammatory response 
(Fathi et al., 2018). Apoptosis could occur during normal cellular function and in diseased 
condition thus improper regulation of the apoptotic machinery could contribute to 
disorders such as autoimmune diseases, AIDS, anaemia, stroke, neurodegenerative 
disorders, viral infections and cancer (De-Silva & Kim, 2018; Häcker, 2017; Wyllie, 1997). 
Apoptosis can be triggered by signals such as chemotherapeutic drugs, irradiation, 
oncogenes, bacterial or viral infection, growth factors, tumour necrosis factor and Fas 
ligand (De-Silva & Kim, 2018; Wyllie, 1997). Although several stimuli and factors, both 
pathological and physiological can trigger apoptosis, not all cells will necessarily die in 
response to the same stimuli. For instance, some corticosteroid hormones may lead to 
apoptotic death in thymocytes while other cells are not affected or even stimulated 
(Elmore, 2007). Some cells express TNF or Fas receptors which binds to, and crosslink 
proteins, leading to apoptosis while others may have a default death pathway which must 
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be blocked by a hormone or growth factor (De-Silva & Kim, 2018). Necrosis (cell death 
as a result of disease, failure of blood supply or injury) should not be confused for 
apoptosis as both processes can occur simultaneously, sequentially or independently 
(De-Silva & Kim, 2018; Zeiss, 2003). Apoptosis is also associated with the type / degree 
of stimuli. For instance, at high doses / concentrations, stimuli such as radiation, heat etc., 
could induce necrosis but at low doses, they can induce apoptosis. Apoptosis is an energy 
dependent and highly coordinated process that involves the activation of caspases (a 
group of cysteine proteases) and a complex cascade which initiates apoptosis to the final 
demise of the cells (Elmore, 2007). Activation of caspases leads to the cleavage of certain 
proteins such as the poly(ADP-ribose) polymerase (PARP), DNA-dependent protein 
kinase (DNA-PK),  topoisomerases and lamins (Pucci et al., 2000). It has been 
demonstrated that macrophages play a potential role in promoting apoptosis in some 
tissues; removal of macrophages in eyes of the rat for instance, resulted in the survival 
of vascular endothelial cells that normally undergo apoptosis in the absence of 
macrophages (Wood & Martin, 2017; Diez-Roux & Lang, 1997). 
The cell cycle is a process whereby duplication of genetic information and cell division 
occur to give rise to two daughter cells. To avoid insertion of wrong genetic information 
and incorporation of errors in the genome, the cell cycle is highly regulated by checkpoints 
within the cell. The checkpoints detect DNA damage, incompletely replicated DNA and 
misaligned chromosomes. These checkpoints are mediated by the cyclin-dependent 
kinase inhibitors (CKIs) in interphase and mitosis (Chao et al., 2017). 
Genetic information is transmitted from one generation to another via genomic replication 
during the S-phase and its segregation to form two daughter cells during the M-phase 
(mitosis). The S and M-phases of the cell cycle are crucially ordered to allow for the 
correct duplication of the genome without error (Bertoli et al., 2013). The S-phase occurs 
before the M-phase and the M-phase does not occur until the S-phase is complete. Two 
preparatory gaps – G1 (separates M from S) and G2 (between S and M). After 
differentiation, the cell cycle exits the G1 phase and enters a quiescent state referred to 
as G0 (Pucci et al., 2000). 
The events and timings of the cell cycle are monitored by checkpoints at the G1/S 
boundary in S-phase and during the G2/M phase (Chao et al., 2017). The checkpoints 
are stimulated in the presence of signals such as growth factors, damage to mitotic 
spindle or DNA. When this happens, the cell cycle arrest occurring because of activation 
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of the checkpoint, enables the cell to repair the damage (Chao et al., 2017). Once the 
damage is repaired, progression of the cell cycle continues. If the damage cannot be 
corrected or repaired, apoptosis occurs (Chao et al., 2017). Cell cycle progression (Figure 
1.1) is effected by a series of mechanisms involving activation and inactivation of the 
cyclin-dependent kinase (Cdks) which are enzymes belonging to a well-conserved family 
of serine/threonine protein kinases and their activity is dependent on the presence of 
cyclins (enzymes responsible for initiation of certain processes of mitosis). 
 
Figure 1.1: Relationship between Cdks and Cdk regulators during the cell cycle (Pucci et al., 2000). 
 
Specific cyclins are abundant in some phases of the cell cycle (where they are needed) 
and decreases during phases in which they are not needed. During early G1 phase of the 
cell cycle, Cdk4 and Cdk6 associates with cyclin-D. Phosphorylation of the G1 kinases 
activates gene transcription necessary for S-phase of the cell cycle (Law et al., 2015). 
Cyclin D/Cdk complexes are activated during mitosis, allowing the progression of the cell 
cycle from G0 to G1. On passing the restriction point (R-point), the cells are ready to enter 
the S-phase which no longer requires the activity of the D/Cdk (Law et al., 2015). Cdk2 is 
activated by cyclin E during the G1-to-S-phase transition, allowing cyclin A to bind to Cdk2 
during S-phase or to Cdk2 in the G2-to-M-phase transition (Law et al., 2015). Cdk-
activating kinase (CAK) regulates the Cdk complexes via phosphorylation of the 
Cdk/cyclin complex (Law et al., 2015). The activity of Cdk is suppressed by 
phosphorylation of tyrosine and threonine residues whereas the Cdc25 phosphatase 
family mediates dephosphorylation and subsequent activation of Cdk (MacLachlan et al., 
1995). Cdk activity is also regulated by the Cdk-inhibitory subunits (CKIs). The CKIs are 
classified into two; the inhibitors of Cdk4 (Ink4) and the Cip/Kip families. They provide a 
tissue-specific mechanism by which progression of the cell cycle is suppressed in 
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response to intracellular and extracellular signals (Sonawane et al., 2016). The Ink4 
consists of four members; p15Ink4b, p16Ink4, p18Ink4c and p19Ink4d. Some of these 
genes are often deleted or mutated in some human cancers – such as cancers of the 
lung (Harper & Elledge, 1996; Sonawane et al., 2016). p21Cip1, p27Kip1 and 
p57Kip2 constitutes the Cip/Kip family which inhibits the Cdks, preventing the transition 
from the G1-to-S-phase (Harper & Elledge, 1996; Sonawane et al., 2016). 
The retinoblastoma protein (pRb) is a tumour suppressor protein which negatively 
regulates cell growth. This protein is deleted or mutated in certain cancers such as 
cancers of the prostrate, bone, bladder, breast and lungs (Engel et al., 2015; Riley et al., 
1994). The pRb protein also encompasses p107 and pRb2/p130 (Engel et al., 2015). The 
activities of these proteins are overlapping yet distinct in cell cycle regulation. 
Phosphorylated form of these proteins actively blocks transcription of genes during the 
S-phase of the cell cycle. Blockage of gene transcription depends on their ability to bind 
and actively repress the E2F factors (Engel et al., 2015), which are transcription activators 
consisting of the DP (Dimerization Partner) family of proteins and the E2F protein (Lam 
& La-Thangue, 1994). Stimulation of mitogen activates phosphorylation of pRb by G1-
phase Cdk (Law et al., 2015), releasing the E2F complex and allowing expression of 
genes for DNA synthesis (Pucci et al., 2000). 
 
1.1.1.1.1 Mechanisms of Apoptosis 
 
Apoptosis involves a highly complex cascade of energy-dependent molecular events 
(Figure 1.2). Two pathways; the mitochondrial or intrinsic pathway and the death receptor 
or extrinsic pathway have been identified. 
These pathways are however linked together and influence the activities of one another 
(Pucci et al., 2000). Another apoptotic pathway involving perforin-granzyme-dependent 
killing of the cells, and T-cell mediated cytotoxicity has been reported (Igney & Krammer, 
2002). The perforin-granzyme pathway induces apoptosis by activating either granzyme 
A or B. The granzyme A pathway initiates a caspase-independent cell death pathway via 
single strand DNA damage whereas the granzyme B pathway converges on the execution 
pathway together with the intrinsic and extrinsic pathways. The cleavage of caspase-3 
initiates this pathway, resulting in DNA degradation and fragmentation of the cytoskeleton 
and nuclear proteins, cross-linkage of proteins, ligand expression for receptors of 
phagocytic cells and formation of apoptotic bodies which are killed by phagocytic cells 
(Martinvalet et al., 2005). 
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Several biochemical modifications exist during apoptosis such as expression of caspases 
in an inactive proenzyme form which once activated, leads to the activation of other 
caspases, initiating a cascade of procaspases. Some procaspases can auto-activate or 
aggregate, leading to a rapid cascade and amplification of the apoptotic signalling 
pathways (Hengartner, 2000). Caspases are proteolytic in nature, cleaving aspartate 
residues from proteins (although some caspases are specific to specific amino acids) 
(Yuan et al., 2016). Once caspases initiation occurs, there tend to be an irreversible 
commitment towards apoptosis (programmed cell death) (Yuan et al., 2016). 
Researchers have identified ten major caspases which are classified into initiators 
(caspases 2, 8, 9, 10), executioners or effectors (caspases 3, 6, 7) and inflammatory 
caspases (caspases 1, 4, 5) (Yuan et al., 2016; Rai et al., 2005). Caspase-11 (associated 
with apoptotic regulation and maturation of cytokine during septic shock) and caspase-
12 (associated with mediation of endoplasmic-specific apoptotic responses and 
cytotoxicity by amyloid-β) have been reported. Other caspases such as caspase-13 (a 
bovine gene) and caspase-14 (whose expression is restricted to embryonic tissues only) 
have also been reported (Hu et al., 1998; Kang et al., 2002; Koenig et al., 2001; 
Nakagawa et al., 2000).  
 
Figure 1.2: Schematic representation of apoptotic events. 
The apoptosis pathway comprises of the intrinsic and extrinsic pathway. These pathways require triggering 
signals for an energy-dependent molecular cascade event. These pathways are activated by initiator 
caspases – 8, 9 and 10, which in turn activates the executioner caspase-3. Granzyme A operates in a 
caspase-independent manner during the executioner pathway, resulting in cytomorphological changes 
such as phagocytosis of the apoptotic bodies by macrophages, neoplastic cells or parenchymal cells; 




Flaws with the machinery regulating cell death can give rise to diseases such as cancer, 
neuro-degenerative diseases (such as Huntington’s disease, Alzheimer’s disease and 
Parkinson’s disease), ischemia, autoimmune lymphoproliferative syndrome and AIDS 
(Favaloro et al., 2012), whereas insufficient or excessive apoptosis is responsible for 
some diseased conditions (Favaloro et al., 2012). 
Cancer occur when the mechanisms regulating the cell cycle are dysfunctional with either 
a decreased removal and/or over proliferation of cells (Favaloro et al., 2012). It has been 
proven that suppression of apoptosis during carcinogenesis could play an essential role 
in some cancer development and progression (Favaloro et al., 2012; Kerr et al., 1994). 
Tumour cells employ several mechanisms to suppress apoptosis such as mutation or 
down-regulation of proapoptotic protein such as Bax or by expression of antiapoptotic 
protein such as Bcl-2. Expression of Bax and Bcl-2 is regulated by the p53 tumour 
suppressor gene (Favaloro et al., 2012). There are evidences that there is an over-
expression of Bcl-2 in certain forms of B cell lymphoma and this finding is a strong pointer 
to the fact that failure of apoptosis gives rise to cancer (Favaloro et al., 2012; Vaux et al., 
1988). Evasion of immune surveillance is another method involving apoptosis 
suppression (Smyth et al., 2001). The death-receptor pathway (perforin/granzyme B 
pathway) is used by some immune cells such as the natural killer cells and the T-cells to 
destroy tumour cells (Cheng et al., 1994). Some tumour cells evade immune destruction 
by decreasing the response of the death receptor pathway to FasL produced by T cells 
via expression of non-functioning Fas receptor, downregulation of the Fas receptor on 
tumour cells, expression of Fas ligand on tumour cell surfaces and secretion of soluble 
Fas receptor that will sequestrate the Fas ligand (Cheng et al., 1994; Elnemr et al., 2001; 
Liou, 2017; Martinez-Lostao et al., 2015). Fas ligand-mediated counterattack in some 
tumour cells have been reported (Koyama et al., 2001). This attack depletes the activated 
tumour infiltrating lymphocytes thus depletion of apoptosis. 
Cancers can also result from the alteration of signalling pathways, which leads to 
dysregulation of apoptosis. The tumour suppressor gene (p53), a transcription factor 
involved in cell cycle regulation is mostly mutated in tumourigenesis (Mitra et al., 2018). 
The p53 gene is mutated in over 50 % of all cancers and is responsible for activation of 
the proteins involved in DNA repair when the DNA is damaged (Mitra et al., 2018). The 
p53 gene is also involved in regulation of the cell cycle at the G1/S, preventing any further 
cell cycle activity on recognition of DNA damage and can even initiate apoptosis if the 
DNA damage cannot be repaired (Mitra et al., 2018). The inability of the p53 gene 
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regulatory machinery to function properly will result in tumourigenesis (Mitra et al., 2018). 
Viruses such as the Human papillomavirus (HPV), chemicals and radiation can damage 
the p53 gene. The Li–Fraumeni syndrome has been reported in patients who inherits only 
one functional copy of the p53 gene (Mitra et al., 2018) and is characterised by tumour 
development in early adulthood (Gu et al., 2001). 
Another gene associated with tumourigenesis is the ataxia telangiectasia-mutated gene 
(ATM) which elicits tumourigenesis via the ATM/p53 signalling pathway (Kitagawa & 
Kastan, 2005; Mitra et al., 2018). Activation of the ATM gene stimulates DNA repair and 
inhibits the progression of the cell cycle via phosphorylation of p53 (Mitra et al., 2018; 
Kurz & Lees-Miller, 2004). Phosphorylation of the p53 signals cell cycle arrest at the G1/S 
checkpoint to allow for DNA repair. This system can be inactivated by epigenetic / somatic 
alterations and expression of oncogenes such as the HPV, resulting in tumourigenesis 
(Mitra et al., 2018). 
Tumourigenesis also occur from malfunctioning of other cell signalling pathways such as 
the phosphatidylinositol 3-kinase/AKT pathway. This pathway also regulates other 
cellular pathways such as cytoskeletal rearrangement, growth and cell proliferation 
(Vivanco & Sawyers, 2002). 
Excessive apoptosis could give rise to many pathological conditions such as cancers, 
ischaemia, AIDS and neurodegenerative diseases (Favaloro et al., 2012). Inhibition of 
apoptosis artificially may be key to cancer prevention and therapy. Anti-apoptotic therapy 
involves stimulation of the PKB/Akt (protein kinase B) pathway, inhibition of Bcl-2 
proteins, poly [ADP-ribose] polymerase (PARP) inhibition, caspase inhibition and 
stimulation of the inhibitors of apoptosis proteins (IAP) (Favaloro et al., 2012). The IAPs 
are the most important apoptotic regulators because of their involvement in regulation of 
both extrinsic and intrinsic pathways (Favaloro et al., 2012). In addition to survivin and 
XIAP (X-linked mammalian inhibitor of apoptosis protein), eight human IAPs have been 
characterised (Colnaghi et al., 2006; Silke et al., 2002). PARP has a dual role as an 
enzyme involved in apoptosis, and DNA repair. PARP inhibitors may attenuate 
inflammation, enhancing the cytotoxicity of anticancer agents pharmacologically 
(Graziani & Szabo, 2005; Jeswani & Paul, 2017). Veliparib (a new PARP-1 and PARP-2 
inhibitor) is used as a chemo-sensitizing drug with additional antitumour activities. This 
drug accelerates the cytotoxicity of DNA-damaging agents and inhibits DNA repair 
mechanisms in tumours and has indicated promising results in phase III clinical trials for 
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metastatic breast cancer, metastatic melanoma, Non-small-cell lung carcinoma (NSCLC), 
advanced ovarian cancer and triple-negative breast cancer (Jeswani & Paul, 2017). 
The problem of cancer has persisted because most cancer treatments cannot target 
cancer stem cells which are the progenitors of cancers (Pistollato et al., 2015; Zhou et 
al., 2009). Cancer relapse and increasing resistance of cancer cells to chemotherapy 
could be traceable to the inability of conventional therapies to destroy cancer stem cells, 
and therefore the need for novel chemotherapeutic strategies which could target and 
destroy stem cells (Zhou et al., 2009), and these conventional therapies are often harmful 
and have life altering side effects. Most conventional drug are poorly absorbed into the 
cells, and rapidly efflux out of the cells, which is mediated by the ATP binding cassette 
(ABC) such as glycoprotein P, leading to chemotherapy failure (Hida, et al., 2017; Li et 
al., 2015). Water soluble drugs on the other hand enter the cell by accompanying 
transporters and carriers as they move across cell membranes (Dalbeth et al., 2014). This 
implies that as carriers and transporters uptake into target cells drops, the intracellular 
drug concentration also drops thus a reduction in drug efficacy (Dalbeth et al., 2014). An 
increase in expression of target organs and DNA repair is another mechanism where 
water soluble compounds exert therapeutic effect on cancer cells (Zhang et al., 2017; 
Liang et al., 2017). Resistance to cancer is associated with regulation of cell cycle, 
immune responses, programmed cell death, differentiation of cells, DNA mismatch, tissue 
architecture and replicative aging (Hochberg & Nobel, 2017), and other factors aids the 
development from host factors and genetic predisposition such as the environment and 
agents we are constantly exposed to, prolonged infection, age and lifestyle, and this is so 
because cancer is a complex disease arising from a multifaceted triggers (Catalano et 
al., 2013; Chen et al., 2017; Merlo et al., 2012; Carillo-Infante et al., 2007). 
Cancer relapse occur because stem cells have the characteristics of auto-renewing itself 
by bypassing the G1/S checkpoint of the cell cycle (Hatfield et al., 2005). This results in 
development of malignant cancer cells. These cancer cells undergo metastasis, 
reproduce and become malignant growths (tumour cells) (National Cancer Institute, 
2014). Some chemotherapy such as cisplatin, carboplastin etc. can inhibit the growth of 
some cancer cells such as cancers of the breast, lungs and brain, limiting their growth 
(Pollyea et al., 2014). 
The effects of anticancer agents are potentiated via combinational therapy using 
liposomes (Hatfield et al., 2005). Liposomes are vesicles of phospholipid bilayers used in 
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encapsulating both lipophilic and hydrophilic drugs, protecting them from degradation and 
have been used extensively as nano-carriers for drug delivery (Pandey et al., 2016) and 
have been successfully used as effective stem cell destruction agents (Hatfield et al., 
2005).  
The environment a person is constantly exposed to is crucial in cancer incidence. For 
instance, regular exposure to Bisphenol A (Tse et al., 2017), cigarette smoke, crystalline 
silica, alcohol and oral contraceptives, as well as exposure to heavy metals, agricultural 
pesticides and solvents, certain infection and ultraviolet light, has been linked to cancer 
(Parks et al., 2017). 
Viral infection such as hepatitis B, and bacterial infection such as Mycoplasma pulmonis 
can trigger acute localise inflammation which if not regulated by the body could lead to 
the activation of neoplasm (Carillo-Infante et al., 2007), leading to the release of 
inflammation causing cells such as isoforms of nitric oxide synthase, nitric oxides and 
cytokines which are capable of influencing cell proliferation and neo-angiogenesis thus 
leading to direct DNA damage (Carillo-Infante et al., 2007; Parks et al., 2017). 
Genetics is a major cause of cancer as mutation in genetic material occurs spontaneously 
and is being transmitted from one generation to another. These mutations are often 
associated with environmental exposure to mutagenic agents and radiation (Stoppa-
Lyonnet, 2016). 
Chemotherapeutic agents (such as parthenolide) from plants have proven to target 
cancer stem cell selectively, killing them (Ghantous et al., 2010; Guzman et al., 2005; 
Pollyea et al., 2014). These findings are very important as it could offer a new insight into 
the use of plant agents in cancer treatment. 
 
1.1.2  Cancer Epidemiology 
 
Cancer accounts for about 8 million deaths yearly. This equates to about 13% of global 
mortality from cancer (Cheung-Ong et al., 2013), with colorectal, lung, breast, prostate, 
stomach and liver cancers accounting for the most commonly diagnosed cancers; these 
figures are higher in developing countries, especially liver, oesophageal and cervical 
cancers which are common in developing countries (Merlo et al., 2012). Annually, 1.36 
million people are affected by colorectal cancer, which is the 2nd most common cancer 
in females, and 3rd most common cancer in males and it is treated via local excision, 
adjuvant chemotherapy, radiation and surgical resection (Moore & Aulet, 2017; Fazeli & 
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Keremati, 2015; Kim, 2015). In local excision, an area <3cm in diameter is removed and 
has the advantage of little postoperative complications but a much higher rate of 
recurrence up to about 21% (Fazeli & Keremati, 2015; Kim, 2015). Colorectal cancer 
usually results from inflammation in the gut which induces carcinogenic mutagenesis, 
allowing lymphoid and myeloid infiltration in the colon (Chen et al., 2017). Since colorectal 
cancer is prevalent in the elderly aged 65 years and above, postoperative chemotherapy 
became the treatment of choice for colon cancer in 1990s, accounting for 26 % reduction 
in mortality in patients with stage III colon cancers compared to surgery alone (Kim, 2015). 
Surgery alongside adjuvant chemotherapy is relatively effective in the treatment of colon 
cancer but often not applied in patients with colon cancers due to the potential toxicity of 
the agents to the elderly who are often associated with colon cancers (Kim, 2015). 78% 
of 55 – 64-year-old received this therapy globally; this figure drops as the age increases 
with only 11 % of adults aged 85 – 89 years old been given adjuvant chemotherapy (Kim, 
2015). Eating habit has been correlated to the prevalence of colorectal cancer; a 
Mediterranean diet rich in vegetables, fruits, complex carbohydrates, daily consumption 
of red wine, low consumption of fish and meat is associated with less prevalence of 
colorectal cancer as these components have chemopreventive effects on colorectal 
cancers (Farinetti et al., 2017; Wark & Peto, 2017). 
Breast cancer occurs when breast tissues, mainly ducts and lobules which are 
responsible for milk production, develops malignant tumour, with ductal carcinoma in situ 
(DCIS) accounting for 20% diagnosis of all new cancer cases (Karlsson, 2017; Klevos et 
al., 2017). Although the exact cause of breast cancer is unknown, risk factors include 
inheritance of susceptibility genes such as BRCA2 and BRCA1, oestrogen exposure, 
obesity, alcohol consumption and increasing age (Klevos et al., 2017). The BRCA2 and 
BRCA1 genes located in chromosome 13 and 17 are the key suspects in pathogenesis 
of breast cancer (Klevos et al., 2017; Lee et al., 2017). Breast cancer is worsened as two-
third of women who suffer from breast cancer eventually develops liver metastasis. 
Others also develop hepatic and bone metastasis (Kenny et al., 2017). 
Cancer is a major health concern worldwide, resulting in the death of a quarter of all 
deaths in many countries. In 2002, cancer accounted for about 7 million deaths 
worldwide. This is equivalent to 1 in 8 of all deaths. 11 million people were also diagnosed 
with cancer the same year (Parkin et al., 2005). The number of people diagnosed with 
cancer is on the increase as the world population keeps increasing and as life expectancy 
is on the increase and it is estimated that 15 million new cases will be diagnosed every 
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year by 2020 (Parkin et al., 2005). Of these cancers, lung, breast and colorectal cancers 
(1.4 million, 1.2 million and 1 million cases) are the most commonly diagnosed cancers. 
Lung cancer account for 1.2 million deaths, followed by stomach cancer (700,000 deaths) 
and liver cancer (600,000 deaths) (Parkin et al., 2005). Liver and pancreas cancers have 
similar mortality rates because of poor prognosis of these cancers. Unlike liver cancer, 
mortality from breast cancer is much lower due to relatively good prognosis of breast 
cancer especially in developing countries (Parkin et al., 2005). Incidences and mortality 
of age-specific cancers such as prostate cancer is falling while other cancers such as 
lung cancer are on the increase due to increase in cigarette smoking and an increase in 
mortality rate for cigarette related cancers. On the other hand, death rate from non-
smoking related cancers has decreased (Pato et al., 2006). 
 
1.1.2.1  Causes of Cancer 
 
There are multifaceted causes of cancer that can be linked to lifestyle / environment, 
gene mutation and occupational and environmental carcinogens 
1.1.2.1.1  Lifestyle and Environment 
 
Lifestyle and environmental factors responsible for cancer include tobacco, the effects 
of diet and overweight, reproductive and hormonal factors, viruses, bacteria, and 
parasites (Karlsson, 2017; Klevos et al., 2017). 
1.1.2.1.1.1  Tobacco 
 
Tobacco is a cancer-causing agent (carcinogen). Continuous smoking has been 
associated with high incidences of lung cancer but remains constant in ex-smokers. The 
risk increases in people who have been smoking from a young age and continue 
throughout life. The effect of tobacco smoking is even worse in passive smokers who are 
constantly been exposed to tobacco smoke (Petra and Wark, 2017). In most developed 
countries, cigarette smoking among young males was on the increase in the first half of 
the twentieth century. This led to a surge in the incidence of lung cancer many decades 
later (Petra and Wark, 2017). Carcinogenic effect of tobacco was previously thought to 
be restricted to the lung, kidney, bladder, pancreas, and oesophagus. Recently, there are 
indications that colorectal, myeloid leukaemia, cervix, liver and stomach cancers are also 
increased by tobacco smoking (Petra and Wark, 2017), thus smoking is an important risk 
factor for cancer. Smoking causes more death in China where liver cancer is common, 




1.1.2.1.1.2  The Effects of Diet 
 
Cancer epidemiology as a result of nutrition is a complex process. For instance, the risk 
of cancer in old age may be dependent on diets eaten in early life and not just on current 
diets. Dietary factors do not show strong and consistent effects that will enable 
researchers establish them as unequivocal carcinogens. However, consumption of 
aflatoxin contaminated food and drinking excessive alcohol over a long period have been 
associated with cancers (Petra and Wark, 2017). During the past two decades, extensive 
research has indicated that certain diets are associated with cancer development, but 
opinion still differ on the authenticity of these evidences. In late 20th century, fat and meat 
where the main focus of nutritional epidemiology as the causes of cancer, while the β-
carotene, vitamins A, C, and E, vegetables, fruits and dietary fibre were seen as the 
protective factors against cancer (Wark and Peto 2017). Recently, researchers are 
concentrating on processed meat and red meat as risk factors while whole grains (e.g., 
wheat), vegetables, specific non-nutrient components of fruits, selenium, calcium, vitamin 
D, B-vitamins and folate are the protective factors (Wark & Peto, 2017). The belief that 
fatty foods are hazardous, and vegetables and fruits are protective does not seem 
convincing as previously thought and more mechanisms underlying the role of diet in 
cancer epidemiology are being investigated (Wark & Peto, 2017). Nevertheless, the role 
of saturated fat (bad fat) in cancer epidemiology is being reviewed by the World Cancer 
Research Fund / American Institute for Cancer Research and research findings have 
indicated that diets rich in n-3 unsaturated fatty acids (present mainly in fishes) is 
beneficial in preventing cancer (Wark & Peto, 2017). Natural foods rich in antioxidants 
are beneficial in preventing cancers compared to dietary supplements. For instance, a 
12-year randomised trial indicates that administration of dietary supplements of β-
carotene did not reduce the risk of cancer, but β-Carotene obtained from dietary carrot 
proved to be effective in reducing the risk of cancer (Greenwald et al., 2007). Most reports 
have concluded that a change in the dietary intake from saturated fats to unsaturated 
fats, fruits and vegetables and dietary fibre might reduce one-third of cancer deaths, and 
there is a consensus that obesity-associated cancers are avoidable (Wark & Peto, 2017). 
Another consensus is that cancer is common with obese or overweight people. This 
evidence is strongest for kidney, gallbladder, endometrium and postmenopausal breast 
cancers (Calle et al., 1999). Evidence to this is the finding that many obese non-smokers 
in America are mostly affected by diet associated cancer deaths (Calle et al., 1999). This 
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finding also indicates that mortality from non-malignant cancers also increase in those 
who are too fat or too thin. Since obesity is common in Western societies, mortality from 
weight related cancers may be on the increase as the intake of diets rich in saturated fats 
increases. 
 
1.1.2.1.1.3  Reproductive and Hormonal Factors 
 
The effect of both exogenous and endogenous hormones and reproductive factors have 
been linked to ovarian and breast cancers especially the hormonal changes occurring 
during pregnancy. An important hormone which triggers ovarian and breast 
carcinogenesis is oestrogen which promotes cell proliferation of both neoplastic and 
normal breast epithelium (Russo & Russo, 2006). Early child birth, early menopause and 
late menarche reduces the risk of breast and ovarian cancers (Wark & Peto, 2017). 
Administration of hormone replacement therapy (HRT) and oral contraceptives is also 
associated with breast cancer incidence. Administration of HRT is also associated with a 
transient increase in incidences of endometrial cancer while a combination of progestin 
and oestrogen HRT increases the risk of breast cancers, but this risk is smaller for 
endometrial cancers. Administration of oral contraceptives alone is safe, and no ovarian 
and endometrial incidences have been associated with the use of oral contraceptives 
(Wark & Peto, 2017). Both HRT and oral contraceptives appears to reduce the risk of 
colorectal cancer (Wark & Peto, 2017). There is also a correlation between the Western 
diet and postmenopausal obesity and early menarche which increases the production of 
endogenous oestrogen. Breast cancer is common in most Western countries (such as 
Belgium, Denmark and the UK) than in many developing countries (Wark & Peto, 2017). 
 
1.1.2.1.1.4  Viruses, Bacteria, and Parasites 
 
The role of infectious agents in cancer epidemiology globally accounts for about 21 % of 
all cancers (Parkin, 2006). Over 100 species of human papillomaviruses (HPVs) have 
been isolated. Analysis of the DNA of sexually transmitted HPVs (constituting a small 
group) which includes HPV-16, HPV-18 and HPV-45 indicates these viruses are 
presented in all cervical cancers diagnosed globally (Wark & Peto, 2017). Other HPVs in 
addition to HPV-16, HPV-18 and HPV-45 have also been isolated in virtually all anogenital 
cancers globally, and also in cancers of the pharynx and mouth (Wark & Peto, 2017). 
Vaccines have been developed to curb the effect of some HPVs strains. However, these 
vaccines are expensive making it difficult for developing countries (with poor cervical 
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cancer screening facilities) to purchase these vaccines. The effect of these vaccines will 
be greatest in developing countries (with poor cervical cancer screening facilities), and 
not in developed countries which have organised cervical screening facilities in place 
(Wark & Peto, 2017). HPVs vaccines are only effective against some strains of HPVs thus 
they lack the ability to protect against all HPVs (Wark & Peto, 2017). 
The hepatitis B virus (HBV) is also a major agent responsible for hepatic cancer including 
hepatocellular carcinoma and liver cirrhosis especially in high incidence regions such as 
the Amazon basin, Sub-Saharan Africa, Southeast Asia and central Asian republics 
where the carrier rate is over 8 % (Franco et al., 2012). The World Health Organization 
has estimated that over 2 billion people are infected with HBV and an additional 378 
million carriers globally. 620,000 HBV related deaths have been reported globally. It is 
also estimated that 4.5 million new HBV infections occur yearly globally (Franco et al., 
2012). The Mediterranean basin, some Eastern European countries and the Middle East 
are considered intermediate endemic areas and the carrier rate is estimated at 2 - 8 %. 
United States, part of South America, Australia and Northern Europe have an HBV 
prevalence rate of less than 2 % (Franco et al., 2012). Specific co-factors such as malaria 
(Burkitt's lymphoma in Africa), aflatoxin (liver cancer), smoking (cervix and liver cancers) 
and salted fish (nasopharynx cancer), in combination with HBV is responsible for cancers 
stated above (Buell et al., 2005). Therapeutic immunosuppressant causes an increase in 
incidences of non-melanoma skin cancer and virally induced cancers. 
Immunosuppressant have also been linked to an increase prevalence of epithelial 
cancers (Buell et al., 2005). This suggests that unidentified viruses may be responsible 
for many other cancers as well. Helicobacter pylori, a bacterium responsible for chronic 
gastric bacterial infection has been isolated from stomach cancer, and accounts for about 
63 % of stomach cancers and 6 % of all cancers globally. It therefore implies that over 50 
% of stomach cancers can be prevented if H. pylori is eradicated (Mbulaiteye et al., 2009). 
 
1.1.2.1.2  Occupational and Environmental Carcinogens 
 
Occupational exposure to specific carcinogens such as asbestos and combustion 
products of coal has caused an increase to certain cancers such as mesothelioma and 
lung cancers. The effect of occupational exposure to asbestos in the 1940s was only 
apparent in the 1980s when over 250,000 cases of lung cancer and mesothelioma was 
reported in Western Europe due to the long latency of the disease (Wark & Peto, 2017). 
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The tragic effect of asbestos was preventable as the danger associated with its continued 
use was known by 1960s but because the early warnings from epidemiological data were 
ignored, mesothelioma became evident in the 1990s (Wark & Peto, 2017). Due to the 
latent periods of many cancers, laboratory testing of potential carcinogens (such as 
studies on chromosomal aberration in lymphocytes) should be the first line of action 
aimed at stopping potentially carcinogenic new agents especially those which may affect 
the paracrine and endocrine signalling pathways. 
 
1.1.2.1.3 Molecular and Genetic Epidemiology of Cancer 
Many cancers are linked to a genetic predisposition or epigenetic cause where gene 
mutation is passed from one generation to another for example cancer of the breast 
where defective genes often affect metabolism of carcinogens which could impair 
apoptosis (programmed cell death), control of the cell cycle, detection and repair of DNA 
damage (Wark & Peto, 2017).  
Family history of people with a particular type of cancer can be compared with those 
without cancer with the aim of measuring potential risk factors associated with the cancer 
type. About 34 % of men whose father suffered prostate cancer are twice more liking to 
develop prostate cancer (Kicinski et al., 2011) while women with female relatives with 
breast cancer has a two-fold risk of developing breast cancer compared to those without 
a family history of breast cancer (Kharazmi et al., 2014). Cancer epidemiology therefore 
tends to increase in regions with family history of cancer. 
 
1.1.3  Cancer Treatment 
 
Several approaches have been used in cancer treatment such as the use of radiation, 
surgery and chemotherapy (Gregory et al., 1991). The scope of this work is limited to the 
use of chemotherapy (from phytochemicals) in cancer treatment. This work shall focus 
on the use of two different approaches to developing phytochemicals for use as 
anticancer and antimicrobial agents:  
i) The extraction of novel compounds from a plant belonging to a group of a well-
known sources of bioactive compounds – Inula helenium. 
ii) The synthetic modification of a well-known flavonoid (chrysin) with promising 
activities. 
The specific aims and objectives shall be discussed in detail in section 1.6. 
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To discuss cancer treatment, one needs to consider the development and approval of 
anticancer drugs, a specific or selected anti-cancer agent or drug, methods of treatment, 
amongst others. To treat cancers, cure through destruction and total removal of malignant 
cells which usually refuse to respond to some treatments, particularly stem cells (which 
can regenerate into new cancerous growths) (Hatfield et al., 2005) is required. 
Radiotherapy and surgery have been used to treat localised cancers; these treatment 
options cannot be used in treating metastasis in interior organs and tissues (Zimmermann 
et al, 2014). Metastasis can only be treated by using chemotherapeutic agents which 
could attack such migrant cells. Unfortunately, chemotherapeutic drugs currently 
available in the market do not show specificity to tumour or cancer cells as most of them 
act by either interfering with DNA synthesis or by completely damaging the DNA 
machinery. By this, they do not only destroy cancerous cells but normal cells as well 
including cells that are rapidly dividing such as the bone marrow cells responsible for 
forming blood cells, epithelial cells of the gastrointestinal tract and hair follicle cells (King, 
1996; Siddik, 2005). Toxicity from chemotherapeutics affects populations of normal cells. 
Interestingly, some solid tumours and other malignant tumours like those of breast, lung, 
rectum and colon have very few dividing cells. Due to this limitation of dividing cells, they 
are less susceptible or sensitive to chemotherapeutics. One limitation of 
chemotherapeutic drugs which limits their effectiveness is therefore their toxicities on 
normal cells. Many drugs have been employed in cancer treatment, and they operate via 
several mechanisms such as inhibition of M2 macrophages and myeloid-derived 
suppressor cells, inhibition of microtubule synthesis, simulation of ligands to their receptor 
etc. (Zimmermann et al, 2014; Zitvogel et al., 2013; Pratt et al., 1994). Available 
chemotherapeutic agents elicit cytotoxicity and apoptosis by interfering with the 
mechanism of DNA replication. However, cancer cells have the ability of repairing and 
renewing their damaged DNA. In addition to this, cancer stem cells can efflux drugs from 
within the cell environment via transporters known as ATP-binding cassette, rendering 
protection to these cells from cytotoxic agents (Liu et al., 2008). Because malignant cells 
can relapse and survive during chemotherapeutic treatment, there is need to find better 
alternatives to them and compounds isolated from natural products / their secondary 
metabolites may offer these solutions. Recently, the role of nitric oxide base compounds 
in cancer chemotherapy has been reviewed and it is believed these compounds offer very 
promising anticancer properties against tumour cells in vivo. However, at low 
concentration nitric oxide-based compounds are chemostatic, promoting the growth of 
cancer cells. Nevertheless, specialised delivery system of these nitric oxide-based 
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compounds into cells is being developed to ensure these compounds gets to their target 




The use of drugs to kill cancerous growths or tumours, hindering their ability to grow and 
divide is known as chemotherapy. It involves administering anticancer drugs 
systematically into the bloodstream to distribute the drug throughout the body. 
Chemotherapy involves interference with DNA replication and inhibition of cell growth and 
division. The fundamental goal of clinical efficiency of any anticancer drug requires such 
drug to kill malignant cancerous growths in-vivo at doses sufficient enough to allow 
recuperation of critical tissues of the patient such as gastrointestinal tract and bone 
marrow, enabling such tissues to survive, and enable recovery (Hartner, 2018; Vannini et 
al., 2017). Chemotherapy can elicit their actions via one or more mechanism of action 
such as inhibition of DNA synthesis (Vannini et al., 2017; Colvin, 2003), inhibition of DNA 
elongation (Taşkın-Tok & Gowder, 2014), interference with microtubule functioning 
(White et al., 2017; Takimoto & Calvo, 2007), by covalently bonding to the phosphate, 
sulfhydryl, carboxyl and amino groups of important biological molecules (Elzoghby et al., 
2015; Malhorta & Perry, 2003). Chemotherapy can be classified base on their mechanism 
of action into eight groups: anti-tumour antibiotics, antimitotic agents, anti-metabolites, 
alkylating agents, DNA reactive agents, hormone therapy and immunotherapy. Another 
class of chemotherapeutic agents are those derived from plants. The different classes of 
chemotherapeutic agents are discussed below; their history structures, application and 
potential side effects. 
1.1.3.1.1  Anti-tumour antibiotics 
 
Antitumour antibiotics was introduced into the Clinic by Sidney Faber in 1954 when 
actinomycin D, a cytotoxic drug which he isolated from Streptomyces was used in the 
treatment of Wilm’s metastatic tumour in children (Waksman & Woodruff, 1940). The 
potent nature of actinomycin D paved the way for the development of varieties of 
antibiotics which exhibited potent biologic actions against malignancies in humans and 
rats. Mitomycin has been employed in the treatment of clinical cases of myelogenous 
leukaemia (Crooke & Bradner, 1976), doxorubicin and daunorubicin were used in treating 
solid tumours and leukaemia (Arcamone et al., 1969). Among these drugs, doxorubicin 
was the most potent against a range of solid tumours. These drugs elicit their action by 
binding to the double helix of DNA by inserting their planar rings between base pair stacks 
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of DNA, leading to distortion of the DNA conformation (Mansilla et al., 2010; Pratt et al., 
1994). Bleomycin acts by intercalating DNA at a guanine-thymine and guanine-cytosine 
sequence, resulting in the formation of reactive oxygen species (ROS) that splits the DNA 
strand (Mansilla et al., 2010).  
1.1.3.1.1.1  Bleomycin  
 
Bleomycin (Structure 1.1) was originally isolated from Streptomyces verticillus and occurs 
naturally as Cu-chelate (Bolzán & Bianchi, 2018), and elicits its anti-tumour activities by 
binding Fe(II) inside cells, it complex with Fe(II) which involves reduction of oxygen, this 
leads to a release of –OH radicals which cleaves the DNA, and inhibits incorporation of 
thymidine into DNA and consists of three domains; metal binding domain, DNA binding 
domain and carbohydrate binding domain (Bolzán & Bianchi, 2018; Heydari-Bafrooei et 
al., 2017). 
 
Structure 1.1: Structure of Bleomycin showing DNA binding sites 
(Anticancer compounds, 2009; Murakami et al., 1973) 
 
Bleomycin has been employed to treat several cancer types including vulva, cervix, skin 
(non-melanoma), and cancers of oesophagus, neck and head, laryngeal, Hodgkin 
lymphoma, non- Hodgkin lymphoma, and cancer of the testes. It works by binding to 
cancer cells DNA, inhibition of cell growth and division by producing free radicals as ROS 
which destroys the DNA. Some of bleomycin advantage is that it produces little or no 
depression to bone marrow unlike other drugs. It also drains the fluids built up in the body 
by some cancer types (Shaw & Agarwal, 2004; Pratt et al., 1994). The histidine imidazole 
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ring is therefore essential for bleomycin activities and is responsible for the scission in the 
DNA strand (Sergeev & Zarytova, 1996; Murakami et al., 1973). Bleomycin on its own 
cannot damage dsDNA unless it is complexed to a metal ion. 
1.1.3.1.2  Antimitotic Agents 
 
Antimitotic agents (vinblastine and paclitaxel) inhibit the polymerisation mechanics of 
microtubule via inactivation of microtubule spindle assembly checkpoint (SAC), 
preventing the transition of the cell cycle from metaphase to anaphase (Masawang et al., 
2014). Since antimitotic drugs disrupts chromosome orientation and the formation of 
spindle, cells remain in senescence-like G1 state or a prolong state of mitotic arrest 
leading to a subsequent induction of apoptosis (Mitchison, 2012). Microtubules are vital 
for cell division during mitosis and for correct chromosome segregation. They are formed 
during interphase (Dumontet & Jordan, 2010). Vinca alkaloid and colchicine alkaloids are 
examples of antimitotic agents (Takimoto & Calvo, 2007). Other important members 
include Taxol which causes protracted mitotic arrest of the microtubule dynamics, 
disrupting it. This leads to a resultant cell death (Olson et al., 2017). During mitosis, 
microtubule formation is faster compared to its formation during interphase, thus by 
targeting the microtubules, cancer progression can be halted and apoptosis initiated 
(Dumontet and Jordan, 2010). 
 
Figure 1.3: Poisoning of microtubules by colchicine leading to mitosis arrest. 
The points of inhibition of the microtubule by vinblastine, colchicine and paclitaxel are represented as A, B 
and C respectively. These drugs elicit their inhibition by either binding to β-tubulin only (vinblastine) or by 
binding to the interface between α and β-tubulin (colchicine) or by binding to non-toxoid and non-vinca sites 
(paclitaxel) (Anticancer compounds 2009). 
 
Antimitotic agents inhibit cell division by binding to tubulin and affecting the tubulin 
microtubule equilibrium which is the precursor for the synthesis of chromosomal proteins, 
thus preventing the formation of chromosomal proteins. Microtubules within the cells are 
created by tubulin proteins because without microtubules, cell division cannot occur 
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(Botta et al., 2009; Olson et al., 2017; Tsvetkov et al., 2011; Zhou & Giannakakou, 2005). 
Although antimitotic agents have a broad spectrum of activity against various tumour cells 
especially breast cancer (Masawang et al., 2014), variable clinical responses have been 
reported. These variable clinical responses are associated with Tumour-associated 
macrophages (TAMs), which are responsible for suppression of the duration of mitosis 
arrest induced by Taxol in breast cancer, promoting early mitotic slippage, decreased p53 
activation, a decrease in phosphorylation of histone (H2AX) and cancer cell viability at 
interphase (Olson et al., 2017). 
Homeostasis of the cell requires the birth of new cells, and death of old cells. Aged, 
aberrant or infected cells must be killed and / or removed from the cellular environment 
in an efficient manner which will not disturb the homeostasis of the cell. TAM receptor 
tyrosine kinases are therefore responsible for this task. The TAM receptors consist of 
three receptor proteins – Tyro3, Axl, and Mer which are activated by the binding of the 
protein-S and Gas-6 proteins which dimerizes, sending a “eat-me” signal which activates 
phosphotidylserine (Nagata et al., 2010). Activation of phosphotidylserine triggers 
phagocytosis (eating-up of death cells) (Nagata et al., 2010). When phosphotidylserine is 
masked, apoptotic cell phagocytosis is inhibited (Balasubramanian & Schroit, 2003). 
TAMs are therefore responsible for phagocytosis of aged cells by the process of 
apoptosis.  
Apoptosis and Taxol-induced DNA damage is increased by TAMs, increasing the efficacy 
of Taxol in clinical trials. This is so because the cytotoxic effect of Taxol is suppressed by 
TAMs, partly through non-autonomous modulation of mitotic arrest in cancer cells (Olson 
et al., 2017). Targeting TAM-cancer cell interactions therefore increases the efficacy of 
Taxol. 
Colchicine extracted first from Colchicum plant blocks the polymerization of microtubules 
by binding to β-tubulin (Figure 1.3) resulting in a tubulin-colchicine complex which is one 
of the two tubulin proteins which makes up the main composition of microtubule. This 
way, colchicine poisons the tubulin which is required for mitosis to occur, arresting mitosis 
as a result of spindle poisoning. This inhibition of mitotic spindles has been employed in 
genetics studies (Dalbeth et al., 2014). 
Antimitotic agents are divided into two groups according to their mechanism of actions as 
either microtubule stabilizing agents or microtubule destabilizing agents. Destabilizing 
agents inhibits microtubule assembly (polymerization) and binds to either the taxoid-
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binding domain or the vinca domain (Jordan & Kamath, 2007; Kavallaris, 2010). Drugs 
which binds to the vinca domain which is located at the interface between α and β-tubulin 
(Figure 1.3 - B) are called vinca alkaloids and include eribulin, vindesine, vinorelbine, 
vincristine, vinflunine etc. (Liu et al., 2014). Drugs which binds to colchicine domain 
include combretastatin-A4, dolastatins, cryptophycins etc. (Attard et al., 2006). Drugs 
which binds to colchicine domain enhances polymerisation of microtubules, stabilise 




Structure 1.2: structure of vinblastine and vincristine 
(Anticancer compounds, 2009). 
Vinblastin,  taxane and many other drugs belonging to these groups binds to β-tubulin 
(Figure 1.3 – A) (Altmann, 2001). Other drugs bind to overlapping non-taxoid and non-
vinca sites (Figure 1.3 – C) on drug resistant βIII-tubulin-tubulin isotype. These classes 
of drugs are mainly microtubule-stabilizing drugs eg paclitaxel, laulimalide and peloruside 
A (Kanakkanthara et al., 2012). The mechanism of action of paclitaxel and peloruside A 
include arresting the cell cycle at G2/M phase of the cell cycle, resulting in cell death 
(Kanakkanthara et al., 2012). These compounds are difficult to efflux from the cell by 
efflux pumps thus making them superior antimitotic agents compared to vinca alkaloids 
and taxane which can be easily effluxed from the cell (Pryor et al., 2002; Yang et al., 
2016). Vinblastine and Paclitaxel are the most common vinca alkaloids whose 
mechanism of action involves inhibition of microtubule spindle formation (Figure 1.3) and 
a total arrest of replication (van de Velde et al., 2017). Tubulin assembly is blocked by 
vinca alkaloids, preventing aggregation of the mitotic spindle, an inability of chromosome 
segregation prior to cell division thus leading to aggregation of cells in the G2/M phase of 
the cell cycle (van de Velde, 2017). Vinblastine and Vincristine are used in the treatment 
of tumours of the brain, breast, liver, lung, kidney, neuroblastomas, sarcomas, 
lymphomas and acute lymphoblastic leukaemia, and act by binding to β-tubulin, 
stabilizing the mitotic spindle and preventing its separation; this is key to the preservation 
of genetic information which is transferred from generation to generation (Aboubaker et 
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al, 2017; van de Velde et al., 2017). Structurally, vincristine (R=CHO) and vinblastine 
(R=CH3) - Structure 1.2 are identical except for the substitution of –CHO for CH3 on the 
lower indoline nitrogen. The difference in structural groups attached to the indoline 
nitrogen results in difference in toxicity and clinical activities. Vincristine is used mainly in 
the treatment of acute lymphocytic leukaemia in children and often results in peripheral 
neuropathy at doses > 5.0 mg/m². Vinblastine is used primarily in the treatment of 
Hodgkin’s disease and elicits toxicity at the bone marrow at doses > 6.0 mg/m² (Voss et 
al., 2009). 
       
            Structure 1.3: Vindesine               Structure 1.4: Vinorelbine    Structure 1.5:  Vinflunine                                                  
      (Scholar 2007). 
The need to reduce the unwanted side effect of vinca alkaloid has led to the production 
of other semi-synthetic vinca alkaloids with clinical importance including vinorelbine, 
vindesine and vinflunine (Structure 1.3 – 1.5) (Aboubakr et al., 2017). 
1.1.3.1.3  Anti-metabolites 
 
Antimetabolites comprise of a large group of anticancer compounds which are structural 
analogues of natural metabolites involved in RNA and DNA synthesis but differ in such a 
manner as to interfere with their metabolism. Antimetabolites include analogues of purine 
such as cladribine, pentostatin, fludarabine phosphate, 6-thioguanine and 6-
mercaptopurine (Structure 1.6 – 1.10), antagonists of folic acid such as methotrexate 
(Structure 1.11), and analogues of pyrimidine such as gemcitabine, cytarabine, 5-
fluorodeoxyuridine and 5-fluorouracil (Structure 1.12 – 1.15) (Bolzán & Bianchi, 2018; 
Scholar, 2007). Antimetabolites act by disrupting the synthesis of nucleic acids by 
substituting for the natural metabolite or by interfering with the production of an important 
nucleotide metabolite (Bolzán & Bianchi, 2018; Scholar, 2007). 
 




Structure 1.9: thioguanine   Structure 1.10: mercaptopurine 
Structure 1.6 – 1.10: Antimetabolites in clinical practice. 
 
Normal cells of the gastro intestinal track and the bone marrow are often exposed to 
toxicities from antimetabolites as they are effective mainly in the S phase but not the G0 
phase and are very effective in cancers with high growth fractions (Malhorta & Perry, 
2003; Scholar, 2007). Severe toxicities and even toxic deaths (2 patients) have been 
reported for antimetabolites (Dogan et al., 2012). 
   
Structure 1.11: structure of methotrexate – a folic acid inhibitor 
                   
Structure 1.12: Gemcitabine 1.13: Cytarabine       1.14: 5-Fluorodeoxyuridine  1.15: 5-
Fluorouracil      
                   Pyrimidine antagonist 
(Bolzán & Bianchi, 2018; Scholar, 2007). 
 
Gastrointestinal malignancies, osteosarcoma, dermatitis and mucositis are some adverse 
effects reported in a certain clinical trial in Turkey (Dogan et al., 2012). In another phase 
II clinical trials, four deaths were reported when high doses (375 mg/m2) of 
antimetabolites were administered (Ferreri et al., 2015). There is an increased demand 
for metabolites in rapidly proliferating cells; the pyrimidine, purine and folate therefore 
come into prominence as they are the building block of DNA. On attainment of a certain 
dose (300 – 700 mg/m2) (Ferreri et al., 2015), antimetabolites will not kill any more cells 
irrespective of any increase in dosage; however, 5-Fluorouracil is an exception because 
5-Fluorouracil in addition to other mechanism of action, acts as an inhibitor of thymidylate 
synthase, blocking thymidine synthesis, which is a nucleoside used in DNA replication 
(Avendaño & Menéndez, 2015; Malhorta & Perry, 2003). Antimetabolites are closely 
similar in structure to purine and pyrimidine bases and act by preventing synthesis of 
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normal cellular metabolites. The structures of antimetabolites commonly employed in 
cancer treatment are listed in Structure 1.6 – 1.15. 
Figure 1.4 is a schematic representation of inhibition of primers used in DNA synthesis. 
Folic acid is a requirement for the synthesis of dihydrofolic acid. The main source of folic 
acid used by humans is obtained from the diet. Another pathway involves the conversion 
of para-aminobenzoic acid (PABA) to dihydropteridinesyre, which is then converted to 
folic acid. This step is inhibited by antibacterial sulphonamide, which is also a rate limiting 
step in this reaction (Hu et al., 2017). Sulphonamide is bacteriostatic implying it does not 
kill bacteria but stops its growth, and oftentimes sulphonamide is administered alongside 
with Trimethoprim which is bactericidal and can kill bacteria (Hu et al., 2017). 
 
Figure 1.4: Inhibition of primers used in DNA synthesis 
Antibacterial sulphonamide inhibits the conversion of PABA to dehydropteridinesyre which is the precursor for 
dihydrofolic acid synthesis. The second inhibition occurs at the stage where dihydrofolic acid is converted to 
tetrahydrofolic acid. This step is inhibited by trimethoprim (Anticancer compounds, 2009). 
Dihydrofolic acid is then converted to tetrahydrofolic acid essential for DNA synthesis in 
animals and bacteria. Trimethoprim inhibits the conversion of dihydrofolic acid to 
tetrahydrofolic acid. Most antimetabolites also interfere with DNA synthesis at this point, 
inserting mismatch nucleotides into the DNA (Anticancer compounds, 2009). Nucleoside 
analogues act as antimetabolites via the following mechanisms: incorporation of DNA or 
RNA leading to misreading of the base sequence (Scholar, 2007), inhibition of enzymes 
involved in purine / pyrimidine biosynthesis (Bolzán & Bianchi, 2018), inhibition of DNA 
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kinase (Scholar, 2007; Bolzán & Bianchi, 2018), inhibition of DNA polymerases (Bolzán 
& Bianchi, 2018; Takimoto & Calvo, 2007). 
1.1.3.1.4  Alkylating agents 
 
Alkylation involves replacement of an atom of hydrogen by an alkyl groups, forming cross-
linkages in the DNA strand. This leads to carcinogenic, mutagenic, and cytotoxic effects 
elicited by these compounds. Alkylating agents therefore refers to a group of diverse 
anticancer agents which covalently binds a substituted alkyl or an alkyl group to the 
contents of a cell. Once bound to cells, they form carbonium ion intermediates due to their 
strong electrophilic nature or they may pair with the target molecule, forming transition 
complexes. Strong covalent linkages result from alkylation of alkylating agents with 
nucleophilic groups such as carboxyl or sulfhydryl groups (Bolzán & Bianchi, 2018; 
Scholar, 2007). Clinically, alkylating agents are known to effect cell division and DNA 
synthesis. Even though alkylating agents elicits their anticancer activities in all phases of 
the cell cycle, their toxicities and therapeutic effects are linked to interference with cells 
undergoing rapid proliferation (Scholar, 2007). Alkylating agents include dacarbazine, 
altretamine, triethylenemelamine, thiotepa, temozolamide, streptozotocin, procarbazine, 
mitomycin C, melphalan, mechlorethamine, ifosphamide, cyclophosphamide, 
chlorozotocin, chlorambucil, semustine, carmustine (BCNU) and busulfan (Scholar, 2007; 
Sharma et al., 2018). These class of chemotherapeutic drugs binds to DNA, preventing 
correct DNA replication and possess chemical groups which can permanently form 
covalent bonding with nucleophilic site on the DNA. They react with proteins which bond 
to the double helix of DNA, inserting an alkyl group to some or all the double helix of DNA. 
This hinders the linking up of proteins, leading to DNA strand breakage, and eventual cell 
death (Bolzán & Bianchi, 2018; Takimoto & Calvo, 2007). Alkylating agents can both be 
used in treating cancers as well as in inducing cancers. This is because alkylating agents 
are carcinogenic, teratogenic and cytotoxic (Sharma et al., 2018) and most alkylating 
agents are associated with bone marrow and gastrointestinal toxicities. Toxicities to other 
organs may also occur. It therefore implies that alkylating agents should be use when the 
benefits outweigh its side effects. 
Alkylating agents are categorised into seven major groups:  
a) Nitrogen mustards: ifosfamide, estramustine, cyclophosphamide, chlorambucil, 
melphalan, mechlorethamine (Sharma et al., 2018; Takimoto & Calvo, 2007; Taşkın-
Tok & Gowder, 2014). 
b) Nitrosoureas: streptozocin, lomustine (Colvin, 2003; Takimoto & Calvo, 2007). 
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c) Alkyl sulphonates: busulfan (Sharma et al., 2018; Takimoto & Calvo, 2007). 
d) Platinum complexes: oxaliplatin, cisplatin, carboplatin (Takimoto & Calvo, 2007). 
e) Non-classic alkylators: temozolomide, procarbazine, dacarbazine, altretamine 
(Sharma et al., 2018; Takimoto & Calvo, 2007). 
f) Aziridine: thiotepa (Avendaño & Menéndez, 2008; Takimoto & Calvo, 2007). 
g) Triazene and related compound (Marchesi et al., 2007; Sharma et al., 2018). 
 
1.1.3.1.5  DNA Reactive Agents 
 
Platinum based agents offer distinctive possibilities for designing chemotherapeutic 
agents for cancer therapy. The wide spectrum of reactivity, accessible redox states, 
geometries, range of coordination numbers, ligand and intrinsic property associated with 
the cationic metal ion, kinetic and thermodynamic potentials enables this metal to offer 
distinctive biological action against cancer cells. An important DNA reactive agent – 
cisplatin and its derivatives carboplatin and oxaliplatin (Structure 1.16 – 1.18), elicits their 
cytotoxic activity via the formation of DNA-drug-adduct. This adduct prevents DNA 
replication and apoptosis and this property is exploited in the treatment of several cancer 
types including cancers of the testis, bladder, neck, head and ovaries. 90% cure rate has 
been reported for these cancers (Brabec et al., 2017; Cheung-Ong et al., 2013). 
 
Structure 1.16: Cisplatin  Structure 1.17: Carboplatin   Structure 1.18: 
Oxaliplatin 
(Brabec et al., 2017). 
On entering the cell, cisplatin becomes activated by displacement of its chlorine atom by 
water molecules, energising it to becoming a strong electrophile which then reacts with 
nucleophiles including the atoms donating nitrogen on nucleic acid base residue. Intra-
strand is the most prevalent DNA-adduct induced by cisplatin, where the platinum atom 
pairs to the imidazole ring at N7 position of two-guanine adjacent to each other and this 
accounts for about 60 – 65 % of all adducts. In other cases, where one guanine and 
adenine are involved, about 20% of these adducts are formed (Brabec et al., 2017). 
Mitochondrial DNA also seems to be a target for cisplatin (Shu et al., 2016). Apart from 
intra-strand DNA-adducts, inter-strand and monofunctional adducts have also been 
hypothesised as responsible for the toxicity of cisplatin (Brabec et al., 2017; Dasari & 
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Tchounwou, 2014; Johnstone et al., 2014; Millard & Wilkes, 2000), which conflicts with 
other reports (Pinto & Lippard, 1985). 
Cisplatin has been hypothesised to induce thermal cytotoxicity which sensitizes tumour 
cells to cisplatin (Dasari & Tchounwou, 2014). The reaction of cisplatin with DNA is 
thought to be through the formation of increased inter-stand cross-linkage in the DNA 
adduct which results in an increased inter-strand cross-linkage of 2.4% at 25°C and 
11.5% at 45°C. This increased cisplatin-DNA inter-strand cross-linkage is enhanced in 
negatively supercoiled DNA compared to linear DNA, an indication that the DNA topology 
also influences the amount of inter-strand cross-linkages (Brabec et al., 1992; Heymann 
et al., 2014; Malina et al., 2000). Cisplatin elicits its action via apoptosis and necrosis. In 
necrosis, the cytosol swells, losing the integrity of the plasma membranes. Once the 
plasma membranes integrity is lost, cisplatin gushes into the cytosol at concentrations 
>800 µM. At concentrations ~ 8.0 µM, apoptosis results, if cells are exposed to cisplatin 
over several days leading to the shrinkage of the cell, DNA fragmentation and chromatin 
condensation (Tuorkey, 2016). When therapeutic treatments are carefully managed, 
apoptosis occur (Tuorkey, 2016). In mammalian cells, apoptosis follows two main 
pathways: extrinsic and intrinsic pathways. The extrinsic pathway requires binding of 
ligands to tumour necrosis factors (TNF-α), leading to activation of caspase 3, 7 and 9, 
which in turn activates the death domain proteins associated with the death receptors. 
This leads to cell death (Tuorkey, 2016). In intrinsic pathway, modulation of the 
mitochondrial pathway potential leads to the release of cytochrome C and the modulation 
of apoptotic gene. Bax, a pro-apoptosis gene is then upregulated with Bcl-2, an anti-
apoptotic gene, which is down-regulated simultaneously. This mechanism leads to cell 
proliferation (Dasari & Tchounwou, 2014; Tuorkey, 2016). 
There is increased resistance to platinum-based drugs due to epigenetic and genetic 
factors on the one hand, and poor delivery of the drug into its target organ, leading to 
increased rate of metabolism, poor bioavailability and increase rate of excretion out of the 
body, thus limiting the amount of drug reaching the target organ (Brabec et al., 2017). 
Tumour cell resistance also occurs when either or all of the following occur: the DNA base 
repair mechanism is activated such that upregulation of genes (such as BRCA1 and 
BRCA2) involved in drug-induced DNA repair occurs, failure of the cell cycle check-points, 
alteration of drug cellular target, enhanced by-pass of DNA adducts, increased levels of 
detoxification through increased cellular thiol production, and increase tolerance to DNA 
damage (Brabec et al., 2017; Cheung-Ong et al., 2013). Multidrug resistance to 
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structurally similar drug can also occur when cells exhibit cross-resistance to a particular 
drug (Brabec et al., 2017). Carboplatin (Structure 1.17) was developed because its six-
membered ring conjugation gives it advantage by increasing its half-life from ~ 3.6 hours 
to over 30 hours and providing aqueous stability to the platinum base drug, reduces the 
side effect of carboplatin - such as neuropathy (dysfunction or disease of one or more 
peripheral nerves, typically causing numbness or weakness) but does not eliminate the 
resistance observed in cisplatin (Brabec et al., 2017; Dasari & Tchounwou, 2014). The 
problem of cisplatin resistance is overcome by oxaliplatin which although binds to the 
same site of DNA, and forming the same adduct like cisplatin; however, they are 
differentially recognised by repair proteins (Brabec et al., 2017). 
 
1.1.3.1.6  Hormone Therapy 
 
Hormone therapy is a non-toxic and effective cancer therapy option for prostate cancer 
and involves binding the hormone therapy to progesterone and oestrogen receptors. 
Testosterone and oestradiol are controlled by the gonadal-pituitary-hypothalamic 
pathways with oestradiol produced by conversion of peripheral adrenal androgens by 
aromatase in postmenopausal women, while the ovaries in premenopausal women, 
produces oestradiol (Tuorkey et al., 2016). Treatment of prostate cancer and breast 
cancer in premenopausal women is usually achieved by castration (Tuorkey et al., 2016), 
while aromatase inhibitors or selective oestrogen receptor modulators such as tamoxifen 
(Structure 1.19) are used in postmenopausal cancers (Tuorkey et al., 2016). Prior to 
radiotherapy or radical surgery, hormone therapy is often used to shrink the size of the 
cancers or to prevent or minimise recurrence (Abraham & Staffurth, 2016). Patients with 
metastatic disease or locally advanced cancers usually respond positively to hormone 
therapy, although cancer relapse especially those involving ‘castrate-refractory’ diseases 
have been reported (Abraham & Staffurth, 2016). Tamoxifen is structurally similar to 
oestrogen and binds at the receptor sight of oestrogen. It possesses both anti-oestrogenic 
and oestrogenic effects depending on the tissue involved. In mammary tissues, it is anti-
oestrogenic and for this reason, it is used in breast cancer treatment and prevention, while 
on uterine epithelium, it is pro-oestrogenic (Shagufta & Ahmad, 2017). Therefore, 
tamoxifen is called selective oestrogen receptor modulator as women treated with 





Structure 1.19: Tamoxifen         Structure 1.20: Raloxifen  Structure 1.21: Droloxifene 
 
Structure 1.22: Idoxifene Structure 1.23: Lasofoxifene      Structure 1.24: Toremifene 
 
                  Structure 1.25: Ospemifene   
  (Shagufta & Ahmad, 2017). 
For this reason, derivatives of Tamoxifen such as ospemifene, toromifene, lasofoxifene, 
idoxifene and droloxifene (Structure 1.19 – 1.25) have been developed and are currently 
undergoing clinical trials (Shagufta & Ahmad, 2017). 
 
1.1.3.1.7  Immunotherapy 
 
Monoclonal antibodies have been employed in treating cancer over the past decade for 
many types of cancers. The use of these antibodies in cancer treatment is known as 
immunotherapy. Immunotherapy also encompasses distinct tactical treatments including 
immunocytokines, enzyme inhibitors, immunomodulating checkpoint inhibitors and 
vaccines (Redman et al., 2017). Sipuleucel-T vaccine has received approval for the 
treatment of prostate cancer in the US (Redman et al., 2017), while checkpoint inhibitors 
have found modern application in the treatment of Hodgkin’s lymphoma, urothelial 
carcinoma, non-small cell lung cancer, kidney, and melanoma cancer (Balar et al., 2017; 
Chan et al., 2017; Rosenberg et al., 2016). Sipuleucel-T vaccine is a novel personalised 
vaccine which work by programming each patient's immune system to seek out foreign 
bodies (cancer) and attack it. This vaccine is not just a preventive vaccine but also a 
therapeutic vaccine due to its immunostimulant abilities (Redman et al., 2017). These 
antagonist monoclonal antibodies elicit their antitumour activity acting as 
immunomodulators which targets regulatory molecules on the surfaces of cells, 
potentiating antitumour immunity. The check-point widely studied includes programmed 
death ligands-1 (PD-L1), programmed cells death proteins-1 (PD-1), and inhibitor of 
cytotoxic T lymphocyte associated proteins-4. These checkpoints regulate the activity of 
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the T-cells (Balar et al., 2017; Chan et al., 2017; Rosenberg et al., 2016). When these 
molecules are blocked, interactions in the tumour microenvironment and other immune 
compartments are affected. This further dampens natural inhibitory functions of the 
immune system, resulting in cell death. Although only Sipuleucel-T vaccine has been 
approved for the treatment of prostate cancers, other immunotherapeutic agents currently 
undergoing clinical trials with good success include, Olaparib – (a PARP inhibitor), 
Ipilimumab, Pembrolizumab, Nivolumab, ProstAtak, DCVAC/PCa, PROSTVAC (PSA-
TRICOM) (Redman et al., 2017). 
Immunotherapy relies on the ability of these agents to induce an immune response, 
enabling the body to identify tumour growths as foreign bodies. Identification of tumour 
cells as foreign bodies could elicit phagocytosis, activation of T-cells and other cellular 
mechanisms which will eventually lead to tumour cell death (Balar et al., 2017; Chan et 
al., 2017; Redman et al., 2017). The safety of monoclonal therapeutic antibodies and its 
efficacy depends on the target antigen accessibility and abundance, allowing the binding 
of these agents to special targets. These antigens are often exclusively on the surfaces 
of the tumour cells and are usually homogenous in nature, allowing limited antigen 
secretion, allowing the immunotherapeutic agents to target cancer cells (Balar et al., 
2017; Redman et al., 2017). 
1.1.3.1.8  Protein Kinase Inhibitors 
 
A variety of cellular activities are involved in post-translation modification (PTM) of which 
phosphatases and protein kinases are the most widely studied. Phosphatase and protein 
kinases are enzymes involved in dephosphorylation and phosphorylation reactions and 
genomic analysis indicates encoding of these enzymes by the human genome in a 
magnitude of between 3 and 5 % of these enzymes. Phosphorylation of proteins allows 
conformational changes which either activates or deactivates the enzyme complex in 
single or complex enzyme binding sites and these conformational changes are 
responsible for regulating the protein kinases when phosphorylation and 
dephosphorylation of protein kinases occur (Singh et al., 2017). Normal cellular 
functioning requires phosphorylation and the malfunctioning of this key metabolic function 
may lead to the onset of cancer which may lead to mutation of genes responsible for 
proliferation and normal cell growth. Mutation of these genes may disrupt the homeostasis 
of proteins leading to impairment of signal transduction (Reggi & Diviani, 2017; Singh et 
al., 2017). By targeting protein kinases, cancer growth can be inhibited and destroyed by 
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small molecules such as sunitinib, sorafenib, imatinib, and gefitinib (Structure 1.26 – 
1.29). 
 
          Structure 1.26: Sunitinib                                   Structure 1.27: Sorafenib 
 
            Structure 1.28: Imatinib                                        Structure 1.29: Gefitinib                                                           
                                                      (Singh et al., 2017). 
 
Phosphorylation regulates vast cellular functions including cell signalling, apoptosis, 
differentiation and cell growth in healthy cells. Cancer results when phosphorylation 
malfunctions, releasing oncoproteins which are linked to cancer growth (Singh et al., 
2017). Oncoproteins are used in marking tumour cells. Signalling pathways such as 
Cyclin-dependent kinases, Cadherin-catenin complex, MAP kinase, Tyrosine kinase etc. 
are important cell cycle players involved in phosphorylation-dephosphorylation cascades 
and deregulation of this process leads to cancerous growths (Singh et al., 2017) and 
tyrosine kinases encompasses majority of oncoproteins of which MAPK cascade, and 
Bcl2 family plays a role in cancer progression and development. Bcl2 cascade proteins 
act as anti-apoptotic proteins as well as apoptotic proteins, with cyclins regulating the cell 
cycles, whereas the catenin- cadherin complex controls cell adhesion (Reggi & Diviani, 
2017; Singh et al., 2017). When phosphorylation is altered in any or all of these pathways, 
cancer results and by targeting tyrosine kinase, drugs inhibiting ERK, PI3K, and MEK 
signalling pathways can be used to treat cancers (Reggi & Diviani, 2017; Singh et al., 
2017). Crizonib has been approved for treatment of NSCLC cancer treatment while 
lorlatinib, entrectinib, cabozantinib and ceritinib are undergoing clinical trials for treatment 
of lung cancer (Roskoski 2017), thus crizotinib is classified as a type I tyrosine ROS1 
protein kinase inhibitor (Roskoski 2017). Drugs which can target phosphorylation 




1.1.3.1.9  Anticancer Agents from Plants 
Natural products are an important resource of novel drugs, drug analogues and important 
chemical entities. This is more so because of the need to discovering anti-infectious and 
anticancer agents. This has continued to present new leads of which many have been 
successful in clinical trials. Interestingly, plant and other natural products are used in 
pharmaceutical preparations and pharmaceutical care of which various agents derived 
from plants are successfully used in treating cancers. Currently, several classes of 
cytotoxic plants derived natural products have been characterised and are currently being 
investigated for development and improvement of novel drugs (Shah et al., 2013; Twilley 
& Lall, 2018). These plant products can be classified mainly into four groups namely 
taxane diterpenoids, epipodophyllotoxin lignans, vinca alkaloids, and camptothecin 
alkaloids (including quinolone). 
 
1.1.3.1.9.1   Taxanes 
 
Taxanes were isolated from Taxus brevifolia. They act mainly by disrupting the equilibria 
between microtubules and free tubulin by causing a shift in the assembly position but not 
by disassembling them, as is the case with other microtubule antagonists (Takimoto & 
Calvo, 2007; Twilley & Lall, 2018). 
 
Structure 1.30: structure of Taxol 
(Anticancer compounds 2009) 
Paclitaxel (Taxol) was the first taxane discovered. No natural compound has been 
successfully applied in treatment of cancer like paclitaxel. It is the first anti-tumour agent 
known to promote the over-proliferation of microtubules which are essential elements in 
cancer chemotherapy. It has been used in Non-small-cell lung carcinoma (NSCLC), 
breast and ovarian cancer treatment (Twilley & Lall, 2018). Analogues of Paclitaxel which 
have elicited better anticancer activity have been synthesised such as docetaxel (Twilley 
& Lall, 2018). In 2009, Taxolog (Milataxel) was successful in phase II trials for colorectal 
tumour, however, its high toxicity at doses above 35 mg/m2 is of clinical concern 
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(Ramanathan et al., 2008). Several taxanes and their metabolites are currently 
undergoing clinical trials with the aim of assessing their tolerance, safety and their 
continuous daily dosage especially if they advance to phase II clinical trials in patients 
with solid tumours at advanced stages; an example of such drug is Tasetaxel BMS-
275183, BMS-184476 (Heath et al., 2011; Plummer et al., 2002). RPR 109881A, a 
taxane, which possess a cyclopropyl ring, had advantage over docetaxel as it elicited 
cytotoxicity against docetaxel sensitive tumour cells (Gelmon et al., 2000). Ortataxel is 
potent against tumours resistant to docetaxel and paclitaxel, as well as in NSSLC taxane 
resistant tumours (Beer et al., 2008), taxanes therefore appears to offer promising results 
as chemotherapeutics with minimal toxicities. Carbazitaxel and docetaxel downregulates 
the survival signal of ERK1/2 in a manner not disturbing nuclear translocation of the 
androgen receptor (AP), an indication that other pathways other than the AP pathways 
are responsible for toxicities induced by these drugs (Mang et al., 2017). 
 
1.1.3.1.9.2  Podophyllotoxin Lignans and Its Analogues 
 
Podophyllotoxin, a lignin derivative and an inhibitor of microtubule assembly was isolated 
from Podophyllum peltatum.  
 
Structure 1.31: Podophyllotoxin      1.32: Etoposide  1.33: Teniposide 
                         Podophyllotoxin lignans and analogues 
                         (Merzouki et al., 2012). 
Teniposide and etoposide elicited cytotoxicity by reversibly binding to tubulin in a manner 
different from the lead compound, by inhibiting topoisomerase II enzyme (Srivastava et 
al., 2005). The discovery of teniposide and etoposide has opened the door to much 
research aimed at synthesizing analogues of podophyllotoxin. This is important because 
podophyllotoxins have poor solubility, are easily inactivated in bio-systems, and cells 
become easily resistant to podophyllotoxins. Many compounds with better activities than 
podophyllotoxin have been synthesized and tested (Kamal et al., 2014; Khazir et al., 




1.1.3.1.9.3  Vinca Alkaloids 
Vinca alkaloids were discovered in 1950s in Madagascar periwinkles (Catharanthus 
roseus). Four vinca alkaloids which have been used in cancer treatment include 
vindesine, vincristine, vinorelbine, and vinblastine (Pratt et al., 1994; Twilley & Lall, 2018). 
The first compounds isolated – vincristine and vinblastine, are used in treating several 
cancers, and have been subject to several biochemical and pharmacological 
investigations (Twilley & Lall, 2018). Vinca alkaloids in clinical use are classified mainly 
into four groups: vindesine, vincristine, vinorelbine, and vinblastine (Moudi et al., 2013).  
Previously, it was considered that vinca alkaloids acted mainly by inhibiting tubulin 
polymerization into microtubules, blocking mitotic spindle formation, and resulting in cells 
death due to metaphase arrest (Jordan et al., 1991b; Panjawatanan et al., 2014). 
Vintafolide has produced promising clinical results as a potent anti-tumour agent in the 
treatment of ovarian cancer (Leamon et al., 2014). It consists of folic acid, a di-sulfide, 
hydrophilic peptide-spacer, and desacetyl-vinblastine hydrazide (DAVLBH) – a cytotoxic 
drug. A comparison of vintafolide and other folate-targeted vinca alkaloids such as 
vindesine, vinorelbine, vinflunine, and vincristine proved the potency of Vintafolide, 
compared to other drugs (Leamon et al., 2014). 
Several clinical trials on vinca alkaloids are currently ongoing including hydravin 
(anhydrovinblastine) with clinical trials for treatment of lung metastatic sarcoma. By 2003, 
stage-I clinical trials revealed a 21 mg/mL recommended dose (Ramnath et al., 2003). 
Because of the limitation of lead vinca alkaloids compounds (such as an increased anti-
tumour spectrum, and increased safety), amino acids and derivatives have been grafted 
into vinxaltine and vintripol to overcome these limitations, with successful phase III clinical 
trials for vinorelbin in patients with carcinoma of the breast (Budman 1992).  
 
                      Structure 1.34: Structure of vinca alkaloid  
                   (Anticancer compounds, 2009; O’Boyle et al., 2011) 
Vinblastine prevents angiogenesis by attacking the mitotic spindle which shuts-down 
mitosis, and blocks the cell cycle (Tsvetkov et al., 2011), leading to cell death. Agents 
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that target tubulin elicit cytotoxicity by either destabilising or stabilising microtubules by 
disrupting its dynamics, arresting mitosis, and inducing apoptosis (Botta et al., 2009). 
Microtubules are very sensitive such that even slight alteration of the dynamics of the 
microtubules has the potential of affecting the mitotic spindle, arresting cell division and 
causing eventual cell death (Zhou & Giannakakou, 2005). Experimentally, three binding 
sites have been discovered namely vinca alkaloids, colchicine and taxoid binding sites 
(Botta et al., 2009). Targeting these binding sites could be future targets for cancer 
chemotherapy. Vinca alkaloid binds to free tubulin (Figure 1.5) forming vinca-bound 
tubulin dimer aggregates to form paracrystalline aggregates, leading to cell cycle arrest. 
 
Figure 1.5: metaphase arrest by vinca alkaloids via suppression of microtubule dynamics. 
Vinca alkaloids (such as vinblastine) binds to free tubulin dimers (consisting of α and β tubulin) forming 
vinca-bound tubulin dimer. These dimers aggregate thus bringing about cell cycle arrest in cancer cells 
(such as breast, Hodgkin lymphomas etc.), including cancers of the germ cell (Anticancer compounds 
2009).  
Vinca alkaloids are known for their side-effects of anaemia and reduced resistance to 
infection but finds application in the treatment of tumours of germ cells, breast cancers, 
Hodgkin lymphomas (Tsvetkov et al., 2011; Zhou & Giannakakou, 2005). Vinca alkaloids 
such as vincristine bind strongly to tubulin dimers in a reversible manner. It does this by 
binding to a dimer at one end, poisoning it, dissociating from it, and binding to another 
end, poisoning it. By this poisoning, the dimers cannot re-assemble to form microtubules, 
resulting in cell death (Figure 1.5) during the G2-M transition and G1 phase (Lobert & 
Puozzo, 2008; Simoens et al., 2006). 
 
1.1.3.1.9.4  Camptothecin 
 
This group of compounds where characterised from a Chinese tree called Camptotheca 
acuminata. It is an inhibitor of nucleic acid biosynthesis and an inducer of DNA strand 
breaks. It elicits cytotoxicity by inhibiting topoisomerase-I in the DNA (Efferth et al., 2007; 
Twilley & Lall, 2018). Preliminary clinical trial of camptothecin shows promising anticancer 
activities but also adverse toxicities, lactone instability, reversal of interaction between 
drug and its targets, drug reactions and low solubility (Beretta et al., 2012). Due to these 
disadvantages, several semisynthetic analogues have been synthesized to overcome this 
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challenge, of which topotecan (hyacamtin), irinotecan (Takimoto & Calvo, 2007), and 
belatecan have been given approval for use as chemotherapeutic drugs. Recently, a 
conjugate of comptothecin and artusunate elicited a better anticancer activity, and lower 
toxicities in vivo than camptothecin (Li et al., 2015). These drugs are employed in the 
treatment of NSCLC, colorectal and ovarian cancers (Oberlies & Kroll, 2004; Twilley & 
Lall, 2018). Camptothecin bind to DNA topo-I complex, giving rise to a stable complex. 
This inhibits re-ligation of DNA and eventual DNA damage and apoptosis (Yikrazuul, 
2009). 
 
Structure 1.35: Camptothecin and its analogues 
(Anticancer compounds 2009) 
The E-ring interacts with the enzymes at three different positions with the hydroxyl group 
forming hydrogen bonds at position 20 with aspartate-533 of the enzyme, and the lactone 
pairs with arginine-364 (Structure 1.36). The topo-I DNA complex is stabilised by the 
interaction of cytosine with the D-ring, forming H-bond. The H-bonding takes place 
between the amino group present in pyrimidine ring of cytosine and carbonyl groups on 
the D-ring at position 17 (Adams et al., 2006; Beretta et al, 2013; Redinbo et al., 1998).  
 
Structure 1.36: Binding of Camptothecin to DNA and topo-I 
(Yikrazuul, 2009). 
Other semisynthetic camptothecin analogues such as Karenitecin have been successful 
in clinical trials against melanoma in phase II trials (Daud et al., 2005). Stage II trials with 
keranitecin are successful with acceptable toxicity levels (Munster & Daud, 2011). 
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Namitecan, a hydrophilic derivative of camptothecin is another chemotherapeutic drug 
offering promising results due to improved cytotoxic potency like topoisomerase I 
inhibition, stability of the complex where DNA cleavage occurs, enhanced accumulation 
within the cell, and a distinct sub-cellular localisation (Beretta et al., 2013; Beretta et al., 
2012), stability of the lactone ring with favourable pharmacokinetics (Beretta et al., 2012) 
and cytotoxic efficacy in a variation of tumour xenograft of humans including tumours 
resistant to irinotecan, and topotecan, especially of carcinomas of the squamous cells 
(Beretta et al., 2013; Beretta et al., 2012). It is currently undergoing clinical studies. 9-
Aminocamptothecin elicited potent activities in pre-clinical trials but has not replicated 
same as a clinical anti-tumour agent. Although it elicited mild activities against colon and 
lung cancers, this was not clinically useful and for this reason, it was discontinued in 1999 
(Khazir et al., 2014; Twilley & Lall, 2018) as it lacked potency against glioblastoma (Farray 
et al., 2006). Gimatecan has entered trials for treatment of solid tumour at advanced 
stages, as they poison DNA topoisomerase-IB, inhibiting the relaxation of supercoil DNA 
(Prada et al., 2013; Zhu et al., 2009). Further studies on camptothecin has led to the 
discovery of exatecan mesylate (Ajani et al., 2005), EZN-2208, TP-300 (Patnaik et al., 
2013), and other derivatives which aims at overcoming the limitations of lead 
camptothecins such as poor solubility, toxicity, amongst others. 
Several other anticancer agents derived from natural products have been isolated and 
they include: curcumin, betulinic acid, flavopiridol, omacetaxine mepesuccinate, 
combretastatin (Jabeena et al., 2014) and colchicine (Anticancer compounds 2009). 
Combretestatin A4 (Figure 1.6) is a natural cis-stilbene, isolated from the South African 
bushwillow tree (Combretum caffrum) in 1989 (Cirla & Mann, 2003; McNulty et al., 2015).  
 
Figure 1.6: Structure of combretastatin A-1 (up) and A-4 (down) (Grisham et al., 2018) 
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Combretestatin A4 and colchicine belong to a class of compound known as colchicinoids. 
They are potent microtubule targeting agent (MTA) and have been reported to inhibit 
cancer cell proliferation in-vitro and can destroy newly formed vasculature in-vivo, as 
found in tumour environments. They are therefore called vascular disrupting agent (VDA) 
(Parkins et al., 2000; Penthala et al., 2015). Phosphate derivative of combretestatin A4 – 
combretastatin-A4-phosphate (CA4P) has shown an ability to regress tumour vasculature 
in a variety of cancer cells because it is more soluble than combretestatin A4 and has the 
advantage of being tolerated better than combretastatin A4 as it does not suppress the 
immune system; a characteristic of combretastatin A4 (Siemann et al., 2009; Young & 
Chaplin, 2004). Despite this advantage, CA4P is a poor monotherapy. Nevertheless, the 
FDA has given it a fast-tracked status for treatment of platinum-resistant ovarian cancer 
(Cooney et al., 2006; Nagaiah & Remick, 2010). Clinical research examining the potency 
of CA4P as an adjuvant therapeutic agent has been concluded (Nagaiah & Remick, 2010; 
Rustin et al., 2010) and the final stages of clinical trials is ongoing (Grisham et al., 2018). 
It has been reported that CA4P is safe with less side-effect except mild hypertension 
when taken for prolonged periods (Grisham et al., 2018). Combretestatin A-4 elicits 
maximum bioactivity when the aromatic rings are in cis orientation (Figure 1.6). However, 
this compound could easily isomerise spontaneously to inactive trans-stilbene (Figure 
1.6) under the influence of protic media, heat or light (Tron et al., 2006). Medicinal 
chemists are focussing on synthesising derivatives of CA4 with conformational rigidity 
and to improve the improved pharmokinetic profile by incorporation of the ethylene linker 
into a ring system, which prevents spontaneous isomerization (McNulty et al., 2017; 
McNulty et al., 2015). They have been used against leukaemia, colon and lung cancers 
(McNulty et al., 2015; Penthala et al., 2015). Combretastatin, curcumin, and betulinic acid 
are being investigated in several clinical trials against several cancer cells (Dark et al., 
1997; Goel, Kunnumakkara, & Aggarwal, 2008; Nathan et al., 2012). 
Some phytochemicals isolated from plants are important anticancer agents with 
application in the treatment of several cancers and tumours. A summary of 
phytochemicals in clinical use or in clinical trials are presented in the (Table 1.1) below. 














Induces phase 2 
detoxification enzymes; 
inhibits tumour growth 
in breast cancers; 
antiproliferate effects 
Clinical trials with oral 
administration of cruciferous 
vegetable preparation with 
sulphoraphane 
(Gamie et al., 2017; 
Pledgie-Tracy et al., 
2007; Cornblatt et 








s brevifolia L 
Microtubule disruptor; 
block mitosis; induce 
apoptosis; microtubules 
are polymerized and 
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clinical trials; early treatment 
settings; non-small lung cancer, 
breast cancer, ovarian cancer, 
Kaposi sarcoma. Nanoparticles 
(Cragg & Newman, 
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Pro-apoptotic effects; 
cell cycle interference 
Lymphomas and testicular 
cancer trials 
(Solowey et al., 












apoptotic properties and 
induce cell cycle arrest; 
anti-tumour activity 
Lymphomas, sarcomas and 
leukaemias; in clinical use; 
combination trials 
(Solowey et al., 
2014 ; Amin et al., 
2009. 
Vinblastine Testicular cancer, Hodgkins 
disease and lymphoma; in 
clinical use; combination trials 
(Solowey et al., 
2014; Amin et al., 
2009 
Vinorelbine Non-small cell lung cancer; 
single and combination trials; 
Phase I-III 
(Solowey et al., 
2014; Jordan & 
Wilson, 2004) 
Vindesine Clinical trials for acute 
lymphocytic leukaemia 
(Solowey et al., 2014 
& Amin et al., 2009) 
Vinflunine Clinical trials for activity against 
solid tumours; Phase III clinical 
trials 
(Unnati et al., 2013 









damage of DNA. 
Cytotoxicity of cancer 
cells 
Growth inhibition in six human 
cancer cell lines: ACHN 
(kidney), NCI-H23 (lung), PC-3 
(prostate), MDA-MB-231 
(breast), LOX-IMVI (Melanoma), 
HCT-15 (colon) 
(Amin et al., 2009 & 







DNA damage from 
oxidative stress; anti-
proliferative effects 
Clinical trials in prostate cancer 
treatment; Phase I clinical study 
for oral dose administration 
(Amin et al., 2009; 
Raza & John, 2005 










vascular shut-down of 
tumours; tumour 
necrosis 
Early trials; mimics developed; 
clinical and preclinical trials 
Cragg & Newman, 
2005) 
Roscovitine Derived from 
olomucine.  
Inhibition of cyclin 
dependent kinases 






tyrosine kinase activity; 
growth inhibitory effects 
Phase I and Phase II clinical 
trials in solid tumours, 
lymphomas, leukaemias 
Cragg & Newman, 
2005 & Newcomb, 
2004) 






tumour growth and 
progression 
Phase I and II clinical trials; 
limited solubility; research into 
alternative administration of 
drug using analogues and 
nanotechnology. 
(Chen et al., 2015; 
Jyoti et al., 2015; 
Henary et al., 2014) 
(Greenwell & Rahman, 2015). 
Sulphoraphane (Fahey et al., 2017; Gamie et al., 2017), Taxol (Zhang et al., 2014), 
Eppodophyllotoxin (Hande, 1998), Vincristine (Solowey et al., 2014) are in clinical use. 
Newly approved anticancer drugs listed in Table 1.2 are being recommended by 
physicians for the treatment of different cancers. However, some of these drugs are under 
investigation in phase IV clinical trials with good results. Table 1.2 describes important 
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Preparation of film-coated tablet of 
trofosfamide with mixture of different film 
former in order to prevent environment 
contamination and drug hydrolysis 




David M. DeWitt 2012 
Efficient and high-yielding method of 
preparation of nanoparticle using 96 well 
plate for different drugs including 
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4 EP 2244714 A1 
Ronald A. Martell, 
David A. Karlin 
2010 
Combined delivery of picoplatin and 







Shamrao Gharge,  
2015 
Preparation of lyophilized and 
polymorphic forms of treosulfan 





Vaccines prepared by combination of 
genetically modified autologous and/or 
allogeneic cancer cells for improving the 
body immunogenicity 
7 EP 2852413 A4 
Steven J. Sucheck, 
Katherine A. Wall, 
Sourav Sarkar 
2016 
Method for incorporating lipid-bound 
xenoantigen onto the target antigen and 




Shyam S. Biswal, 
Anju Singh  
2014 
Preparation method and composition of 
nuclear factor erythroid-2 related factor-










Method of intervention comprising 
analogs of (deoxy)nucleoside or 
(deoxy)nucleotide in conjugation with 






Peter De Porre, 
Willy Dries, Marc 
Francois 
2007 
Preparation method for IV administration 








Compositions of compounds that inhibit 







Use of different small molecules to 
inhibit anaplastic lymphoma kinase for 








Method of presenting monoclonal 
antibody for HLA-A2- restricted peptide 
PR-1 recognition and their use in 
diagnosis and treatment thereof 
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14 EP 2956484 A2 Harry M. Meade 2015 
Method of modification of glycosylation 
models and production of associated 
antibodies 
15 EP 2101747 B1 
Andrew P. 
Feinberg, Andre 
Levchenko, Dan L.  
2015 
Inhibition of signal by loss of imprinting 
of the insulin-like growth factor II gene 








Administration of mammalian target of 
rapamycin inhibitor for prevention of 
head and neck squamous cell 
carcinoma 
(Jeswani & Paul, 2017).  
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1.2  Infectious Disease. 
 
Infectious diseases are disorders caused by pathogenic organisms such as parasites, 
fungi, viruses or bacteria. Some microorganisms live normally in our bodies and some 
are even helpful and harmless but under certain conditions, they inflict pain and cause 
diseases to their hosts. Symptoms of infectious diseases vary depending on the causal 
agent, and they include: diarrhoea, coughing, sneezing, muscle ache, fatigue, fever etc. 
(Sanchez & Doron, 2017). 
Infection is often not synonymous with disease as most infections do not lead to diseases 
whereas others do lead to varying diseases which could vary in its severity in the affected 
hosts, and a manifestation of clinical signs and symptoms is often evident in this case. 
Although several factors contribute to virulence of infectious agents, and the activities 
occurring between the hosts – virus is a key contributory factor and a determinant of the 
virulence of infections. Virulence is often associated with the pathogenicity or non-
pathogenicity of an infectious agent. Virulence is therefore a relative term explaining or 
comparing two variables; for instance, one could say bacteria A is more virulent than 
bacteria B or bacterial strains A is more virulent in humans than in monkeys. The term 
virulence and pathogenicity refer to the ability of a microorganism to cause diseases in 
the hosts. 
For a microorganism to cause disease, the host must first be infected by the organism 
after which they spread within the organism, damaging target tissues and may invade the 
totality of the organism. However, some infections remain localised. After infecting their 
host, microorganisms are propagated / transmitted to individuals susceptible to them via 
excretion or secretion into surrounding environments, taken up by a vector or individuals 
within the vicinity or from one family member to another living within a close range. 
Microorganisms enter the body via different routes such as the gastrointestinal tract, the 
respiratory tract, the skin and other routes such as body fluids. 
In this study, we shall concentrate on isolating and developing antimicrobial agents from 
natural product sources (plant) which could potentially kill bacteria and fungi. 
1.2.1  Microbial Infection 
 
Development and identification of specific chemical or biological medicine to prevent, 
control, or treat patients suffering from microbial infections which causes disease was a 
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major breakthrough in medical science. This breakthrough was short-lived as the onset 
of antibacterial resistance emerged, making it difficult to treat certain infections.    
Bacterial infection has claimed millions of lives throughout history and many have died 
globally from diseases caused by bacteria such as tuberculosis – caused by 
Mycobacterium tuberculosis (Clark et al., 2017), black- death or bubonic plague which is 
caused by, and Yersinia pestisbacteria (Gonzalez & Miller, 2016) as well as many other 
bacterial infections which have devastated humans for centuries. There is a need to 
develop measures that can curtail the rampant spread of infection and mortality. This 
includes; provision of portable drinking water, increased sanitation and hygiene, improved 
education on subjects (especially on disease prevention and control) and most 
importantly the development of antibiotics to combat these infections. The discovery and 
introduction of antibiotics has offered many health benefits including decrease in death 
rate from bacterial infections (Clark et al., 2017; Gonzalez & Miller, 2016; MacGowan & 
Macnaughton, 2017). 
Despite the many benefits of antibiotics, many bacterial strains have developed 
antibacterial resistance to current therapies. As antibiotic resistance increases, the 
development of new antibiotics is drying up. With just over eighty years of antibiotics use, 
most infections which were easily treated are now difficult to treat. Antimicrobials have 
not only gained prominence in the treatment of bacteria alone but also in many other 
areas of medical practices such as immunosuppressive treatments (MacGowan & 
Macnaughton, 2017), which depend on antibiotic prophylaxis and its effectiveness in 
treatment of infective complications. Resistance to antibiotics therefore is a serious health 
concern as antibiotic use correlates with antibiotic resistance (MacGowan & 
Macnaughton, 2017). There is therefore a need to develop new antimicrobials to replace 
the already depleting ones. 
1.2.1.1 Bacterial infection 
 
Bacteria causing infection can be classified into Gram-positive and Gram-negative 
bacteria depending on the bacterial surface morphology and their differential abilities to 
stain to the Gram dye. Among bacterial organism, the Gram-positive organisms are the 
leading cause of infectious diseases and nosocomial blood infections in both the industry 
and clinics globally (Paterson & Bonono, 2005; Sanchez & Doron, 2017). In the 20th 
century, a major breakthrough was the discovery of antibiotics which have been used in 
treating diseases and through upgrades of the existing antibiotics, to treat pathogenic 
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microorganisms via successful clinical trials. However, many of these antibiotics have 
been abused and used wrongly, giving rise to antibiotic resistance which has become a 
major concern in public health. The pressure caused by resistant microorganisms such 
as vancomycin-resistant Enterococci, Klebsiella pneumoniae, Streptococcus 
pneumoniae and methicillin-resistant Staphylococcus aureus (MRSA), have created a 
huge predicament and medical challenge in the treatment of infectious diseases with a 
consequence of an increased clinical expenses and failures. Paterson & Bonono (2005) 
reported the increased incidences of antimicrobial resistance posed by these drug-
resistant bacteria. 
1.2.1.2 Basic Anatomy of Bacterial Cell 
Nearly every genus of bacteria possesses a rigid, carbohydrate-containing structure that 
surrounds the bacterial cell. This structure is called cell wall. The genus Mycoplasma and 
few exceptions do not have cell walls. The tough rigid structure protects the bacterium 
from damage by encircling it. Despite the rigidity of the cell wall, small molecules can 
easily pass through to the cell membrane thus acting as a coarse filter which exclude 
large molecules. Maintaining the shape of the cell and prevention of cell lysis (bursting) 
because of osmotic pressure is the primary function of the cell wall (Kapoor et al., 2017). 
Peptidoglycan is a complex molecule composed of alternating units of N-acetylmuramic 
acid (NAM) and N-acetylglucosamine (NAG) cross-linked by short peptides. This allows 
the cell wall to be tough and rigid yet allowing the movement of particles. 
 
Figure 1.7: Structure of bacterial cell envelope 
Gram-negative bacteria possess the outer membrane consisting of liposaccharides and proteins. This is 
lacking in the Gram-positive bacteria (Kapoor et al., 2017). 
45 
 
The Gram-positive bacteria consists of cytoplasmic membrane surrounded by a rigid and 
tough mesh known as the cell wall. Gram-negative bacteria consist of a thin cell wall 
surrounded by a second lipid membrane known as the outer membrane (OM). The space 
between the cytoplasmic membrane and the OM is called the periplasm (Figure 1.7). 
Gram-positive bacteria lack the OM, which provides additional protection to the Gram-
negative bacteria and prevents many substances from penetrating the bacteria. Despite 
the role of the OM, porins (channels present in the bacterial membrane) allows the entry 
of molecules such as drugs (Hauser, 2015). The cell wall gives bacteria their shapes and 
prevent it from mechanical and osmotic stress. Ions are prevented from leaking out or 
flowing into the cell by the cytoplasmic membrane (Kapoor et al., 2017). 
Example of Gram-positive bacteria used in this study include Bacillus cereus, 
Staphylococcus aureus, MRSA, Enterococcus faecalis and Pseudomonas fluorescens; 
and Gram-negative bacteria – Pseudomonas aeruginosa, Klebsiella pneumonia, 
Escherichia coli (Kappoe et al., 2017). These bacteria were carefully selected in such a 
manner that the antibacterial activity of compounds tested in this study can be 
investigated against Gram-positive and Gram-negative bacteria, and to investigate the 
antibacterial activities of compounds to be tested against extended-spectrum β-
lactamase (ESBL)-producing bacteria (such as Escherichia coli, Klebsiella pneumoniae 
and Pseudomonas aeruginosa), bacteria associated with food poisoning (Bacillus cereus, 
E. coli), bacteria associated with nosocomial infection (MRSA) (Paterson & Bonomo, 
2005). These bacteria are a major health concerns especially the ESBL as discussed 
below. 
 
1.2.1.2.1  Gram-negative Bacteria 
 
A serious threat to global public health is the emergence of antibiotic-resistant pathogens 
(Boucher et al., 2009). In the year 2009, the United States Infectious Disease Society 
(IDSA) launched an initiative known as the 10 x ‘20 initiative. This initiative is a global 
commitment aimed at developing 10 novel antibiotics by 2020 (IDSA, 2020) to treat 
infections caused by “ESKAPE” pathogens (Enterococcus faecium, Staphylococcus 
aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, 
and Enterobacter species) (Mo et al., 2019). This initiative has been applauded by the 
World Health Organization (WHO) who has listed carbapenem-resistant 
Enterobacteriaceae (CRE), A. baumannii and P. aeruginosa as multidrug-resistant (MDR) 
Gram-negative pathogens which requires urgent public health attention. The American 
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Food and Drug Administration (FDA) have approved four clinically active drugs against 
Gram-negative pathogens including plazomicin (June 2018), meropenem / vaborbactam 
(MER/VAB) (August 2017), ceftazidime /avibactam (CAZ/AVI) (February 2015) and 
ceftolazane/tazobactam (C/T) (December 2014) (Mo et al., 2019). Several other antibiotic 
candidates are being developed against Gram-negative bacteria - cefepime/VNRX-5133, 
eravacycline, cefiderocol, aztreonam/avibactam and imipenem/cilastatin/relebactam (Mo 
et al., 2019). 
1.2.1.2.1.1  Escherichia coli 
 
Escherichia coli dwell mainly in the intestine of humans and animals; the pathogenic 
strains can cause bloody diarrhoea – such as the diarrheagenic E. coli (DEC) (Rehman 
et al. 2018), vomiting and severe abdominal cramp. It is one of the major causes of food 
poisoning. It is a rod-shaped, facultative, anaerobic Gram-negative bacterium (Vogt & 
Dippold, 2005). E. coli cause diseases mainly via the faecal-oral transmission route. 
Another strain of E. coli is the extended-spectrum β-lactamase (ESBL)-producing E. coli. 
ESBL are enzymes that confers antimicrobial resistance to most β-lactam antibiotics such 
as monobactam aztreonam, cephalosporins and penicillins (Ben-Ami et al., 2009). 
Hospitals and community-acquired ESBL producing E. coli are prevalent globally as their 
identification in clinical laboratories can be challenging (Ben-Ami et al., 2009). 
Carbapenems have been reported to be the best antibacterial agents for treatment of 
ESBL-producing organisms (Papp-Wallace et al., 2011). Beta-lactamases are enzymes 
that open the beta-lactam ring, inactivating the antibiotic (Ben-Ami et al., 2009). 
1.2.1.2.1.2  Pseudomonas aeruginosa 
 
Pseudomonas aeruginosa is a rod-shaped Gram-negative bacterium which is a multi-
drug resistant pathogen. It is an opportunistic bacterium which causes ventilator-
associated pneumonia and other nosocomial infections and sepsis disorder. It is 
pervasive in those whose resistance to disease has been destroyed and it is the root 
cause of mortality and morbidity in cystic fibrosis (Fine et al., 1996). Its ability to grow at 
25 – 37 °C and even at 42 °C enable P. aeruginosa to be distinguished from other 
Pseudomonas species (Prince, 2012). It causes disease in both plants and animals, 
including humans especially in patients with cystic fibrosis, cancer and those with poor 
immunity (eg. AIDS patients) (Prince, 2012). The increased prevalence of antibiotic 
resistant bacteria has continuously challenged modern medicine. As an opportunistic 
pathogen, P. aeruginosa is a major cause of multidrug resistant diseases, especially in 
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hospitalized and immune-compromised individuals (Gholizadeh et al., 2017). Recently, 
World Health Organisation (WHO) has identified P. aeruginosa as a priority pathogen due 
to the threat of drug resistant diseases (Skariyachan et al., 2018) and the ability of this 
bacterium to form biofilm. Biofilm formation worsens severe infections especially in cystic 
fibrosis patients (Rodriguez-Sevilla et al., 2018). Biofilms are microbial communities 
(usually adherent to surfaces) encapsulated in a complex of extracellular matrices 
composed mainly of different lipids, extracellular DNA, proteins and polysaccharides 
(Flemming et al., 2016). Clinical consequence of biofilms includes wide range of drug-
resistance (Kafil & Mobarez, 2015). Bacterial cells inside the biofilms show unmistakable 
features from their planktonic partners, making them 1000-overlay more prominent than 
planktonic cells (Hall et al., 2018; Mah et al., 2003). Diminished helplessness of biofilms 
permits biofilm-based diseases to hold on regardless of anti-microbial treatment 
(Aghazadeh et al., 2016; Hall and Mah, 2017). A few hereditary systems have been found 
to be responsible for formation of biolfilms in P. aeruginosa, in which some are very much 
understood, while others are poorly comprehended (Hall et al., 2018). 
1.2.1.2.1.3  Klebsiella pneumonia 
 
Klebsiella pneumonia is a non-motile Gram-negative, facultative, lactose-fermenting rod-
shaped bacterium. Although it is present in the intestine, skin and mouth as a normal flora 
of these tissues, it can damage the lungs (alveoli) if inhaled. They are resistant to most 
drugs (Arnold et al., 2011). It belongs to Klebsiella genus of Enterobacteriaceae and it is 
the most important clinical member of this group and the third microorganism commonly 
isolated in blood cultures of patients with sepsis (Xu et al., 2011). It is present in 
immunocompromised humans and affects mainly the liver and other organs, blood 
(sepsis), urinary tract and lung (Williams et al., 1990). It is an opportunistic pathogen 
frequently encountered in hospitals globally and the bacterium is developing resistance 
to multiple antibiotics including the β-lactams and the cephalosporins and are associated 
with high mortality rates especially in immunodeficient individuals (Stahlhut et al, 2012). 
Mortality reported for K. pneumonia in studies from Asia (44.82%), Europe (50.06), South 
America (46.71) and North America (33.24) (Xu et al., 2017) indicates alarming death 
rates globally from K. pneumonia with Europe having the highest mortality rate. Globally, 
the mortality rate of patients with blood stream infections is 54.30 %, and 13.52 % for 
those with urinary tract infection. However, the mortality rate for patients with urinary tract 
infection admitted to the intensive care unit (ICU) was significantly higher (43.13 %) 
compared to patients not admitted to ICU. The mortality rate for patients admitted to ICU 
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with bloodstream infection remains high (48.9) (Xu et al., 2017), an indication that K. 
pneumonia is a serious nosocomial health problem. This rate is believed to be 
significantly higher in hospitals than in reported data (Kanoksil et al., 2013). From January 
2007 to December 2008, a large outbreak was reported in a Greek university hospital 
with 50 patients out of which 34 were in ICU. 18 were infected while 32 were colonised 
by KPC-2-producing K. pneumoniae. 37.5 % mortality rate was reported for non-ICU and 
58.8 % for ICU (Souli et al., 2010). The New Delhi multiple DNA resistant strains (NDM-
1) accounted for most of the cases reported in India and has been isolated from a French 
patient who has never travelled to India (Arpin et al., 2012) and this strain has now been 
a global concern, causing epidemics in Asia, Europe and North America. Another K. 
pneumonia strain – the ST11 first reported in France in 1997, is commonly isolated in 
Brazil, Spain, Portugal, Norway, Netherlands, South Korea, Hungary and China (Andrade 
et al., 2011). 
Table 1.3 summarizes selected clinical trials of newer antimicrobial agents against MDR 
Gram-negative bacteria. 
 
Table 1.3: Selected clinical trials of newer antimicrobial agents against MDR Gram-negative 
bacteria 
Study (year) Design Indication Study drugs Results 
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eradication at TOC (71.2% vs. 
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-Microbiological eradication at 
TOC (77.4% vs. 71%) 
REPRISE (Carmeli 









CAZ/AVI 2.5 g q8 
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21 days 
-Clinical cure at TOC (91% 
vs. 91%) 
RECLAIM 







CAZ/AVI 2.5 g q8 
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metronidazole 
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-Clinical cure at TOC in 
mMITT population (81.6% 
vs.85.1%) 
-Clinical cure at TOC in MITT 
population (82.5% vs. 84.9%) 
-Clinical cure at TOC in CE 
population (91.7% vs. 92.5%) 
REPROVE (Torres 
et al., 2018) 
Phase III, 
R, DB, 




-Clinical cure at TOC in 
mCITT population 







-Clinical cure at TOC in CE 
population 










C/T 1.5 g q8 hrs vs. 
levofloxacin 750 mg 
IV q24hrs for 
7 days 
-A composite of 
microbiological eradication 
and clinical cure in mMITT 
(76.8% vs. 68.4%) 
ASPECT-cIAI 







C/T 1.5 g q8 hrs (+ 
metronidazole 
500 mg q8hrs) vs. 
meropenem 1 g 
q8hrs for 4–14 days 
-Clinical cure at TOC in MITT 
population (83% vs. 87.3%) 
-Clinical cure at TOC in 
microbiologically evaluable 
population (94.2% vs. 94.7%) 
Meropenem/vaborbactam (MER/VAB) 








MER/VAB 4 g q8 
hrs vs. piperacillin-
tazobactam 4.5 q8 
hrs up to 10 days 
-Clinical cure or improvement 
or microbiological eradication 
at EOIVT (98.4% vs. 94%) 
TANGO-II (Kaye et 
al., 
2017; Wunderink 










q8hrs vs. BAT, for 
7–14 days 
-Clinical cure at EDT (64.3% 
vs. 33.3%) 
-Clinical cure at TOC (57.1% 
vs. 26.7%) 
−28-day mortality (17.9% vs. 
33.3%) 
Plazomicin 








vs. MER 1 g q8hrs 
(± levofloxacin po 
500 mg q24hrs), for 
7–10 days 
-Composite cure in mMITT 
population at TOC (81.7% vs. 
70.1%) 
CARE (McKinnell 









vs. colistin 300-mg 
lading dose; 
5 mg/kg/ 
-All-cause mortality at day 28 
in mMITT population (11.8% 
vs. 40%) 
Imipenem/cilastatin/relebactam (IMI/REL) 
Lucasti et al. 









(125 mg or 250 mg) 
q6hrs vs.  
-Clinical response rates at 
DCIV 
(98.8% [REL 125 mg] vs. 
96.3% [REL 250 mg] vs. 
95.2%) 
Sims et al. (Sims 









(125 mg or 250 mg) 
q6hrs vs. IMI 
(500 mg q6hrs) 
-Microbiological response rate 
at DCIV in ME population 
(98.6% [REL 125 mg] vs. 













Cefiderocol (2 g) q8 
hrs vs. IMI (1 g) q8 
hrs, for 7 to 14 days 
-The composite of clinical or 
microbiological response at 
TOC in MITT population 
(72.6% vs. 54.6%) 
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(Mo et al., 2019) 
R = randomized; ME = microbiologically evaluable; DCIV = discontinuation of IV therapy; EDT = end of 
therapy; CRE = carbapenem-resistant Enterobacteriaceae; clinically evaluable = CE; EOIVT = end of IV 
therapy; mCITT = clinically modified intention-to-treat; VABP = ventilator-associated bacterial pneumonia; 
mMITT = microbiologically modified intention to treat, HABP = hospital-acquired bacterial pneumonia; 
BAT = nest available therapy; cIAI = complicated intra-abdominal infection; TOC = test of cure; 
DB = double blind; cUTI = complicated urinary tract infection. 
 
1.2.1.2.2  Gram-positive Bacteria 
 
1.2.1.2.2.1  Staphylococcus aureus 
 
Staphylococcus aureus are species of bacteria which can cause various types of 
diseases. It is a coccal Gram-positive bacterium found on the skin, respiratory tract and 
nose, and is responsible for food poisoning, abscess, skin and soft tissue infections, 
wound and respiratory infections. It is also responsible for toxic shock syndrome, cellulitis, 
impetigo, and boils (sinusitis) (Cole et al., 2001; Kluytmans et al., 1997). Over one 
hundred and seventy-nine Staphylococcal strains have been isolated in humans (Xu et 
al., 2011), and among all species isolated, S. aureus has been a leading health concern 
in the industry, public and the community and has caused a negative impact on the 
economy and medical sectors of many nations (Sanchez & Doron, 2017). S. aureus 
commonly colonises healthy humans. Staphylococcus aureus usually colonise areas 
such as the nose, throat, genitals, rectum and the perineum of humans (Sanchez & 
Doron, 2017). It is estimated that 20 to 50 cases / 100,000 population per year are 
affected by S. aureus bacteria globally, with a mortality rate of 10 % and 30 % (Val-Hal et 
al., 2012). This accounts for a greater number of deaths compared to deaths from viral 
hepatitis, tuberculosis and AIDS combined. The number of deaths recorded from invasive 
S. aureus was double (25 – 50 %) globally prior to the introduction of penicillin (van-Hal 
et al., 2012).  
1.2.1.2.2.2  Enterococcus 
 
Enterococci are a dominant group of bacteria in the intestinal flora of animals and 
humans. It is a Gram-positive bacterium (classified previously as Streptococcus faecalis). 
It is a commensal bacterium which is resistant to most antibiotics used clinically and it is 
implicated for urinary tract infection, pelvic and abdominal abscess (Sharifi et al., 2013). 
-Clinical response rate in 




Enterococcus is associated with nosocomial infections due to its intrinsic resistant 
mechanisms against antibacterial agents as it rapidly acquires antibacterial resistance 
(Kilbas & Ciftci, 2018). Enterococcus have also developed resistance to vancomycin 
(vancomycin-resistant Enterococci). Two species of these bacteria has been identified: 
Enterococcus faecalis and Enterococcus faecium. Again, integrons have been associated 
with Enterococcus faecalis and is essential to the resistance of this bacterium to some 
antimicrobial agents (Deng et al., 2015; Sanchez & Doron, 2017). Many factors are 
responsible for the increase incidence of enterococcal infections such as extensive use 
of broad-spectrum antibiotics, long intensive treatments for haematology–oncology 
patients, increasing numbers of immunocompromised patients and the spread of multi-
resistant enterococci (Devrim, Gülfidan et al. 2015). Enterococci has a natural ability to 
acquire, accumulate and share extrachromosomal elements encoding antibiotic 
resistance genes or virulence traits thus their increasing importance as nosocomial 
pathogens (Klibi, Gharbi et al. 2006) as they do not just cause hospital infections but also 
seen increasingly in community-related infections (Aguş et al., 2006), thus their increasing 
importance as bacterial specie. 
  
1.2.1.2.2.3  Bacillus cereus 
 
Bacillus cereus is a rod-shape, aerobic, Gram-positive haemolytic bacterium. Its toxins 
cause vomiting, nausea and diarrhoea. It causes food poisoning especially from fried rice 
(Tewari & Abdullah, 2015). It is also known as a mesothelic microorganism because it 
can grow at temperature range of 10 – 50 °C (with an optimum growth temperature of 28 
– 37 °C). Only few strains can grow below 7 °C or above 45 °C. B. cereus grows at an 
optimum pH ranging from 6.0 – 7.0 but can still grow at pH range 4.3 – 9.3. Its spores 
survive drying and freezing and are moderately heat resistant. Other strains require heat 
activation for spores to germinate and grow (Tewari & Abdullah, 2015). B. cereus can 
also grow in the intestinal tract of insects and animals, decaying matter, vegetables, 
water, and soil (where toxins can persist) (Garofalo et al., 2017; Osimani et al., 2017). 
Two enterotoxins namely non-haemolytic enterotoxin (NHE) and haemolysin BL (HBL) 
have been identified in B. cereus. These enterotoxins combine to manifest their 
pathogenicity (usually 8 – 16 h after ingestion) (Kumari & Sarkar, 2016). The NHE is the 
cause of food poisoning while the haemolysin BL possesses dermo-necrotic and 
haemolytic activities and can cause accumulation of fluid in rabbit ileal loops (Ghelardi et 
al., 2002) but their mechanism of action is not fully understood (Tausch et al., 2017). It 
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has been reported also that the ATCC 10876 strain harbours both the HBL and NHE 
genes (Sastalla et al., 2013). Nevertheless, infections caused by B. cereus are self-
limiting and have short durations in their host and oftentimes do not present post illness 
treats (Sastalla et al., 2013). In European Member States, 287 cases of B. cereus 
outbreaks have been reported out of a total of 3073 cases (with 8 % hospitalisation) in 
2014. This figure remained relatively constant in 2015 (291 outbreak out of 3131 cases), 
with 3 % hospitalization rate. Other outbreaks (4 out of 17 cases) in Norway and France 
(15 outbreaks) in the same year were also reported (EFSA and ECDC., 2016). These 
outbreaks were traced to B. cereus toxins in mixed foods with almond based food 
accounting for 2 outbreaks and cereal-based food (8 %) (EFSA and ECDC., 2016). 
. 
1.2.2   Antibacterial Drugs 
 
Antibacterial drug is a term referring to a group of drugs that includes antiprotozoal, 
antifungals and antibacterial (Vardanyan and Hruby 2016). The term also includes 
antibiotics (produced by microorganisms). The discovery of sulphonamide was a 
significant milestone event in microbiology due to its activity against both Gram-negative 
and Gram-positive bacteria (Vardanyan & Hruby, 2016). It should be noted that the 
anticancer activity of sulphonamide has been presented in section 1.1.3.1.3. This section 
therefore focuses on the antibacterial activity of sulphonamide. 
The use of antimicrobial agents in treating infectious diseases could be traced to the year 
1910 when herbs and mercury salts were used for this purpose. In the 20th century, 
salvarsan - (hydroxyaniline derivative of arsenic) obtained by screening substances used 
in the dye industry in the year 1910. The next antibacterial agent was sulfa drugs in 1930s. 
On discovery the sulfa drugs acts by inhibiting the folate pathways. Pyrimidine class of 
compounds were optimized in 1960s and used to screen a variety of bacteria, and 
trimethoprim (Structure 1.37) indicated good antimicrobial activity (Silver, 2011). 
However, the discovery of penicillin from Penicillium notatum in 1928 by Alexander 
Fleming brought about a revolution in antibacterial agents as penicillin was the most 
effective treatment against Staphylococcus and other Gram-positive bacteria (Silver, 
2011; Singh & Barrett, 2006). Penicillin was purified in 1940. 
For nucleic acids to be produced, p-aminobenzoic acid is required by certain bacteria for 
the synthesis of dihydrofolic acid (used for nucleic acid synthesis). p-Aminobenzoic acid 
is a key enzyme in folic acid synthesis. Sulphonamides (an antimetabolite), substitutes 
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for p-aminobenzoic acid resulting in inhibition of enzymes needed for synthesis of purine 
bases (Vardanyan & Hruby, 2016). 
                          
Structure 1.37: trimethoprim (Silver, 2011). 
 
Sulphonamides are among the oldest and widely used antibacterial and they inhibit a vital 
enzyme (dihydropteroate synthetase) which converts p-aminobenzoic acid to 
dihydrofolate which is a precursor for tetrahydrofolate formation. Tetrahydrofolate is 
required for the de novo synthesis of purines, thymidylate and some amino acids (such 
as glycine and tryptophan). Inhibition of folate synthesis in bacteria leads to inhibition of 
bacterial growth (Vardanyan & Hruby, 2016). 
Quinolones are synthetic, broad spectrum bactericidal antibacterial agents which inhibits 
the DNA gyrase (topoisomerase II), an enzyme required for the replication of the bacteria. 
Blocking this enzyme leads to inhibition of DNA replication and transcription thus inhibition 
of bacterial growth (Vardanyan & Hruby, 2016). This unique mechanism of bacterial 
growth inhibition by the quinolones birth the synthesis of the nitrofurans (synthetic broad-
spectrum antibacterial drugs) characterised by the 5-nitro-2-furanyl scaffold (Vardanyan 
& Hruby, 2016). The mechanism of actions of the nitrofurans is not fully understood but 
the nitrofurans inhibits bacterial enzymes especially those involved in carbohydrate 
synthesis (Vardanyan & Hruby, 2016), thus inhibition of key bacterial enzymes by the 
quinolones will inhibit bacterial growth and reproduction. 
 
1.2.2.1 Classes of Antibacterial Drugs 
 
Antibacterial drugs are classified into the following classes: Sulphonamides such as co-
trimoxazole (Bactrim) and trimethoprim (Proloprim). Other classes of antibiotics include 
the: aminoglycosides such as gentamycin (Garamycin) and tobramycin (Tobrex), 
tetracyclines such as tetracycline (Sumycin, Panmycin) and doxycycline (Vibramycin), 
fluoroquinolones such as ciprofolxacin (Cipro), levofloxacin (Levaquin), and ofloxacin 
(Floxin), macrolides such as erythromycin (E-Mycin), clarithromycin (Biaxin), and 
azithromycin (Zithromax), cephalosporins such as cephalexin (Keflex) and penicillin such 
as penicillin and amoxicillin (Kapoor, Saigal et al. 2017, Ullah and Ali 2017). Antibacterial 
agents are also classified base on their mode of action into those involved in: i) Inhibition 
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of cell wall synthesis, ii) inhibition of protein synthesis, iii) inhibition of key metabolites 
necessary for survival of pathogen, iii) disruption of cellular homeostasis by disrupting the 
permeability of bacterial cell membrane, iv) alteration of nucleic acid synthesis and v) 
inhibition of bacterial nucleic acid synthesis – Figure 1.8. (Vardanyan & Hruby, 2016; 
Kapoor et al., 2017). 
 
Figure 1.8: Mechanism of action of antibiotics. 
Diagram is an illustration of the classes of bacterial agents involved in inhibition of cell wall synthesis (β-lactams, 
vancomycin), nucleic acid synthesis (folate inhibitors, inhibitors of DNS gyrase, and inhibitors of RNA polymerase) and 
protein synthesis. Inhibitors of protein synthesis are classified into inhibitors of the 50S and 30S sub-units respectively. 
The inhibitor of folate synthesis – sulphonamide, inhibits the conversion of para-aminobenzoic acid (PABA) to 
dihydrofolic acid (DHF A); trimethoprim inhibits the conversion of DHF A to trihydrofolic acid (THF A) (Kapoor et al., 
2017). 
1.2.2.1.1 Inhibition of bacterial cell wall synthesis 
 
Antibacterial agents involved in inhibition of cell wall synthesis include i) the 
cephalosporins – 1st generation – cephalexin, cephazolin, 2nd generation – cefoxitin, 
cefuroxime, 3rd generation – ceftriaxone, cefotaxime, 4th generation – cefepime, ii) 
penicillin: these class of bacteria are grouped based on the relationship between these 
class of drug and its interaction with the bacterial enzymes thus; a) penicillin with beta-
lactase inhibitors – amoxy-clavulanate, b) peniclinase susceptible with activity against 
Gram-negative bacilli – piperocillin, amoxil , ampicillin, c) penicillinase resistance – 
oxacillin, methicillin and d) penicillinase susceptible – pen V and G (Vardanyan & Hruby, 
2016; Ullah & Ali, 2017), iii) carbopenems — meropenem, imipenem, iv) Glycopeptide 
derivatives — bleomycin, teichoplanin and vancomycin (Ullah & Ali, 2017). 
Most antimicrobial agents target the synthesis of bacterial cell wall. However, the 
composition of bacterial cell wall differs from specie to species. By targeting the cell wall, 
antimicrobial agents can kill bacteria whose cell wall is susceptible to these antimicrobials. 
The polymer murein also known as peptidoglycan is an important constituent of the cell 
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wall. Its location and quantity in a bacterial cell wall differ between Gram-positive and 
Gram-negative bacteria. Murein consists of repeating units of N-acetylmuramic acid 
(NAM) and N-acetylglucosamine (NAG) disaccharide subunits. These disaccharide chain 
crosslink with peptide side chains of neighbouring murein units, offering mechanical 
strength to it, and allows for diversity in the biochemical nature of the cross-linkages 
between and within bacterial species (Krishnamoorthy et al., 2017; Mandal et al., 2017; 
McDermott et al., 2003), a diversity exploited by antimicrobial agents. 
Biosynthesis of peptidoglycans proceeds in four stages: 
i) Precursor synthesis in the cytoplasm (Vardanyan & Hruby, 2016). 
ii) Transportation of precursors across the cytoplasm (Vardanyan & Hruby, 2016; 
Krishnamoorthy et al., 2017). 
iii) Insertion of glycan units into the cell wall (Vardanyan & Hruby, 2016). 
iv) Maturation and linking of transpeptIdes (Krishnamoorthy et al., 2017; McDermott 
et al., 2003). 
 
Bacitracin and D-cycloserine inhibits peptidoglycan synthesis at stage 1 and 2 while 
glycopeptides and β-lactams inhibit bacteria at stage 3 and 4.  β-lactam are the most 
common bacterial cell wall inhibitors and include cephalosporins and its derivatives such 
as cefelexin and cefadroxil (Structure 1.38 –  1.40) and penicillin and its derivatives such 
as cloxacillin and ampicillin (Structures 1.41 – 1.43, which binds to transpeptidases 
forming antibiotic-enzyme covalent complexes and generate mature molecule of 
peptidoglycan. For β-lactams to exert antibiotic effect on Gram-negative bacteria, they 
must pass through porins, which are proteins in the cell wall before reaching their targets 
known as penicillin-binding proteins (PBPs) (McDermott et al., 2003). 
                    
 Structure 1.38: Cephalosporin     Structure 1.39: Cefalexin        Structure 1.40: 
Cefadroxil           
                      
   Structure 1.41: Cloxacillin         Structure 1.42: Penicillin          Structure 1.43: 
Ampicillin 
                    (Krishnamoorthy et al., 2017). 
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The ability of antibacterial agents to bind to cell wall transpeptidases depends on the 
agents and PBP involved. Others inhibits the formation of cell walls which easily lyse 
under increased osmotic pressure. 
Some bacteria develop resistance to β-lactams via one or more mechanisms such as: 
i) A change in the porins of cell walls which leads to limitation of movement of the 
antibiotic across the osmotic membrane (Krishnamoorthy et al., 2017; McDermott 
et al., 2003). 
ii) Inactivation of the antimicrobial agent by one or more β-lactamase (McDermott et 
al., 2003; Vardanyan & Hruby, 2016). 
iii) Mutation in the targeted PBP (Vardanyan & Hruby, 2016; Krishnamoorthy et al., 
2017). 
iv) Decreased drug affinity (D'Costa et al., 2011). 
v) Active efflux of antimicrobials mediated by energy-dependent pumps, out of the 
cell (D'Costa et al., 2011).   
 
Gram-negative bacteria exhibit resistance to drugs by the production of β-lactamase, 
which hydrolyse the β-lactam ring, and inactivate the drug.  
  
Structure 1.44: teicoplanin   Structure 1.45: Vancomycin  
(Marrubini et al., 2019)    (Drennan et al., 2018) 
Although many drugs have been developed to overcome β-lactamase-induced drug 
resistance, over time, more β-lactamase isoenzymes have been produced and have been 
able to induce drug resistance in Gram-negative bacteria (Mandal et al., 2017). Another 
group of antimicrobials that are inhibitors of cell wall synthesis are the glycopeptides, 
example teicoplanin (Structure 1.44) and vancomycin (Structure 1.45) which are large 
heterocyclic complexes consisting of heptapeptide backbone, where substituted sugars 
attaches to the heptapeptide backbone (McDermott et al., 2003). Activity of glycopeptides 
are often limited to Gram-positive bacteria and not Gram-negative bacteria as their large 
57 
 
size prevents them from passing across the outer membrane of Gram-negative bacteria 
which are intrinsically resistant. Staphylococcus and Enterococci are the most resistant 
organisms to glycoproteins (McDermott et al., 2003). Beta-lactam antibiotics target the 
penicillin binding proteins (PBPs) (Kapoor, 2017). The β-lactam ring mimics the D-alanine 
portion of peptide chain that normally binds to the PBP which in turn interacts with the β-
lactam ring (Figure 1.9). This interaction prevents the synthesis of new peptidoglycan due 
to unavailability of PBP (Kapoor et al., 2017). 
 
Figure 1.9: Mechanism of action of β-lactam antibiotics 
The penicillin-binding-protein (PBP) is the target of β-lactam antibiotics. The β-lactam antibiotics ring mimics 
the D-alanine portion of peptide chain [link to N-Acetylmuramic acid (NAMA) and N-Acetylglucosamine-6-
phosphate (NAGA)] that normally binds to the PBP which in turn interacts with the β-lactam ring. This 
interaction prevents the synthesis of new peptidoglycan due to unavailability of PBP (Kapoor et al., 2017). 
Absence of the PBP leads to lysis of the bacteria – (Džidić et al., 2008; Kapoor et al., 
2017). A detail description of the mechanism of drug resistance by β-lactam is presented 
in section 1.2.2.2 (below). 
 1.2.2.1.2 Inhibition of key metabolites necessary for survival of 
pathogen 
 
Inhibition of key metabolic steps necessary for bacterial growth and reproduction such as 
heterotrophic metabolism, respiration, fermentation, electron transport and oxidative 
phosphorylation, bacterial photosynthesis, anaerobic respiration and the nitrogen cycle, 
can cause damage to the bacteria, killing it (Jurtshuk, 1996; Mandal et al., 2017). One 
key element required for metabolic processes to occur in bacteria is hydrogen transfer. 
Bacteria require ATP and vitamin B complex as coenzyme for redox reactions, so they 
can grow and multiply. Thiobacillus thiooxidans for instance requires inorganic salts and 
sulphur to grow and multiply. Inhibition of one or more metabolites necessary for bacterial 
growth will therefore lead to bacteria death (Jurtshuk, 1996; Mandal et al., 2017). Some 
antimicrobials also interrupt the methylerythritol-4-phosphate, a precursor for the 
synthesis of isoprenoid. Isoprenoids are key components of the electron transport chain, 
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or as components of quinones, sterols, hormones containing gibberellin, or components 
of membranes (Jurtshuk, 1996; McDermott et al., 2003). Some antibiotics inhibit essential 
cellular processes required for the survival of pathogens. Trimethoprim and 
sulphonamides disrupt the folic acid pathway; a step necessary for production of 
precursors required for DNA synthesis. Trimethoprim targets dihydrofolate reductase, 
sulphonamides binds to and target dihydropteroate synthase. These enzymes act at the 
rate limiting steps required for folic acid production in bacteria. Humans lack the ability to 
produce this important vitamin – folic acid (Serrano-Amatriain et al., 2016). 
 
Structure 1.46: Colistin (Fiaccadori et al., 2016) 
 
 
Structure 1.47: Polymyxin 
       (Serrano-Amatriain et al., 2016). 
1.2.2.1.3 Disruption of cellular homeostasis by disrupting the 
permeability of bacterial cell membrane 
 
Cell membrane is a barrier that regulates and segregates the extracellular and 
intracellular flow of substances and when damaged or disrupted, leakage of essential 
solutes necessary for the survival of the bacteria occurs. The ability of bacteria to keep 
out foreign agents from permeating bacterial membranes is necessary for its survival 
because these bacteria are exposed to extreme conditions of the host environment such 
as extreme pH, hypertonic environment, as well as the body defence agents. Without 
protection, the bacteria will experience stress and die. Because cell membranes exist in 
both prokaryotes and eukaryotes, these classes of antibiotics are poorly selective and 
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could be toxic to mammalian tissues. Clinically, they are mostly applied topically (Serrano-
Amatriain et al., 2016).  
1.2.2.1.4 Alteration of nucleic acid synthesis 
 
For replication to occur in living cells, RNA and DNA play important roles. Some 
antibiotics such as rifampicin, metronidazole and quinolones (Structure 1.48 – 1.50) bind 
to components involved in RNA and DNA synthesis. Others resemble the substrate used 
in DNA synthesis. This way, they bind to and inhibit RNA and DNA synthesis leading to 
bacteria death (McDermott et al., 2003). Generally, antimicrobials involved in disruption 
of RNA and DNA synthesis act by interfering with nucleic acids – e.g. rifamycins 
(Vardanyan & Hruby, 2016). Antibacterial agents which target DNA synthesis could 
thereby kill bacteria, preventing the outspread of bacterial infection. Antibacterial agents 
involved in inhibition of bacterial nucleic acid synthesis include: i) the quinolones – 1st 
generation (not available), 2nd generation (norfloxacin, ciprofloxacin), 3rd generation 
(moxifloxacin), ii) rifampicin, iii) pyrimidine derivatives – trimethoprim, iv) metronidazole 
and v) sulfonamides – Sulfisoxazole, Sulfamethoxazole (Vardanyan & Hruby, 2016). 
   
  
    Structure 1.48: Rifampine  Structure 1.49: Metronidazole Structure 1.50: 
Quinolone 
                                             (Gao et al., 2019). 
 
Some modifications have been made to the first-generation antibacterial agents involved 
in inhibition of the bacterial nucleic acid synthesis such as the quinolone. The insertion of 
fluorine at the C6 position is perhaps important finding which paved way for the 
development of fluoroquinolones whose antibacterial activity was much better than those 
of quinolone (Boteva and Krasnykh 2009). Flumequine was the first fluoroquinolone 
synthesised. It was in use until ocular toxicity was reported. Newer agents with improved 
antibacterial activity were made such as sitafloxacin, sparfloxacin and grepafloxacin. 
These agents were discontinued due to reports of significant phototoxicity (Castro, 
Navarro et al. 2013). The 4th generational quinolones still maintains its broad-spectrum 
antibacterial activities against both Gram-positive and Gram-negative bacteria, yet it also 
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inhibits the growth of anaerobic bacteria (Vardanyan & Hruby, 2016). Their hepatotoxicity 
has been a major drawback to its use (Vardanyan & Hruby, 2016) and should therefore 
be used as a last resort in treating life-threatening infections. 
 
1.2.2.1.5 Inhibitors of protein synthesis 
 
The information in bacterial DNA is used to synthesise the messenger RNA (m-RNA) in 
a process known as transcription (Figure 1.10 below). The ribosome then synthesizes 
proteins from the mRNA, a process known as translation (Kapoor et al., 2017). 
Translation of mRNA into proteins is catalysed by the cytoplasmic factors and ribosomes 
(Kapoor et al., 2017). The bacteria contain the 70S unit which is composed of the 30S 
and 50S ribosomal sub-units (Yoneyama & Katsumata, 2006). By targeting the 30S and 
50S sub-units, antimicrobials inhibit bacterial growth and development (Johnston et al., 
2002). 
Aminoglycosides (AG) are inhibitors of the 30S sub-unit and are positively charged. They 
attach to the negatively charged OM leading to the formation of large pores which allows 
penetration of antibiotics inside the bacteria (Kapoon et al., 2017). The primary target site 
is the ribosome. For AG to enter the ribosome, an energy dependent active bacterial 
transport mechanism is required, allowing AG to pass through the cytoplasmic 
membrane. 
 
Figure 1.10: Site of action of protein biosynthesis inhibitors. 
Transcription of DNA into mRNA which is then translated into protein. This process occurs at the 70S unit 
(consisting of 30S and 50S sub-units) in the ribosome. Inhibition of the 30S or 50S units leads to inhibition 
of bacterial growth. Aminoglycosides and tetracyclines inhibits the 30S unit; Chloramphenicol, macrolide, 
lincosamides, streptogramins and oxazolidonones inhibits the 50S unit (Kapoor et al., 2017). 
 
This process requires oxygen (Kapoon et al., 2017). AG therefore works best in aerobic 
conditions and indicates poor activity against anaerobic bacteria (Kapoon et al., 2017). 
Antibiotics acts synergistically with AG thus inhibiting the synthesis of cell wall (such as 
glycopeptides and β-lactam). 
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Hydrogen bonds enables the interaction between the 16S rRNA and AG. This binding 
leads to misreading and premature termination of mRNA translation (Kapoon et al., 2017). 
Antibacterial agents involved in inhibition of protein synthesis include: i) lincomycins – 
clindamycin, ii) chloramphenicol, iii) Tetracyclines – Tetracycline, Doxycycline, iv) 
macrolides – Erythromycin, Clarithromycin, Azithromycin and v) aminoglycosides – 
Gentamicin, Tobramycin, Amikacin (Vardanyan & Hruby, 2016; Ullah & Ali, 2017). 
Derived from the bacterium Streptomyces venezuelae, chloramphenicol (CAM) is a 
broad-spectrum antibacterial agent which inhibits protein synthesis and was first 
introduced in 1940s (Ehrlich et al., 1947). Due to the suppression of the bone-marrow 
and aplastic anaemia caused by systemic administration of CAM, its use has been 
hampered by its toxicity (Feder-Jr et al., 1981). This limitation has restricted the use of 
CAM to topical administration in treatment of ear and eye infection. The antibacterial 
activity of CAM has been preserved due to its limited use enabling it to exhibit antibacterial 
activity against the MRSA bacterium (Fayyaz et al., 2013).  
Despite the antibacterial activities of antibacterial drugs, intrinsic resistance is common in 
certain groups of bacteria due to their biochemical makeup. Gram-negative bacteria 
therefore contain pumps which efflux macrolides out of the cells as this agent is slowly 
absorbed into the cell thus, they develop intrinsic resistance to macrolides 
(Krishnamoorthy et al., 2017). Other bacteria may lack the target sites of some drugs, 
inhibiting the drug activity. Acquired resistance results from the ability of bacteria to 
develop biochemical mechanism aimed at dealing with a particular drug being 
administered constantly. They do this via enzymes that can modify the activity of the 
antibiotic before it reaches the target site. Several drug modifying enzymes which can 
modify antibacterial agents have been identified such as the β-lactamases which 
hydrolysis cephalosporins and penicillin (Krishnamoorthy et al., 2017; Mandal et al., 
2017). Cell susceptible to antimicrobial agents are easily killed by these agents. 
1.2.2.2 Mechanisms of Antimicrobial Resistance 
 
1.2.2.2.1 Prevention of accumulation of antimicrobials either by 
decreasing uptake or increasing efflux of the antimicrobial 
from the cell 
Drugs can be transferred by diffusion through the lipid bilayers, porins and by self-uptake 
into a bacterial cell. Porins are located in the OM of Gram-negative bacteria, allowing 
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quinolones and β-lactams (small hydrophilic molecules) to cross into the cell. A decrease 
in porin numbers across the OM leads to decreased entry of fluoroquinolone (FQ) and β-
lactam antibiotics (Kapoor et al., 2017). The low OM permeability is responsible for the 
acquired resistance of P. aeruginosa to all antibiotic classes (Kapoor et al., 2017). 
Efflux pumps are membrane proteins in bacteria that are responsible for exporting 
antibiotics out of the cell thus reducing the intracellular concentration of antibiotics (Džidić 
et al., 2008). Efflux pumps ensures antibiotics are pumped out of the cells at a similar 
speed to the rate of entry of the antibiotics into the cells, preventing the antibiotics from 
reaching its target (Wise, 1999). Unlike porins which are present in OM, efflux pumps are 
present in the cytoplasmic membrane (Wise, 1999). With exception of the polymyxin, all 
classes of antibiotics are susceptible to the action of efflux pumps which can act 
specifically to certain antibiotics (Lambert, 2002). Most efflux pumps can pump a wide 
range of unrelated antibiotics (multidrug transporters), including the FQ, tetracyclines and 
macrolides and therefore contribute to multidrug resistant organisms (Dzidic et al., 2008). 
Modification of target molecules is another way bacteria reduces the potency of 
antibiotics. Mutation of bacterial gene could prevent binding of antibiotics thus eliciting a 
massive alteration in the activity of the antibiotics that could either decrease uptake or 
increase efflux of the antimicrobial from the cell (Kapoor et al., 2017). 
i) Altered cell wall precursors: glycopeptides such as teicoplanin and vancomycin can 
inhibit cell wall synthesis in Gram-positive bacteria by binding to the D-alanyl-D-
alanine residues of peptidoglycan precursors, changing it to D-alanyl-lactate thus 
preventing the cross-linkage of glycopeptides, thus development of bacterial 
resistance (Dzidic et al., 2008). 
ii) Alteration in the 30S or 50S sub-units of the ribosome (Figure 1.10) leads to 
resistance of drugs that affects protein synthesis such as the AGs, chloramphenicol, 
tetracycline and macrolides (Lambert, 2002). Streptogramin B, lincosamides, 
macrolides and chloramphenicol bind to the 50S ribosomal sub-unit to suppress 
protein synthesis (Tenover, 2006). E. faecalis and Enterococcus faecium strains are 
resistant to teicoplanin and vancomycin (Giedraitiene et al., 2011). 
iii) Alteration in penicillin-binding protein (PBP): PBP modification confers resistance to 
Gram-positive bacteria while β-lactamase production confers resistance to Gram-
negative bacteria (Kapoor et al., 2017). Mutation of the PBP reduces affinity to β-
lactam antibiotics. The resistance of Streptococcus pneumonia to penicillin and E. 
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faecium to ampicillin is by this mechanism (Alekshun & Levy, 2007; Džidić et al., 
2008). Resistance of S. aureus to oxacillin and methicillin is linked to the integration 
of the staphylococcal cassette chromosome mec – a mobile genetic element, into the 
chromosome of S. aureus. This element contains the mec A resistant gene (Alekshun 
& Levy, 2007; Džidić et al., 2008; Hiramatsu et al., 2001). 
iv) Mutation of the RNA polymerase confers resistance to rifampicin (Kapoor et al., 
2017). 
v) Mechanisms protecting the bacterial ribosomes also imparts resistance to 
tetracyclines (Kapoor et al., 2017). 
vi) Mutation of topoisomerase IV (coded by genes par C and par E) and DNA gyrase 
(coded by genes gyr A and gyr B) leads to FQ resistance (Kapoor et al., 2017; Kim 
et al., 2002).  
 
1.2.2.2.2 Inactivation of Antibiotics 
Three main enzymes are responsible for antibiotics inactivation such as β-lactamases, 
aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferases (AACs) 
(Dockrell et al. 2004). 
β-lactamases hydrolyses the amide and ester bonds of nearly all β-lactams e.g., 
carbapenems, monobactams, cephalosporins and penicillin (Dockrell et al., 2004). About 
300 β-lactamases have been identified and are classified using two classification 
systems; Bush–Jacoby–Medeiros (functional) and Ambler (structural) (Alekshun & Levy, 
2007). Below is a description of the Ambler classification system: 
i) Class A β-lactamases are a class of β-lactamases also known as the penicillinase and 
are susceptible to clavulanic acid (Dockrell et al., 2004; Rice et al., 2003). Class-A β-
lactamases commonly encountered are the penicillinases belonging to the 
Enterobacteriaceae and are designated as SHV-1 and TEM-1; they elicit little or no 
activity against cephalosporin (Rice et al., 2003). These β-lactamases are progenitors 
of extended-spectrum β-lactamases (ESBL) whose amino acid composition has been 
substituted allowing hydrolysis of most cephalosporins. They are resistant to third 
generation cephalosporins (e.g., ceftriaxone, cefotaxime ceftazidime), cefoperazone, 
ceftazidime, ceftriaxone, aztreonam, but are sensitive to methoxy-cephalosporins e.g., 
carbapenems and cephamycin. They are also inhibited by inhibitors of β-lactamases 
such as tazobactam, sulbactam and clavulanic acid (Jacoby & Munoz-Price, 2005; Ma 




ii) Class B β-lactamases are metallo-β-lactamases requiring metals such as zinc for 
catalysis. Their activities are inhibited by chelating agents. They are resistant to 
inactivation by carbapenems e.g., New Delhi metallo-β-lactamase, aztreonam, 
sulbactam and clavulanate (Rasmussen & Bush, 1997). 
 
iii) Class C β-lactamases are also known as cephalosporinases. Except for Klebsiella 
and Salmonella, all Gram-negative bacteria produce the cephalosporinases. Class C 
β-lactamases hydrolysis the extended spectrum cephalosporins (Crichlow et al., 
1999). Class C β-lactamases can bind to bulky extended spectrum penicillin because 
they have large cavities compared to class A β-lactamases which have small cavities. 
Class C β-lactamases include the Amp C β-lactamases. Except the carbapems, the 
Amp C β-lactamases are not inhibited by clavulanate (Lobkovsky et al., 1994). 
 
iv) Class D β-lactamases are found predominantly in P. aeruginosa and 
Enterobacteriaceae, they hydrolysis oxacillin. These enzymes confer resistance to 
methicillin, oxacillin, cloxacillin and penicillin (Naas & Nordmann, 1999). 
 
1.2.2.2.3 Aminoglycoside (AG) modifying enzymes (AMEs) 
Aminoglycosides are neutralised by specific enzymes such as denylyl-transferases, 
nucleotidyl-transferases and phosphoryl-transferases. These aminoglycoside-modifying 
enzymes (AMEs) disrupts binding to the 30S ribosomal subunit thus reducing the affinity 
of antibiotics (Strateva & Yordanov, 2009). AMEs provides extended spectrum resistance 
to FQ and AG. AMEs have been identified in S. pneumonia, E. faecalis and S. aureus 
(Maurice et al., 2008). 
A summary of the various classes of antibacterial drug, their site of action and their 
primary target sites is presented in Table 1.4 below. The mechanism of resistance against 
different classes of antibacterial drugs is presented in Table 1.5. 
 
Table 1.4: Class of antibacterial drugs, site of action and their primary targets 
Antibiotic Class Antibiotic Name Primary Target 
Cell wall synthesis inhibitors 
β-lactams Penicillins [Piperacillin, 
Carbenicillin, Ampicillin, 






Lipopeptides Polymyxin B Disruption of inner and outer membranes 
through binding to lipopolysaccharide (LPS) in 
the outer membrane 
Others Alafosfalin Peptidoglycan units terminal D-Ala-D-Ala 
dipeptide 
Bacitracin 50S-isoprenyl pyrophosphate 
D-cycloserine D-alanine ligase and alanine racemase 
Fosfomycin UDP-N-actetylglucosamine-3-
enolpyruvyltransferase 
DNA synthesis inhibitors 
Fluoroquinolones Nalixidic acid, Ciprofloxacin, 
Levofloxacin, Sparfloxacin, 
Norfloxacin 
Topoisomerase II (DNA gyrase), 
topoisomerase IV 
Sulfonamides Sulfamethazine, Sulfapyridine, 
Sulfamethoxazole, 
Sulfadiazine, Sulfamerazine 
Competitive inhibitor for DHPS involved in 
folate synthesis 
Others Novobiocin DNA gyrase 
RNA synthesis inhibitors 
Rifamycins Rifampicin, Rifabutin, 
Rifaximin 
DNA-dependent RNA polymerase 
Protein synthesis inhibitors 
Tetracyclines Oxytetracycline, Doxycycline, 
Tetracycline, Demeclocycline, 
Minocycline 
30S ribosome (inhibit aminoacyl tRNA binding 
to ribosome) 
Aminoglycosides Tobramycin, Gentamicin, 
Amikacin, Streptomycin, 
Spectinomycin 
30S ribosome (mistranslation by tRNA 
mismatching) 
Macrolides Erythromycin, Clarithromycin, 
Midecamycin, Roxithromycin, 
Spiramycin, Azithromycin 
50S ribosome (stimulating dissociation of the 




50S ribosome (inhibit elongation step) 
Lincosamides Clindamycin, Lincomycin 50S ribosome (stimulate dissociation of the 
peptidyl-tRNA molecule from the ribosomes 
during elongation) 
Pleuromutilins Tiamulin 50S ribosome (prevent correct positioning of 
the CCA ends of tRNA for peptide 
transferase) 
DNA replication (intercalators) 
Anthracyclines Doxorubicin, Epirubicin, 
Idarubicin 
Intercalate DNA/RNA strand topoisomerase II 
Others Actinomycin D Intercalates G-C base pairs and minor groove 
DNA at the transcription initiation complex 
Mithramycin Intercalates GC-rich DNA strands 
Tetracenomycin Intercalates DNA 
Anaerobic DNA inhibitors 
Nitrofurans Furazolidone, Nitrofurantoin Highly reactive reduced form (by nitrofuran 
reductase) 
Nitro-imidazole Ornidazole Damages bacterial DNA 
(Hindler & Kelley, 1986; Peach et al., 2013). 
 



























Destruction of beta-lactam rings by beta-
lactamase enzymes.  With the beta-lactam 
ring destroyed, the antibiotic will no longer 
have the ability to bind to PBP (Penicillin-




penicillin;   
  
Altered target Changes in penicillin binding 
proteins. Mutational changes in original 
PBPs or acquisition of different PBPs will 
lead to inability of the antibiotic to bind to 







Porin channel formation is decreased. Since 
this is where beta-lactams cross the outer 
membrane to reach the PBP of Gram-
negative bacteria, a change in the number 
or character of these channels can 
reduce beta-lactam uptake. 
Resistance of E. 
aerogenes, K. 







Altered target Alteration in the molecular structure of cell 
wall precursor components decreases 
binding of vancomycin so that cell wall 
















Modifying enzymes alter various sites on 
the aminoglycoside molecule so that the 
ability of this drug to bind the ribosome and 
halt protein synthesis is greatly diminished 
or lost entirely. 







Change in number or character of porin 
channels (through which aminoglycosides 
cross the outer membrane to reach the 
ribosomes of gram-negative bacteria) so 
that aminoglycoside uptake is diminished. 
Resistance of a 
variety of Gram-
negative bacteria to 
aminoglycosides 
Altered target Modification of ribosomal proteins or of 16s 
rRNA. This reduces the ability of 
aminoglycoside to successfully bind and 
inhibit protein synthesis 
Resistance 











Alterations in the outer 
membrane diminishes uptake of drug and/or 
activation of an “efflux” pump that removes 
quinolones before intracellular 





mechanism only) to 
various quinolones 
Altered target Changes in DNA gyrase subunits decrease 
the ability of quinolones to bind this enzyme 
and interfere with DNA processes 
Gram-negative and 
Gram-positive 
resistance to various 
quinolones 
(Berger-Bachi, 2002; Forbes et al., 1998; Kapoor et al., 2017). 
 
Modification of side chains of antibiotics could lead to an increase or decrease bioactivity 
or a complete loss of activity. In some instances, modification of a side-chain could retain 
the antibiotic characteristic of a drug as well as improve the solubility, bioavailable or 
safety. In penicillin, the spectrum of antibacterial activity is dependent on a number of 




i) substituting R for NH2 will reduce the polarity of the drug. This implies the drug can 
easily pass through porins leading to an increase bioactivity against Gram-negative 
and Gram-positive bacteria (Nooraldeen, 2016). 
ii) Substituting R for α-COOH will increase the hydrophilicity of the drug and a decrease 
bioactivity against Gram-positive bacteria (e.g. carbenicillin) (Nooraldeen, 2016). 
iii) Acid resistance of α-NH penicillins > α-OH (α-aminobenzylpenicillins > α-
hydroxybenzylpenicillins) (Nooraldeen, 2016). 
 
Table 1.6: Effect of alteration of the side chain of antibiotics on drug activity. 
 
Altering the side-chain of antibiotics could significantly alter its bioactivity, lead to an 
increase in the spectrum of activity and or stability of the antibiotics against enzymatic 
degradation and vice versa (Nooraldeen, 2016). 
 
1.2.3  Fungal infection 
 
Fungus (fungi – plural) were once viewed as crude members of the plant kingdom, just 
marginally more developed than bacterium. However, recent studies indicate that fungi 
are not primitive at all. Studies show that fungi and animals both belong to the group – 
Opisthokonta and they are more firmly identified with animals than they are to plants 
(Carris et al., 2012). Most fungi are heterotrophic in nature (obtain energy from other 
organisms), others are saprotrophs (obtain nutrients from dead matter), whereas some 
are necrotrophs – kill host cells to obtain their nutrients (Carris et al., 2012; Wilson, 2018). 
Thus, fungi are adaptive and can survive in many conditions. 
In humans, mycosis (fungal infection) occur; the most common being dermatophytes-
related mycosis (growths that colonize dead keratinized tissue including toenails, fingers 
and skin) (Carris et al., 2012). Infections such as ringworms are caused by dermatophytes 
and are difficult to treat, others are resident members of normal microflora in healthy 
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humans but become pathogenic in people with reduced immunity. An example is Candida 
specie that causes yeast infections in the mucosal tissues of many healthy people and is 
the cause of candidiasis (red, itchy rash on the skin) in immunocompromised individuals 
and babies (Wilson, 2018). Some fungi are inhaled as spores and initiates infections 
(such as valley fever) only when they get to the lungs, e.g. Histoplasma capsulatum and 
Coccidioides immitis (Carris et al., 2012). Another class of fungal pathogens 
(opportunistic fungi) are normally not associated with animals and humans. However, in 
immunocompromised individuals and in wounds of normal humans, opportunistic fungi 
can cause serious infection (Carris et al., 2012; Wilson, 2018). 
The C. albicans fungus is a lifelong, harmless commensal member of the normal human 
microbiome. However, this fungus can cause infections that range from minor skin rashes 
to life-threatening blood / systemic infections under certain circumstances (Mayer et al., 
2013). Several activities and factors have been identified which contributes to the 
pathogenic nature of this fungus. This include the yeast-to-hypha transition, biofilm 
formation, secretion of hydrolases, molecules which mediate invasion and adhesion to 
the host cells, phenotypic switching and thigmotropism (response of plants to direction, 
physical contact with solid object or touch) (Mayer et al., 2013). In humans, C. albicans 
is causes two main infections – superficial infections, such as vaginal or oral candidiasis 
and life-threatening systemic infections which could spread into vital organs (Wilson, 
2018). C. albicans (up to 75%) is present in the oral cavity and remains benign in normal 
humans but could cause recalcitrant oral cavity infection in immunocompromised 
individuals and can affect the oropharynx and/or the oesophagus of humans with 
HIV/AIDS (and other immunocompromised individuals). Other risk factors include old age 
and wearing of dentures (Mayer et al., 2013; Wilson, 2018). About 75% of all women 
suffer from vulvovaginal candidiasis (VVC) at least once in their lifetime, with 40–50% 
experiencing at least one additional episode of infection (Sobel, 2007). 5-8% of women 
suffer from at least four recurrent VVC per year (Foxman et al., 1998). Hormone therapy, 
pregnancy, oral contraceptives, use of antibiotics and diabetes are some predisposing 
factors associated with VVC (Fidel, 2004). Despite the high morbidity associated with C. 
albicans, superficial C. albicans infections are non-lethal. Nonetheless, systemic 
candidiasis is responsible for high crude mortality rate, even with first line antifungal 
therapy (Pfaller & Diekema, 2010; Wilson, 2018). 




Treatment of fungal infections such as candidiasis is challenging due to limited antifungal 
options in the clinics and with an increase in the incidence of drug resistance, interaction 
and toxicity. There is therefore a need to develop novel antifungal agents to increase 
treatment outcomes in patients with invasive fungal infections such as candidiasis, thus 
this research. The therapeutic strategies for treatment of candidiasis involves treatment 
in a timely manner with an antifungal agent that can overcome the limitation of resistance 
to antifungal agents reported by C. albicans and other fungi (Bassetti et al., 2016). Azoles 
(such as fluconazole, voriconazole, posaconazole, isavuconazole and itraconazole), 
echinocandins (micafungin, anidulafungin and caspofungin) and polyenes (amphotericin 
B) are current therapies in the treatment of candidiasis (Bassetti et al., 2016). Fluconazole 
and echinocandin are first-line treatment options depending on the patient’s condition 
(Arendrup & Patterson, 2017). Antifungal resistance to candidiasis has been reported 
especially in patients with chronic mucocutaneous candidiasis (Nami et al., 2019). Among 
clinical isolates of Candida, C. auris, C. glabrata and C. krusei are least resistant to 
antifungal agents compared to C. albicans (Nami et al., 2019; Arendrup & Patterson, 
2017). C. albicans and C. krusei are emerging global health threat that have caused 
intrinsic multidrug-resistant (MDR) relative to polyenes, triazoles and echinocandins 
(Nami et al., 2019; Vallabhaneni et al., 2017; Borman et al., 2016). The emergence of 
MDR Candida spp., issue of organ transplantation and the concomitant use of 
immunosuppressive drugs have caused problems in the effective treatment of invasive 
candidiasis. This limitation suggests the need for new therapeutic options thus this 
research – the isolation and synthesis of novel agents for the treatment of fungal 
infections associated with C. albicans. Table 1.7 represents some common antifungal 
drugs in clinical use. 
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1.3 Phytochemicals as Anticancer and Antimicrobial Agents 
 
Phytochemicals are sources of important compounds for the treatment of infectious 
diseases and cancer and have become an important area of research for drug discovery 
in handling clinical challenges pose by resistant microorganisms and cancer cells, to 
drugs currently in use. In plants, isoprenoids serve as the backbone from which most 
phytochemicals are biosynthesised via the cytosolic mevalonate (MVA) pathway and the 
2C-methyl-d-erythritol-4-phosphate (MEP) Pathway (Hemmerlin et al., 2012). Some 
phytochemicals (like the flavonoids) are synthesised via the phenylpropanoid pathway 
(Ferreyra et al., 2012). Phytochemicals obtained from natural products have exhibited 
antimicrobial inhibition against clinically resistant microbial strains such as MRSA 
(Sanchez & Doron, 2017), and cancerous growths (Seca et al., 2014), by interfering with 
the internal replication mechanism of the organism. Phytochemicals from natural products 
elicit their bioactivities by modulating various mechanisms in the bacteria or cancer such 
as angiogenesis, apoptosis, metastasis, differentiation and cell proliferation (van de Velde 
et al., 2017; Xuan et al., 2016) or by lysing the bacterial cell wall (Sanchez & Doron, 
2017). The increase in research targeted at developing new chemotherapies for cancer 
and infectious diseases has gained momentum due to the cost effective and less toxic 
effect of phytochemicals. 
1.3.1 The Mevalonate (MVA) and 2C-methyl-d-erythritol 4-phosphate 
(MEP) Pathway Provides Isoprenoid, the Building Block of Most 
Phytochemicals 
 
In plants, isoprenoids (precursors for the synthesis of most phytochemicals) are 
biosynthesised via the MVA pathway in the cytosol (Hemmerlin et al., 2012). Isoprenoids 
are structurally and functionally the most diversified group of metabolites. Over 50,000 
molecules have been identified (Thulasiram et al., 2007). Isoprenoids are dominant 
primary metabolites that functions in respiration, membrane fluidity and photosynthesis. 
As secondary metabolites, they are involved in the plant-pathogen and allelopathic 
interactions (Vranová et al., 2012). Many plant isoprenoids possess pharmacological, 
commercial and agricultural values as drugs, colourants, rubber, polymer and essential 
oils (Vranová et al., 2012). Isoprenoids are derived from isopentenyldiphosphate (IPP) 
which is synthesised by two different pathways in plants (Figure 1.11) – The cytoplasmic 
mevalonate (MVA) pathway and the plastidial 2C-methyl-d-erythritol 4-phosphate (MEP) 
pathway (Vranová et al., 2012; Rohmer et al., 1999). The (MVA) pathway begins with the 
condensation of three units of acetyl-CoA to 3-hydroxy-3-methylglutaryl-CoA (HMG-
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CoA). This is reduced to mevalonate (MVA) and a subsequent phosphorylation steps at 
C-5 of mevalonate. Decarboxylation of mevalonate forms isopentenyl pyrophosphate 
(IPP) (Croteau et al., 2000). IPP is then used to synthesise mitochondrial and cytosolic 
isoprenoids such as sesquiterpene lactones, the side chain of ubiquinone and sterols 
(Vranová et al., 2012). The MEP pathway births plastid isoprenoids derived from IPP 
(Vranová et al., 2012). The first reaction in this pathway involves the condensation of C1 
aldehyde group of D-glyceraldehyde 3-phosphate (GA-3P) with (hydroxyethyl)thiamin 
derived from pyruvate to produce deoxyxylulose-5-phosphate (DXP). Intracellular 
reduction and rearrangement of DXP by DXP reductoisomerase (CPZ) yields MEP which 
is subsequently converted to 2-C-methyl-D-erythritol 2,4-cyclodiphosphate (ME-2,4cPP). 
 
Figure 1.11: Isoprenoid biosynthesis pathway in plants. 
“The MVA pathway occurs in the cytosol. It begins with the condensation of two units of acetyl-coA to 
acetoacetyl-CoA by the enzyme acetoacetyl-CoA thiolase. Condensation of acetyl-coA and acetoacetyl-
coA to form S-3-hydroxy-3-methylglutaryl-coenzyme A. This step is catalysed by 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) synthase. 3-hydroxy-3-methylglutaryl-coenzyme A reductase 
converts 3-hydroxy-3-methylglutaryl-coenzyme A to MVA. MVA is then converted to mevalonate 5-
phosphate via a phosphorylation reaction catalysed by mevalonate kinase. Mevalonate 5-phosphate is then 
converted to mevalonate 5-diphosphate in another phosphorylation reaction catalysed by 
phosphomevalonate kinase. Mevalonate 5-diphosphate is then converted to isopentenyl diphosphate. This 
step is catalysed by the enzyme diphosphomevalonate decarboxylase. Isopentenyl diphosphate 
synthesised from the MVA pathway is the universal precursor of isoprenoids including sesquiterpenes, 
triterpenes, isoprenes, artemisinin, dolichols, monoterpenes, cytokinins, dolichols, polyprenol, ubiquinone, 
prenylated proteins and diterpenes. The MEP pathway occurs in the plastid (green) with the enzymes in 
the MEP pathway as indicated. Enzymes are shown in blue. Substrates and intermediates are shown in 
black. Active components or end-products are shown in red. Arrows between plastid and cytosolic 
compartments indicate metabolic flow between them” (Liao et al., 2016). 
 
This occurs in three steps (catalysed by enzymes). Reduction of ME-2,4cPP produces 
HMBPP in a reaction catalysed by 1-hydroxy-2-methyl-2-butenyl 4-diphosphate (HMBPP) 
synthase (HDS). HMBPP is converted to a mixture of dimethylallyl diphosphate (DMADP) 
and IPP by the enzyme HMBPP reductase (HDR) (Rodríguez-Concepción, 2006). IPP is 
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converted to DMAPP by IPP isomerase (IPPI) which reversibly converts IPP to DMAPP 
(Nakamura et al., 2001). 
Longer chain isoprenoids are synthesised by condensation of IPP subunits (C5) to 
generate linear polymers such as C10, C15, C20 etc. These polymers have defined chain 
lengths. Different classes of isoprenoid compounds are then synthesis from these defined 
chain lengths (Figure 1.11). The synthesis of C10 (Emmerstorfer-Augustin, 2016; Tholl et 
al., 2004; Wang and Dixon, 2009), C20 (Sitthithaworn et al., 2001; Okada et al., 2000), 
C25 (Hsieh et al., 2011), C30 (Emmerstorfer-Augustin, 2016), C35 (Emmerstorfer-
Augustin, 2016; Hsieh et al., 2011), C40 (Bartley et al., 1992; Emmerstorfer-Augustin, 
2016), C45 (Hirooka et al., 2005; Emmerstorfer-Augustin, 2016) and polyprenyls in the 
range of C50–C130 (Cunillera et al., 2000; Oh et al., 2000; Sakaihara et al., 2000;  Ibata 
et al., 1983) has been reported in plants. Isoprene, cytokinins and other hemiterpenoids 
are synthesised from DMAPP (C5). Monoterpenoids are synthesised from geranyl 
diphosphate – GPP (C10). Sesquiterpenoids – from farnesyldiphosphate (FPP; C15). 
Diterpenoids such as tocopherols, phylloquinone, the side-chain of chlorophyll and 
gibberellic acid are synthesised from geranylgeranyl diphosphate (GGPP; C20). 
1.3.2  Phenylpropanoid Pathway for Synthesis of Flavonoids 
 
In plants, two pathways exist for the biosynthesis of flavonoid-based compounds: the 
shikimic pathway and the acetate pathway (Nabavi et al., 2018). The shikimic pathway 
generates the phenyl propanoids (C6-C3) skeleton while the acetate pathway serves as 
the building block for polymeric 2-carbon units (Nabavi et al., 2018). The shikimate 
pathway is a seven-step metabolic route used by plants, algae, fungi, archaea, bacteria 
and some protozoans for the biosynthesis of folates and aromatic amino acids 
(tryptophan, tyrosine, and phenylalanine). Seven enzymes are involved in this pathway 
including DAHP synthase, 3-dehydroquinate synthase, 3-dehydroquinate dehydratase, 
shikimate dehydrogenase, shikimate kinase, EPSP synthase, and chorismate synthase 
(Herrmann & Weaver, 1999). The pathway starts with two substrates, erythrose-4-
phosphate and phosphoenol pyruvate (PEP) and ends with chorismate, a substrate used 
for the synthesis of the aromatic amino acids required for the synthesis of flavonoids. 
The fifth enzyme involved is the shikimate kinase, an enzyme that catalyses the ATP-
dependent phosphorylation of shikimate to form shikimate 3-phosphate. The coupling of 
Shikimate 3-phosphate and phosphoenol pyruvate produces 5-enolpyruvylshikimate-3-
phosphate. This step is catalysed by the enzyme 5-enolpyruvylshikimate-3-phosphate 
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(EPSP) synthase. Claisen rearrangement of chorismate by chorismate mutase leads to 
the synthesis of prephenic acid (not shown). Oxidative decarboxylation of prephenic acid 
gives p-hydroxyphenylpyruvate trans-aminated using glutamate to give α-ketoglutarate 
and tyrosine (Herrmann & Weaver, 1999). An overview of the biosynthetic pathway for 
flavonoids is presented in Figure 1.12. A detailed description of flavonoid chemistry and 
biological activity is presented in section 1.5. In this section, the biosynthesis and 
regulation of secondary metabolites involved in flavonoid synthesis shall be discussed. 











Figure 1.12:  An overview of flavonoids biosynthetic pathway. 
The shikimate pathway links metabolism of carbohydrates to biosynthesis of aromatic compounds. In a 
sequence of seven metabolic steps, phosphoenolpyruvate and erythrose 4-phosphate are converted to 
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chorismate, the precursor of the aromatic amino acids and many aromatic secondary metabolites. All 
pathway intermediates can also be considered branch point compounds that may serve as substrates for 
other metabolic pathways. The shikimate pathway is found only in microorganisms and plants, never in 
animals (Nabavi et al., 2018). 
Flavonoids are a group of phenolic compounds that are constructed from a 15-carbon 
skeleton and composed of two benzene rings (A and B) (Figure 1.20, section 1.5, page 
99), connected by 3-carbon linking chain; thus, they are called the C6-C3-C6 compounds 
(as seen in chalcone) (Ferreyra et al., 2012). In many flavonoids, the linker chain forms a 
further heterocyclic pyrone or pyran ring (C) (Corradini et al., 2011). Cyclisation of three 
malonyl-coA molecules (in acetate pathway) leads to the formation of ring-A. 4-
coumaroyl-CoA are the substrates for the synthesis of ring-B from phenylalanine via the 
shikimate pathway (Nabivi et al., 2018). Chalcones are formed via the condensation of 
rings A and B. The chalcone scaffold serves as the building block from which all flavonoids 
are derived (Ferreyra et al., 2012). The central pathway for the synthesis of flavonoids is 
conserved in plants; however, a group of enzymes, such as Fe2+/2- oxoglutarate-
dependent dioxygenases, hydroxylases, reductases and isomerases modify the basic 
flavonoid skeleton, leading to the different flavonoid subclasses (Martens et al., 2010). 
Isomerase-catalysed cyclisation of rings A and B leads to the formation of flavonone. 
Flavonones are then utilised for the synthesis of other flavonoids (Khoo et al., 2017). This 
biosynthetic pathway is common to all flavonoids with the flavan (2-phenylchroman) 
having the simplest structural units (Figure 1.12). The degree of oxidation and / or 
unsaturation of ring-C leads to structural diversity in flavonoids such as 2-
phenylchromanes (flavan-3,4-diols, flavan-3-ols and flavans), 2-phenylochromones (di-
OH-flavonols, flavanones, flavonols and flavones) and 2-phenylchromenyliums 
(anthocyanins / anthocyanidins) (Khoo et al., 2017).  
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1.4  Inula Species 
 
Inula belongs to the compositae family of which over 100 species have been identified. It 
is widespread in Africa, Europe, and Asia and found predominantly in the Mediterranean 
area (Wang, Gao et al. 2018). Inula helenium is an herb, rigid in nature, and can grow to 
a height of 1.5 meters; with large and toothed leaves, the upper parts embracing the stem 
and the lower part stalked; its flowers are yellowish in colour, about 5cm wide, with many 
petals, each having at its extremity – three notches. The root is mucilaginous, thick and 
branching, bitter to taste, with an odour of camphor, and having sweet floral undertones 
(Amin et al.,   2013; Nikolaev et al., 2006; Rong, 1979). 
 1.4.1  Traditional Uses of Inula Species 
 
Inula has been used in ethnomedicine for decades especially in Chinese medicine. Due 
to their importance in traditional medicine, species such as Inula britannica, Inula 
racemosa and Inula helenium have been used in herbal preparation for commercial 
purposes (Han et al., 2010). Inula helenium has been used in Ventrofit, as an antiulcer 
drug (Nikolaev et al., 2006), and many of these medical applications of Inula have been 
documented in several European pharmacopeias (Trendafilova et al., 2010). Inula 
helenium is thought to be the herb used by Prophet Job who used it in the treatment of 
boils (Al-Gammal, 1998). Hippocrates also wrote that Inula helenium is an effective cure 
for treating skin infections and multiple itching, lung, stomach and head diseases (Al-
Gammal, 1998). Jarić et al. (2011), in his review of medical manuscripts dating back to 
the 12th century reported the usefulness of this herb in the management of dandruff, 
freckles and wounds. The flowers and roots of Inula helenium were used in the treatment 
of bronchitis, emphysema and asthmatic conditions (Ram et al., 2011). 
By using the root of Inula helenium in folklore medicine, the treatment of many ailments 
such as helminthic ailments, infectious diseases, tuberculosis, enterogastritis, 
indigestion, disorders of the lungs, bronchitis, cough and asthma including herpes, 
dermatitis and dark phlegm was achieved (Grimaud, 2009; Gyatso & Hakim, 2010; Huo 
et al., 2010; Huo et al., 2008). In China, Inula have been employed as antibacterial, 
antiemetics, diaphoretics, antitussives and expectorants, antidiabetic, antiulcer agents as 
well as in the cure of bronchitis (Qin et al., 2011). The roots and leaves of Inula cappa are 
utilized as a part of the treatment of jungle fever, hepatitis, dysentery, and arthritis in 
conventional medicine (Wang et al., 2012) as well as abdominal pain, laryngo-tracheitis 
and rheumatism (Zhao et al., 2013; Zou et al., 2008). Recent data suggests constituents 
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of Inula helenium are effective in treatment of atopic dermatitis-like skin infection by 
regulating the expression of cytokines (Wang et al., 2018). 
Inula sasoloides, Inula ammophila and Inula schugnanica have been used in China in the 
treatment of diuresis and fever (Hu et al., 2011). Additionally, other Inula species such as 
Inula asperrima, Inula nervosa, Inula venosa, Inula esquiroli and Inula nitida are used in 
the treatment of rheumatism and stomach problems (Yan et al., 2010). Inula helianthus 
is used in treating cancers of the brain, colon, breast, gastric and oesophagus (Zeng et 
al., 2009). 
Inula racemosa is employed in the treatment of dermal infections, tuberculosis, and used 
as bronchodilators and expectorants (Shishodia et al., 2008). Inula racemosa has been 
used in the management of diabetes (Krishnaraju et al., 2005), treatment of dyspnoea 
and angina, promoting the functioning of the circulatory system, and in the reduction of 
cholesterol (Mahmood et al., 2010; Mangethayaru et al., 2009; Millers, 1998). It is also 
used as an antibacterial agent and in the management of asthma (Vadnere et al., 2009; 
Xu & Shi, 2011). 
Inula obtusifolia and Inula royleana has been used in the treatment of hypertension, used 
as diuretics, expectorants, antiseptics, anthelmintic, stimulants of the nervous system and 
hypotensive agents, as well as infections of the larynx and gastrointestinal system 
(Grimaud, 2009; Haq et al., 2011). 
Additionally, the antiseptic, antipyretic, anti-inflammatory, anti-scabbies, antiphlogistic 
and basalmic activity of Inula viscosa have been documented (Fontana et al., 2007). Inula 
viscosa stem and roots are used in the treatment of catarrh and cough, and as 
expectorants in loosening phlegm from the mucus membrane and has been reported to 
heal over forty diseases in the holy land (Palevitch & Yaniv, 1991; Saad & Said, 2011), 
and in the treatment of infertility and muscle ache in Palestine (Kaileh et al., 2007). 
In Europe and China, Inula britannica, and Inula japonica finds application in the 
management of some tumours, hepatitis, viral infections, inflammation, bronchitis, 
digestive disorders, excessive sputum, hiccup, nausea, acute pleurisy, bronchitis and 
asthma (Khan et al., 2010; Liu et al., 2011; Nam et al., 2009; Zhao et al., 2006). 
With these reports, Inula spp. can be said to be useful as: (ii) bactericidal and fungicidal 
agents in the treating dermatitis, (ii) in the treatment of biliary dyskinesia, (iii) in the 
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treatment of chronic cough, (iv) in the management of obesity and diabetes, (v) and as 
antipruritic agents.  
1.4.2  Isolated Metabolites from Inula 
 
Most bioactive compounds isolated from Inula specie are the sesquiterpene lactone. In 
Inula japonica, sesquiterpene dimers – Inulanolide (Jin et al., 2006), bigelovin (Zeng et 
al., 2009), ergolide (Whan et al., 2001), acetylbritannilactone, (Liu et al., 2007), 
tomentosin, britanin (Lu et al., 2012), and inuviscolide (Rozenblat et al., 2008) have been 
isolated. 
                    
Structure 1.51: Numbering system for sesquiterpene lactones 
 
In Inula britannica, five phytochemicals have been isolated, and they include the 
flavonoids, triterpenes, diterpenes, and sesquiterpene lactones. Sesquiterpene lactones 
are classified into the eudesmanolides, guaianolides, pseudoguaianolides, 
germacranolides, xanthanolides and the dimeric sesquiterpene lactones based on the 
chemical structures of these compounds (Fischedick et al., 2013; Seca et al., 2014). 
Eudesmanolides (Structure 1.52 – 1.53) are the dominating group of metabolites present 
in Inula and the pharmacological activities of Inula are associated with the presence of 
these metabolites and their biological activities include: antibacterial, anticancer and anti-
inflammatory actions (Picman 1986).  
                                                
              Structure 1.52: alantolactone                          Structure 1.53: Isoalantolactone  
Structure 1.52-1.53: basic structure of eudesmanolide (Jiang et al., 2011). 
The following eudesmanolides have been extracted from Inula racemosa root: 11α,13-
dihydroalantolactone, 12-hydroxyeudesmane-5(6)-7(11)-dien-12,8-olide, and other 
hydroxylated eudesmanolides (Zhang et al., 2012; Zhang et al., 2010). 
From the aerial part of Inula hupehensis, 6α-hydroxy-4-epi-septuplinolide, 6α-
hydroxyisoalloalantolactone, and 3-Oxo-6α-hydroxyeudesmane-4(5)11(13)-dien-12-8β-
olide (Qin et al., 2012) have been isolated. Isolated from Inula britannica flowers are 1-
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O-acetylbritanilactone, britanilactone, and 1,6-O,O-diacetyl-britannilactone (Qi et al., 
2008). 5α-epoxyalantolactone, isoalantolactone, alantolactone and 4α,5α-
epoxyalantolactone have been isolated from Inula helenium root (Jiang et al., 2011; 
Konishi et al., 2002). 
 
Figure 1.13: Structures of eudesmanolide derivatives isolated from Inula spp. 
The numbers below the structures corresponds to the compound class and names presented in detail on 
Table 1.8 below. For instance (2) corresponds to 4α,5α-Epoxyalantolactone (Seca et al., 2014). 
 
It therefore implies that the eudesmanolides are very useful sources of sesquiterpene 
lactones since they offer a range of pharmacologic activity which may be useful in clinical 
trials against pathologic conditions. 
Guaianolides (Structure 1.54) have been isolated mainly from the whole parts of Inula 
hookeri and they include: inuchinenolide, 2α-acetoxy-inuviscolide, gaillardin, and 5α-6α-
epoxy-2α-acetoxyl-4α-hydroxyl-1β,7α-guaiane-11-(13)-en-12,8α-olide (Cheng et al., 
2012), and from the aerial part of Inula hurpehensis, and Inula falconeri and they include 
inuviscolide and its analogues, which are potent anti-inflammation agents (Cheng et al., 
2011; Qin et al., 2011).  
 
Structure 1.54: Guanolide – basic structure of guanolide - inuviscolide 
(Abraham et al., 2010; Seca et al., 2014). 
 





Figure 1.14: Structures of guaianolides isolated from Inula spp. 
The numbers below the structures corresponds to the serial numbers on Table 1.8 below (Seca et al., 
2014). 
Pseudoguaianolides (Structure 1.55) have been extracted mainly from Inula hupehensis 
(aerial parts), and Inula japonica, and they include britanin (Lu et al., 2012), ergolide – 
from the leaves of I. falconeri (Cheng et al., 2011), and bigelovin – from the leaves and 
flowers of Inula helianthus (Zeng et al., 2009). Pseudoguaianolides inhibit the production 
of lipopolysaccharide instigated NO in RAW264.7 macrophage. Ethanol fractions of 
extracts from Inula hupehensis strongly inhibited the growth of U937 leukaemia tumour 
cells at very low concentration of 2μM which is supportive of the traditional application in 
the treatment of gastric cancer in China.  
               
   Structure 1.55: Pseudoguainolide       Structure 1.56: Germacranolide 
                                                                       (Seca et al., 2014).   
 
Pseudoguanolides differs from guanolides in the arrangement of carbonyl groups at 
carbon 5, and not carbon 4 (in guanolides). 
 
Figure 1.15: bioactive pseudoguainolides isolated from Inula spp. 




This is the reason Inula extracts acts against inflammation and diabetes (Qin et al., 2011; 
Zeng et al., 2009). Below is a diagrammatic representation of bioactive pseudoguanolides 
isolated from Inula spp 
Germacranolide (Structure 1.56) is known to be an inducer of cytotoxicity to colorectal 
cancer cell line (HCT-116), and HeLa cells (Bai et al., 2006). A notable group of 
germacranolides are the parthenolide extracted from feverfew; it is currently undergoing 
clinical trials for anticancer activities (Ghantous et al., 2013; Jafari et al., 2018). 
Parthenolide (Structure 1.57) is a small molecule, the first of its kind, reported to exhibit 
selectivity against cancerous stem cells (Ghantous et al., 2013). This it does by targeting 
specific signal pathways and destroying tumour cells from its root (Ghantous et al., 2013). 
Other potent bioactive derivatives of parthenolide – such as (±)-7-epi-parthenolide (Li et 
al., 2016) and 9α-hydroxyparthenolide (Zaki et al. 2016) have been synthesised and they 
elicit interesting anticancer activities (Jafari et al., 2018; Seca et al., 2014). Derivatives or 
analogues of germacranolide can be used in treatment of tumours, which is supportive of 
their traditional uses (Hu et al., 2011).  
 
Structure 1.57: parthenolide, a germacranolide. 
   (Kwok et al., 2001; Seca et al., 2014). 
Other germacranolides isolated from the aerial parts of Inula cappa, Inula verbasifolia, 
and Inula japonica include ineupatolide, epoxygermacranolide, acetyl neobritannilactone 
B and eupatolide (Bai et al., 2006; Qin et al., 2010; Wang et al., 2012; Zhao et al., 
2006). Below is a representation of the bioactive germacronolide isolated from Inula 
spp. 
Epoxygermacranolide inhibited the growth of HCT116 cells (Harvala et al., 2002), Hela 
cells were susceptible to inhibition by neobritannilactone B (Bai et al., 2006), whereas 





Figure 1.16: Structures of germacranolides isolated from Inula spp. 
The numbers below the structures corresponds to the serial numbers on Table 1.8 below (Seca et al., 
2014). 
Xanthanolide isolated from Inula hupehensis (tomentosin), elicited interesting response 
on RAW264.7 macrophage. It inhibited RAW264.7 macrophage at (IC50 9.9 μM) and its 
activity was comparable to the control agent aminoguanidine (IC50 7.9 μM) (Qin et al., 
2011).  
 
Structure 1.58: Tomentosin – a xanthanolide 
(Abraham et al., 2010; Seca et al., 2014). 
 
Below are the structures of xanthanolide isolated from Inula spp. 
 
Figure 1.17: Xanthanolides isolated from Inula spp. 
The numbers below the structures corresponds to the serial numbers on Table 1.8 below (Seca et al., 
2014). 
 
Xanthanolide are known to prevent ulcer by its cytoprotective activities on the gastric 
canal of the stomach by preventing sulfhydryl’s nucleophilic attack on the gastric (Favier 
et al., 2005). 
Dimeric sesquiterpenes have been isolated from Inula Japonica and they include: 
inulonide B and inulonide C (Jin et al., 2006; Xu et al., 2015), neojapanicone A, E, F, and 
J (Qin et al., 2010), and their anti-inflammatory potentials reported. Analogues from 
related compounds have shown promising results in their potential usefulness as anti-




Structure 1.59: Japonicone - a dimeric sesquiterpene lactone 
(Hu et al., 2012). 
Recently, a potent sesquiterpene dimer Inulanolide E, and neojaponicone B have been 
isolated from Inula japonica, and tested against Jurkat cell and 6T-CEM cell lines.  
Below are the structures of bioactive dimeric sesquiterpene lactones isolated from Inula 
spp. 
 
Figure 1.18: Dimeric sesquiterpene lactones isolated from Inula spp. 
The numbers below the structures corresponds to the serial numbers on Table 1.8 below (Seca et al., 
2014). 
Both compounds elicited cytotoxicity against Jurkat and 6T-CEM cells (IC50 values 2.5 - 
5.9 µM) (Xu et al., 2015). Japonicone F inhibited RAW 264.7 macrophage, preventing NO 
production induced by LPS (Qin et al., 2010). 
Flavonoids are also present in Inula viscosa and are known for their antioxidant and 
radical scavenging properties and are known to be beneficial in ameliorating disease 
conditions where ROS plays a pivotal role (Nijveldt et al., 2001). 
 
 
R = H Sukuranetin; R = OH 7-O-Methylaromadendrin 
Structure 1.60: Flavonoids from Inula viscosa 




Flavonoids display important biological activities: antibacterial, antioxidants, anti-
inflammatory and anticancer activities. Since flavonoids are known for their wide range of 
activities, it could therefore be stated that the traditional medicinal uses of Inula is 
because of their presence. Flavonoids such as 7-O-methylaromadendrin, 3-
Acetylaromadendrin, sakuranetin have been isolated from Inula britannica and Inula 
viscosa (Seca et al., 2014). 
Below are the structures of bioactive flavonoids isolated from Inula spp. 
 
Figure 1.19: Bioactive flavonoids isolated from Inula spp. 
The numbers below the structures corresponds to the serial numbers on Table 1.8 below (Seca et al., 
2014). 
Other secondary metabolites such as Inulavosin, quinic acid and its derivatives have been 
isolated from Inula crithemoide, Inula nervosa and the roots of Inula hupehensis (Seca et 
al., 2014). 
Table 1.8: Bioactive compounds isolated from Inula specie 
No. Compound class and name Species Parts of plant References 
Eudesmanolides 
1 Alantolactone Inula helenium Roots (Lawrence et al., 2001) 
2 4α,5α-Epoxyalantolactone Inula helenium Roots Jiang et al. (2011) 
3 Diplophyllin Inula helenium Roots 
essential oil 
Stojanović-Radić et al. 
(2012) 
4 5α-Epoxyalantolactone Inula helenium Roots Im et al. (2007) 
5 2α-Hydroxyeudesma-4,11(13)-
dien-12,8β-olide 
Inula racemose Roots Zhang et al. (2012a) 
6 11α,13-Dihydroalantolactone Inula racemose Roots Zhang et al. (2010a) 
7 12-Hydroxy-eudesma-
5(6),7(11)-dien-12,8-olide 
Inula racemose Roots Zhang et al. (2010a) 
8 3-oxo-6α-Hydroxy-eudesma-
4(5),11(13)-dien-12,8β-olide 
Inula hupehensis Aerial part Qin et al. (2012b) 
9 6α-Hydroxyisoalloalantolactone Inula hupehensis Aerial part Qin et al. (2012b) 
10 6α-Hydroxy-4-epi-
septuplinolide 
Inula hupehensis Aerial part Qin et al. (2012b) 




dien-12,8β-olide (also named 
isoalantolactone) 
Inula japonica Aerial parts Wang et al. (2007) 
13 1,6-O,O-Diacetylbritannilactone Inula Britannica Flowers Qi et al. (2008) 
Inula britannicavar Flowers Rafi et al. (2005) 
14 Britannilactone Inula Britannica Flowers Qi et al. (2008) 
Inula britannicava.  Flowers Liu et al. (2009) 
15 1-O-Acetylbritannilactone Inula Britannica Flowers Qi et al. (2008) 









Inula hookeri Whole parts Cheng et al. (2012) 
18 Gaillardin Inula hookeri Whole parts Cheng et al. (2012) 
19 2α-Acetoxy-inuviscolide Inula hookeri Whole parts Cheng et al. (2012) 




Inula hupehensis Aerial parts Qin et al. (2011a) 
22 8-epi-Inuviscolide Inula hupehensis Aerial parts Qin et al. (2011a) 
23 4-epi-Isoinuviscolide Inula hupehensis Aerial parts Qin et al. (2011a) 




Inula falconeri Aerial parts Cheng et al. (2011) 
26 4α,5α-Epoxy-10α,14H-1-epi-
inuviscolide 
Inula falconeri Aerial parts Cheng et al. (2011) 
27 Inuviscolide Inula viscosab Leaves Rozenblat et al. (2008) 
Pseudoguaianolides 





Inula hupehensis Aerial parts Qin et al. (2011a) 
30 Carpesiolin Inula hupehensis Aerial parts Qin et al. (2011a) 
31 Graveolide (2,3-
dihydroaromaticin) 
Inula hupehensis Aerial parts Qin et al. (2011a) 
32 Confertin Inula hupehensis Aerial parts Qin et al. (2011a) 





























Inula hupehensis Aerial parts Qin et al. (2011a) 
40 Britanin (also named britannin) Inula lineariifoliac Aerial parts Nie et al. (2010), 
Inula japonica Flowers Lu et al. (2012) 
Inula aucherianad Not identified Moghadam et al. 
(2012) 
41 2-O-Acetyl-4-epi-pulchellin Inula lineariifoliac Aerial parts Nie et al. (2010) 
42 2-Desoxy-4-epi-pulchellin Inula lineariifoliac Aerial parts Nie et al. (2010) 
43 Aromaticin Inula hookeri Whole parts Cheng et al. (2012) 




Inula hookeri Whole parts Cheng et al. (2012) 
46 Ergolide Inula falconeri Aerial parts Cheng et al. (2011) 




Inula japonica Aerial parts Qin et al. (2010b) 




Zeng et al. (2009) 
Germacranolides 
50 Epoxygermacranolide Inula 
verbascifoliasubsp. 
Methaneae 
Aerial parts Zhao et al. 








Inula montbretianaf Aerial parts 
(with flowers) 
Gökbulut et al. (2012) 
53 Inulasalsolide Inula salsoloides Aerial parts Hu et al (2011) 
54 4α,5β-Epoxyeupatolide Inula salsoloides Aerial parts Hu et al (2011) 
55 Inulacappolide Inula cappa Whole plant Xie et al. (2007) 
56 Ineupatolide Inula cappa Aerial plant Wang et al. (2012) 
57 11(13)-Dehydroivaxillin Inula hupehensis Aerial plant Qin et al. (2012b) 
Inula hookeri Whole plant Cheng et al. (2012) 
58 Acetyl neobritannilactone B Inula britannica Flowers Bai et al. (2006) 
59 Eupatolide Inula japonica Aerial parts Qin et al. (2010b) 
Inula britannicavar. Aerial parts Jin et al. (2006) 
60 9β-Acetoxy-eupatolide Inula hupehensis Aerial parts Qin et al. (2012b) 
61 Isocostunolide Inula helenium Roots Chen et al. (2007) 
62 [1(10)E]-5β-Hydroxygermacra-
1(10),4(15),11-trien-8,12-olide 
Inula racemose Roots Zhang et al. (2012a) 
Xanthanolides 
64 6β-Hydroxytomentosin Inula hupehensis Aerial parts Qin et al. (2012b) 
65 6α-Hydroxytomentosin Inula hupehensis Aerial parts Qin et al. (2012b) 
66 Inuchinenolide A Inula hupehensis Aerial parts Qin et al. (2012b) 
(Seca et al., 2014). 
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1.4.3  Pharmacological and Biological Activities 
 
Some plants have been used as sources of medication in treating ailments and diseased 
conditions (Chinsembu 2016), because most plants (or metabolites isolated from these 
plants) are known to have little or no side effects; they are less toxic/ poisonous when 
compared to synthetic drugs (Ochwangi et al., 2018). Herbal extracts are also known for 
their efficacy in the treatment of several ailments and there are reports on their usefulness 
in the management of several disease conditions both in traditional medicine and in the 
laboratory (Mangethayaru et al., 2009; Greenwell & Rahman, 2015). 
A review of literature of pharmacological activity of extracts and / or pure compounds from 
Inula specie reveals a striking finding; some authors in their report of antibacterial activity 
for instance, did not indicate the dosage and / or plant part used in their study. Others 
only mentioned the fraction (example hexane fraction) indicating the bioactivity without 
mentioning the dosage in which such bioactivity occurred. This noted, a summary of the 
plant part of Inula species, biological activity evaluated, solvent used for extraction and 
the activity of the extract are presented in Table 1.9 below. 
Table 1.9: Summary of the plant part, biological activity evaluated, solvent used for extraction 















, methanol and 
aqueous 
extracts 
The aqueous extract exhibited potent anti-
implantation, mid-term abortion and 









Growth inhibitory effect against SiHa and 
HeLa cell lines respectively harbouring 
HPV16 and HPV18 (IC50 54 and 







The multi-drug resistant clinical isolates 
and reference bacteria were tested, and 
the most susceptible organism was the 
clinical bacteria Pseudomonas 
aeruginosa (MIC 8.0 mg/mL) 







This extract prevents significantly the 
development of hypertension induced by 
L-NAME and showed a dose-dependent 
negative inotropic effect in cardiac muscle 







The extract showed weak cytotoxicity 
against L929sA cell line 
(IC50600±54 µg/mL) 















In Allium cepa test, extract (at 10 mg/mL) 
induced the cell death, ghost cells, cells 
with membrane damage, binucleated 
cells, chromosomal aberrations and 











The tested extract, at a dose of 20 mg/kg 
showed hypoglycaemic activity by 
reducing blood glucose levels, without 
effect on plasma insulin but not affect the 
total cholesterol and triglycerides 
Zeggwagh 







The extract was active 
against Tetranychus cinnabarinus with a 
mortality of 92% at the concentration of 
2 mg/mL 








The extract acts as moderate HSP70 
inducer, with a safe induction index (SI) of 
80 (SI-cell viability (%) at a concentration 
that doubles the expression of HSP70) 
Yamashita 













The water fraction showed the strongest 
antioxidant activity by DPPH 
(IC50 20.7 μg/mL) and ABTS methods 
(IC50 39.4 μg/mL) and it protects the cells 
from HO-induced damage (increasing cell 
survival by 35.0–77.0% at a concentration 
range of 62.5–250 μg/mL and decrease 
intracellular ROS of 34–39%) 











The extract exhibited a weak NO-
production inhibitory activity but a 
histamine-release inhibition of 86% at 
0.1 mg/mL was obtained 






The extract inhibited the OVA-induced 
airway inflammation by reducing the 
leukocyte infiltration, AHR, Th2 cytokines, 
IgE level and mucus hypersecretation 




vitro and in 
vivo) 
Ethanolic extract 
The extract modulates eicosanoids 
generation and degranulation through the 
suppression of SCF-mediated signalling 
pathways 






The Leptinotarsa decemlineata larvae 
was very sensitive to the extract 
(ED500.2 μg/cm2) while Spodoptera 
littoralishad neglectable sensitivity 
























The chloroform extract from flowers/fruits 
showed highest tumour cell-inhibitory 
activity against HeLa (IC50 2.68 μg/mL) 
(cisplatin IC503.73 µg/mL; doxorubicin 
IC500.089 µg/mL) 












The maximum anti-inflammatory effect 
was observed in water extract followed by 










The influenza A and HSV-1 virus were 
inhibited by the extract (IC50 6.50 and 
96.9 µg/mL, respectively) while the extract 
was well tolerated by the host cells of 
virus HeLa, MDCK and GMK 














extracts of each 
plant parts 
Weak but broad activity against a wide 
range of microorganisms, being the 
ethanol extracts of leaves and stem the 
most effective mainly against Bacillus 
subtilis, Staphylococcus 
aureus, Escherichia coli and Candida 
albicans (MIC value of 250–500 μg/mL to 
the extracts, 2.5–50 μg/mL to gentamicin 
and 1.25 μg/mL nystatin) 
Kunduhoglu 













The hexane fraction presented 100% 
inhibitory effect to germination of lettuce 
seeds and hexane subfraction 
demonstrated 13.3 mm of inhibition zone 
at 5 mg/disc against Alternaria 
alternata and Rhizoctonia 
Khan et al. 
(2010c) 
(Seca et al., 2014) 
The leaves extract of Inula viscosa have been reported to induce abortion in rats (in vivo) 
at doses above 626 mg/kg intra peritoneally, confirming its anti-fertility potential as 
previously reported in the traditional uses of aqueous extracts from this plant (Al-Dissi et 
al., 2001). The successful application of extracts from the flowers of Inula viscosa as 
antimicrobial agents in the laboratory has received further boost as its low toxicity on 
human cell lines (202.43 ± 3.70 μg/mL) has been confirmed (Talib & Mahasneh, 2010). 
Lu et al. (2012) stated the anti-inflammatory effect of extracts from Inula Japonica (ethanol 
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extract of the flower, no dosage mentioned), identifying tomentosin and britanin using 
HPLC as the active substances with anti-allergic effects. He stated further that extracts 
from this plant have been employed in treating inflammation, disorders of the gut and 
bronchitis in ethnomedicine. Antibacterial activities of extracts from Inula helenium have 
been reported against a clinical strain of Staphylococcus aureus (O'Shea et al., 2009). In 
his work, O’Shea et al., (2009) tested the antimicrobial activity of extracts of Inula 
helenium against 200 clinical strains of Irish S. aureus isolates consisting of the 
Methicillin-sensitive Staphylococcus aureus (MSSA) and the MRSA. By measuring the 
zones of inhibition, he reported a 100 % inhibition against all bacteria tested, with 93 % 
of these inhibitions falling between the +++ and ++ groups (+++ indicates good bacterial 
inhibition; ++ indicates moderate inhibition). The minimum bactericidal concentration 
ranged from 0.9 – 9.0 mg/mL against all bacteria including the MSSA and the MRSA 
(O'Shea et al., 2009). 
Chloroform extracts from the flowers and fruit portion of Inula ensifolia elicited strong 
cytotoxic and anti-proliferative effects against HeLa cells and this activity was highly 
selective (36%) for dividing cells (Réthy et al., 2007). 
Hexane extracts from the shoots and leaves of Inula specie elicited fungicidal activities 
against the Candida albicans fungus at inhibitory concentration of 10 - 30 µg/mL (Cohen, 
1998; Cafarchia et al., 2003). 
 
1.4.4  Cytotoxic / Antitumour Activity 
 
Sesquiterpenes and other active components extracted from Inula such as Japonicone 
(extracted from Inula japonica) have been reported as possessing anti-tumour and 
cytotoxic activity. This dimeric sesquiterpene - Japanicone elicited potent in-vivo and in-
vitro anticancer activities on Burkitt's lymphoma cells. Another interesting compound 
acetylbritannilactone (from Inula britannica) is known to suppress proliferation of 
abnormal cells of the vascular smooth muscle, inducing cell death (apoptosis) in-vitro. 
Anti-inflammatory activities of britanin – an active component extracted from Inula 
britannica have been reported (Seca et al., 2014; Wang et al., 2014). Sesquiterpenes 
from Inula japonica showed an IC50 value of 2.2 μM, and elicited cytotoxicity against 
Jurkat and 6T-CEM cell lines (Xu et al., 2015). These sesquiterpene lactones known as 
Inulalonide and neojapanicone B are dimers and elicit cytotoxicity at low concentrations 
(Xu et al., 2015). Sesquiterpenes containing α-methylene-γ-carbonyl groups isolated from 
Inula wissmanniana inhibited LPS-induced NO production at 1.04 μM IC50 value in RAW 
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264.7 macrophage (Cheng et al., 2014). The presence of α-methylene-γ-carbonyl groups 
mainly found in guaiane sesquiterpenes is the motif responsible for the anticancer efficacy 
of sesquiterpenes as seen in parthenolide, thapsiagargin and artemisinin of which some 
have been proposed for clinical trials because they tend to be selective against cancers 
and tumour stem cell (Ghantous et al., 2010; Lu, 2002). One important feature of 
sesquiterpene lactones which gives them advantage over some other compounds is their 
ability to elicit cytotoxicity against drug resistant and sensitive cell lines. Isolated 
sequiterpenes from Inula britannica elicited this cytotoxic effect (Fischedick et al., 2013). 
Several isolates from Inula specie have been tested and found useful in the treatment of 
leukaemia cells (Cragg et al., 2006), of which sesquiterpenes have been reported as 
potent anticancer agents (Réthy et al., 2007; Zeng et al., 2009). Some products isolated 
from Inula species have shown anticancer activities against some cell lines such as MCF-
7, HeLa, HL-60 and H549 (Seca et al., 2014) of which some have shown IC50 values lower 
than 10 μM which is comparable with those of conventional drug daunorubicin, and others 
have been shown to be effective against the leukaemia U-937 cell line (Seca et al., 2014). 
Japonicone A69 isolated from Inula is more potent than doxorubicin (DOX) against 
cancerous cells from lymphoblast leukaemia cells (CEM), colon LOVO and MDA-MB-435 
(Table 1.10). Some studies have reported the cytotoxicity of extracts from Inula britannica 
(Qi et al., 2008) and inhibition of cancer growth in K-562, 293T, SGC-7901 and B16 cells 
(Zeng et al., 2009). However, one important point to note is that in these studies, neither 
the detailed mechanisms of action nor the controls used for validation were reported. 
Future research needs to be done to confirm their cytotoxicity and their mechanisms of 
action (Seca et al., 2014). A confirmation on some of the signalling pathways proposed 
by some research on the mechanism of action of these isolated agents; such as induction 
of apoptosis, JNK/MAPK signalling pathway activation, and activation of ROS (Pan et al., 
2007), need to be verified. Some findings in the research of Inula species seems 
promising but some of these findings needs to be confirmed as some did not indicate the 
composition, purity and IC50 values of the extracted compounds (Seca et al., 2014). 
Some secondary metabolites isolated from Inula species (Table 1.10) are more cytotoxic 
than conventional cancer therapeutics (Jordan et al., 1991a; Liu et al., 2005; Nathan et 
al., 2012). An isolated compound extracted from Inula britannica; acetylbritannilactone 
and its synthetic analogues exhibited stronger cytotoxicity against Bel-7402 and HL-60 
cell lines (Liu et al., 2004). Despite the good cytotoxic activity of acetylbritannilactone and 
its synthetic analogues against cancer cell lines, the researcher did not mention any 
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positive control used for this experiment. The cytotoxicity of these compounds could be 
due to the activities of (HO)-1 group of heme oxygenase which is responsible for mopping 
oxidants, which are the agents responsible for the onset of many disease conditions. 
Sesquiterpene lactones have the structural unit called α-methylene-γ-butyrolactone (CH-
BL), which can interact with these oxidants (Jeong et al., 2007). Therefore, the CH-BL 
backbone of sesquiterpenes is responsible for the cytotoxic activities elicited by them 
(Jeong et al., 2007). This is important, as the level of activities reported in sesquiterpene 
lactones is greatly dependent on the activities on the C-6 substitution (Seca et al., 2014). 
Cytotoxicity therefore depends on the substituted groups, their structures, and point of 
attachment (Seca et al., 2014). This finding seems to be different from sesquiterpene 
lactone group known as the pseudoguaianolides. Cytotoxicity elicited by 
pseudoguaianolides was stronger in HepG2, HeLa, MGC-803 and PC cell lines compared 
to cytotoxicity elicited by other groups of sesquiterpenes, implying that the α,-β-
unsaturated cyclopentenones units but not the (CH-BL), is responsible for the cytotoxicity 
of the pseudoguaianolides (Seca et al., 2014). 
Tomentosin and inuviscolide isolated from Inula viscosa leaves elicited anticancer 
activities against 1363-mel, 624-mel and SK-28 melanoma cell lines. These isolated 
compounds caused the cell cycle arrest at the G2/M phase of the cell cycle, followed by 
a subsequent appearance of G0; an indication of apoptosis. This also altered the matrix 
metalloproteinases (MMP) which is caspase 3 dependent (Rozenblat et al., 2008). 
Inhibition of phosphorylation was observed at Tyr15 and Thr14 (of MMP), leading to a 
subsequent inhibition of the p53 anti-apoptosis protein of NF-kB (Rozenblat et al., 2008). 
Bigelovin elicited strong inhibitory activities against the K-562, 293-T, B-16, and SGC-
7901 cells (IC50 value 3 µM). An interesting result was seen which showed inhibitory 
activities at IC50 value of 0.47 µM against the histiocytic lymphoma (U937) cell line (Zeng 
et al., 2009). The mechanism of action of bigelovin includes arresting the cell cycles at 
G0/G1 stage, apoptosis induction (Gach & Janecka, 2014; Zeng et al., 2009), and 
inactivation of JAK2 via inhibition of STAT3 signalling (Zhang et al., 2015).  
It appears that solvents play very important roles during extraction of phytochemicals from 
Inula as the hexane fraction elicited a significant activity against cell growth compared to 
the methanol extract. Hexane fraction was found to solubilise seven fractions from Inula 
species which elicited antiproliferative action against B16F10, Hela and MK-1 cell lines 
(Konishi, Kondo, & Uchiyama, 2008). Others have reported that cytotoxicity elicited by 
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petroleum ether extract, or methanol extracts at ratios ranging from 50-70% (solvent: 
water) ratio showed the most profound cytotoxicity (Attard & Cuschieri, 2009; Ojha et al., 
2010) in Inula crithmoides. The ability of extracts from Inula crithmoides in counteracting 
oxidative stress in ochratoxin A, preventing kidney and liver damage, and thereby 
protecting these organs against mutagenesis has been reported (Abdel-Wahhab et al., 
2008). 
Some compounds extracted from Inula specie such as helenin – containing a mixture of 
60% isoalantolactone and 40% alantolactone is more potent in the inhibition of the Raji 
lymphoblastoid cells when compared to conventional drugs such as fluorouracil and 
cyclophosphamide, an activity comparable to that of methotrexate (Spiridonov et al., 
2005). 1-O-acetylbritannilactone at very low IC50 values of 2.91 to 6.78 µM elicited 
cytotoxicity against HeLa, HCT116 and HepG2 cells in vitro. This was comparable to 
cytotoxicity indicated by the standard anticancer drug – etoposide (IC50 2.13 to 4.79 µM). 
Cytotoxicity of compounds isolated from plants are often selective against normal cells 
(Spiridonov et al., 2005). 1,6-O,O-diacetylbritannilactone (OABL), an analogue of 
acetylbritanilactone (ABL) isolated from Inula britannica showed cytotoxicity which was 
about ten times more potent than that elicited by ABL in MCF-7 and HL-60 cells (Bing-
Nan et al., 1993;  Liu et al., 2004). Semi-synthetic analogues of ABL elicited cytotoxicity 
against HeLa, HepG2 and HCT 116 cell lines. Insertion of a 12-carbon lauroyl group on 
the 6-OH increased the cytotoxicity of these compounds (Dong et al., 2014). 
The proposed mechanism of action of OABL is apoptosis associated with activation of 
caspases 3, 8 and 9, elevation from the mitochondrial compartment of cytochrome C in 
HL-60 cell line (Pan et al., 2007). This enhanced activity of OABL is linked with the 6-
hydroxy group (6-OH) at C-6 which makes this compound highly lipophilic (Dong et al., 
2014; Liu et al., 2005). This increased activity is also potentiated by the availability of α-
methylene-γ-lactone, an electrophilic moiety which has ability of binding to the thiol 
groups of proteins or can acts as an alkylating agent, and by inducing the fragmentation 
of DNA and apoptosis which is thought to occur due to depletion of glutathione in cells 
(Amslinger, 2010; Dong et al., 2014). Mechanisms of anticancer action of 5α-
epoxyalantolactone and alantolactone isolated from Inula species include: induction of 
glutathione transferase (GST), quinone reductase and other detoxifying enzymes such 
as heme oxygenase, glutathione reductase and glutamylcysteine synthase which was 
reported in methanol extract of Inula species (Seo et al., 2008). This induction occurs via 
the potentiation of JNK and PI3K signal pathways, resulting into the efflux of Nrf2, and a 
94 
 
resultant encoding of ARE and Nrf2 (Seo et al., 2008), an activity regulated by (HO-1) 
which inhibits phosphorylation of IkBα and NF-Κb in RAW264.7 cells activated by LPS 
(Park et al., 2013).  Anti-mutagenic effects are also responsible for cytotoxicity of 
compounds isolated from Inula. 
Lawrence et al., (2001), reported the isolation of alantolactone and isoalantolactone from 
the roots of Inula helenium. Extraction was done using methanol and the brown root 
extracts were partitioned using chloroform, ethyl acetate and hexane. Alantolactone and 
isoalantolactone isolated from the hexane fraction indicated very good cytotoxic activity 
against K562 cell line with IC50 0.7 and 1.2 μM. In a Michael type amine addition reaction 
of isoalantolactone and alantolactone, Lawrence et al. (2001) targeted the α-methylene 
lactone ring which they reported is responsible for the cytotoxic activity of these 
sesquiterpene lactones. Several derivatives of α-methylamino lactone were synthesised 
and screened against K562 cell lines. The diethylamine adduct of isoalantolactone 
possessed similar cytotoxicity IC50 2.0 μM, and the ethylamine adduct of alantolactone 
indicated a similar cytotoxicity IC50 0.7 μM, to the parent compound – alantolactone. 
These amines induced apoptosis by acting as alkylating agents. Due to the promising 
anticancer activities of alantolactone (AL) and isoalantolactone (IAL) isolated from Inula, 
in vivo studies on the metabolism of alantolactone and isoalantolactone has been 
investigated by (Zhou et al., 2018) who reported the conjugation of glutathione (GSH) to 
these compounds. Non conjugation with cysteine (Cys) was also observed giving rise to 
four metabolites: IAL-Cys, IAL-GSH, AL-Cys and AL-GSH; an indication that the thiol of 
Cys and GSH reacts with the α,β-unsaturated carbonyl (exomethylene carbon) of IAL and 
AL. When injected into rats, the bioavailability of these metabolites (IAL, IAL-GSH, IAL-
Cys) and (AL, AL-GSH, AL-Cys) was 13.07 % and 8.39 %, to parent compounds IAL and 
AL are (1.88 %) and 2.32 % respectively. This finding indicates the bioavailability of AL 
and IAL when administered orally. AL and IAL metabolism in-vivo is mainly via the 
biotransformation of AL and IAL by addition of thiol groups at C11 and C13, confirming 
the bioavailability of these compounds in vivo (Yao et al., 2016). 
Anti-proliferation and cytotoxicity of compounds isolated from Inula was via induction of 
apoptosis through various channels such as: 
i) Blockage of Nf-kB signal pathway in Jurkat thymus cells as exemplified by ergolide 
and inuviscolide on SK-28 melanoma cells (Rozenblat et al., 2008). 
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ii) DNA damage and denaturation as elicited by alantolactone in HepG2, inuviscolide 
and tomentosin in SK-28 cells by alkylation of DNA which subsequently leads to 
activation of the kinases and a resultant cell cycle arrest at G2/M (Rozenblat et al., 
2008; Lei et al., 2012). 
iii) A decrease in survivin level; a member of a family known as inhibitors of 
apopotosis (Zhiqin et al, 2014 ) via Cyt-C discharge, splitting of ADP ribosyl-
polymerase and caspase activation of 1,6-O-diacetylbritannilactone in U87 and 
HL-60 cell lines (Pan et al., 2007; Khan et al., 2012). 
iv) Activation of JNK and MAPK, and release of ROS (Pan et al., 2007; Khan et al., 
2010). 
v) Alantolactone and isoalantolactone elicits cytotoxicity by acting as alkylating 
agents (Lawrence et al., 2001). 
A summary of the anticancer activity of purified compounds isolated from Inula species 
are presented in Table 1.10 below: 
Table 1.10: Summary of anticancer activity of purified compounds isolated from Inula species 
Cell line Compounds IC50values (IC50to positive control) References 
B16F10 1 (Structure 1.52), 4 (Fig 1.14) 3.6–4.7 µM (5-Fluorouracil 1.1 µM) Konishi et al. (2002) 
MK-1 1 (Structure 1.52), 4 (Fig 1.14) 6.9 µM (5-Fluorouracil 19.2 µM) Konishi et al. (2002) 
T47D 13 (Figure 1.14) 7.50 µM Rafi et al. (2005) 
PA-I 13 (Figure 1.14) 8.00 µM Rafi et al. (2005) 
OVCAR 13 (Figure 1.14) 10.00 µM Rafi et al. (2005) 
DU-145 13 (Figure 1.14) 10.00 µM Rafi et al. (2005) 
DUPro-I 13 (Figure 1.14) 5.00 µM Rafi et al. (2005) 
DUPro-I 15 (Figure 1.14) 10.00 µM Rafi et al. (2005) 
MCF-7 13 (Figure 1.14) 5.00 µM Rafi et al. (2005) 
MCF-7 15 (Figure 1.14) 10.00 µM Rafi et al. (2005) 
MCF-7 44 (Figure 1.16) 9.1 µM Park and Kim (1998) 
MCF-7 85 (Figure 1.20) 
5.87 µg/mL (Vincristine sulfate 
10.03 µg/mL, SI >17) 
Talib et al. (2012) 
Malme3 44 (Figure 1.16) 8.3 µM Park and Kim (1998) 
HeLa 1 (Structure 1.52), 4 (Fig 1.14) 6.5–6.9 µM (5-Fluorouracil 12.3 µM) Konishi et al. (2002) 
HeLa 48 (Figure 1.16) 5.5 µM (DOX 0.4 µM) Cheng et al. (2012) 
HeLa 55 (Figure 1.17) 1.2 μM Xie et al. (2007) 
K-562 55 (Figure 1.17) 3.8 μM Xie et al. (2007) 
KB 55 (Figure 1.17) 5.3 μM Xie et al. (2007) 
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Cell line Compounds IC50values (IC50to positive control) References 
Jurkat T 46 (Figure 1.16) 3.56 µM Song et al. (2005) 
AGS 58 (Figure 1.17) 5.4 µM Bai et al. (2006) 
HL-60 56 (Figure 1.17) 1.50 μM (DOX 0.059 μM) Wang et al. (2012) 
HL-60 46, 48 (Figure 1.16) 2.7–5.6 µM (DOX 0.15 μM) Park and Kim (1998) 
HCT-116 50 (Figure 1.17) 0.39 μg/mL (Daunorubicin 0.28 μg/mL) Chin et al. (2009) 
HCT-15 44 (Figure 1.16) 8.7 µM Park and Kim (1998) 
HepG-2 40 (Figure 1.16) 2.2 µg/mL 
Moghadam et al. 
(2012) 
HepG-2 61 (Figure 1.17) 2.0 µg/mL Chen et al. (2007) 
HepG-2 
43, 44, 45, 48, (Figure 
1.16); 57 (Figure 1.17) 
2.5–4.1 µM (DOX 0.2 µM) Cheng et al. (2012) 
PC-3 
16 (Figure 1.15), 43, 44, 45, 48 
(Figure 1.16) 
1.3–2.9 µM (DOX 0.3 µM) Cheng et al. (2012) 
PC-3 30 (Figure 1.16) 8.7 µM (DOX 0.3 µM) Cheng et al. (2012) 
MGC803 43, 44, 48, (Figure 1.16) 1.0–1.4 µM (DOX 0.3 µM) Cheng et al. (2012) 
MGC803 
16, 17, 18, 19, 20 (Figure 
1.15), 30, 31, 45, 46 (Figure 
1.16), 68 (Figure 1.18) 
6.5–10.1 µM (DOX 0.3 µM) Cheng et al. (2012) 
U-937 48 (Figure 1.16) 0.47 μM Zeng et al. (2009) 
A-549 40 (Figure 1.16) 3.5 µg/mL 
Moghadam et al. 
(2012) 
 
1.4.5  Antimicrobial Activity of Inula 
 
Ethanol extracts from Inula crithemoides and Inula helenium have shown inhibitory 
activities against a range of bacterial and fungal species. Extracts of Inula species 
showed potent activities against all the tested bacteria - Staphylococcus aureus, 
Escherichia coli, Enterococcus faecalis, Bacillus cereus, and Bacillus subtilis (Diguţă et 
al., 2014; Jallali et al., 2014), and also on anaerobic bacteria such as Porphyromonas 
gingivalis, Parvimonas micra, Fusobacterium nucleatum and Prevotella intermedia at a 
MIC (minimum inhibitory concentration) range of 0.06 -10.00 mg/mL, and also inhibited 
oral bacteria (Karygianni et al., 2014). This is an indication that Inula species may be 
employed as anti-bacterial agents considering the wide range of activities reported by 
these researchers. The thymol derivatives from Inula hupehensis elicited strong anti-
fungal activities against pathogenic fungi of plants in Rhizoctonia solani, Peronophythora 
litchi and Phytophthora melonis at very low concentrations (EC50 157, 141, and 180 μg/ 
mL) (Zhao et al., 2010). 
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Studies on alantolactone (ALA), and isoalantolactone (IAL) reveals its antibacterial 
activities are comparable to that of streptomycin, against B. cereus, P. aeruginosa and 
Shigella dysenteriae (Lokhande et al., 2007). Lokhande et al., (2007) reported a zone of 
inhibition of 21 mm (ALA), 17 mm (IAL) and 27 mm for streptomycin against B. cereus; 
21 mm (ALA), 18 mm (IAL) and 28 mm for streptomycin against P. auruginosa and 16 
mm (ALA), 12 mm (IAL) and 24 mm for streptomycin against S.  Shigella dysenteriae. 
The mechanism of eliciting this effect is not known (Lokhande et al., 2007), and 
isoalantolactone inhibited the expression (at very low concentration of 8 µg/mL) of α-toxin 
in S. aureus (Qiu et al., 2011). Alantolactone can elicit a more potent antibacterial effect 
if combined with another agent. For instance, a combination of alantolactone, 
isoalantolactone and diplophylin elicited a potent inhibition against S. aureus at MIC 20 
µg/ml (Stojanović-Radić et al., 2012). Another isolate from Inula, 4α,5α-
epoxyalantolactone elicited a more potent inhibitory activities (MIC 15.5 µg/mL) when 
compared to ampicillin (MIC, 25.0 µg/ml) against Bacillus aureus (Jiang et al., 2011), an 
activity attributed to the presence of the methylene ring on the alantolactone (Jiang et al., 
2011). 
Some isolates such as epoxyalantolactone were more potent than ampicillin against a 
strain of Bacillus cereus (Jiang et al., 2011). Alantolactone, isoalantolactone and 
diplophyllin have been identified as the agents eliciting activity against Staphylococcus in 
essential oils extracted from the roots of Inula helenium (Stojanović-Radić et al., 2012). 
Quercetin and its derivatives were found to elicit antimicrobial activity against 
Mycobacterium tuberculosis, Salmonella typhimorium and Bacillus cereus by inhibiting 
isocitrate lyase, and damaging the cell walls of bacteria and the cytosolic membrane in 
Salmonella typhimorium and Bacillus cereus (Shukla et al., 2015; Talib et al., 2012). 
Anti-fungal activity of tomentosin has been reported against Trichophyton 
mentagrophytes, Microsporum gypseum, and Microsporum canis at concentration of 1 
mg/ml (Cafarchia et al., 2001), whereas isoalantolactone has been used against the fungi 
Candida albicans, Geotrichum candidum, Aspergillus niger, Candida tropicalis and 
Aspergillus flavus at doses of 25, 25, 50, 25 and 50 μg/mL (Tan et al., 1998), as well as 
Plasmopara viticola, a fungus which causes mildew (Cohen et al., 2006). 
Most of the antibacterial activities on isolates from Inula were carried out on mixtures or 
impure compounds (Seca et al., 2014). Purification of isolates before application on 
98 
 
bacterial strains is therefore necessary to further confirm the pharmacological activities 
of extracts from Inula. 
Even though over 100 species of plants belong to the genus Inula, only very few of these 
species have been characterised chemically. The species characterised mostly include 
Inula japonica, Inula racemosa, Inula britannica, Inula hupehensis and Inula viscosa. 
There is therefore a need to study the anticancer – against cancer cell lines such as Caco-
2 etc., and physiological conditions such as hypoxia (which has not been previously 
investigated) and antimicrobial activities of Inula helenium. Investigation of the anticancer 
activity of sesquiterpene lactones isolated from Inula helenium against the leukaemia cell 
line (K562) during physiological conditions such as hypoxia and hypoglycaemia, could 
offer insight into the subject matter of the potential use of these sesquiterpene lactones 
against cancers in low oxygen concentrations and in hyperglycaemic conditions such as 
cancers associated with diabetes. This area has not been investigated despite the 
significant cytotoxic inhibition of the leukaemia cell line (K562) reported by Lawrence et 
al., (2001). There also reports of isolation of bioactive flavonoids with significant 
anticancer activities in some Inula species but not in Inula helenium. A review of the 
literature suggests there are flaws in the extraction and purification techniques used in 
extraction of bioactive compounds from Inula helenium as no author reported the use of 
the centrifugation technique (as a pre-purification technique) prior to the use of high-
performance liquid chromatography (HPLC). This could aid in the isolation of compounds 
which may be present in traces or small quantities.  
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1.5  Flavonoids 
 
Flavonoids are a group of substances, naturally occurring, with various phenolic ring 
structures, usually found in wine, tea, flowers, stems, roots, barks, grains, vegetables and 
fruits and have beneficial health effects. Due to their beneficial health effects, isolation of 
phyto-active compounds from flavonoids has been made, and flavonoids are 
indispensable components of cosmetics, medicines, pharmaceuticals and nutraceuticals 
due to their anti-carcinogenic, anti-mutagenic, anti-inflammatory and anti-oxidative 
properties, and their ability to modulate key enzymes involved in cellular functions 
(Panche et al., 2016). Flavonoids are also inhibitors of many enzymes such as 
phosphoinositide 3-kinase, lipoxygenase, cyclo-oxygenase and xanthine oxidase and are 
classified into several subgroups such as isoflavones, flavonols, flavones and chalcones, 
depending on the C ring carbon on which the B ring attaches to, the oxidation of the C-
ring and the degree of unsaturation (Panche et al., 2016). 
 
Figure 1.20: Flavonoids – classes of flavonoids and their skeletal structure. 
Flavonoids are classified into flavones, flavonols, isoflavones, flavonols, chalcones and anthocyanins 
(Panche et al., 2016). 
Isoflavones are flavonoids where the B ring is linked to the C ring in position 3. 
Neoflavones occur when the B ring is linked to the C ring in position 4. When the B ring 
is linked to the C ring in position 2, several subgroups of flavonoids results, and they are 
grouped base on the structural features on the C ring, giving rise to chalcones, 
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anthocyanins, catechins or flavanols, flavanonols, flavanones and flavonols (Figure 1.20) 
(Panche et al., 2016). 
 
1.5.1  Classification 
1.5.1.1 Flavanones  
 
Flavanones also known as dihydroflavones, are present mostly in citrus fruits – grapes, 
lemons and oranges, giving the peel and juices from citrus fruit a bitter taste. Eriodictyol, 
naringenin and hesperitin are examples. Theses flavanones exert cholesterol-lowering, 
blood lipid-lowering, anti-inflammatory and antioxidant effects. Their C ring is saturated, 
and the double bond between position 2 and 3 is saturated unlike in flavones where they 
are unsaturated (Iwashina, 2013). 
 
Figure 1.21: Flavonoid natural sources, classes and subclasses 
(Panche et al., 2016). 
1.5.1.2 Flavones 
Flavones are found mainly in the fruits, flowers and leaves of glucosides. Ginkgo biloba, 
mint, chamomile, red peppers, parsley and celery are rich in flavones. Tangeritin, 
apigenin and luteolin are examples of flavones (Figure 1.21). Flavones have a ketone in 
position 4 of the C ring and a double bond between position 2 and 3. Sinensetin, nobiletin, 
tageretin, chrysin and polymethoxylated flavones are also found in the peels of citrus. 
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Other flavones have a hydroxyl group in position 7 of the ring A, others in position 5 of 
the ring A, or the 3’ and 4’ position of ring B (Panche et al., 2016). 
1.5.1.3 Flavonols 
 
Flavonols contain a ketone group and provides the building block for proanthocyanins 
and are abundant in some vegetables and fruits such as berries, grapes, apples, 
tomatoes, lettuce, kale and onions. 
 
Figure 1.22: Bioactive roles of flavonoids. 
Bioactive roles of flavonoids include; inhibition of NF-kB activation, anti-inflammatory, antimicrobial, 
antimutagenic, anticarcinogenic etc. (Panche et al., 2016). 
 
Flavonols include fisetin, myricetin, quercetin and kaempferol (Figure 1.21) which are 
potent antioxidant agents. Unlike flavones, hydroxyl group is attached to position 3 of ring 
C. Glycosylation may also occur at this position 3. Due to the numerous glycosylation 
pattern observed in flavonols, they are the largest group of flavonoids known (Iwashina, 
2013; Panche et al., 2016). 
 
1.5.1.4 Chalcones 
Chalcones lack ring C of flavonoid skeleton (Figure 1.21) and a sub-class of flavonoids. 
Chalcones include chalconaringenin, phloretin, arbutin and phloridzin (Figure 1.21). 
Chalcones are present in wheat bearberries, strawberries, pears and tomatoes. 
Chalcones are known to be potent anticancer, antioxidant, antimicrobial agents, and also 
elicit numerous biological activities as highlighted in Figure 1.22 (Panche et al., 2016). 
Chalcones have a wide range of biological activities including inhibition of 






Isoflavonoids are mainly present in legumes especially soybeans, and in microbes. They 
induce metabolic and hormonal changes which activate the disease fighting potential of 
isoflavonoids. They act on oestrogen, inducing hormonal changes, which activate the 
machinery necessary for fighting infection. Daidzein and genistein are example of 




Neoflavonoids differ from other flavonoids because they have a 4-phenylchromen 
backbone, whereas other flavonoids possess the 2-phenylchromen-4-one backbone. 
Hydroxyl group substitution is also lacking at position 2 of neoflavonoids. They contain 15 
carbons. They were first isolated in the seed of Calophyllum inophyllum in 1951 
(Nishimura et al, 2000). 
1.5.1.7 Catechins, flavan-3-ols or flavanols 
 
Catechins are also known as dihydroflavanols or flavanonols. They are a divers and multi-
substituted subgroup also referred to as flavan-3-ol because the position 3 of the C ring 
is where the hydroxyl group binds. It is distinct from other flavonoids because no double 
bond exists between position 2 and 3. Pears, peaches, blueberries, apples and bananas 
are rich in catechins (Panche et al., 2016). 
1.5.1.8 Anthocyanins 
Antacynins are pigments which are responsible for the diverse colours in fruits, flowers 
and plants. Peonidin, pelargonidin, malvidin, delphinidin and cyanidin are the most 
studied anthocyanins. They are predominantly found in the outer layers of fruits. The 
intensity of the colour of anthocyanins depends on factors such as acylation, methylation 
and pH on the A and B ring (Iwashina, 2013). 
 
1.5.2  Pharmacological Activities of Flavonoids 
 
The following activities have been reported for flavonoids: combating neurodegenerative 
diseases, anti-inflammation, xanthine oxidase inhibition, radical scavenging, disease-
combating activity, countering antibiotic resistance, xanthine oxidase modulators, steroid-
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genesis modulators, anti-inflammatory and anti-cholinesterase activity (Panche et al., 
2016). 
1.5.2.1 Anti-inflammatory activity 
 
The anti-inflammatory activity of flavonoids involves inhibition of activities and synthesis 
of several proinflammatory mediators such as C-reactive protein, adhesion molecules, 
cytokines and eicosanoids (Serafini et al., 2010; Ribeiro et al., 2015). Flavonoids 
molecular activities includes activation of nuclear factor-erythroid 2-related factor 2 (Nrf2) 
and inhibition of transcription factors such as NF-kappaB (Serafini et al., 2010). Flavones 
and flavonols which contain 2, 3-double bond are preferential inhibitors of COX-2, an 
enzyme expressed during inflammatory responses. COX-2 synthesises prostaglandins 
which induces inflammation and pain. Flavonoids such as celecoxib, naringenin, taxifolin, 
esculatin, daidzein, genistein, hesperitin, scopoletin, galangin and silbinin are effective 
inhibitors of COX-2 (Madeswaran et al., 2012; Panche et al., 2016). 
1.5.2.2 Anticancer Activities of Flavonoids 
1.5.2.2.1 Flavonoid containing 2-phenyl-4H-chromen-4-one 
system 
 
Anticancer activity of flavonoids has been reported against a variety of cell lines and in a 
certain study, the seed extracts of Abrus precatorius elicited anticancer effect against 
nineteen cancer cell lines (Patil et al., 2015), with HepG2, HeLa, NCI-H460 and MCF 7 
susceptible to these flavonoids. Flavonoids from Arrabidaea chica extracts inhibited the 
growth of Ehrlich solid tumour in rats and vicenin. 4′,7-dimethylapigenin and kaempferol 
were the phyto-active constituents eliciting these activities (Barbosa et al., 2008). 
Importantly, flavonoids kill cancer cells without affecting normal cells as seen in isolinariin 
A, isolinarin B, linariin and pectolinarin, isolated from the genus Linaria. These 
compounds indicated cytotoxicity on C32, Caco-2, COR-L23 and MCF-7 cell lines without 
killing normal cell lines – MRC-5. Isolates from Heterotheca inuloides such as eriodictol, 
luteolin, kaempferol, catechin and quercetin were cytotoxic against MCF7, HCT-15, and 
K562 cell lines with IC50 as low as 1.45 μM (Rodríguez-Chávez et al., 2017; Thamere et 
al., 2005). 
The anticancer activities of chrysin, quercetin, hesperetin, rutin, flavone and 3-
Hydroxyflavone were studied using 5-fluorouracil as standard drug against Caco-2 cell 
line. Interestingly, Chrysin, flavone and 3-Hydroxyflavone were more potent against 
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Caco-2 IC50 (5.5, 21.01 and 42.1 μM) compared to an IC50 of 60 μM for 5-Fluorouracil, 
which was comparable to the anticancer activity indicated by hesperetin (IC50 = 66.67 
μM) whereas quercetin was less active against Caco-2. rutin and hesperedin were 
inactive. These results are a pointer that the chemical group substitution plays a vital role 
in the biological responses observed. The OH group in A ring of chrysin increased its 
cytotoxicity. It implies that the position of the OH group in flavonoids is vital to their 
cytotoxicity; 3-Hydroxyflavone with an OH group at C ring indicated a decreased activity 
compared to chrysin and flavone. Additional OH groups at ring B – as seen in hesperetin 
(Structure 1.66), further decreased their cytotoxicity (Ibrahim et al., 2014) an indication 
that a free B ring is an important feature of an anticancer flavonoid against colon cancers. 
Flavonoids such as genistein, formononetin, 2′-Hydroxyflavonone, apigenin and 
quercetin elicit their anticancer activity by inducing apoptosis and overexpressing NAG-1 
protein. NAG-1 belong to the TGF-β family and is being regulated by transcription factors 
PPARγ, Sp1, ATF-3, p53, EGR-1. These transcription factors are also flavonoid targets 
such as 2′-hydroxyflavonone which inactivates AKT/STAT3, changing Bcl-2 gene 
expression, resulting in growth inhibition and apoptosis (Wu et al., 2014; Yang et al., 
2014). 
Unlike some groups of anticancer agents, flavonoids can interfere with tumour cells 
growth in all phases by modulating different receptors and enzymes which partake in 
reverse multidrug resistance, metastasis, angiogenesis, apoptosis, differentiation and cell 
proliferation. Flavonoids acts mainly by inhibiting protein kinases and topoisomerases:  
serine, threonine kinases / protein tyrosine kinase and phosphatidylinositol 3-kinase 
(Kaleem & Ahmad, 2018). 
 
                             
 
       Structure 1.65: Rutin    Structure 1.66: Hesperidin             
Structures 1.61 – 1.66: bioactive flavonoids isolated from plants (Abdallah et al., 2015; Frutos et al., 2019; 
Kosari-Nasab et al., 2018; Rha et al., 2019) 
Structures 1.61: Chrysin 1.62: Flavone 
 




Flavonoids also act as anti-angiogenic agents by regulating the expression of EGFR, 
MMPs and VEGF and inhibition of ERK ½, PI3-K/AkT and NFkB signal pathways. 
Flavonoids also elicit antioxidant activities via alteration of processes involved in P-
glycoprotein expression, they mitigate nitric oxide induced oxidative stress, chelate trace 
metals and inhibit oxidases involved in production of superoxide anion and scavenging of 
ROS etc. (Abdallah et al., 2015; Ravishankar et al., 2013). Flavonoids are therefore 
important sources of anticancer agents. 
1.5.2.2.2  Pro-apoptotic flavonoids 
 
As described in section 1.1.1.1 (page 1), apoptosis or programmed cell death involves a 
plethora of processes such as apoptosis induction, pro-apoptotic proteins activation, 
caspase cascade (cysteine proteases), reorganization / degradation of organelles in cells, 
cell fragmentation into apoptotic bodies, and phagocytosis of fragmented cells. This 
process is sophisticated and complex, requiring a cascade of energy dependent cellular 
events via inhibition of signal pathways and / or expression of several biomolecules 
involving caspases, MAPS, p53, FAS, TNF, TRAIL and Bcl-2 family (Raffa et al., 2017). 
Casticin, Jaceosidin and other flavonoids interfere with various mechanisms of apoptosis 
such as inhibition of growth factors, by activating or transducing transcription and by ROS 
/ mitochondrial mediated apoptotic pathways (Millimouno et al., 2014; Raffa et al., 2017).  
The PI3K/Akt/FoxO1, PI3K/MEK/ERK, JNK/ caspase/mitochondria, transcription factors 
B of NF-kB1 family and the p53 tumour suppressor family are the main targets of 
flavonoids (Raffa et al., 2017). 
Clinical trials involving quercetin are in the late phase, an indication of promising 
antitumour activity (Akhlaghi et al., 2018). The mechanism of action of quercetin involves 
proliferation of antiapoptotic proteins, downregulation of cell survival, angiogenesis and 
induction of apoptosis via inhibition of Akt and NF-κB signalling pathways. Up-regulation 
of Bcl2, down-regulation of p53, bax and caspase 3 is responsible for quercetin pro-
apoptotic activity (Primikyri et al., 2014; Akhlaghi et al., 2018). Quercetin and kaempferol 
indicated an IC50 of 1.54 and 12.05 ng/ml against A375 cell line (Gopal et al., 2015), and 
quercetin was bound to Bcl-xL protein and the BH3 domain of Bcl2, resulting in a BH3-
mimetic property which led to apoptosis (Primikyri et al., 2014). For instance, kaempferol 
3-O-α-l-rhamnopyranoside inhibited K562 cancerous growth at IC50 of 4.1 μM and acted 
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via inhibition of NF-kB. No toxicity was recorded on non-tumour cell at IC50 of 50 μM 
(Okoye et al., 2015).  
Targeting TRAIL (TNF-Related Apoptosis Inducing Ligand) receptors as a means of 
inducing apoptosis has offered promising results as TRAILS do not kill normal cells but 
inhibit cancerous growths. Chrysin was shown to inhibit STAT3, downregulating Mcl-1 
anti-apoptosis protein, enabling apoptotic induction of TRAILS. Similarly, tectochrysin 
(Structure 1.67) increases the expression of Fas and DR3 and inhibits phosphorylation of 
STAT3, resulting in apoptosis (Lirdprapamongkol et al., 2013).  
 
Structure 1.67: Tectochrysin 
(Lirdprapamongkol et al., 2013). 
 
Other flavonoids such as icariin, wogonin, dihydromyricetin, sylibin, fisetin, flavone B, 
flavone A, calycopterin, vitexin, fisetin, hesperetin, myricetin, luteolin and apigenin also 
induce apoptosis via multiple and different signal transduction pathways. These 
flavonoids are naturally occurring (Raffa et al., 2017) and are readily available. 
1.5.2.2.3  Flavonoids affecting caspase cascade 
Caspases are enzymes responsible for cleavage of proteins at specific aspartate residues 
during apoptosis. When caspase activation malfunctions, apoptosis occurs. By targeting 
caspases, unwanted cells can be killed. Myricetin, luteolin, apigenin, HLBT-100, 
isoquercitrin, kaempferol and quercetin are naturally occurring flavonoids which target 
caspases. 
The pro-apoptotic flavonoid – luteolin inhibited the growth of MCF-7 cancer cells via 
inactivation of PARP, activation of caspase cascades and expression of DR5 death 
receptors. Furthermore, luteolin induces the release of cytochrome C, collapse of 
mitochondrial membrane potential, inhibits Bcl-2 expression and an increase in Bax 
expression (Park et al., 2014). Apigenin inhibited the growth of cancers of the prostate, 
colon, leukaemia, thyroid, skin and breast by apoptotic cell death, inhibition of invasion 
and migration of T24 cancer cells of the bladder, leading to apoptosis via caspase-3 and 
PARP activation, regulation of Bcl-2 family and Akt/ PI3K pathways (Zhu & Zhu, 2013). 
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Isoquercitrin, isolated from extract of Bidens pilosa inhibited cancer cells of the pancreas 
in in vitro and in vivo studies, inducing apoptosis and G1 cell cycle arrest via activation of 
caspases-3, 8 and 9; this reduces the potential of the mitochondrial membrane. 
Isoquercitrin also inhibited δ opioid receptors, promoting the MAPK signalling pathways 
(Chen et al., 2015), thus caspases play important roles in cancer therapy and by targeting 
caspases; apoptosis can be achieved. 
 
1.5.2.2.4  Flavonoids acting on DNA topoisomerases 
 
Topoisomerases unwinds and reseals broken DNA strands. Two types exist: 
topoisomerase I responsible for cleavage of one DNA strand, and topoisomerase II 
responsible for double strand cleavage, and generates a staggered double-strand break. 
Chemotherapeutics with potentials to interfere with topoisomerase can therefore kill 
cancers. Pinostrobin, isolated from Kaempferia pandurate acts on both DNA and 
topoisomerase I, forming a stable complex which makes them candidate for clinical trials. 
Cudraflavanone A, morin, fisetin, rutin, quercetin, silybin, wogonin, epigallocatechin-3-
gallate, luteolin, kaempferol, apigenin, genistenin and chrysin are natural flavonoids with 
the potential of targeting DNA isomerases in humans (Raffa et al., 2017). 
1.5.2.2.5  Flavonoids endowed with anti-angiogenic activity 
Angiogenesis describes the formation of new blood vessels in disease and good health. 
Cancer cells have an increase demand for nutrients and oxygen, and for this to be 
sustained, mediators of pro-angiogenesis such as matrix-degrading enzymes, bioactive 
lipids and cytokines come to prominence. New blood vessels can therefore be prevented 
if angiogenesis factors are targeted as these blood vessels serves as invasion routes for 
the spread of cancers (Fernando et al., 2015). The anti-angiogenic activity of luteolin 
against T47-D and BT-474 hormone-responsive breast cancer cells has been described 
to include blockage of secretion of the progestin-dependent VEGF in these hormone-
responsive cancer cell lines and this effect was superior for luteolin compared to apigenin, 
which elicited a similar response (Cook et al., 2015).   
 
1.5.2.2.6  Activities of other flavonoids-like structures 
1.5.2.2.6.1  Chalcones 
Chalcones or 1,3-diphenyl-2-propen-1-ones differs from conventional flavonoids due to 
the presence of an open ring (Structure 1.69) and the chalcone – naringin is the precursor 
for flavonoids (Evranos et al., 2011). Naringenin chalcone inhibited the production of pro-
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inflammatory mediators (nitric oxide, MCP-1 and TNF-α) in RAW 264 LPS stimulated 
macrophages, promotes PPARγ transcription by enhancing secretion and expression of 
adiponectin from adipocyte, and enhances AdipoR2 expression (Hirai et al., 2007). In 
HepG2 cells, naringenin chalcone inhibits the synthesis of triglyceride by inhibiting the 
expression of DGAT-1 and activity of MTP (Casaschi et al., 2004), inhibits the activation 
of NF-κB and pro-inflammatory gene expression in hepatocytes and HSC (Fernando et 
al., 2015). 
                                      
Structure 1.68: Basic structure of Chalcone and Flavonoid backbone (Raffa et al., 2017). 
 
Xanthohumol exerted anti-proliferative, pro-apoptotic and anti-migratory effect against 
HepG2 and HCC cell lines. Anti-inflammatory effect was elicited via inhibition of 
interleukin-8 and TNF-α induced NF-κB activity (Dorn et al., 2010).  
Butein isolated from Toxicodendron vernicifluum induced apoptosis by activating the 
apoptotic pathway, and inhibition of proliferation of hepatoma cancers at G2/M phase of 
the cell cycle which is dependent on activation of JNK and generation of ROS. In vivo, 
butein inhibited the activity of uPA and MMP-9 by down-regulation of ATP synthesis, 
suppression of cancer metastasis and suppression of NF-κB and signalling pathways 
involving Akt/mTOR/p70S6K (Liu et al., 2014). Other chalcone such as licochalcone A 
and phloretin have been studied in rat models and in HepG2 cells. Their anticancer 
activities involve uPA inhibition by downregulation of JNK/MKK4 pathways, activation of 
NF-κB, and inhibition of Bcl-2, Akt and GLUT2 signalling pathways. These compounds 
stimulate both extrinsic and intrinsic apoptotic pathways, exerting anti-tumour activities 
both in vitro and in vivo (Tsai et al., 2014; Wu et al., 2009). These activities were also 
reported for MCF-7 cancer cell lines (Kang et al., 2017). 
Since flavonoids are present in natural food sources, their cytoprotective, anti-




1.5.3  Chrysin – a Flavonoid 
1.5.3.1 Source of Chrysin 
Chrysin (Structure 1.61) is a flavonoid that is present predominantly in honey, blue 
passion flower, and propolis and it possess great medicinal and economic impact such 
as anticancer, antibacterial, anti-inflammatory activities (Mani & Natesan, 2018). 
1.5.3.2 Pharmacological Activities of Chrysin 
Chrysin possesses numerous health benefits which are still nascent and poorly exploited 
due to poor absorption and bioavailability of chrysin. It is a potent inhibitor of HIV virus, 
and aromatase (Li et al., 2014). Chrysin also indicates anticancer, antioxidant, and anti-
inflammatory activities via induction of apoptosis in a range of cancer cell lines, thus the 
following activities of chrysin have also been reported: antiarthritic, antidepressant, 
antidiabetic, antiasthmatic, antibacterial, antienteroviral, and neuroprotective (Mani & 
Natesan, 2018). 
1.5.3.2.1 Anticancer Activity of Chrysin 
Anticancer activities of chrysin on several cancer cell lines including cancers of the 
prostate, pancreas, thyroid, glioblastoma, liver, cervical, nasopharyngeal, breast, lungs, 
and haematological cancers such as MCF-7, DU145, HCT 116, HepG2, Hep3B, A549, 
H1975, H157, H460, TNBC, 4T1, JB6 P+, HTh7; KAT18 have been reported with IC50 
ranging from 1.0-50.0 μM, with A549 indicating the lowest IC50 reported (Mani & Natesan, 
2018). Chrysin elicits its action via apoptosis, inhibition of cell proliferation and removal 
of inflammatory responses (Xue et al., 2016), inhibition of β-arrestin-2 expression, 
suppression of NF-ĸB and angiogenesis. It also stabilises the expression of p53 thereby 
activation of ERK1/2 which allows phosphorylation of p53 in HepG2 (Li et al., 2015). Due 
to the promising role of chrysin as an anticancer agent, and the role of 
organotin(iv)compounds as anticancer agents, chrysin-Sn complex was synthesised and 
tested against MCF-7, HeLa and A549 cancers in vitro. Interestingly, the anti-proliferative 
effect of chrysin-Sn complex was much stronger compared to chrysin and this effect was 
time and dose dependent (Xuan et al., 2016). Inhibition of cell proliferation was by 
apoptosis due to activation of caspase 3, increase in the level of LC3-II/LC3-1 ratio, 
suggesting that autophagy and apoptosis were responsible for the anti-proliferative effect 
of chrysin-Sn complex (Xuan et al., 2016). 
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Chrysin also preferentially kill cancer cells but not normal cells such that even cancer 
cells with acquired or primary drug resistance can be killed by chrysin. Wang et al. (2007), 
reported the suppression of interleukin-6 dehydrogenase expression in NSCLC cells via 
AKR1C1/1C2 superfamily responsible for aldo-keto reaction, and overcame drug 
resistance to Adriamycin and cisplatin. Chrysin also increase the sensitivity of BEL-7402 
to doxorubicin (BEL-7402 is resistant to doxorubicin) by inhibition of nrf2 expression and 
its genes downstream - MRP5, AKR1B10 and Homooxygenase-1 gene by suppressing 
PI3K-Akt and ERK pathways (Gao et al., 2013).  
 
Figure 1.23: the role of detoxifying enzymes in prevention of carcinogenesis. 
Diagram representing multi-step carcinogenesis and how chrysin intervenes in inhibiting cancer cell 
progression. Carcinogenesis begins with the transformation of healthy cells into cancer cells. These cells 
(cancer cells) progresses into preneoplastic cells and then into neoplastic cells. Carcinogenesis is inhibited 
by chrysin via inhibition of procarcinogen activation, or via stimulation of the detoxification of carcinogens, 
inhibition and suppression of growth via apoptosis, inhibition of cell proliferation by inhibition of cell 
inflammation, metastasis, invasion and angiogenesis (Kasala et al., 2015). 
 
BCRP-mediated multi drug resistance (MDR) was also reversed by chrysin as it inhibited 
the efflux of BCRP, allowing BCRP to accumulate in cells, restoring the MDR cells 
sensitivity to anticancer agents (Zhang et al., 2004). Hursting et al., (1999), proposed the 
mechanism of action of chrysin to include inhibition of cancer processes such as initiation, 
proliferation and progression. Carcinogen biotransformation is modulated, allowing the 
mopping up of free radicals and alteration of gene expression in genes which take part in 
signalling pathways. Initiation of carcinogenesis can be prevented by detoxifying 
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enzymes such as NAD(P)H quinone oxidoreductase or glutathione S-transferase (Figure 
1.23). 
Chrysin can also prevent the effect of chemically induced cancers, including models of 
xenograft tumours by inducing detoxification and antioxidant enzymes, inhibition of cell 
proliferation, induction of apoptosis and inhibition of cyt-p450 monooxygenases. 
Carcinogenesis from 7,12-dimethylbenz(a)anthracene – induced carcinoma in hamster 
buccal pouch was inhibited by chrysin via several mechanisms such as metastasis, 
angiogenesis, inhibition of tumour cell proliferation, induction of apoptosis, invasion, 
glutathione reductase, glutathione peroxidase, upregulation of antioxidant and pro-
carcinogen inhibition (Karthikeyan et al., 2013). In breast cancer cells, chrysin induces 
the BCRP (breast cancer resistance protein) by modulating enzymes of phase I and II, 
through the AhR (aryl hydrocarbon receptor) - Figure 1.23 and Figure 1.24 (Karthikeyan 
et al., 2013). Chrysin has been reported to also inhibit carcinogenesis resulting from 
sulphation mediated by phenolsulphotransferases in HepG2 (Eaton et al., 1996; Kasala 
et al., 2015). 
Chrysin also exert anticancer activities in vivo. Using animal models, chrysin at doses of 
20 and 40 mg/kg corrected ferric nitrilotriacetate and N-nitrosodiethylamine (DEN) 
induced renal carcinogenesis by ameliorating inflammation and oxidative stress via NF-
κB pathway (Burkard et al., 2017) and also suppressed the growth of colorectal cancer 
induced by 1,2-dimethylhydrazine in Wistar rats by reducing cell proliferation, nitrosative 
stress, and the recovery of the antioxidant mineral in intestinal mucosa (Rehman et al., 
2013; Sequetto et al., 2013). Chrysin also ameliorates lung carcinogenesis induced by 
benzo(a)pyrene in Wistar rats by decreasing the levels of both non-enzymatic (vitamin C, 
vitamin E and glutathione) and enzymatic antioxidants such as glutathione reductase, 
glutathione peroxidase, catalase and superoxide dismutase. Immunoblotting and 
histopathology analysis indicated downregulation of the expression of NF-κB, COX-2 and 
PCNA (Kasala et al., 2015). 
Dimethylchrysin, a chrysin derivative also attenuated the signalling of NF-κB pathways 
by upregulating the expression of apoptotic genes in DEN induced hepoto-carcinogenesis 
in Wistar rats and inhibited colon carcinogenesis induced by azoxymethane in rats (Khan 
et al., 2011). 
Xenograft model studies indicate chrysin elicited antitumour effects against 4T1, HTh7, 
MDA-MB-231 and Ehrlich ascites carcinoma cells via induction of apoptosis and 
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angiogenesis. In leukaemia xenograft model of mouse induced by implantation of WEHI-
3 cells in Balb/c mouse, chrysin inhibited tumour growth by promoting phagocytosis of 
macrophage, and enhancing B and T-cells, and inhibition of cytotoxicity induced by 
natural killer cells (Lin et al., 2012). Chrysin therefore exhibit anticancer, anti-angiogenic, 
anti-metastatic, anti-invasive, apoptosis and antiproliferative properties both in vivo and 
in vitro. 
Mechanism of action of chrysin therefore include apoptosis, inhibition of metastasis, 
angiogenesis, cell proliferation, NF-κB, Wnt signalling, EGFR, PPARγ, Ubiquitin-
proteasome and the Nrf2 pathways (Figure 1.24) (Fonseca et al., 2017; Gao et al., 2013; 
Kasala et al., 2015). 
Despite the cytotoxic activities of chrysin, poor bioavailability of chrysin has been 
observed because it is poorly absorbed, rapidly metabolised and eliminated rapidly from 
the system. It has been reported that some athletes including body-builders, ingest up to 
3g of chrysin daily without any side effect. Another study indicates that after oral intake of 
400 mg chrysin, below 0.1 μM mean plasma concentration was found. This was traced 
to systematic hepatic and intestinal sulphation, glucuronidation, hydrolysis and efflux of 
systemic metabolite into the intestine and elimination via the faeces. Administration of 
5mg/kg chrysin orally (single dose), chrysin was found in faeces and only tiny amounts of 
glucoronides of chrysin were found in the urine. After intraperitoneal and intravenous 
administration of chrysin (1-5 mg/kg), a 10-fold increase in glucoronides of chrysin were 
found in the bile, 10-times higher than chrysin sulphates (Walle et al., 2001). Doses of 
chrysin – up to 625 mg were administered orally to humans without toxicity, an indication 
of efficacy and safety of chrysin. 
Due to poor bioavailability of chrysin, efforts have been made to improve its bioavailability 
such as the use of nanoparticles of chrysin (Sabzichi et al., 2017), the use of liposomal 
chrysin (Kasala et al., 2015), and by use of synthetic chrysin analogues (Kasala et al., 
2015; Mani & Natesan, 2018; Patel et al., 2016). By conjugation of Sn to chrysin (Xuan 
et al., 2016), chrysin-piperazine conjugates (Patel et al., 2016) and other chrysin 
conjugates (Mani & Natesan, 2018), an increased bioavailability and absorption of chrysin 
has been observed. There are also indications that the use of chrysin and other 
anticancer compounds potentiates the anticancer activities of these compounds with little 
systemic toxicities (Mani & Natesan, 2018). There is therefore a need to synthesize 




1.5.3.2.2 Mechanism of Anticancer Activity of Chrysin 
Chrysin exerts its anticancer activity by acting thus:  i) as an apoptotic gene, ii) as 
proliferation markers, iii) triggering the release of protein kinases, iv) alteration of activities 
of key metabolic enzymes, v) inhibition of angiogenesis, vi) inhibition of growth-factor 
releasing hormone etc (Figure 1.25) (Khoo et al., 2010). 
Nuclear factor-E2-related factor 2 (Nrf2) is an important cytoprotective transcription factor 
which plays important roles in detoxification and antioxidant processes (Gao et al., 2013) 
and development of chemoresistance is associated with the constitutive activation of the 
Nrf2-mediated signalling pathway in many types of cancer cells (Gao et al., 2013). 
Investigation of the drug reversal effect of chrysin on Nrf2-associated drug resistance 
BEL-7402/ADM (doxorubicin resistant BEL-7402) cells indicated a significantly higher 
level of Nrf2 and its target proteins in BEL-7402/ADM cells compared to BEL-7402 cell 
only (Gao et al., 2013). Significantly lower intracellular Nrf2 protein level were also 
reported (Gao et al., 2013). ADM resistance was reversed by Nrf2 siRNA in BEL-
7402/ADM cells (Gao et al., 2013), an indication that chrysin is a potent inhibitor of Nrf2 
which sensitizes BEL-7402/ADM cells to ADM and increases intracellular concentration 
of ADM (Gao et al., 2013). 
 
Figure 1.24: Molecular target of chrysin. 
Dark and light-coloured rectangular boxes denote the targets inhibited and promoted by chrysin 
respectively (Kasala et al, 2015). 
 
Chrysin therefore reduces the expression of Nrf2 at both the mRNA and protein levels 
down-regulating ERK and PI3K-Akt pathways (Figure 1.24). Consequently, expression of 
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MRP5, AKR1B10 and HO-1 (Nrf2-downstream genes) were reduced and the Nrf2-
dependent chemoresistance was suppressed (Gao et al., 2013). Chrysin therefore acts 
as an effective sensitizer to reduce anticancer drug resistance by down-regulating Nrf2 
signalling pathway. 
Chrysin also acts by upregulating the apoptotic genes Cyt c, Bax, TRAIL, PLC-c1, 
caspases 3, 8 and 9, PIG3, B-arrestin and PARP (Gao et al., 2013), and down-regulation 
of Bcl2, Bcl-xL, C-Flip, survivin and Mcl-1 (Gao et al., 2013). 
In a study by Zhang et al., (2004), he demonstrated that phosphorylated derivatives of 
chrysin at the 5-OH and 7-OH positions indicated better cytotoxicity in human cervical 
carcinoma (HeLa) cell via induction of apoptosis and down-regulation of the proliferating 
cell nuclear antigen (PCNA) in cells. Chrysin also induce apoptosis via induction of the 
p38 and activation of NFkappaB/p65 in the HeLa cells (von Brandenstein et al., 2008). 
Chrysin also sensitises the TNFalpha-induced apoptosis in nasopharyngeal carcinoma 
cell line (CNE-1), human liver cancer cell line (HepG2) and in human colorectal cancer 
cell line (HCT-116). This sensitization is associated with inhibitory effect on NFkappaB 
activation in Hela cells (Li et al., 2010). Although both chrysin and its phosphorylated 
adduct inhibited proliferation of cancer (HeLa) cells and induced apoptosis, the 
phosphorylated adducts (IC50 9.8 μM) indicated better cytotoxic inhibition against HeLa 
cells than chrysin (IC50 14.2 μM) (Zhang et al., 2004). Against the human leukaemia cell 
U937, apoptotic induction is associated with caspase-3 activation involving inactivation of 
Protein Kinases B (PKB) or Akt signalling and down-regulation of X-linked inhibitor of 
apoptosis protein (XIAP) in the U937 cells (Woo et al., 2004). This finding unlocked a 
more detailed molecular mechanism of induction of apoptosis via Akt dephosphorylation 
of the phosphoinositide-3-kinase (PI3K) signalling pathway in leukaemia cells. 
The signalling pathway (requiring Akt) from PI3K to phosphoinositide-dependent kinase-
1 (PDK1) and from PDK1 to Akt is responsible for apoptotic induction in cancer cells 
(Figure 1.25). Phosphorylation of Akt prevents apoptosis whereas dephosphorylation 
initiates apoptosis (Hou et al., 2018). Phosphorylation of Akt activates caspase-9 and 
phosphorylates Bcl-2-associated death protein (BAD). Phosphorylated BAD binds to the 
14-3-3 proteins in the cytosol, preventing the heterodimerization with Bcl-2 at the 
mitochondrial membrane (Bui et al., 2018). BAD is released from cytosolic 14-3-3 proteins 
via dephosphorylation which subsequently form heterodimers with Bcl-2 family proteins 
and migrate into the mitochondrial membrane.  
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This migration signals the release of cytoplasmic cytochrome c (Inamdar et al., 2018; 
Pelengaris et al., 2002). Cytoplasmic cytochrome C then combines with caspase-9 and 
apaf-1 to form an apoptosome (a complex). Caspase-9 activation via phosphorylation (by 
ATP) is required for the formation of apoptosomes (Attaran-Bandarabadi et al., 2017; 
Pelengaris et al., 2002). Activation of caspase-9 leads to activation of caspase-3 
(downstream executor caspase), leading to apoptosis (Debatin, 2004; Zamaraev et al., 
2017). Consequently, activation of caspase-9 by phosphorylated Akt prevents formation 
of the apoptosome complex, and therefore inhibition of the downstream event of 
apoptosis (Debatin, 2004). 
 
Figure 1.25: The PI3K/Akt signalling pathway. 
Chrysin acts via activation of caspases and inactivation of Akt signalling in leukaemia cells. (•) depicts 
chrysin (Ediriweera et al., 2019; George et al., 2018; Khoo et al., 2010). 
 
A summary of bioactive flavonoids, their mechanism and site of action is presented in 
Table 1.11 below. 
Table 1.11: Mechanisms of action and target sites of bioactive flavonoids 
Flavonoid Target References 
Apigenin Direct DNA damage, ATM mediated cell cycle 
checkpointsignallingactivation, p53 accumulation, 
down-regulation of anti-apoptotic Bcl-2, up-regulation 
of apoptotic Apaf-1 and p21, inhibition of PI3K/Atk and 
NF-kBsignallingpathway. 
(Meng et al., 2017; 
Erdogana et al., 2017) 
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Flavonoid Target References 
Luteolin  Activation of MEK/ERKsignallingpathway, inhibition of 
gene expression, production and secretion of 
MUC5AC mucin via regulation of NF-
kBsignallingpathway. 
(Meng et al., 2016; Lee et 
al., 2015) 
Myricetin  RSK2 binding, increased expression of Mad1. (Feng et al., 2015) 
Hesperetin Alteration of JAK/STAT pathway, KIT 
receptorsignallingand growth hormone receptor 
signaling. 
(Adan & Baran 2016) 
Fisetin  Alteration of JAK/STAT pathway, KIT 
receptorsignallingand growth hormone receptor 
signaling. 
(Adan & Baran 2016) 
Vitexin  Activation of MEK/ERKsignallingpathway. (Yang et al., 2013) 
Flavone A  Decrease unphosphorylated ERK and S6, inactivation 
of the survival proteins Bcl-xL or Bcl-2. 
(LeJeune et al., 2015) 
Flavone B  Upregulation of the activated forms of ERK and c-
JUN. 
(LeJeune et al., 2015) 
Dyhydromyricetin  AMPK and p38MAPK activation, downregulation of Sox2. (Sengupta et al., 2016) 
Calycopterin ROS production, Bcl-2 family protein expression, 
mitochondria depolarization and MMP disruption. 
(Esmaeili et al., 2014; Kim 
et al., 2013) 
Wogonin Inhibition in E6/E7 expression, induction and increase 
in p53 mRNA expression. 
(Chen et al., 2013; Kim et 
al., 2013) 
Icariin  Increases in the EC109 and TE1 cell apoptotic index, 
Caspase 9 activity, reactive oxygen species (ROS), 
and nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase activity. Upregulated the levels of 
ERS-related molecules (p-PERK, GRP78, ATF4, p-
eIF2α, CHOP), and a pro-apoptotic protein (PUMA). 
Downregulation of Bcl-2. 
(Fan et al., 2016) 
Sylibin 53 Modulation of receptor tirosin kinases, androgen 
receptor, STATs, NF-kB,signallingpathways, 
downregulation of MicroRNA-21 and MicroRNA-155, 
upregulation of CASP-9 and BID. 
(Gandara et al., 2014; 
Zadeh et al., 2016) 
(Raffa et al., 2017) 
 
1.5.3.2.3 Antibacterial Activity of Chrysin Derivatives 
The antibacterial activities of propolis has previously been reported against Gram-positive 
and Gram-negative bacteria. Ruffato et al., (2018) reported a MIC of 125 μg/ml for the 
crude ethanol extracts of Brazillian propolis against Staphylococcus aureus with the 
hexane fraction indicating an MIC of 62.5 μg/ml. Chrysin has been identified as the main 
constituent of propolis (Surech et al., 2006). Antimicrobial activities of propolis with MIC 
ranging from 62.5 – 500 μg/ml against a range of bacteria has been documented (Braca 
et al., 2008, Cabral et al., 2012, Castro et al & Daltro 2009, Fabri et al., 2011, Gonçalves 
et al., 2011). 
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Suresh et al., (2006) reported the antibacterial activity of chrysin against three Gram-
positive bacteria – Bacillus subtilis Bacillus spaericus and S. aureus at MIC values 50, 50 
and 25 μg/ml, and three Gram-negative bacteria – Chromobacterium violaceum and 
Klebsiella aerogenes at MIC values 25 and 50 μg/ml but no inhibition against 
Pseudomonas aeruginosa. Surech et al., (2006) further synthesised derivatives of 
chrysin, grouping them into three series: series 1 (3-carbon spacer in between chrysin 
and heterocyclic moiety), series 2 (separated by 4-carbon spacer) and series 3 
compounds (separated by 6-carbon spacer in between chrysin and the substituent). All 
chrysin derivatives synthesised showed antibacterial activities ranging from 6.25 – 25 
μg/ml against all bacteria tested except P. aeruginosa. There was no peculiar difference 
between the pattern of inhibition between the Gram-negative and Gram-positive bacteria 
(except P. aeruginosa). These activities were better than those indicated by chrysin and 
comparable to those indicated by Streptomycin and Penicillin (MIC 1.56 to 12.5 
respectively). The work of Surech et al., (2006) is a clear indicator that the modification 
of a compounds could significantly alter its biological activities. 
1.5.4  7-O-Chrysin Derivatives Previously Synthesised 
1.5.4.1 7-O-bromochrysin adducts 
 
7-O-Bromochrysin adducts: 7-O-2-bromoethylchrysin, 7-O-3-bromopropylchrysin, 7-O-4-
bromobutylchrysin, 7-O-5-bromopentylchrysin, 7-O-6-bromohexylchrysin have been 
previously made and their anthelminthic activities on nematodes investigated (Valdez-
Calderón et al., 2016). These chrysin-adduct inhibited the growth of nematode at the 
larval stage.  The method of synthesis of these compounds used involved dissolving the 
reactants in acetone and allowing the reacting mixture to run for 24 hours. 
1.5.4.2  7-O-Alkylchrysin Adducts 
 
7-O-alkylchrysin adducts: 7-O-butylchrysin and 7-O-hexyl chrysin have been synthesised 
previously and their antidiabetic activity investigated (Cheng et al., 2014). These 
compounds inhibited α-glucosidase, and a subsequent reduction in sugar levels in vivo. 
7-O-Isopropylchrysin has been made previously and reported to modulate cancer cell 
resistance to cancer therapy and to enhance binding affinity towards P-glycoprotein 




1.5.5 Justification / Rational behind the Synthesis of 7-O-Chrysin 
Derivatives 
 
Even though chrysin has indicated significant biological activities in in-vitro and in-vivo 
studies, the limitation of this molecule has made it difficult to transform the use of this 
molecule with promising biological activities into clinical trials. This study therefore aims 
to synthesise 7-O-Chrysin derivatives with different functional groups in an attempt to 
make molecules that are more cytotoxic to bacteria, fungi and cancer cells, yet indicating 
less toxicity to normal cells. The synthesis of 7-O-chrysin derivatives with different 
functional groups and chain length could also overcome the limitations of chrysin (poor 
absorption and bioavailability) in living systems. Although some 7-O-bromochrysin and 7-
O-alkylchrysin derivatives have been previously made (Comte et al., 2001; Valdez-
Calderón et al., 2016), no bio-availability data has been provided for these compounds. 
Zhou et al., (2012) has postulated that the 5-OH position of chrysin is the active site, 
whereas Babu et al., (2006) has postulated that the aromatic ring is the active site of this 
molecule. Synthetic chrysin derivatives at the 5-OH position or at the aromatic ring 
position might be a waste of resources as some authors have postulated that these 
regions are the active sites of the chrysin molecule. 5-O-chrysin derivatives are relatively 
inactive biological molecules due to the hydrogen-bonding effect at the 5-OH position 
(Zheng et al., 2016) and also because the 5-OH position is the active site of this molecule 
(Zhou et al., 2012). Blocking them could imply total loss of bioactivity. 
One of the aims of this project (section 1.6) is to synthesise derivatives of chrysin 
(Structure 1.61) with increased cytotoxicity compared to the parent compound. The –OH 
groups at C-5 and C-7 are important for the cytotoxicity indicated by chrysin. Dao et al. 
(2003) and Shin et al., (1999) synthesised chrysin derivatives by targeting the –OH 
groups at both C-5 and C-7 of the chrysin molecule and reported weak anticancer 
activities at the 5-OH position and also reported an increase in cytotoxic activity via the 
introduction of a bromide ion in chrysin molecule. Comte et al. (2001), Valdez-Calderón 
et al. (2016) and Cheng et al. (2014) also synthesised chrysin derivatives by targeting 
other positions (position 6 and 8) of the chrysin molecule and reported the biological 
activities of these compounds. Based on these previous works, there is a need to 
synthesise chrysin derivatives with focus on C-7 and not C-5 of chrysin.  




Despite the promising antibacterial and anticancer activities reported in the literature, no 
flavonoids are in clinical use for treatment of bacterial infection or as a cancer 
chemotherapeutics. However, quercetin was successfully used in phase I clinical trials as 
an inhibitor of tyrosine kinase (anticancer activity) up to a dose of 1400 mg/m2 without an 
indication of adverse side effects and has been recommended for phase II clinical trials 
(Ferry et al., 1996). Randomized, double-blind, placebo-controlled, crossover trials also 
indicated significant reduction of systolic blood pressure with no significant adverse 
effects on inflammatory biomarkers or cardiovascular (CVD) risk factors (Zahedi et al., 
2013). Administration of quercetin-3-glycoside had no effect in CVD risk factors, insulin 
resistance or flow-mediated dilation (Dower et al., 2015a), and contributed to 
cardioprotection by reduction of inflammation and improvement of endothelial functions 




1.6  Project Aims 
 
This work is divided into two distinct sections: a) focussing on extraction isolation and 
characterisation of novel drug candidates from a plant (Inula helenium) with well-known 
use in herbal focussing on using chemical synthesis to improve the potency and safety 
index of a well-known cytotoxic agent. This work is also subdivided into two sections: i) 
antimicrobial studies using compounds isolated from a) and compounds synthesised from 
b) above and ii) anticancer studies using compounds isolated from a) and compounds 
synthesised from b). 
The choice of bacteria and fungus – Candida albicans selected for this work is based on 
the clinical importance associated with them as described in section 1.2.1 above with 
emphasis on extended spectrum beta lactamase (ESBL) bacteria.  
The choice of cancer cell lines selected for these studies is based on their diversification 
(origin): leukaemia – K562 and Molt-4 cell lines, colorectal cancers – Caco-2 (for 
compounds obtained as described in objective a) and b) above) and HCT 116 cell lines), 
breast cancer (MCF-7 and MDA-MB 468 cell lines), liver cancer – HepG2 cell line, lung 
cancer – (A549 cell line), skin cancer (HacaT cell line) and mesothelioma (Mero 14 cell 
line). This is meant to track the cytotoxicity of synthetic adducts on a range of cancer cell 
lines of different origins. The cytotoxicity of compounds isolated from Inula helenium (but 
not compounds synthesised from chrysin) on leukaemia cell line (K562) during hypoxia 
and normoxia, hyperglycaemia and normoglycaemia, shall also be investigated as there 
is no published data on the inhibition of leukaemia cancer cell (K562) growth by 
compounds from Inula helenium during hypoxia and hyperglycaemia despite their potent 
cytotoxicity – alantolactone and isoalantolactone (IC50 0.7 and 1.2 μM) against the K562 
cell line (Lawrence et al., 2001). The specific objectives of this work are highlighted below: 
 
1.6.1  Isolation Work 
 
The search for novel anticancer agents from plant – Inula helenium: 
i) To obtain extracts from Inula helenium using different extraction methods: 
Microwave-assisted-extraction (MAE), ultrasound-assisted extraction (UAE) and 
Soxhlet extraction (SE), determine the extraction yields, and test their anticancer and 
antibacterial (see definition of antibacterial drugs on section 1.2.1) activities. 
 
ii) To fractionate the extracts obtained from MAE, UAE and SE using different solvents: 




iii) To purify and characterise bioactive components using different purification and 
characterisation techniques such as HPLC, NMR, MS and infrared spectroscopy. 
 
iv) To test purified compounds isolated from Inula helenium on bacteria (see section 
1.2.1.1) and study the cytotoxicity of bioactive compounds on K562 cell line in 
hypoxia, normoxia, hypoglycaemia and hyperglycaemia. This is because the 
cytotoxicity of compounds isolated from Inula helenium on cancer cell line has been 
well documented but no report on the cytotoxicity of these compounds in hypoxia, 
hypoglycaemia and hyperglycaemia has been documented. 
 
1.6.2  Synthetic Work 
 
The synthetic work is based on chrysin (Structure 1.61), a natural occurring flavonoid 
found in honey. This study is based broadly on the chemistry of the 7-OH (hydroxyl 
group). The 7-OH of the chrysin molecule interacts with other molecules, strengthening 
the hydrogen bond at position 5-OH (Cai et al. 2017), thus making the chrysin molecule 
insoluble in most organic solvents (except DMSO) (Zhou et al. 2014), which is also the 
reason for the poor bioavailability of chrysin in living systems (Walle et al., 2001). By 
targeting the 7-OH position of chrysin, its derivatives with better bioactivity, safety indices 
and solubilities could be synthesised thus overcoming the challenges of poor solubility 
and bioavailability. The aims are listed below. 
 
i) To synthesise 7-O-Chrysin derivatives with increased cytotoxicity compared to the 
parent compound. 
ii) Focussing on the 7–OH position of chrysin, to synthesise chrysin-aryl derivatives 
with different functional groups attached to the aryl ring and to investigate their 
anticancer and antimicrobial activities. 
iii) Focussing on the 7–OH position of chrysin, to synthesise 7-O-haloalkylchrysin 
adducts and to investigate the role of halogenation of 7-O-Haloalkylchrysin-adduct 
in cancer and microbial growth inhibitions. 
iv) Focussing on the 7–OH position of chrysin, to synthesize 7-O-alkylchrysin adducts 
lacking halogen groups and to compare the cytotoxic and microbial activities of 
these adducts. 
v) Focussing on the 7–OH position, to synthesis aliphatic 7-O-alkylchrysin adducts 
containing branched chains and to investigate their anticancer and antimicrobial 
activities compared to aliphatic chrysin adducts without branch chains. 
 
vi) To synthesise other 7-O-chrysin derivatives and to investigate their anticancer and 
antimicrobial activities.  
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Chapter 2  Methodology 
 
2.1  Isolation and Purification of Natural Products Experimental 
2.1.1  Extraction of compounds from Inula helenium 
 
Three extraction techniques were used: Soxhlet extraction (SE), ultrasound-assisted 
extraction (UAE) and microwave-assisted extraction (MAE). Three different solvents were 
used to fractionate compounds extracted from Inula helenium: methanol, ethyl acetate 
and hexane. 1100 g of dry root sample of Inula helenium (crushed to fine powder) was 
purchased from Bristol Botannicals, UK. 1000g of this sample was divided into three equal 
parts: 333.3 g and extracted in 70 % methanol using SE, MAE and UAE. 
The Soxhlet apparatus for this experiment consists of an extraction flask (1000 mL), a 
Soxhlet chamber and a condenser. Dried root (33.3 g x 10) were placed in an extraction 
thimble with 400 mL of methanol in an extraction flask, and the extraction allowed 
occurring in three cycles of extractions (such that the liquid in the extraction chamber 
becomes colourless). Analytical grade methanol (99.9%) was used for extraction (Fischer 
Scientific, UK). 
The Soxhlet extractor operates via heat reflux. Heat is applied to the base of flask, causing 
the vapour to travel into the extraction chamber housing the extraction thimble and the 
solute to be extracted. The warm distilled solvent causes the solute in the extraction 
chamber to dissolve, dissolving some desired compounds. As the solvent fills the 
extraction chamber, the solvent is siphoned back to the flask. The extraction thimble 
prevent insoluble compounds from passing into the extraction flask. As each cycle of 
siphoning occurs, substances are constantly being dissolved.  After several cycles of 
siphoning, the desired compounds become concentrated in the distillation flask. The 
apparatus is disassembled, and the concentrated extracts concentrated further by means 
of a rotary evaporator. 
MAE was done using Sonicor Instrument Corporation, Copiague, New York. Dried roots 
of Inula helenium were extracted such that the temperature remained steady. This was 
done by using fluctuating radiation, and extraction conditions chosen as stated by Nkhili 
et al. (2009). Power was 400 W and temperature 60 °C for 40 minutes. The solvent used 
for extraction was 99.9 % analytical grade methanol (Fischer Scientific, UK). 
MAE has the advantage over conventional extraction methods in that it requires less 
quantity of polluting non-environmentally friendly solvent and is less time-consuming, 
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leading to increased yield and quality of compound extracted from natural products (Xiao 
et al., 2013). This is achievable because the sample and solvents are enclosed in a sealed 
extraction vessel under controlled conditions of pressure and temperature. This allows 
for a quick rise in temperature of the solvents which allows efficient bond breaking of the 
compounds to be extracted in a very short period, leading to an eventual shortening of 
extraction time and an increased yield (Simić et al., 2016). MAE is therefore known as a 
“green” extraction procedure because it requires lower extraction time and relatively 
inexpensive (Karabegović et al., 2013).  
The energy transfers and heating mechanism in MAE occurs via two mechanisms: ionic 
conduction and dipole rotation through displacement and reversal of charged ions present 
in the solvent and the solute. Unlike other heating methods which utilise radiation, 
conduction and convection of heat energy through to material to be extracted, MAE 
involves direct delivery of energy to the solute / solvent through interaction of molecular 
species with the electromagnetic field, thereby converting electromagnetic energy into 
heat (Thostenson & Chou, 1999). 
UAE was performed using the Cole Parmer Sonicor instruments, Illinois, USA; ultrasonic 
model (power 130 W, 2.8 L, 28H) was used in carrying out the extraction. Dried roots 
(33.3 g) of Inula helenium were placed in a beaker with 300 mL of solvent with operational 
conditions of 25 °C, frequency of 50 kHz for 60 minutes. It consists of an amplitude control 
which allowed the ultrasound vibration probe to be set / adjusted to any limit within the 10 
– 100 % range of the nominal power. 
On completion of sonication, extracts were centrifuged for 8 minutes at 3000 rpm to 
sediment the extracts of interest.  
2.1.2  Determination of extraction yield 
 
Extracts of various components were evaporated in a rotary evaporator to a total volume 
of 5 – 20% and stored at -30ºC freezer and were then freeze-dried in a bench-top freeze-
dryer - SJIA-10N-50 (Shanghai Beiyi Bioequip Information Co., Ltd.) to obtain dried 
samples. The extraction yield of various procedures was expressed as percent of mass 
of the extract obtained in relation to the dry matter of Inula helenium that was used in the 




2.1.3  Statistical analysis 
 
The extraction process was divided into two sets based on the experimental design. The 
experiment sets were compared in terms of extraction yield. One-way analysis of variance 
(ANOVA) was applied to detect differences among all the groups whereas the student t-
test was applied in detecting differences within groups. Analysis were performed using 
the Origin 9.1 software. A significant level of α = 0.05 was selected and significant 
difference was considered at p < 0.05. The factors examined are the extraction methods 
(three levels; SE, MAE and UAE) and the extraction solvent (three types methanol, n-
hexane and ethyl acetate). 
 
2.1.4  High-performance liquid chromatography (HPLC) 
2.1.4.1 Apparatus and chromatographic conditions 
 
High performance liquid chromatography (HPLC) analysis was performed using Agilent 
1200 LC system (Agilent Technologies Deutschland, Germany) equipped with a G1313A 
auto-sampler, a G1316A column thermostat, a G1315B UV–vis photodiode array 
detector, G1354A solvent delivery unit, a fraction collector, an Ace 5 C18-Amide column 
(Hichrom Limited, Reading, UK), (250 mm × 21.2 mm, 6 μM). Methanol-water was used 
as the mobile phase starting from a gradient of 30:70, 40:60, 50:50, 60:40, 75:25 (v/v) 
and the column temperature was set at 40 °C, the flow rate was set at 5 ml / min, and 
detection wavelength 250 nm. 0.1 % formic acid was also introduced to the water-
methanol used as the mobile phase to enhance good resolution of peaks. Freeze-dried 
extracts from Inula helenium were analysed by HPLC under optimum analytical conditions 
and the various fractions obtained collected by an automated fraction collector. The same 
parameters were used for qualitative HPLC analysis except that a column size (250 mm 
× 4.6 mm, 5 μM) and a flow rate of 1 ml / min were used. 
 
2.1.4.2 Pre-HPLC sample preparation 
 
Prior to HPLC analysis, only precipitates obtained from the hexane fractions were re-
dissolved in 80 % methanol. A total of 14.57 g of precipitates from hexane fraction 
(dissolved in 80 % methanol at 10 mg / mL) was injected into the HPLC compartment and 
pure compounds collected in the auto-sample collector. 




The numbering system used for analysis follows the numbering system in chrysin 
(Structure 1.61, page 104). All NMR spectra data were recorded on a Bruker AC400 
spectrometer using CDCl3 as an internal standard unless stated otherwise (7.28 ppm for 
1H NMR and 77.0 ppm for 13C NMR). All solvents used for NMR analysis were purchased 
from Sigma Aldrich, UK. 
Mass spectrometry data were recorded on an Agilent Technology 6120 Quadrupole 
LC/MS. High Resolution Mass Spectrometry was recorded using the positive electrospray 
ionisation time-of-flight mass spectrometry (TOF MS ES) on Waters i-class UPLC at 
Cambridge Analytical Services, University of Cambridge, UK. 
Infrared spectrometry data were recorded on Thermo-scientific Nicolet iS10. 
Melting point analysis was recorded on a Stuart Melting Point SMP 20. 
Silica gel chromatography was conducted using silica gel 60 Å with a pore size of 40-63 
µM (Fluorochem Limited). Silica thin layer chromatography was performed on pre-coated 
aluminium sheets with 0.2mm thickness obtained from Thermo-Fisher Scientific, UK. Two 
methods: microwave irradiation and the method previously used by Cheng et al., 2014) 
was used in synthesis of these chrysin adducts with modifications in solvent type used, 
reaction time and purification procedures. 
Novel analytical data can be found in the appendix. 
2.2.1  Synthesis of 7-O-bromoalkylchrysin derivatives (C13-C17) 
 
Potassium carbonate (4.00 eq, 0.52 g, 8.4 mmol) was suspended in acetonitrile (10.0 ml) 
and stirred in a microwave tube for 30 minutes. 5,7-Dihydroxyflavone (0.12 g, 0.47 mmol) 
and the corresponding dibromoalkane was added and the resulting suspension stirred for 
24 hours at 80 °C in the presence of bright light to produce a pale-yellow suspension. The 
resulting suspension was allowed to cool to room temperature and poured into crushed 
ice, leading to the formation of pale-yellow precipitate which was left at 4 °C for 24 hours. 
After 24 hours, the precipitate was filtered and washed with ice cold water, followed by 
petroleum ether and eluted in silica gel using 2:1 ethyl acetate: petroleum ether, v/v. The 
solvent was evaporated, and the precipitate dried in an oven for 24 hours at 50 °C to yield 
the pure compound. 
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2.2.2  Synthesis of 7-O-alkylchrysin Derivatives (C4-C12) 
2.2.2.1 Method A for synthesis of 7-O-Alkyl derivatives of Chrysin 
 
The aliphatic (7-O-alkyl) derivatives of chrysin were made by suspending potassium 
carbonate (2.00 eq, 0.26 g, 4.2 mmol) in acetonitrile (10.0 ml). The corresponding 
bromoalkane (2.00 eq) was added to a thick-walled microwave tube and the resulting 
suspension irradiated vigorously in a microwave reactor at 120 °C for 8 minutes at 900 
W. The reaction was cooled rapidly by means of an auto-installed cooler system to a 
temperature of about 30 °C and poured unto crushed ice. The precipitate formed was left 
at 4 °C for 8 – 12 hours after which the precipitate was washed with ice cold water, 
followed by petroleum ether and dried in an oven at 50 °C for 12 hours to yield the pure 
compounds. 
 
2.2.2.2 Method B for synthesis of 7-O-alkylchrysin derivatives  
To chrysin (0.12 g, 0.47 mmol), potassium carbonate (2.00 eq, 0.26 g, 4.2 mmol) and 
tetrabutylammonium bromide (13.0 mg, 0.040 mmol) in dimethylformamide (DMF) was 
added the bromoalkane (2.00 eq, 4.72 mmol) in a microwave reaction bottle. This was 
irradiated in a microwave reactor in 8-successive 3.0 minutes microwave irradiations at 
900 W (with a pause time to return the reaction to 35 °C). Ice cold water was added to 
the mixture which was subsequently acidified with 6 N HCl and extracted with ethyl 
acetate. The organic layer was concentrated to dryness and the brown residue obtained 
chromatographed on silica gel using ethyl acetate: petroleum ether (1:3 to 4:1) mobile 
phase to yield between 62 – 84 % yields of pure compounds. 
 
2.2.2.3 Method C for synthesis of 7-O-alkylchrysin derivatives 
7-O-alkyl derivatives of chrysin were made by dissolving potassium carbonate (2.0 eq, 
0.26 g, 9.44 mmol) in acetone (10 mL). 5,7-Dihydroxyflavone (0.12 g, 0.47 mmol) was 
added and stirred for 15 minutes. The bromoalkane (2.00 eq) was added and the resulting 
suspension stirred for 72 hours at 70 °C The resulting suspension was allowed to cool to 
room temperature and poured into crushed ice, leading to the formation of pale-yellow 
precipitate which was left at 4 °C for 24 hours. After 24 hours, the precipitate was filtered 
and washed with ice cold water, followed by petroleum ether and eluted in silica gel using 
2:1 ethyl acetate: petroleum ether, v/v. The solvent was evaporated, and the precipitate 
dried in an oven for 24 hours at 50 °C to yield the pure compounds with yields ranging 
from 54 – 68 %. The percentage yields for method A and C are reported in Table 4.1. 
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2.2.3  Synthesis of Methylated 7-O-alkylchrysin derivatives 
 
One of the aims of this Project is to synthesise methylated 7-O-alkylchrysin derivatives 
and to study the antimicrobial effect of alkylation of these derivatives. The first compound 
synthesised in this category is 5-hydroxy-7-isopropoxy-3-phenyl-4H-chromen-4-one. 
 
2.2.3.1 Synthesis of 7-O-Isopropylchrysin 5-Hydroxy-7-isopropoxy-
3-phenyl-4H-chromen-4-one (C4) 
 
2.2.3.1.1 Method A: Synthesis using the microwave reactor 
Tetrabutylammonium bromide (0.08 mmol; 0.2 eq) was suspended in acetonitrile (10.0 
ml) and stirred for 1 minute at room temperature. 5,7-Dihydroxyflavone (1 e.q., 0.12 g, 
0.47 mmol), potassium carbonate (4.00 eq, 0.522 g, 8.4 mmol) and 2-bromopropane (4.0 
eq, 152 μl, 12.4 mmol) were added and the resulting suspension irradiated in a microwave 
reactor for 10 minutes at 120 °C, 900 W. The resulting suspension was cooled rapidly in 
dry ice to a temperature of about 4 °C and left at this temperature for 24 hours. After 24 
hours, the pale brown precipitate was filtered and washed with ice cold water, followed 
by petroleum ether and eluted in silica gel using 2:1 ethyl acetate: petroleum ether, v/v. 
The solvent was evaporated, and the precipitate dried in an oven for 24 hours at 50 °C to 
yield pure 5-hydroxy-7-isopropoxy-3-phenyl-4H-chromen-4-one. 
 
2.2.3.1.2 Method B: Stirring the Reaction Mixture 
 
To a solution of chrysin (100 mg of chrysin (0.40 mmol), 0.120 g K2CO3 (0.79 mmol; 2.0 
eq) and 0.025 g of tetrabutylammonium bromide (0.08 mmol; 0.2 eq) in 
dimethylformamide (10 mL) was added 2-bromopropane (88 μL, 0.94 mmol, 2.0 eq). The 
reaction was allowed to stir for 72 hours at 50 °C. After 72 hours, the mixture was diluted 
with ice cold water, acidified with HCl (6 N) and extracted with ethyl acetate. The organic 
layer was concentrated to yield a yellowish-brown precipitate which was 
chromatographed on silica gel using ethyl acetate: petroleum ether (4:1) as mobile phase 
to yield pure 5-hydroxy-7-isopropoxy-3-phenyl-4H-chromen-4-one. 
 
2.2.3.2 5-Hydroxy-7-isobutoxy-3-phenyl-4H-chromen-4-one or 7-O-
Chrysin-2-Methylpropane (C5) – novel  
 
To a solution of chrysin (100 mg, 0.40 mmol), 0.120 g K2CO3 (0.79 mmol; 2.0 eq) and 
0.025 g of tetrabutylammonium bromide (0.08 mmol; 0.2 eq) in dimethylformamide (10 
mL) was added 1-bromo-2-methylpropane (84 μL, 0.99 mmol, 2.0 eq). The reaction was 
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allowed to stir for 72 hours at 50 °C. After 72 hours, the mixture was diluted with ice cold 
water, acidified with HCl (6 N) and extracted with ethyl acetate. The organic layer was 
concentrated to yield a yellowish-brown precipitate which was chromatographed on silica 
gel using ethyl acetate: petroleum ether (20:80 to 100:0) as mobile phase to yield pure 5-
hydroxy-7-isobutoxy-3-phenyl-4H-chromen-4-one. 
 
2.2.4  Synthesis of other Chrysin Derivatives (C1-C3) 
2.2.4.1 Synthesis of 7-O-Chrysinbutyl acetate [4-((5-Hydroxy-4-
oxo-2-phenyl-4H-chromen-7-yl)oxy)butyl acetate] – (C1) 
 
2.2.4.1.1 Method A: Irradiated in a microwave reactor 
 
Potassium carbonate (4.0 eq, 0.52 g, 8.4 mmol) was suspended in acetone (10.0 ml). 
Chrysin (5,7-Dihydroxyflavone) (0.12 g, 4.7 mmol) and 4-bromobutyl acetate (2.0 eq, 184 
µl, 9.4 mmol) were added and the resulting suspension irradiated in a microwave reactor 
for 10 minutes at 120 °C, 900 W. This was rapidly cooled by means of a vapour coolant 
to room temperature. This was then poured into crushed ice, leading to the formation of 
a pale brown precipitate which was left at 4 °C for 24 hours. After 24 hours, the precipitate 
was filtered and washed with ice cold water, followed by petroleum ether and eluted in 
silica gel using 2:1 ethyl acetate: petroleum ether, v/v. The solvent was evaporated and 
the precipitate dried in an oven for 24 hours at 50 °C to yield pure 4-((5-Hydroxy-4-oxo-
2-phenyl-4H-chromen-7-yl)oxy)butyl acetate: (yield 0.196 g, 80.20 %); m.p. 122 – 124 °C; 
Rf = 0.74 (Silica 60 Å, 2:1 ethyl acetate: petroleum ether, v/v). 
 
2.2.4.1.2 Method B: Stirring the reaction mixture 
 
The method for synthesis reported previously by Cheng et al., (2014) was used for 
synthesis of 7-O-Chrysinbutyl acetate with some modifications. 
Potassium carbonate (4.0 eq, 0.52 g, 8.4 mmol) was suspended in acetone (10.0 ml) and 
stirred vigorously in a thick-walled microwave tube (not microwave reactor) for 10 
minutes. 5,7-Dihydroxyflavone (0.12 g, 4.7 mmol) was added and the resulting 
suspension stirred for 1 hour. 4-Bromobutyl acetate (2.0 eq, 184 µl, 9.4 mmol) was added 
and the resulting suspension allowed stirring for 19 hours. The resulting suspension was 
allowed to cool to room temperature and poured into crushed ice, leading to the formation 
of ivory white precipitate which was left at 4 °C for 24 hours. After 24 hours, the precipitate 
was filtered and washed with ice cold water, followed by petroleum ether. This was dried 
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in an oven for 24 hours at 50 °C to yield pure 4-((5-Hydroxy-4-oxo-2-phenyl-4H-chromen-
7-yl)oxy)butyl acetate 
2.2.4.2 Synthesis of 7-O-Chrysin-3,5-dimethylbenzene [7-((3,5-
Dimethylbenzyl)oxy)-5-hydroxy-2-phenyl-4H-chromen-4-
one] – (C2) 
 
2.2.4.2.1 Method A: Irradiation in a microwave reactor 
7-O-Chrysin-3,5-dimethylbenzene was prepared by alkylation of chrysin at 7-OH with 1-
(Bromomethyl)-3,5-dimethylbenzene (2.00 eq, 0.085 g, 6.4 mmol). Potassium carbonate 
(4.0 eq, 0.52 g, 8.4 mmol) was suspended in acetonitrile (10.0 ml). Chrysin (5,7-
Dihydroxyflavone) (0.12 g, 4.7 mmol) was added and the resulting suspension irradiated 
in a microwave reactor for 5.0 minutes at 80 °C, 900 W. This was rapidly cooled by means 
of a vapour coolant to room temperature. This was then poured into crushed ice, leading 
to the formation of a floral-white precipitate which was left at 4 °C for 24 hours. After 24 
hours, the precipitate was filtered and washed with ice cold water, followed by petroleum 
ether and eluted in silica gel using 2:1 ethyl acetate: petroleum ether, v/v. The solvent 
was evaporated and the precipitate dried in an oven for 24 hours at 50 °C to yield pure 4-
((5-Hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)butyl acetate. 
 
2.2.4.2.2 Method B: Stirring the reaction mixture 
7-((3,5-dimethylbenzyl)oxy)-5-hydroxy-2-phenyl-4H-chromen-4-one (C2), was made by 
dissolving potassium carbonate (2.0 eq, 0.26 g, 9.44 mmol) in acetonitrile (10 mL). 5,7-
Dihydroxyflavone (0.12 g, 0.47 mmol) was added and stirred for 15 minutes. 1-
(Bromomethyl)-3,5-dimethylbenzene (2.00 eq, 0.08 g, 6.4 mmol) was added dropwise 
and the resulting suspension stirred for 4.0 hours at room temperature to form a floral-
white suspension.  
The resulting suspension was poured into crushed ice, leading to the formation of floral 
white precipitate which was left at 4 °C for 4 hours. After 4 hours, the precipitate was 
filtered and washed with ice cold water, followed by petroleum ether. This was dried in an 









2.2.4.3.1 Method A: Irradiation in a microwave reactor 
Potassium carbonate (4.00 eq, 0.522 g, 8.4 mmol) was suspended in methanol (10.0 ml) 
with vigorous stirring in a thick- walled microwave tube. 5,7-Dihydroxyflavone (0.12 g, 
0.42 mmol) and 1-bromo-2,4-dinitrobenzene (116.6 g, 4.7 mmol) was added and the 
resulting suspension irradiated in a microwave reactor for 10 minutes at 120 °C, 900 W. 
The resulting suspension was poured into crushed ice, leading to the formation of a pale 
brown precipitate which was left at 4 °C for 30 minutes. This is because the precipitate 
formed was very distinct in appearance. After 30 minutes, the precipitate was filtered and 
washed with ice cold water, followed by petroleum ether and eluted in silica gel using 2:1 
ethyl acetate: petroleum ether, v/v. The solvent was evaporated, and the precipitate dried 
in an oven for 24 hours at 50 °C to yield pure 7-(2,4-dinitrophenoxy)-5-hydroxy-3-phenyl-
4H-chromen-4-one. 
 
2.2.4.3.2 Method B: Stirring the reaction mixture 
Potassium carbonate (4.00 eq, 0.52 g, 8.4 mmol) was suspended in acetonitrile (10.0 ml) 
and stirred for 30 minutes. 5,7-Dihydroxyflavone (0.12 g, 0.47 mmol), and 1-bromo-2,4-
dinitrobenzene (116.6 g, 4.7 mmol) was added and the resulting suspension stirred for 
36 hours. The resulting suspension was cooled rapidly in dry ice to a temperature of about 
4 °C. At 4 °C, the suspension was transferred to crushed ice at about 4 °C and left for 24 
hours. After 24 hours, the pale brown precipitate was filtered and washed with ice cold 
water, followed by petroleum ether and eluted in silica gel using 1:3 ethyl acetate: 
petroleum ether, v/v. The solvent was evaporated, and the precipitate dried in an oven 
for 24 hours at 50 °C to yield pure 7-(2,4-Dinitrophenoxy)-5-hydroxy-3-phenyl-4H-
chromen-4-one. This was dried in an oven for 48 hours at 50 °C to yield pure 7-(2,4-
Dinitrophenoxy)-5-hydroxy-3-phenyl-4H-chromen-4-one. 
2.2.5  Determination of Hydrophilicity of Chrysin Derivatives 
Hydrophilicity of chrysin derivatives were established using the function HC = RfX / RfC 
after TLC on C18 reverse-phase silica gel 20- × 20-cm plates in solvent : water (8:2). 
Methanol, dimethylformamide (DMF) and tetrahydrofuran (THF) where HC is the 
hydrophilicity index of chrysin derivatives (ability to dissolve in polar solvents). RfX = Rf 
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value (ratio of the distance moved by the solute to the distance moved by the solvent) of 
chrysin derivatives. RfC = Rf value of chrysin. 
2.3  Antimicrobial Studies Experimental  
2.3.1  Culture Media and Microbial Strain 
Nutrient agar (Sigma-Aldrich, UK) was used to culture the bacteria to be tested whereas 
the Mueller Hinton Broth (Sigma-Aldrich, UK) was used for minimum inhibitory 
concentration (MIC) assay (Kuete et al., 2011). The Sabouraud dextrose was used to 
culture the Candida albicans fungus (MTCC 227). The following bacterial strains were 
used for antimicrobial assay studies: 
Gram positive bacteria: 
i) Enterococcus faecalis NCIMB 13280 (Kuch, et al., 2012). 
ii)  Staphylococcus aureus 25923 (Taleb-Contini et al., 2003). 
iii) Bacillus cereus ATCC 10876 (Fakruddin et al., 2012). 
iv)  (MRSA252 obtained from Public Health England) (Holden et al., 2004). 
 
Gram negative bacteria: 
i) Escherichia coli NCTC 13353 –  strain EO 487. CTX-M-15 ESBL producer 
(Woodford et al., 2004). 
ii) Klebsiella pneumoniae NCTC 13439 – VIM-1 metallo-carbapenemase (outbreak 
strain (Woodford et al., 2006). 
iii) Pseudomonas fluorescens ATCC 13525 (Yadav et al., 2014). 
iv) Pseudomonas aeruginosa NCTC 13437 – VIM-10 metallo-carbapenemase; VEB-
1 ESBL (Woodford et al., 2008). 
 
2.3.2   Bacterial Preparation 
Strains of bacteria were cultured overnight (22 - 25 h) at 37 °C on nutrient broth for the 
preparation of cell suspensions. Suspensions of bacterial cells (dissolved in PBS) were 
homogenised such that the spectrophotometry standard of 5 × 105 CFU/mL (0.5 
McFarland standards) was obtained. 
 
2.3.3  Bacterial positive control 
Gentamycin (Sigma-Aldrich, UK) was the reference antibiotic (RA) used. Isolates from 




2.3.4  Agar well diffusion assay 
Agar well diffusion assay was done as described before (Balouiri et al., 2016). The test 
compounds were assayed to determine antimicrobial activity via the disc diffusion method 
against MTCC microbial strains. The antibacterial activity of each extracts was 
determined in duplicate and compared to standard antibiotic disc of Gentamycin 10 
μg/mL. Mueller Hinton agar plates were pre-warmed and inoculated with 106 CFU/mL of 
bacterial strain. Test compound were dissolved in DMSO (10 µg/mL); 40 µL of each test 
compound (100 µg/mL) was pipetted unto 10 mm sterile paper disc which was placed on 
the surface of inoculated agar plate and incubated for 23-25 hours at 37 °C and the 
inhibition band of each extracts recorded. Antibacterial activity was expressed as the 
diameter of zone of inhibition recorded by these extracts. DMSO served as the negative 
control. Only fractions from extraction methods which indicated good inhibitory activities 
via the disc diffusion method were tested for MIC. 
2.3.5 Colorimetric assay for Minimum Inhibitory Concentration (MIC) 
A rapid p-iodonitrotetrazolium chloride (INT) colorimetric assay was carried out as 
previously described (Kuete et al., 2009). The assay measures the production of NADH 
by coupling it to the reduction of 2-(p-iodophenyl)-3(p-nitrophenyl)-5-phenyl tetrazolium 
chloride (INT). INT accepts an electron via an intermediate electron carrier, either 
lipoamide dehydrogenase or phenazine methosulfate and is reduced to a red-coloured 
formazan, which can be quantified by the spectrophotometer. All samples to be tested 
were dissolved in Mueller Hinton Broth (MHB) / DMSO such that the DMSO final 
concentration was below 5%. This was necessary to prevent interference of microbial 
growth by DMSO. The resulting solution was added to MHB. This was diluted serially in 
the 96 well plates. Inoculum prepared in appropriate broth – MHB (100 µL) was then 
added (Kuete et al., 2009; Kuete et al., 2008). These plates were sealed and agitated 
using a plate shaker (in order to properly mix the contents of the well), incubated for 18 h 
at 37 °C. This assay was repeated at least thrice. A negative control (wells containing 
broth, DMSO and 100 µL of inoculum to a final concentration of 2.5 %) was also prepared. 
In order to determine MIC, 40μl of 0.2 mg / mL of INT was added after incubation for 18 
h at 37 °C. The concentration of sample which prevented colour change of the media and 
inhibited bacterial growth completely is known as the MIC (Eloff, 1998). INT was added 
to aid the reading of the MIC / MBC result (colour change from violet to red). MBC was 
done by adding 60 µl aliquot from the preparations which did not indicate growth activity 
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during the MIC assay to 140 μl of 7H9 broth, and was incubated for 48 h at 37 °C. The 
concentration of fraction which did not indicate a colour change after INT was added as 
stated above is known as MBC. 
2.3.6  Screening for antifungal activity 
Antifungal activity against the Candida albicans fungus was done using the broth 
microdilution with each well containing about 103 fungus cells-inoculum and the different 
test compounds at 400 µg / mL in RPMI 1640 (L-glutamine containing medium without 
sodium bicarbonate) (Sigma-Aldrich, UK). This was buffered with 0.165 M MOPs (3-(N-
morpholino)-propanesulfonic acid) at pH 7.0. The plates were incubated for 48 h at 37 
°C. Minimum inhibitory concentration (MIC) was done in triplicate and the mean MIC 
taken (Riesselman et al., 2000). Fluconazole (Sigma-Aldrich, UK) was used as an 
antifungal standard drug (Riesselman et al., 2000). 
2.4   Anticancer Studies Experimental 
2.4.1  Cell lines 
Ten cancer cell lines – breast cancer (MCF-7 and MDA-MB 468) (Seca et al., 2014), 
colorectal cancer (HCT-116 and Caco-2) (Seca et al., 2014), Leukaemia cancer (K562 
and Molt-4) (Seca et al., 2014), hepatocellular cancer (HepG2) (Seca et al., 2014), lung 
cancer (A549) (Seca et al., 2014), keratinocytes (HacaT) (Nzengue et al., 2008) and one 
normal cell line: BEAS-2 (Park et al., 2015), were used for anticancer inhibition studies. 
MCF-7 was isolated from a 69-year-old woman in 1970 (Soule, Vazquez, Long, Albert, & 
Brennan, 1973). It is a breast cancer cell line known as an oestrogen receptor (ER) 
positive cell line because of its ability to process oestrogen to oestradiol. When treated 
with “anti-oestrogen, modulation and secretion of insulin-like growth factor binding 
protein” ensues. MCF-7 is inhibited by “tumour necrosis factor alpha (TNF alpha)” 
(Lacroix, Toillon, & Leclercq, 2006). It is an adherent cell. Dulbecco's Modified Eagle 
Medium (DMEM), Sigma Aldrich UK, was used as culture media. 
K562 cells are “immortalised myelogenous leukaemia cell lines of the erythroleukaemia 
type, and the line is derived from a 53-year-old female chronic myelogenous leukaemia 
patient in blast crisis” (Lozzio & Lozzio, 1975). They are suspension cells and were 
cultured using Roswell Park Memorial Institute (RPMI) media. Sigma Aldrich, UK. 
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HacaT cells are immortal keratinocytes cells which are spontaneously transformed 
aneuploidy cells with ability to proliferate and differentiate in vitro. Widely used to study 
vitamin D3 metabolism (Lehmann 1997), cancers of the skin (Chorachoo et al., 2016). It 
is an adherent cell. DMEM was used as culture media. 
Caco-2 cell line is a colorectal adenocarcinoma cell of epithelial origin. In pharmaceutical 
industries, Caco-2 is used in studying the absorption of drugs administered orally across 
the small intestine mucosa (Fogh & Trempe, 1975). It is an adherent cell. RPMI was used 
as culture media. DMEM was used as culture media supplemented with 20 % Fetal 
Bovine Serum (FBS, Sigma Aldrich, UK) as these cells grow slowly. 
HepG2 is a perpetual epithelial cell with a well differentiated hepatocellular carcinoma. It 
is derived from the liver tissues and they secret transferrin, albumin, fibrinogen and 
plasminogen and is usually used in the study of liver disease. It is implicated in 
hepatocellular carcinoma (Ma et al., 2016). It is an adherent cell. RPMI media was used 
as culture media. 
MDA-MB 468 was isolated from pleural effusion of breast tissue / mammary gland is used 
in the study of invasion of breast cancer, migration and metastasis. It is an oestrogen 
(ER) alpha negative human breast cancer cell line (Wang et al., 1997). It is an adherent 
cell. RPMI was used as culture media. 
A549 cell line is an adenocarcinoma human alveolar basal epithelial cell line which is 
responsible for transport of substances including electrolytes and water across the alveoli 
of lungs. They contain high lipids (Foster, Oster, Mayer, Avery, & Audus, 1998) 
(unsaturated fatty acids) and can synthesise lecithin. They are squamous adherent cells. 
A549 cell line was cultured in RPMI media 
HCT-116 is a colon adenocarcinoma cancer cell line. It is an adherent colon cancer cell 
from human. It was cultured on McCoy 5a media, Sigma Aldrich, UK. 
Molt-4 is “human T lymphoblast; acute lymphoblastic leukaemia cell line”. It was grown 
on RPMI media. It is a suspension cell. 
Mero 14 is a mesothelioma cell line of human origin, derived from malignant 
mesothelioma due to exposure to asbestos. It was derived from a 60-year-old man. Mero 
14 cell line was cultured in DMEM media. 
Beas-2 is an adherent, epithelial-like, normal human bronchial epithelial cell. These cells 
release cytokines in the lungs which fights organic pollutants inhaled into the lungs 
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thereby preventing respiratory and cardiovascular diseases (Fuentes-Mattei et al., 2010). 
BEAS-2B cell line was cultured in Bronchial Epithelial Basal Medium (BEBM) from Lonza. 
2.4.2  Maintenance of cells 
Cell culture personal protective equipment comprising of blue sterile nitrile gloves, and 
blue laboratory coat was used. RPMI, DMEM, BEBM, Mc-Coy media and PBS were used 
in the cell feeding procedure (as stated in section 2.4.1) above. Unless stated otherwise, 
all media used cytotoxicity studies were purchased from Sigma Aldrich, UK. BEBM was 
purchased from Lonza, UK. Temperature and CO2 conditions of 37 °C and 5% CO2 were 
not exceeded in all the cell work. Cell handling was done in a sterilised manner by using 
Virkon followed by 70% v/v EtOH, in cleaning the cell culture Hood. Every two to three 
days, old media was replaced by fresh media and the flask returned to the incubator. 
Everything was then decontaminated in Virkon (Sigma-Aldrich, UK). 
2.4.3  Splitting Matured Confluent Cells 
Once the cells confluence reaches 70% or above, the cells were either split into three 
flasks, or passaged and split into 1/3. PBS was used to wash metabolic wastes off the 
cells; cells were trypsinised (5 mL) and detached from the flask which was incubated for 
2-5 minutes at 37 °C. After incubation, detached cells were split into 3 new flasks and 
returned to the incubator. Nevertheless, Caco-2 cells were passaged once the confluence 
was about 40-60%. This is because once confluent, they are difficult to disaggregate as 
they adhere very tightly unto the plate and do not plate well. 
2.4.4  Dosing procedure 
The cell lines used in this study were dosed (unless stated otherwise) as described in 
Table 2.1 below – see the plate map below.  
Table 2.1: Dosing design of cancer cell lines in 96 well plate in MTT assay 
  Compound 1 (µM) Compound 2 (µM) Positive control (µM) (DMSO + CELL) (µM) 
  1 2 3 4 5 6 7 8 9 10 11 12 
A 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
B 50.0 50.0 50.0 50.0 50.0 50.0 50.0 50.0 50.0 50.0 50.0 50.0 
C 25.0 25.0 25.0 25.0 25.0 25.0 25.0 25.0 25.0 25.0 25.0 25.0 
D 12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5 
E 6.3 6.3 6.3 6.3 6.3 6.3 6.3 6.3 6.3 6.3 6.3 6.3 
F 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 
G 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 
H 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 
136 
 
The dosage used in this study ranged from 0.8 – 100 µM (unless stated otherwise) for 
cancer cells assays. The dose was increased to concentrations up to 400 (µM) in order 
to investigate the interaction between the normal cell line in comparison to the cancer cell 
lines. 
 
2.4.5  Cell viability assay using MTT 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was done as 
described previously by Holst and Oredsson (2005). 100 μl aliquots of cell suspension 
containing 3000 cells per well (30,000 cell/mL) were seeded in wells of 96 well plates. 
After 24 hours of seeding, compounds were added. The concentration range used in this 
assay was between 2.0 and 125 μg/mL in addition to appropriate DMSO which was used 
as negative control in the same proportion as the compound. MTT solution (5 mg/ml MTT 
in PBS) was added to the 96 wells and the plate returned to the incubator and left for 4 
hour. The medium containing MTT was removed. Live cells were reduced by the 
formation of purple formazan. 200 μl DMSO was added to dissolve the formazan 
precipitate. Absorbance was monitored Thermo Labsystem Multiskan Ascent plate reader 
(Labsystems Oy, Helsinki, Finland) using the Ascent software at 540 nm. Dose response 
curves were drawn based on % of control in Origin 9.1 Software. The inhibitory 
concentration 50 (IC50) was determined from the curves (Mossman, 1983). 
2.4.6  MTS Assay 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTS) assay was done as 
described before (Mosmann 1983). MTS assay (cell proliferation) is a sensitive 
colorimetric assay that quantifies viable cells in cytotoxic and proliferative assay. Its 
principle is based on the ability of viable cells to reduce MTS tetrazolium compound, 
generating a coloured formazan product which dissolves in cell culture medium. The 
enzyme – NAD(P)H-dependent dehydrogenase is thought to be responsible for this 
conversion in active cells. Absorbance of 540 nm was used to measure the colour 
intensity of the formazan formed (Mossman, 1983). 
Unlike MTT assay, MTS reagent is added directly into the cell culture media. DMSO 
detergent is not needed to solubilise the cells as in MTT assay. MTS assay finds 
application in cytotoxic analysis of anticancer compounds, cell proliferation in response 
to nutrients, mitogens, cytokines and growth factors. 
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Chlorpromazine hydrochloride (CPZ) was used as the positive control anticancer agent 
because of its broad-spectrum cytotoxicity against cancer cells in-vitro (Shenoy et al., 
1982; Jessica et al., 2013). Many anticancer drugs in clinical use are specific for certain 
cancer cells and inactive against others. To compare the cytotoxicity of compounds tested 
in this study especially against ten cancer cell lines, there is need to maintain consistency 
in the criteria (anticancer agent) used. 
2.4.7 Cell Culture and dosing of samples used for Hypoxia, 
Normoxia, Hyperglycaemia and Normoglycaemia Studies 
The technique reported for cell culture as stated in section 2.4.1 – 2.4.6 was used with 
some modifications. Two media – one containing high glucose (0.20 mg/mL) and the 
other containing low glucose levels (0.02 mg/mL) were used. Lactose (0.20 mg/mL) was 
added to the high glucose media only and this media was marked as “high glucose 
media”. The media without glucose was marked “low glucose media”. Maintenance, 
splitting and dosing of cell lines was done as stated in section 2.4.1 – 2.4.6. Cells were 
incubated under normal oxygen conditions (normoxia), and under reduced oxygen i.e. < 
30 mmHg (hypoxia – in Baker Ruskinn in vivo tube). RPMI media was used. Cells were 




Chapter 3   Extraction and Purification of Bioactive Agents from 
Inula helenium 
 
The quantity of bioactive constituents of natural products are fairly low. Extraction and 
isolation of bioactive constituents in the laboratory is intensive and time consuming. This 
has been the bottle-neck in drug discovery from natural product, as bioactive products 
(especially those present in minute quantities) could be missed if proper extraction and 
isolation techniques are not used. There was therefore a need to carefully select 
appropriate / optimised methods that will allow for isolation of novel bioactive compounds 
(with good yield). After extraction, there is a need to fractionate the extracted compounds 
using solvents with different polarities. By fractionating extracts, the biological activities 
of fractionated compounds could be tested. Fractions indicating poor or no bioactivity 
could be discarded while fractions with good bioactivity were subjected to further 
purification to obtain pure compounds. The results obtained from these extraction 
methods are presented below. 
3.1       Extracts from Inula helenium 
3.1.1       Extraction of compounds from Inula helenium 
 
Three extraction techniques: Soxhlet extraction (SE), ultrasound-assisted extraction 
(UAE) and microwave-assisted extraction (MAE), and three solvents – with different 
polarities (methanol, ethyl acetate and hexane) were used in the extraction of compounds 
from Inula helenium.  
1000 g (out of the 1100 g) of dry root sample of Inula helenium purchased from Bristol 
botannicals, UK, was divided into three approximate parts: 333.3 g and extracted in 70 % 
methanol using SE, MAE and UAE to yield 36.12 g, 28.18 g and 21.82 g respectively. 
These were further partitioned in hexane, ethyl acetate and methanol – Scheme 3.1. 
For SE, 15.95 g (44.1 %) was extracted using methanol, 13.25 g (36.8 %) using ethyl 
acetate and 6.26 g (17.3 %) using hexane (Table 3.1). For MAE, 12.70 g (45.1 %) was 
extracted using methanol, 10.45 g (37.1 %) using ethyl acetate and 4.4 g (15.6 %) using 
hexane (Table 3.1). For UAE, 8.45 g (39.9 %) was extracted using methanol, 6.75 g (31.9 
%) using ethyl acetate and 5.9 g (27.9 %) using hexane (Table 3.1). 
Results obtained from the extraction yield of extracts from Inula helenium (Table 3.1 – 
Table 3.2) indicate that SE and methanol were the best extraction method, and the 
solvent of choice for the extraction of compounds from Inula helenium in terms of product 
139 
 
yield. The highest yields of extracts were obtained from the SE (34.45 g) whereas the 
lowest yield was obtained from UAE (21.1 g). 
From the solvents used, the highest extract was recorded using methanol as the 
extraction solvent (Table 3.2) and the least reported for hexane extracts. 
 
Scheme 3.1: Percentage yield of compounds extracted from dry roots of Inula helenium 
Although the total yield obtained using hexane was significantly low compared to the 
yields recorded for methanol and ethyl acetate, the percentage yield recorded for UAE 
using hexane was significantly higher than those recorded for SE and MAE (p-value, 
0.000007), and this yield was comparable to those of UAE using methanol and ethyl 
acetate – Scheme 3.1. 
With SE, the student t-test indicated that the yield is significantly affected. Although the 
total yield obtained using hexane was significantly low compared to the yields recorded 
for methanol and ethyl acetate, the percentage yield recorded for UAE using hexane was 
significantly higher than those recorded for SE (p-value, 0.03) and MAE (p-value, 5.6 x 
109). The yield was comparable to those of UAE using methanol and ethyl acetate (Table 
3.1– 3.2). 
Table 3.1: The yield of compounds extracted from Inula helenium using different extraction 
methods and different solvents 
 
Dry 100 g Inula helenium powder 
 
Method of extraction 
 
solvent used 
Dry matter obtained from 100 
g Inula helenium powder 
 
Total yield (g) 
Yield (g) Yield (%) 
Soxhlet extraction (SE) 
Methanol 15.95 44.1 34.45 
Ethyl acetate 13.25 36.8 
Hexane 6.26 17.3 





Ethyl acetate 10.45 37.1 




Methanol 8.45 39.9 21.1 
Ethyl acetate 6.75 31.9 
Hexane 5.90 27.9 
 
The yields recorded for the various extraction methods (SE, MAE and UAE) base on the 
solvents used is presented in Table 3.2. 
 








Total yield (g) 
Methanol 15.95 12.7 8.45 37.1 
Ethyl acetate 13.25 10.45 6.75 30.45 
Hexane 6.25 4.4 5.9 16.55 
 
The yield also for polar solvent – methanol was higher than the yields recorded for less-
polar solvents (ethyl acetate and hexane). The most effective solvents in terms of output 
(yield) for SE were methanol – 15.95 % (100% v/v), whereas the less-polar solvents – 
ethyl acetate and hexane showed the least yields (13.25 %, and 6.25 % respectively per 
gram of dry plant matter) (Table 3.2). 
 
3.1.2  Centrifugation of compounds extracted from Inula helenium 
 
Dried samples extracted from Inula helenium (Table 3.1) were re-suspended in methanol 
and centrifuged in an Allegra X-14R Benchtop Centrifuge at 500   r.p.m. for 1 minute to 
obtain the pellet and supernatants - Scheme 3.2. 
 




For SE, 10.73 9 (69.45 %) yellowish-brown precipitate was obtained from the methanol 
fraction and 4.61 g (29.84 %) yellow precipitate was obtained from the supernatant. 6.31 
g (49.49 %) and 6.28 g (49.41 %) was obtained from the pellet and supernatants obtained 
from the ethyl acetate fraction. There was however a colour change in the colour of the 
precipitate obtained from the hexane fraction. 5.55 g (96.35 %) white precipitate from the 
pellets, and 0.18 g (yellow) precipitate from the supernatant were obtained (Scheme 3.2). 
The white precipitate was isolated and characterised as sesquiterpene lactones as will 
be discussed in the next section. 
For MAE, 10.73 g (48.18 %) yellowish-brown precipitate, and 5.83 g (45.91 %) yellow 
precipitate, were obtained from the pellets and supernatant respectively for the methanol 
fraction - Scheme 3.3. 4.89 g (46.6 %) and 5.01 g (47.94 %) were obtained from the 
pellets and supernatants of the ethyl acetate fraction respectively. 
 
Scheme 3.3: Schematic representation of extraction yields from MAE using different extraction solvents 
 
As observed for the precipitates obtained from the SE, 3.84 g (87.95 %) and 0.49 g (11.14 
%) white precipitate was obtained from the pellets from the hexane fraction - Scheme 3.3. 
The precipitate obtained from the supernatant was yellowish in colour. The white 
precipitate was also characterised as a sesquiterpene lactone. For UAE, a yellow-brown 
precipitate - 5.26 g (62.25 %), and a yellow precipitate – 2.98 g (35.27 %), were obtained 
from the pellets and supernatant obtained from the methanol fraction. Similarly, 3.84 g 
(56.89 %) and 2.78 g (41.19 %) yellow-brown precipitate and yellow precipitate, were 
obtained from the pellets and supernatants obtained from the ethyl acetate fraction - 
Scheme 3.4. 
Like the pellets obtained from SE and MAE, the pellets obtained from the hexane fraction 
were white in colour and were characterised to be sesquiterpene lactones. 5.78 g (97.97 
%) white precipitates were obtained from the pellets, and 0.103 g (1.75 %) pale yellow 
142 
 
precipitates from the supernatant (Scheme 3.4). The precipitates obtained from the 
supernatants and the pellets from each of the extraction methods – SE, MAE and UAE, 
were tested against cancer cell lines, and microbial strains as shall be discussed in the 
next section. Precipitates which indicated promising biological activities were further 
purified via HPLC, isolated, tested on bacterial strains and cancer cell lines, and 
characterised thereafter using NMR, MS and infrared spectroscopy and their melting 
points determined. 
Prior to HPLC analysis, only precipitates obtained from the hexane fraction indicated good 
bioactivities against cancer cell lines and bacterial strains. Since one of the aims of this 
project was to isolate, purify and characterise bioactive components of Inula helenium, 
compounds which did not meet this criterion were dropped and only compounds obtained 
from the hexane fraction were further purified and characterised. 
 
Scheme 3.4: Schematic representation of extraction yields from UAE using different extraction solvents 
 
To do this, the white precipitates obtained from SE, MAE and UAE in Scheme 3.2 - 
Scheme 3.4 were combined because they indicated similar spots on a thin layer 
chromatography (TLC plate). 0.2 g of these precipitates was used for biological analysis 
on cancer cell lines and bacterial strains for each of SE, MAE and UAE, thus 5.58 g (from 
SE), 3.64 g (from MAE) and 5.35 g (from UAE) were summed together; a total yield of 
14.57 g of precipitates from hexane fraction. 
It was observed that the particle sizes were uneven as some were larger and folded into 
small white balls, while others were powdery in nature. The white precipitate was re-
dissolved in methanol and centrifuged at 250 r.p.m for 2 minutes to obtain a white 
supernatant (3.85 g) and a milky colour precipitate (10.43 g) - Scheme 3.5. 
The bioactivity of the supernatant and the pellets were assayed on some cancer cell lines 
and bacteria. The bioactive components were present in the supernatant. The precipitate 
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obtained from the supernatant (3.85 g) was chromatographed (HPLC) as described in 
section 3.1.3 below, to yield three sesquiterpene lactones – alantolactone, 
isoalantolactone and costunolide. 
 
Scheme 3.5: Precipitate obtained from Soxhlet extractor. 
The precipitates obtained were centrifuged at r.p.m 250 for 2 minutes to obtain 10.43 g pellets and 3.85 g 
supernatant. The pellets were re-suspended in methanol, evaporated and purified further via the HPLC. 
 
Interestingly, this is the first time costunolide has been reported (isolated) from Inula 
helenium. Purification and characterisation of bioactive compounds isolated from Inula 
helenium is described in detail in section 3.1.3.1 (below). 
 
3.1.3  High-performance liquid chromatography (HPLC) 
3.1.3.1 Purification of bioactive compounds from Inula helenium 
 
An auto-sample collector, a component of the HPLC system as described in section 2.1.4 
above was used to collect the pure samples. Vials 9 and 18 (Figure 3.1) were eluted at 
35.62 minutes and were characterised via nuclear magnetic resonance (NMR), mass 
spectroscopy (MS) and infrared (IR) spectroscopy to be alantolactone, vial 17 was eluted 
at 37.04 minutes and was characterised to be isoalantolactone. Vial 16 was eluted at 
39.97 minutes and was characterised to be costunolide – a novel compound isolated from 
Inula helenium. These vials (9, 18, 17 and 16 were characterised becaused they indicated 
good bioactivity). The boiling point (b.p), nuclear magnetic resonance (NMR) and masss 
spectroscopy (MS) data of alantolactone, isoalantolactone and costunolide isolated from 
Inula helenium via HPLC is reported below. Figure 3.1 and Figure 3.2 represents the 
HPLC spectrum of pure sesquiterpene lactones isolated from Inula helenium. 
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Figure 3.1: chromatograms showing sample collection at the auto-sample collection 
DAD indicates the ultraviolet (UV) absorbance readings measures at different wavelengths: DAD1A at 210 
nm, DAD1B at 260 nm, DAD 1C at 360 nm. FLD1 indicates the infrared (IR) reading measured at 230 nm. 
The measurement was performed using different UV wavelengths and an HPLC-FT-IR in order to ascertain 
the purity of the purified compounds. Purity obtained via HPLC was ≥ 98 %. Vials 9, 16 and 18 represents 
pure alantolactone, costunolide and isoalantolactone respectively. The green lines indicate the start and 
end point of sample collection. The red lines indicate sample collection but also an indication that less 




Figure 3.2: chromatograms obtained from the UV and HPLC-FT-IR detectors. 
This represents the chromatogragram obtained at the HPLC detectors. Different wavelengths were used to 
ensure pure compounds with purity of over 98 % were obtained by HPLC. The clustering effect of the 


































Although costunolide has been isolated from some other plants, this is the first time 
costunolide has been isolated and characterised from Inula helenium. Figure 3.2 indicate 
the HPLC chromatogram of pure bioactive compounds isolated from Inula helenium – 
alantolactone, isoalantolactone and costunolide. It should be noted that to ensure these 
compounds were pure (above 98 %), different UV wavelengths: 210 nm, 260 nm and 360 
nm and an HPLC-FT-IR wavelength 230 nm were used to detect the compounds in the 
chromatogram. From the chromatogram in Figure 3.2, pure compounds were isolated. 
The sesquiterpene lactones eluted late because the concentration gradient of methanol 
to water was increased from 50 % to over 60 % after 30 minutes of elution. Sesquiterpene 
lactones are poorly soluble in water and non-soluble in methanol. This is the first time 
costunolide, a known sesquiterpene lactone has been isolated from Inula helenium (by 
HPLC). 
3.1.3.1.1 Alantolactone (D1) 
 
Alantolactone (D1), was obtained as a white powdery precipitate by HPLC with 
spectroscopic data given below: 
 
     D 1 
Structure 1.52: Alantolactone 
 
Elution time: 35.83 minutes (methanol : water (65 : 35 % v/v)); (1.3978 g, 36.3 %); m.p. 
75 – 77 °C, Rf = 0.73 (Silica 60 Å, 1 : 1 hexane : ethyl acetate, v/v 1H NMR (400 MHz, 
CDCl3, δ ppm) 1.09 – 1.20 (4H, d, J= 6.7 Hz), 1.21 (3H, s), 1.42 – 1.50 (1H, dddd, J = 
13.3, 10.2, 4.5, 3.1 Hz), 1.54 – 1.67 (4H, dtt, J = 13.4, 10.2, 3.2 Hz), 1.78 – 1.91 (1H, m, 
J = 13.4, 10.2, 3.2, 2.7 Hz), 2.12 – 2.17 (1H, tt, J = 13.4), 3.60 (1H, t, J = 6.7 Hz), 4.85 
(1H, ddd, J = 10.3, 10.1, 3.5), 5.19 (1H, d, J = 6.9 Hz), 5.64 (1H, s), 6.22 (1H, s); 13C NMR 
(100 MHz, CDCl3, δ ppm) 16.73 (CH3), 22.53 (CH2), 28.56 (CH3), 32.64 (CH2), 32.70 (C), 
37.58 (CH), 39.48 (CH), 41.71 (CH2), 42.64 (CH2), 76.42 (C-O), 118.75 (C), 121.64 (CH2), 
139.82 (C), 149.05 (C), 170.43 (C=O); MS (ESI) m/z: calculated for C15H20O2 [M+H]+ = 
232.1463, found 232.32 g/mol. 
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The first approach aimed at isolating pure compound (D1, D2 and D3) was by using 
varying concentrations of the methanol and acetonitrile. This was unsuccessful as these 
compounds (D1, D2 and D3) clustered together. Acetonitrile was replaced with water and 
a gradient of methanol : water (v/v) was allowed to run. It was still difficult to isolate pure 
compounds. In order to overcome this challenge, 0.1 % formic acid was introduced to the 
HPLC solvent system. Pure compounds were then isolated (Figure 3.2). 
Alantolactone (D1) was isolated as a powdery white precipitate and its melting point was 
consistent with that reported in the literature (Naemura & Nakazaki, 1969). In the 1H NMR 
spectrum of alantolactone (D1), the 3 protons (3 H, d, J = 6.9 Hz) having chemical shift δ 
1.08 ppm, corresponds to the protons attached to position 15 (methyl group) of 
alantolactone.  The 3 singlet protons at chemical shift 2.00 in D1 correspond to the methyl 
group at position 14 of D1. The 3 protons stated above appear as part of the multiplet of 
five protons (5 H) with a chemical shift range of δ 1.63 – 1.79 ppm. The other two protons 
are those at position 8 of D1. The 1 H multiplet, 1H triplet-triplet in the aliphatic region 
along with two deshielded 1H (triplet) and 1H (doublet-doublet-doublet) at δ 3.60 and 4.85 
gave evidence for the lactone ring. The 13C NMR spectrum of D1 provided evidence for 
the presence of a carbonyl group through the signals at 170.43. It also provides evidence 
for the existence of a methelene bond at C-6 position of D1 in the 13C NMR spectrum (δ 
118.75 ppm). The mass of 232.32 g/mol is also consistent with the proposed structure. 
3.1.3.1.2 Isoalantolactone (D2) 
 
Isoalantolactone (D2), was isolated as a white needle-like precipitate by HPLC with 
spectroscopic data given below: 
 
     D 2 
Structure: 1.53 Isoalantolactone 
 
Elution time: 37.34 minutes (methanol : water (65 : 35 % v/v)); (1.2374 g, 32.14 %);  m.p. 
105 - 107 °C, Rf = 0.72 (Silica 60 Å, 1 : 1 hexane : ethyl acetate, v/v; 1H NMR (400 MHz, 
CDCl3, δ ppm) 0.83 (3H, s), 1.21 – 1.30 (1H, m, J = 13.3, 10.3, 10.2, 3.5, 2.6 Hz), 1.34 -
1.47 (1H, ddd, J = 13.2, 13.0, 2.6 Hz) 1.50 – 1.66 (4H, m, J = 14.2, 10.3, 10.2 Hz), 1.73 
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– 1.80 (1H, m, J = 14.2, 10.3, 10.2 Hz),  1.86 (1H, d, J = 3.2 Hz), 2.03 (1H, m, J = 14.4, 
10.2, 3.5 Hz), 2.21 (1H, dd, J = 3.5, 3.2 Hz), 2.35 (1H, tt, J = 10.2, 10.0 Hz), 3.0 (1H, m, 
10.2, 10.0, 2.4 Hz), 4.46 (1H, s), 4.51 (1H, t, J = 10.20 Hz), 4.79 (1H, s), 5.60 (1H, s), 
6.14 (1H, s); 13C NMR (100 MHz, CDCl3, δ ppm) 17.63 (CH2), 22.64 (CH2), 27.42 (CH3), 
34.24 (CH2), 36.77 (C), 40.48 (CH2), 41.32 (CH), 42.14 (CH2), 46.16 (CH), 77.32 (C-O), 
106.57 (CH2), 120.00 (CH2), 142.17 (C), 148.92 (C), 170.59 (C=O); MS (ESI) m/z: 
calculated for C15H20O2 [M+H]+ = 232.1463, found 232.32 g/mol 
Isoalantolactone (D2) was isolated as a white needle-like precipitate and its melting point 
was consistent with that reported in the literature (Naemura & Nakazaki, 1969). In the 1H 
NMR spectrum of isoalantolactone (D2), the methyl group at position 15 of alantolactone 
is replaced by a methylene group (C=CH2). In place of 3 protons in alantolactone, only 2 
protons are present in isoalantolactone. This difference is observed as doublets at δ 4.65 
ppm and 4.75 ppm with coupling constants 1.4 Hz respectively. The 3 singlet protons at 
δ 0.83 corresponds to the methyl protons attached to position 14 of D2. The 13C NMR 
spectrum reveals the appearance of a methelene carbon at δ 120 ppm corresponding to 
C15. The 13C NMR spectrum of D2 also reveals the absence of a peak at δ 118.75 ppm 
(as seen with D1). This observation is an indication that the methelene bond at position 
6 of D1 is absent in D2. The 13C NMR spectrum of D2 at position 6 gives a signal at δ 
22.64 corresponding to a CH2 group. The mass of 232.32 g/mol is also consistent with 
the proposed structure. 
3.1.3.1.3 Costunolide (D3) 
 
Costunolide (D3) was isolated as a white semi-crystalline needle-like precipitate by HPLC 
with spectroscopic data given below: 
 
              D 3 
Structure 3.1: Costunolide 
 
Elution time: 40.24 minutes (methanol : water (65 : 35 % v/v)); (0.0568 g, 1.48 %);  m.p. 
102 – 105 °C; Rf = 0.78 (Silica 60 Å, 1:1 hexane : ethyl acetate, v/v;  1H NMR (400 MHz, 
CDCl3, δ ppm) 1.44 (3H, s), 1.65 – 1.76 (4H, dddd, J = 13.6, 9.6, 5.6, 1.6 Hz), 2.01 – 2.38 
149 
 
(7H, m, J = 13.6, 9.6, 5.6, 1.6 Hz), 2.46 (1H, m, J = 13.6, 9.6, 5.6, 1.6 Hz), 2.60 (1H, ddd, 
J = 7.8, 5.6, 2.5 Hz), 4.60 (1H, t, 9.6 Hz), 4.75 (1H, dd, J = 9.3, 6.0 Hz), 4.88 (1H, dd, J = 
9.3, 6.0 Hz), 5.64 (1H, d, J = 3.2 Hz), 6.25 (1H, d, J = 3.2 Hz); 13C NMR (100 MHz, CDCl3, 
δ ppm) 16.12 (CH3), 17.35 (CH3), 26.20 (CH2), 28.04 (CH2), 39.46 (CH2), 40.99 (CH), 
50.41 (CH2), 81.92 (C-O), 119.68 (CH2), 127.05 (CH), 127.27 (CH), 136.97 (C), 140.09 
(C), 141.50 (C), 170.50 (C-O); calculated for C15H20O2 [M+H]+ = 232.1463, found 232.32 
g/mol. 
Costunolide (D3) was isolated as a white semi-crystalline needle-like precipitate and its 
melting point was consistent with that reported in the literature (Naemura & Nakazaki, 
1969). Costunolide (D3) has a chemical shift δ 1.43 ppm and appears as a singlet (3 
protons) at position 15 of D3. In D3 there is ring opening at position 5. This opening gives 
a chemical shift of δ 1.73 ppm, s, corresponding to the 3 protons (methyl group) at position 
14 of costunolide. The chemical shift δ 1.65 - 1.76 appearing as a 4-protons is reality are 
3-protons. Evidence from 13C NMR and 13C-APT, gives an indication that the signal is 
actually a methyl group. The appearance of the methyl groups at chemical shifts δ 1.44 
(singlet) and 1.65 – 1.76 (doublet-doublet) gives an indication that these methyl groups 
may be oriented asymetrically. To confirm this, 13C NMR and 13C-APT and two-
dimensional 1H NMR were done. In the 13C NMR spectrum, chemical shifts were 
observed at very close range to each other in pairs at the aliphatic region – δ 16.12 and 
17.35; 26.20 and 28.04; and 39.46 and 40.99 respectively. These signals give an 
indication that the carbon atoms represented by these signals may be asymmetrical in 
orientation. To verify this, 13C APT (associated proton test) was conducted. From the APT 
signals (see appendix), the asymmetric nature of these carbons was verified. Signals at 
16.12 and 17.35 ppm corresponds to the methyl carbon atoms at positions 14 and 15; 
signals at 26.20 and 28.04 ppm corresponds to CH2. Signals at δ 39.46 and 40.99 also 
corresponds to CH2 carbon atoms. The signal at δ 50.41 and 81.92 ppm gives an 
indication that a lactone ring is present in D3. The signal at δ 170.50 corresponds to a 
carbonyl carbon. The actual mass found in the mass spectrum (232.32 g/mol) was also 
in agreement with the proposed structure. 
In the 13C NMR spectrum, D1 has a chemical shift δ at 16.73 ppm (CH3), D2 at 106.57 
ppm (CH2) and D3 at 17.35 ppm, corresponding to carbon atom 15 of these compounds 
respectively. The significant difference observed in the chemical shifts of D2 (106.57 ppm) 
compared to D1 (16.73 ppm) and D3 (17.35 ppm) is the presence of the methylene bond 
at C15 of D2.  
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In this study, the bioactive compounds were extracted by solid-liquid phase extraction 
using 70 % methanol (v/v) as solvent, and the extraction yield obtained was 8.61 %. This 
result is similar (10.50 %) to the one obtained by Chahmi et al. (2015) studying I. viscosa 
leaves from Morocco. Chahmi et al. (2015) also reported yields of 13.35 %, 20.8 % and 
23.90 (percentage of dry matter w/w) using ethanol. These extracts were obtained from 
different regions of Morocco (Imouzzer, Sefrou and Taounate respectively). The extract 
obtained from this work is lower than values obtained by Bssaibis et al. (2009) in the same 
part of plant of the same origin. The variability of physicochemical properties influencing 
the extraction of bioactive compounds emanates from this structural diversity (Koffi et al., 
2010). The variation observed can be explained by differences in the geographical origin 
of the plant, climatic factors, the harvest period, and the methodological used for 
extraction procedure. 
Although a conventional method of extraction of natural products, SE offers some 
advantages over other methods, as fresh solvent is constantly coming into contact with 
the sample, enhancing the extraction of compounds from these samples (Luque de 
Castro & Priego-Capote, 2010), this constant contact between the sample and the solvent 
tends to override its draw-back of high solvent requirements, energy and time 
consumption (Luque de Castro & Priego-Capote, 2010). SE also produces an increased 
yield of compounds compared to other methods of extraction. Soxhlet extraction also has 
the ability of extracting both high molecular weight compounds and volatile compounds 
(Zhao & Zhang, 2014). 
The increased yield obtained from methanol extract may be as a result of the polarity 
(dissolving power) of the hydroxyl group which combines with hydrogen to form water and 
water has a high dielectric constant (78.5 at room temperature) and this dielectric 
constant can be decreased by simply increasing its temperature (Hartonen et al., 2007). 
This enhances the solute-solvent interaction of water, thus the increased yield. On the 
other hand, less-polar solvents such as ethyl acetate and hexane are considered 
appropriate for extraction of non-polar compounds including lipids, terpenes and 
carotene, whereas water, methanol and ethanol are suitable for extraction of phenolic 
compounds (Barreira et al., 2014; Vázquez et al., 2013), anthocyanins and flavonoids 
(Pereira et al., 2016). 
For SE, the results indicate that solvent polarity plays a role in determining the yield of 
compounds as previous studies have confirmed (Kaneria & Chanda, 2012; Pereira et al., 
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2016). The low extraction yields recorded for ethyl acetate and hexane suggest these 
solvents are not very suitable for extraction of compounds from Inula helenium (in terms 
of yield). It can also be said that the polarity of the solvent, coupled with an increased 
temperature, potentiates the solubilizing ability of solvents on the analyte and 
subsequently decreasing the viscosity of solvents, and allowing a better penetration of 
solvents into matrices of dry matter (Bae et al., 2012; Pereira et al., 2016). The hydroxyl 
group in methanol which has the higher polarity than ethyl acetate therefore showed the 
highest yield, followed by ethyl acetate. It could be seen also that the yield of methanol 
was higher than the yield for hexane. The increased yield could also be attributed to the 
rehydration of the dried plant matter by water as rehydration entails: imbibing of vapour 
into dried organic matter, swelling and leaching of soluble substances (Krokida & 
Maroulis, 2001), especially if the dielectric constant of water is reduced by increasing its 
temperature (Hartonen et al., 2007). Water therefore plays a major role in the yield of 
extracts from Inula helenium, allowing cellular contents to be leached out of the cells. The 
result for SE indicates the important role played by solvents in the extraction yields of 
compounds isolated from Inula helenium; a trend that has been confirmed by various 
studies (Kaneria & Chanda, 2012; Yang et al., 2007). 
For MAE (Table 3.2), the role of hydroxyl group in increasing the yield was also noticed. 
The polar solvent - methanol indicated the highest yields – 45.1 % (Scheme 3.3), 
compared to the non-polar or less polar solvents: hexane and ethyl acetate (15.6 % and 
37.1 %). Polarity also plays an important role here as water appears to penetrate into the 
matrices of the dry matter, rehydrating the dry matter, and enabling the interaction 
between solute and solvent, leading to the leaching of soluble substances from the plants 
(Bae et al., 2012; Krokida & Maroulis, 2001), and the efficiency of extraction is potentiated 
by the effect of increased temperature and pressure within the microwave (Zhao & Zhang, 
2014). However, the yield indicated for MAE was similar (Table 3.2) to the corresponding 
yields for SE and UAE using less polar solvents – hexane and ethyl acetate. In this 
situation, temperature and pressure (but not polarities) are the major parameters 
influencing the extraction efficiency. As the MAE begins, the pressure and temperature 
of the microwave increases, and these conditions favour a rise in the fluid density and a 
corresponding increase in solubility of the solute especially as the pressure begins to 
increase (Zhao & Zhang, 2014). Thus, microwave enables the rapid penetration of 
solvents through dry tissues, breaking them, and releasing substances in the tissues.  
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Because MAE radiation is non-ionised, extraction of materials depends on the heating 
effect and substances which can absorb the energy generated by the microwave can be 
heated thus solvent free extraction can occur in a microwave for extraction of especially 
volatile products. Another factor responsible for the increased yield recorded for the MAE 
is the choice of solvent used as compounds from Inula helenium are relatively soluble in 
the solvents used. As the compounds tend to dissolve in the extraction solvent, a solvent 
film is established and a sort of an equilibrium which allows solvents influx into the cells, 
and solute efflux out of the cells, leading to swelling of the cell. As the cell swells, the 
increased pressure and the high temperature in the cellular compartment cause the cell 
to burst, releasing its contents into the solution. 
UAE employing polar solvents – methanol indicated the highest yields 39.9 % compared 
to less polar solvents – ethyl acetate (31.9 %) and hexane (27.9 %). Among the different 
extraction techniques used in this study, UAE indicated the lowest yields of compounds 
compared to SE and MAE. This is an indication that an increase in temperature and 
pressure (as in SE and MAE) potentiates the yield of extracts from Inula helenium. 
Polarity of the solvent also potentiates the yields of extracts from Inula helenium. 
However, an increased yield of extracts from hexane fraction using UAE was recorded 
compared to the percentage yield using other extraction techniques. 
Interestingly, there was a significant difference (p < 0.0004) between SE and UAE using 
non-polar solvent - hexane (Table 3.2), with a higher yield recorded for methanol. This is 
an indication that the amplitude of sonication (in UAE) is mainly responsible for disruption 
of the cell walls of plant by the phenomena of cavitation, increasing surface area of 
contact between the solute and solvent, allowing influx of solvents into the plant material 
and a subsequent rupture of cell walls and release of solutes into the solvent media 
(Jerman et al., 2010; Kazemi et al, 2016) but not the effect of temperature and pressure 
as seen in the extraction yields recorded for SE. The increase in extraction yield using 
polar solvents, compared to ethyl acetate and hexane is an indication that the 
combination of sonication and polar solvents, sends down shock-waves into the cell wall, 
and by imbibing the water (polar solvents) into the cells, disruption of the cell membrane 
occurs because cavitation produces microscopic bubbles. This releases the cell contents 
into the solvent. Thus polarity (in SE) potentiates the efficiency of extraction of 
compounds due to the interaction of the -OH group in methanol which interacts with 
hydrogen atom to form water, which is imbibed by the dry plant matter, causing it to swell, 
rupture and burst; releasing its contents into the extraction system. The increased 
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extraction yield using MAE is also an indication that the increased pressure and 
temperature accelerates the swelling and softening of compounds, and violently releasing 
them thus the increased yield for MAE compared to UAE (Tao & Sun, 2015; Yao, 2016). 
The effect of a combination of increased temperature (≥ 50 ⁰C) and polarity in increasing 
the ability of solvent to solubilize the analyte, with a subsequent increased yield of 
extracted compounds has been reported (Bae et al., 2012; Gardeli et al., 2008), which 
confirms the findings in this work. Increasing the temperature also decreases the viscosity 
of the extraction solvent (especially the polar solvents), allowing a better penetration of 
solvent into the matrix (Bae et al., 2012; Gardeli et al, 2008).   
This finding indicates that UAE using hexane, resulted in an increase yield of compounds 
from Inula helenium compared to other extraction techniques and UAE is an important 
extraction technique when increase in yield is a factor to consider and hexane is important 
in the extraction of sesquiterpene lactones from natural products as we found out in the 
course of this project. Although the percentage yield recorded using methanol as an 
extraction solvent was higher than those obtained using hexane, it was found that the 
hexane fraction indicated a high yield of sesquiterpene lactones (which are the bioactive 
components isolated from Inula helenium – chapter 3) whereas the methanol fraction 
contained biologically inactive constituents extracted from Inula helenium. Of interest is 
the fact that UAE using hexane produced the highest yield (%) (Scheme 3.4) compared 
to other extraction solvents and the biologically active components were isolated from the 
hexane fractions. 
It has been documented that UAE offers a better extraction yield of up to 50 % at room 
temperature compared to other extraction methods and the extraction time was reduced 
to 10 hours instead of 28 days for conventional extraction methods and an increased yield 
is often obtained when the temperature is increased from room temperature to a 
temperature over 60 °C (Vinatoru 2001) and UAE is a technique of choice used in the 
isolation of compounds of choice compared to other methods as reported in this project. 
A similar finding was also reported by Sun et al., (2011) and Sun (2011) while comparing 
Soxhlet extraction, maceration and other extraction techniques. They reported low 
solvent consumption and an increased extraction yield for extraction of isoflavones from 
Inula tectorum using UAE and in addition to the increased extraction yield of the targeted 
compounds, a significant shorter process and extraction time was recorded compared to 
other extraction techniques. This findings by Sun et al. (2011) and Sun (2011) agrees 
with our findings where we report an increased extraction yield of targeted compounds 
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(sesquiterpene lactones) from Inula helenium) using hexane and a shorter extraction time 
compared to other extraction methods. 
UAE using hexane also provided a good selectivity for extraction of sesquiterpene 
lactones which were the major components of the hexane fraction of compounds isolated 
from Inula helenium. Ultrasound like any sound wave is propagated through rarefaction 
and compression waves which is induced in the medium and molecules through which it 
passes. When the rarefaction and compression power become so great, it exceeds the 
forces of attraction of the molecules, forming cavitation bubbles in the liquid. Rectified 
diffusion therefore results, allowing the bubbles to grow. This implies that gasses or 
vapour enters the bubble from the medium and this bubble is trapped inside the molecule 
and is not expelled during the compression and expansion phase. As successive cycles 
of compression occur, energy is generated, and this great intensity and frequency of 
compression allows cellular contents to be emptied into the extraction medium (Sun et 
al., 2010; Sun et al., 2011). 
Cavitation is responsible for UAE and operates via the passage of ultrasonic waves 
across the solvent; cavitation exerts some hydrodynamic forces creating small localised 
vacuums in the solvent which implodes rapidly, creating shock waves on the sample 
matrix as the solvents pass through the sample; this allows greater penetration of solvents 
through the biological organisation, increasing the area of interaction between the liquid 
and solid phase (Yolmeh et al., 2014). UAE can drastically decrease particle size thereby 
increasing reactive surfaces. The solvents used were methanol, ethyl acetate and 
hexane. 
The result from this finding indicates that UAE provided a better yield when compounds 
from Inula helenium were extracted using hexane. This improved yield could be attributed 
to the collapse of acoustic cavity within the molecule as a result of improved mass transfer 
which disrupts the cell, milling it, with a consequent improved penetration of the solvent 
into the matrices of the molecule (Dezhkunov & Leighton, 2004; Luo et al., 2013). In 
addition, there is a possibility that the application of an ultrasound generates an ultrasonic 
capillary effect. This effect is related to anomalous rise of a liquid in a capillary tube. This 
effect was discovered in 1950 (Luo et al., 2013). Logically, it is supposed that plant 
material has capillaries which could exert the capillary effect. This effect has been ignored 
since its discovery. It has been linked to sonoluminescence (Dezhkunov & Leighton, 
2004). There is usually a movement of materials contained in pores of plant materials. 
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Luo et al., (2013) proved that they exist alternating electrical field at both ends of a 
capillary tube containing an electrolyte solution when an ultrasound is applied. There are 
certainly ionic / polar compounds in plants which can occupy the capillaries and crevices 
within the plant material which could be affected by the capillary effect. 
0.5 g of compounds extracted from the respective extraction techniques were tested 
against several cancer cell lines and bacterial strains and compounds extracted from the 
hexane fraction indicated good cytotoxic activities against the cancer cell lines and 
bacterial strains tested; these compounds were further isolated and purified by other 
purification techniques including High-performance liquid chromatography (HPLC). After 
preparation of samples as stated in Scheme 3.5, dry-freeze precipitates obtained from 
the supernatant (3.85 g) were diluted in 70 % methanol (v/v) and eluted via the HPLC 
system. Bioactive compounds isolated from Inula helenium were isolated / purified via the 
high-performance liquid chromatography (HPLC) to obtain three-known bioactive 
sesquiterpene lactones – alantolactone (ALA), isoalantolactone (ISL) and costunolide 
CST). ALA and ISL has been previously isolated from Inula helenium (Jiang et al., 2011; 
Lawrence et al., 2001; Qiu et al., 2011; Seo et al., 2008; Trendafilova et al., 2010). 
However, this is the first time costunolide has been isolated from the roots of Inula 
helenium. CST has been isolated previously from the root extracts of Saussurea costus 
(Eliza et al., 2009). ALA and ISL were previously isolated from the petroleum ether 
fraction of Inula helenium using the reverse phase C18 column chromatography (Jiang et 
al., 2011; Lawrence et al., 2001). This finding agrees with the findings in this work as 
petroleum ether is a non-polar solvent having the same polarity as hexane (0.1). Most 
authors isolated ALA and ISL using column chromatography which involves multiple steps 
of purification via collection of fractions, comparing similar fractions and oftentimes 
fractions obtained are relatively impure. HPLC (which was used in purification of ALA, ISL 
and CST) offers a better advantage over column chromatography as compounds can be 
monitored and purified via an auto-detector. ALA and ISL were isolated using a gradient 
of 55 % methanol and 45 % water. ALA was isolated first at a retention time of 35.62 
minutes, followed by ISL at a retention time of 37.04 minutes. This observation differed 
from those of Xiao & Hu, (2007) and Huo et al., (2010) who isolated ISL first, followed by 
ALA using Agilent Zorbax XDB-C18 column and Phenomenex Kromasil C18 columns 
respectively. In this study, Agilent ACE C18-Amide coloum was used in purifying the 
compounds via HPLC. This may be attributed to the increased polar retention and 
alternative selectivity of ACE C18-Amide column with ability to efficiently separate polar, 
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phenolic, acidic and basic compounds. ACE C18-Amide column can also separate 
products efficiently at pH ranging from 2 – 11 (Schellinger et al., 2005; Schellinger et al., 
2008a). Agilent ZORBAX Eclipse XDB columns – C18 is efficient at a pH range of 2-3, 
and 6-8. Tailing interactions with compounds to be separated usually occur in the Agilent 
ZORBAX Eclipse XDB columns – C18 columns at pH range outside the one stated above 
(Schellinger et al., 2008a; Schellinger et al., 2008b). This tailing effect is due to the 
silanols constituents of this column. This tailing interaction is also common with the 
Phenomenex Kromasil C18 columns (Schellinger et al., 2008a). The tailing effect, and 
lack of increased polar retention and alternative selectivity of the later columns may be 
responsible for the appearance of ISL before ALA in the HPLC fractions.  
ALA and ISL were isolated as white powders. The LC-MS spectrum displayed a molecular 
ion peak at m/z 232.2 [M+Na]+ consistent with a molecular formula of C15H20O2. This 
finding is consistent with those reported by other authors (Jiang et al., 2011; Lawrence et 
al., 2001; Huo et al., 2010). CST was isolated as a crystalline solid. The HR-ESI-MS 
spectrum displayed a molecular ion peak at m/z 232.1538 [M+Na]+ consistent with a 
molecular formula of C15H20O2. This finding is also consistent with those previously 
reported by Eliza et al., (2009) who isolated costunolide from the roots of Costus 
speciosus. 
It was not surprising isolating costunolide from the root extracts of Inula helenium using 
HPLC. This is because previous studies focussed mainly on the use of column 
chromatography (Huo et al., 2010; Lawrence et al., 2001) or the use of acetonitrile / water 
as the mobile phase (Yang et al., 2017) instead of methanol (used in this study). A higher 
concentration of acetonitrile (≥55%) in the mobile phase is associated with poor resolution 
and separation of ALA and ISL (Yang et al., 2017). It therefore suggests that the type of 
solvent used in the mobile phase in the separation of sesquiterpene lactones could affect 
the resolution or isolation of bioactive compounds. Other authors have not reported the 
use of centrifugation technique in the isolation of compounds from Inula helenium. By 
centrifuging the hexane fraction, it was possible to force the tiny amount of costunolide 
which was in the suspension into the pellets. Considering the tiny amount of costunolide 
isolated from hexane fraction (1.48 %), compared to the yield of alantolactone (35 %) and 
isoalantolactone (32.14 %), other authors may have missed the fractionation of 
costunolide via the use of column chromatography and / or acetonitrile (associated with 




Figure 3.3: Peaks were poorly resolved.  
Good peak resolution was achieved via the introduction of 0.1 % formic acid (Figure 3.2). 
 
It was possible to isolate CST from the roots of Inula helenium because 0.1 % formic acid 
was used to enhance good peak resolution. The effect of use of formic acid or metallic 
ion (such as silver ion) in enhancing good peak resolution has previously been reported 
(Dobson et al., 1995; Yang et al., 2017). It is possible that costunolide or other compounds 
may be appearing on the chromatogram as impurities or clustered to alantolactone or 
isoalantolactone due to the tiny amount of this compound in Inula helenium (1.48 % - 
isolated from hexane fraction). The effect of peak clustering was observed (Figure 3.3) 
when 0.1 % formic acid was not introduced thus preventing proper peak resolution. Huo 
et al., (2010) and Lawrence et al., (2001) did not indicate the use of formic acid for good 
resolution of peaks. This may account for the inability to isolate costunolide from Inula 
specie. It is also possible that the geographical location, climate and season where the 
plant’s (Inula helenium) extract was collected influenced the quantity of phytochemicals 





















Chapter 4  Chemical Synthesis of Modified Chrysin Derivatives to  
 
This chapter is a presentation of data for chemical synthesis of modified chrysin-
derivatives using different synthetic methods such as microwave irradiation, stirring at 
regulated temperatures and / or the use of catalysts. Reaction conditions were modified 
many times during the experiments to synthesise compounds with high yield and purity. 
It should be noted that the mass spectroscopy data for novel compounds are presented 
to 4-decimal places (accurate mass spectroscopy data) whereas data for known data is 
reported to 2-decimal places (measured using the LC-MS). 
The proton NMR data as well as the mass spectrometry data for novel compounds are 
presented in the appendix. 
4.1 4-((5-Hydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)butyl acetate 
(C1) or 7-O-Chrysinbutyl acetate – novel compound 
C1 was synthesised as described in section 2.2.4.1 (page 125). C1 is a novel compound 
and the yield / spectral data can be found below: 
 
Structure 4.1 – Compound C1 
 
Method A: Yield (0.196 g, 80.2 %); m.p. 122 – 124 °C; Rf = 0.74 (Silica 60 Å, 2:1 ethyl 
acetate: petroleum ether, v/v). 
 
Method B: Yield 0.166 g, 68.0 %); m.p. 122 – 124 °C; Rf = 0.75 (Silica 60 Å, 2:1 ethyl 
acetate: petroleum ether, v/v). 
 
Spectral data: 
1H NMR (400 MHz, CDCl3, δ ppm) 1.83-1.94 (4H, 1.87 (quint, J = 7.5 Hz), 1.90 (tt, J = 
7.5, 7.1 Hz)), 2.09 (3H, s), 4.06-4.24 (4H, 4.09 (t, J = 7.1 Hz), 4.18 (t, J = 7.5 Hz)), 6.38 
(1H, d, J = 2.2 Hz), 6.51 (1H, d, J = 2.2 Hz), 6.69 (1H, s), 7.50-7.60 (3H, 7.53 (dddd, J = 
7.8, 7.3, 1.5, 0.4 Hz), 7.57 (tt, J = 7.3, 1.5 Hz)), 7.92 (2H, dtd, J = 7.8, 1.4, 0.4 Hz, 12.71 
(1H, s, 5-OH); 13C NMR (100 MHz, CDCl3, δ ppm) 20.99 (CH3), 25.29 (CH), 25.63 (CH), 
63.92 (OCH2), 67.96 (OCH2), 93.12 (CH), 98.53 (CH), 105.71 (CH), 105.90 (C), 126.29 
Chemical formula: C21H20O6 
Molecular Weight: 368.13 g/mol
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(2’, CH), 126.29 (6’, CH) 129.10 (3’ CH), 129.10 (5’, CH), 131.34 (4’, CH) 131.84, (1’, C) 
157.80 (C-O), 162.17 (C-O), 163.98 (C-OH), 164.91 (C-O), 171.15 (COO), 182.46 (C=O); 
IR 1165.42 cm-1 (C-O-C, large ring C-O stretch), 1031.25 cm-1 and 1242.32 cm-1 (C-O, 
phenolic), 1588.12 cm-1 (C=C aromatic), 1605.21 cm-1 (C=O, ketone), 1751.27 cm-1 (O-
C=O); MS (ESI) m/z: calculated for C21H20O6 [M+H]+ = 368.1338, found 368.1330 g/mol.  
The initial reaction conditions used require stirring the reaction mixture at 30 °C for 12.0 
hours. 2.0 eq potassium carbonate and 1.0 eq of 4-bromobutyl acetate were used. This 
produced 22 % yield. It was found that the reaction conditions could be optimised to give 
a maximum yield of 68 % when the mixture was stirred at 70 °C for 20 hours and the 
concentration of potassium carbonate increased to 4 eq and 4-bromobutyl acetate 
increased to 2.0 eq. In the 1H NMR spectrum of the novel compound – C1, the two 
methylene protons at positions 12 and 13 provides evidence for the proposed structure 
and they appear as 4-protons at δ 1.83 – 1.94 ppm. The two methylene protons at 
positions 11 and 14 appears at δ 4.06-4.24 ppm because they are deshielded compared 
to the former protons. It should be noted that the protons at position 14 would appear first 
before those at position 11 because the protons at position 14 are attached to an oxygen 
that is oriented towards the aliphatic region whereas the protons at position 11 are 
attached to the oxygen that is oriented toward the aromatic region. This provides further 
evidence for the propose structure. The proton δ 12.80 ppm corresponds to the hydroxyl 
group at the 5-OH position of the molecule. In the 13C NMR spectrum, the signals δ 63.92 
(C-14) and 67.96 (C-11) provides further evidence for the synthesis of C1. The mass 
spectroscopy data (ESI) m/z of 368.1330 g/mol is also consistent with the proposed 
structure. 
4.2 7-((3,5-Dimethylbenzyl)oxy)-5-hydroxy-2-phenyl-4H-chromen-4-
one (C2) or 7-O-Chrysin-3,5-dimethylbenzene – novel compound 
C2 was synthesised as described in section 2.2.4.2 (page 126). C2 is a novel compound 
and the yield / spectral data is presented below: 
 
Chemical formula: C24H22O4 
Molecular Weight: 372.14 g/mol 




1H NMR (400 MHz, CDCl3, δ ppm) 2.29 (6H, s), 4.49 (2H, s), 6.36 (1H, d, J = 1.9 Hz), 
6.50 (1H, d, J = 1.9 Hz), 6.58 (1H, s), 6.91 (1H, t, J = 1.9 Hz), 6.98 (2H, dd, J = 1.9, 1.4 
Hz), 7.40-7.50 (3H, 7.46 (dddd, J = 7.8, 7.3, 1.5, 0.4 Hz), 7.80 (2H, dd, J = 7.8, 1.4, 0.4 
Hz), 12.80 (1H, s, 5-OH); 13C NMR (100 MHz, CDCl3, δ ppm) 21.31 (CH3), 21.31 (CH3), 
70.63 (OCH2), 93.54 (CH), 98.94 (CH), 105.85 (CH), 105.91 (C), 125.39 (CH), 125.39 
(CH) 126.31 (2’, CH), 126.31 (6’, CH), 129.10 (3’ CH), 129.10 (5’ CH), 130.07 (4’, CH), 
131.35 (1’, C), 131.84 (CH), 135.56 (C), 138.42 (C), 138.42 (C), 157.77 (C-O), 162.20 
(C-O), 164.01 (C-OH), 164.81 (C-O), 182.50 (C=O); IR 1158.49 cm-1 (C-O-C, large ring 
C-O stretch), 1029.80 cm-1 and 1246.45 cm-1 (C-O, phenolic), 1583.85 cm-1 (C=C 
aromatic), 1602.10 cm-1 (C=O, ketone), 2854.31 (C-H, alkane), 3001.46 cm-1 (C-H, 
aromatic); MS (ESI) m/z: calculated for C24H22O4 [M+H]+ = 372.1439, found 372.1433 
g/mol.     
It was difficult to make compound (C2) with the initial conditions used involving the use of 
acetone and methanol, and temperature ranging from 100 - 130 °C in a microwave reactor 
for a time period ranging from 10 – 15 minutes. Precipitates – a mixture of brown, brick-
red and orange colours were obtained. Attempts were made to purify these precipitates 
without success as the targeted product was not synthesised. TLC analysis indicated the 
presence of lots of impurities and debris. 
The same conditions stated above were used in an attempt to synthesise (C2) except 
that the reaction was stirred at 70 °C for 24 hours; a microwave reactor was not used. It 
was still difficult to make (C 2). The solvents were changed, and acetonitrile used. The 
reaction was stirred at 70 °C for 24 hour and monitored using a TLC after it was purified 
via the chromatographic column. This time, 26 % yield was obtained. In order to optimise 
the yield, the reaction conditions were optimised by stirring the reaction at room 
temperature for 4 hours in acetonitrile. A yield of 81.3 % was recorded. 
In the 1H NMR spectrum of chrysin adduct (C2), the singlet proton (2H, s, OCH2 aromatic) 
and having chemical shift δ 4.49 ppm, corresponds to the point of attachment of 1-
(bromomethyl)-3,5-dimethylbenzene. The proton 6H corresponding to two methyl groups 
on 1-(bromomethyl)-3,5-dimethylbenzene having chemical shift of 2.25 (s) ppm, which is 
absent in the chrysin molecule. The proton δ 12.80 ppm corresponds to the hydroxyl 
group at the 5-OH position of the molecule. In the 13C NMR spectrum, the signals at δ 
138.42 ppm corresponds to the C-1” and C-5” whereas the signals for C-1’ and C-4” 
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(which exist in a similar chemical environment is seen at δ 131.35 (C-1’) and 131.84 (C-
4”). This is an evidence for the synthesis of the proposed compound. The mass 




(C3) or 7-O-Chrysin-2,4-dinitrobenzene – novel compound 
 
C3 was synthesised as described in section 2.2.4.3, page 123. C3 is a novel compound 
and the yield / spectral data is sated below. 
 
Structure 4.3 – Compound C3 
Method A: Yield (0.109 g, 46.2 %); m.p. 292 - 294 °C; Rf = 0.49 (Silica 60 Å, 2:1 ethyl 
acetate: petroleum ether, v/v. 
 
Method B: Yield (0.211 g, 89.6 %); m.p. 292 - 294 °C; Rf = 0.47 (Silica 60 Å, 2:1 ethyl 
acetate: petroleum ether, v/v). 
Spectral data: 
1H NMR (400 MHz, DMSO-d6, δ ppm) 6.73 (1H, d, J = 2.1 Hz), 7.12 (1H, d, J = 2.1 Hz), 
7.20 (1H, s), 7.57-7.69 (4H, 7.60 (dd, J = 7.9, 0.5 Hz), 7.63 (dddd, J = 7.8, 7.3, 1.5, 0.4 
Hz), 7.66 (tt, J = 7.3, 1.5 Hz)), 8.16 (2H, dtd, J = 7.8, 1.4, 0.4 Hz), 8.60 (1H, dd, J = 7.9, 
1.9 Hz), 8.90 (1H, dd, J = 1.9, 0.5 Hz), 13.00 (1H, s, 5-OH); 13C NMR (100 MHz, DMSO-
d6, δ ppm) 98.02 (CH), 102.02 (CH), 105.72 (CH), 107.72 (C) 122.04 (CH), 122.95 (CH), 
126.60 (2’, CH), 126.60 ( 4’, CH), 126.60 ( 6’, CH), 129.16 (3’, CH), 129.16 (5’, CH) 130.23 
(1’, C), 132.45 (CH), 140.65 (C), 143.18 (C), 152.43 (C-O), 157.14 (C-O), 160.43 (C-O), 
161.76 (C-OH), 163.02 (C-O), 182.43 (C=O); IR 1149.55 cm-1 (C-O-C, large ring C-O 
stretch), 1025.24 cm-1 and 1248.32 cm-1 (C-O, phenolic), 1358 cm-1 and 1535 cm-1 (N=O, 
aromatic) 1593.47 cm-1 (C=C aromatic), 1623.80 cm-1 (C=O, ketone); MS (ESI) m/z: 
calculated for C22H16N2O8 [M+H]+ = 420.0671, found 420.0661.   
Synthesis of (C3) via method B offered an increased yield compared to method A. 
However, method A offered a quick synthesis of C3. 
Chemical formula: C22H16O8 
Molecular Weight: 420.32 g/mol
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The 1H NMR spectrum shows a doublet at δ 8.98 ppm and a doublet at 8.57 ppm 
corresponding to the protons at the point of attachment of 1-bromo-2,4-dinitrobenzene. It 
also has a multiplet (4 H) at δ 7.51 – 7.67 ppm, corresponding to the protons at 3’, 4’ and 
5’ positions of chrysin, and C-6” of (C 3). For chrysin, the chemical shift of the protons at 
3’, 4’ and 5’ positions is a multiplet (3 H) at δ 7.56 – 7.69 ppm. The proton corresponding 
to 5-OH is a singlet at δ 12.95 ppm for all Series 1 compounds. In the 13C NMR spectrum, 
aliphatic carbon atoms were absent as seen in C1 (δ 20.00 – 50 ppm). The signals 
appeared beginning from δ 98.02 ppm (corresponding to a C-O signal). The absence of 
aliphatic carbon signals is consistent with the proposed structure. Narrow stretch 
vibrations were observed at 1358 and 1535 cm-1 corresponding to NO2 in the IR spectrum. 
The mass spectroscopy data (ESI) m/z of 372.1433 g/mol is also consistent with the 
proposed structure. 
Series 1 compounds – C1 and C2, are soluble in chloroform and ethyl acetate (Rf values 
0.75 and 0.71). C3 is partially soluble in chloroform and ethyl acetate (Rf = 0.49) and 
soluble in dimethyl sulfoxide (DMSO). 
A higher yield was obtained from method A (synthesis using microwave reactor) for C1 
80.2 % compared to the yield from method B (stirring for 24 h) – 68.0 %.  This was different 
for C2 and C3 which recorded poor yields with method A (53.34 and 46.2 %) compared 
to the increase yields recorded for C2 and C3 using method B (83.1 and 89.6 %). 
In order to investigate the degrading effect of the benzene ring by the microwave, the 
reaction time for synthesis of these compounds – C1 and C2 were reduced from 10 
minutes to 5 minutes (other conditions remaining constant), the impurities recorded on 
the TLC plate for C2 and C3 faded. To investigate further this observation, the reaction 
time was increased from 10 minutes to 14 minutes; more impurities were observed on 
the TLC plate compared to those observed at 10 minutes irradiation. This finding suggests 
that when 7-O-chrysin adducts containing benzene rings are irradiated in the microwave 
reactor for longer periods (≥ 10 minutes), degradation of these compounds may occur. 
 
4.4  Synthesis of Methylated 7-O-alkylchrysin derivatives 
 
One of the aims of this project is to synthesise methylated 7-O-alkylchrysin derivatives 
and to study the antimicrobial effect of alkylation of these derivatives. The first compound 




4.4.1  5-Hydroxy-7-isopropoxy-3-phenyl-4H-chromen-4-one (C4) 
or 7-O-Isopropylchrysin   
 
C4 was synthesised as described in section 2.2.3.1, page 124. The yield / spectral data 
is presented below. 
Method A: Yield (0.209 g, 95.0 %); m.p. 145 – 146 °C; Rf = 0.58 (Silica 60 Å, 2:1 ethyl 
acetate: petroleum ether, v/v). 
 
Method B: Yield (0.138 g, 62.7 %) m.p 145 – 146 °C; Rf = 0.58 (Silica 60 Å, 2:1 ethyl 
acetate: petroleum ether, v/v).  
 
   Structure 4.4 – Compound C4 
Spectral data: 
1H NMR (400 MHz, CDCl3, δ ppm) 1.42 (6H, d, J = 6.6 Hz), 4.67 (1H, sept, J = 6.6 Hz), 
6.38 (1H, d, J = 2.2 Hz), 6.50 (1H, d, J = 2.2 Hz), 6.68 (1H, s), 7.58 (3H, dd, J = 1.5, 0.4 
Hz), 7.9 (2H, dtd, J = 7.8, 1.4, 0.4 Hz, 12.74 (1H, s, 5-OH); 13C NMR (100 MHz, CDCl3, δ 
ppm) 21.92 (CH3), 21.92 (CH3), 70.78 (C-O), 93.94 (CH), 99.28 (CH), 105.42 (CH), 
105.81 (C), 126.27 (2’, CH), 126.27 (6’, CH),  129.07 (3’, CH), 129.07 (5’, CH), 131.38 
(4’, CH), 131.79 (1’, C), 157.86 (C-O), 162.17 (C-O), 163.89 (C-OH), 164.16 (C-O), 
182.40 (C=O); IR 1143.62 cm-1 (C-O-C, large ring C-O stretch), 1041.05 cm-1 and 124.87 
cm-1 (C-O, phenolic), 1589.68 cm-1 (C=C aromatic), 1622.29 cm-1 (C=O, ketone), 2897.36 
(C-H, alkane), 2956.87 (CH3, alkane), 3076.84 (C-H, aromatic); MS (ESI) m/z: calculated 
for C18H16O4 [M+H]+ = 296.1048, found 296.10. 
 
4.4.2  5-Hydroxy-7-isobutoxy-3-phenyl-4H-chromen-4-one (C5) or 
7-O-Chrysin-2-methylpropane - novel 
 
C5 was synthesised as described in section 2.2.3.2, page 124. The yield and spectral 
data are presented below. 
Method A: Yield (0.205 g, 74.7 %); m.p. 143 – 145 °C; Rf = 0.69 (Silica 60 Å, 2:1 ethyl 
acetate: petroleum ether, v/v. 
Method B: Yield (0.138 g, 62.7 %) m.p 145 – 146 °C; Rf = 0.58 (Silica 60 Å, 2:1 ethyl 
acetate: petroleum ether, v/v). 
Chemical formula: C18H16O4 




Structure 4.5 – Compound C5 
1H NMR (400 MHz, CDCl3, δ ppm) 1.05 (6H, d, J = 6.6 Hz), 2.15 (1H, sept, J = 6.7, 6.6 
Hz), 3.81 (2H, d, J = 6.7 Hz), 6.40 (1H, d, J = 2.2 Hz), 6.52 (1H, d, J = 2.2 Hz), 6.69 (1H, 
s), 7.55 (3H, dd, J = 1.5, 0.4 Hz), 7.90 (2H, dd, J = 7.8, 1.4 Hz), 12.78 (1H, s, 5-OH); 13C 
NMR (100 MHz, CDCl3, δ ppm) 19.15 (CH3), 19.15 (CH3), 28.11 (CH), 74.95 (OCH2), 
93.12 (CH), 98.68 (CH), 104.3 (CH), 105.84 (C), 126.28 (2’, CH), 126.28 (6’, CH), 129.09 
(3', CH), 129.09 (5', CH), 131.40 (4', CH), 131.80 (1', C), 157.81 (C-O), 162.13 (C-OH), 
163.91 (C-O), 165.32 (C-O), 182.48 (C=O); IR 1149.55 cm-1 (C-O-C, large ring C-O 
stretch), 1035.01 cm-1 and 123.99 cm-1 (C-O, phenolic), 1587.00 cm-1 (C=C aromatic), 
1614.79 cm-1 (C=O, ketone), 2859.02 (C-H, alkane), 2953.21 (CH3, alkane), 3076.84 (C-
H, aromatic); MS (ESI) m/z: calculated for C19H18O4 [M+H]+ = 310.1283, found 310.1278 
In the 1NMR spectrum of C4, the 6-protons appearing as a doublet at δ 1.42 ppm are 
signals for the two methyl protons. The proton appearing as a septuplet at δ 4.67 ppm 
corresponds to the aliphatic proton in C4 which is the point of attachment of the reactants. 
The hydroxyl proton at position 5 of the chrysin molecule is seen as a signal δ 12.72 ppm. 
The dimethyl carbon atoms are observed in δ 21.92 ppm in the 13C NMR. The 1H NMR 
spectrum of C5, a novel chrysin derivative shows 6-protons appearing as doublet at δ 
1.05 ppm. At the point of attachment of the reactants, the signals appear as 2-protons 
(doublet) at δ 3.81 ppm. In the 13C NMR spectrum, the dimethyl carbon protons appear 
at δ 19.15 ppm. The mass spectroscopy data (ESI) m/z of 310.1278 g/mol is also 
consistent with the proposed structure. 
4.5  7-O-alkylchrysin derivatives 
 
One of the aims of this project is to synthesise chrysin derivatives with aliphatic chain, 
attached to 7-OH with increasing carbon chain where C ≥ 3 with the aim of investigating 
their biological activities against cancer cell lines and bacterial strains. The first compound 
that was synthesised was 7-butoxy-5-hydroxy-3-phenyl-4H-chromen-4-one. 
7-O-alkylchrysin derivatives were synthesised as described in section 2.2.2, page 123. 
The yields recorded for method A ranged from 46 – 58 %. The yields recorded for method 
Chemical formula: C19H18O4 
Molecular Weight: 310.34 g/mol
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B ranged from 54 – 68 %. The yields recorded for method C ranged from 46.0 – 68.4 %. 
Only the yields recorded for method B is reported below. The percentage yields for 
method A and C are reported in Table 4.1. 
 
4.5.1 7-butoxy-5-hydroxy-3-phenyl-4H-chromen-4-one (C6) or 7-
O-Butylchrysin 
 
5,7-dihydroxyflavone (0.12 g, 0.47 mmol), potassium carbonate (2.00 eq, 0.26 g, 4.2 
mmol) and 1-bromobutane (2.00 eq, 0.130 μl, 4.72 mmol) were suspended in acetonitrile 
/ DMF / acetone (10.0 mL) and stirred / irradiated in a microwave reactor as described in 
section 2.2.2, page 123 (methods A, B and C respectively) to yield pure 7-butoxy-5-
hydroxy-3-phenyl-4H-chromen-4-one. 
 
   Structure 4.6 – Compound C6 
Yield (0.138 g, 78.9 %); m.p. 138 – 139 °C; Rf = 0.68 (Silica 60 Å, 2:1 ethyl acetate: 
petroleum ether, v/v; 1H NMR (400 MHz, CDCl3, δ ppm) 1.02 (3H, t, J = 7.1 Hz), 1.52 (2H, 
quint, J = 7.4, 7.1 Hz), 1.88 (2H, quint, J = 7.4 Hz), 4.10 (2H, t, J = 7.4 Hz), 6.40 (1H, 
d, J = 2.2 Hz), 6.58 (1H, d, J = 2.2 Hz), 6.70 (1H, s), 7.50-7.60 (3H, 7.47 (dddd, J = 7.8, 
7.3, 1.5, 0.4 Hz), 7.94 (tt, J = 7.3, 1.5 Hz)), 7.92 (2H, dd, J = 7.8, 1.4, 0.4 Hz), 12.78 (1H, 
s, 5-OH); 13C NMR (100 MHz, CDCl3, δ ppm) 27.62 (CH3), 29.28 (CH2), 33.21 (CH2), 
67.54 (OCH2), 93.07 (CH), 98.56 (CH), 105.73 (CH), 105.87 (C), 126.28 (2', CH), 126.28 
(5’, CH), 129.09 (3', CH), 129.09 (5', CH), 131.31 (4’, CH), 131.85 (1', C), 157.77 (C-O), 
162.19 (C-O), 163.97 (C-OH) 164.84 (C-O), 182.46 (C=O);  IR 1167.10 cm-1 (C-O-C, 
large ring C-O stretch), 1023.65 cm-1 and 1276.54 cm-1 (C-O, phenolic), 1589.89 cm-1 
(C=C aromatic), 1625.97 cm-1 (C=O, ketone), 2852.93 cm-1 (C-H, alkane), 2957.69 cm-1 
(C-H, alkane), 3010.01 cm-1 (C-H, aromatic); MS (ESI) m/z: calculated for C19H18O4 
[M+H]+ = 310.1283, found 310.12 
4.5.2 5-hydroxy-7-(pentyloxy)-3-phenyl-4H-chromen-4-one (C7) 
or 7-O-Pentylchrysin – novel compound 
 
Using the method described in section 2.2.2, page 123, 5-hydroxy-7-(pentyloxy)-3-
phenyl-4H-chromen-4-one (C7) was made using potassium carbonate (2.00 eq, 0.26 g, 
Chemical formula: C19H18O4 
Molecular Weight: 310.34 g/mol
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4.2 mmol), 5,7-dihydroxyflavone (0.12 g, 0.47 mmol) and 1-bromopentane (2 eq, 142.6 
μl, 9.4 mmol). 5-hydroxy-7-(pentyloxy)-3-phenyl-4H-chromen-4-one was obtained as a 
pale-yellow powder: 
 
   Structure 4.7 – Compound C7 
Yield (0.259 g, 88.1 %); m.p. 138 - 140 °C; Rf = 0.69 (Silica 60 Å, 2:1 ethyl acetate: 
petroleum ether, v/v; 1H NMR (400 MHz, CDCl3, δ ppm) 0.99 (3H, t, J = 7.0 Hz), 1.49 (4H, 
quint, J = 7.5, 7.0 Hz), 1.89 (2H, quint, J = 7.5 Hz), 4.08 (2H, t, J = 7.5 Hz), 6.40 (1H, 
d, J = 2.2 Hz), 6.52 (1H, d, J = 2.2 Hz), 6.68 (1H, s), 7.55 (3H, ddd, J = 7.3, 1.5, 0.4 Hz), 
7.90 (2H, dd, J = 7.8, 1.4, 0.4 Hz), 12.78 (1H, s, 5-OH); 13C NMR (100 MHz, CDCl3, δ 
ppm) 14.02 (CH3), 22.41 (CH2), 28.09 (CH2), 28.66 (CH2), 68.70 (OCH2), 93.07 (CH), 
98.62 (CH), 105.56 (CH), 105.80 (C), 126.26 (2', CH), 126.26 (6', CH), 129.07 (3', CH), 
129.07 (5', CH), 131.34 (4', CH), 131.79 (1’, C), 157.78 (C-O), 162.10 (C-O), 163.88 (C-
OH), 165.22 (C-O), 182.44 (C=O); IR 1168.90 cm-1 (C-O-C, large ring C-O stretch), 
903.80 cm-1 and 1272.38 cm-1 (C-O, phenolic), 1587.06 cm-1 (C=C aromatic), 1615.56 
cm-1 (C=O, ketone), 2945.43 cm-1 (C-H, alkane), 2952.33 cm-1 (C-H, alkane), 3064.25 cm-
1 (C-H, aromatic); MS (ESI) m/z: calculated for C20H20O4  [M+H]+ =324.1361, found 324.14 
4.5.3 7-(Hexyloxy)-5-hydroxy-3-phenyl-4H-chromen-4-one (C8) or 
7-O-Hexylchrysin 
 
Using the method described in section 2.2.2, page 123, 7-(hexyloxy)-5-hydroxy-3-phenyl-
4H-chromen-4-one (C8) was made using potassium carbonate (2.00 eq, 0.26 g, 4.2 
mmol), 5,7-dihydroxyflavone (0.12 g, 0.47 mmol) and 1-Bromohextane (2 eq, 142.6 μl, 
9.4 mmol).  7-(hexyloxy)-5-hydroxy-3-phenyl-4H-chromen-4-one was obtained as a pale-
yellow powder:  
 
   Structure 4.8 – Compound C8 
Chemical formula: C20H20O4 
Molecular Weight: 324.37 g/mol
Chemical formula: C21H22O4 
Molecular Weight: 338.40 g/mol
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Yield (0.246 g, 81.2 %); m.p. 136 – 137 °C; Rf = 0.60 (Silica 60 Å, 2:1 ethyl acetate: 
petroleum ether, v/v; 1H NMR (400 MHz, CDCl3, δ ppm) 0.96 (3H, t, J = 7.0 Hz), 1.36 (4H, 
quint, J = 7.0 Hz, J = 7.0 Hz, 1.50 (2H, tt, J = 7.5, 7.0 Hz), 1.86 (2H, quint, J = 7.5 Hz), 
4.05 (2H, t, J = 7.5 Hz), 6.40 (1H, d, J = 2.2 Hz), 6.50 (1H, d, J = 2.2 Hz), 6.70 (1H, s), 
7.55 (3H, ddd, J = 7.3, 1.5, 0.4 Hz), 7.90 (2H, dd, J = 7.8, 1.4, 0.4 Hz), 12.78 (1H, s, 5-
OH); 13C NMR (100 MHz, CDCl3, δ ppm) 14.04 (CH3), 22.59 (CH2), 25.62 (CH2), 28.92 
(CH2), 31.51 (CH2), 68.72 (OCH2), 93.12 (CH), 98.62 (CH), 105.59 (CH), 105.87 (C), 
126.29 (2', CH), 126.29 (6’, CH), 129.09 (3', CH), 129.09 (5', CH), 131.40 (4', CH), 131.80 
(1’, C), 157.81 (C-O), 162.14 (C-O), 163.92 (C-OH), 165.24 (C-O), 182.48 (C=O); IR 
1169.58 cm-1 (C-O-C, large ring C-O stretch), 905.02 cm-1 and 1272.92 cm-1 (C-O, 
phenolic), 1505.98 cm-1 (C=C aromatic), 1662.90 cm-1 (C=O, ketone), 2643.55 cm-1 (C-
H, alkane), 2944.69 cm-1 (C-H, alkane), 3012.13 cm-1 (C-H, aromatic); MS (ESI) m/z: 
calculated for C21H22O4 [M+H]+ = 338.1518, found 338.15 
4.5.4 7-(Heptyloxy)-5-hydroxy-3-phenyl-4H-chromen-4-one (C9) or 
7-O-Heptylchrysin – novel compound 
 
Using the method described in section 2.2.2, page 123, 7-(heptyloxy)-5-hydroxy-3-
phenyl-4H-chromen-4-one (C9) was made using potassium carbonate (2.00 eq, 0.26 g, 
4.2 mmol), 5,7-dihydroxyflavone (0.12 g, 0.47 mmol) and 1-bromoheptane (2 eq, 142.6 
μl, 9.4 mmol).  7-(heptyloxy)-5-hydroxy-3-phenyl-4H-chromen-4-one was obtained as a 
pale-yellow powder:  
 
   Structure 4.9 – Compound C9 
 
Yield (0. 235 g, 81.4 %); m.p. 118 – 120 °C; Rf = 0.69 (Silica 60 Å, 21 ethyl acetate: 
petroleum ether, v/v; 1H NMR (400 MHz, CDCl3, δ ppm) 0.89 (3H, t, J = 7.0 Hz), 1.30-
1.42 (6H, quint, J = 7.1, 7.0 Hz), 1.47 (2H, quint, J = 7.5, 7.1 Hz), 1.85 (2H, quint, J = 7.5 
Hz), 4.03 (2H, t, J = 7.5 Hz), 6.37 (1H, d, J = 2.2 Hz), 6.50 (1H, d, J = 2.2 Hz), 6.68 (1H, 
s), 7.58 (3H, dddd, J = 7.8, 7.3, 1.5, 0.4 Hz), 7.90 (2H, dtd, J = 7.8, 1.4, 0.4 Hz), 12.78 
(1H, s, 5-OH); 13C NMR (100 MHz, CDCl3, δ ppm) 14.09 (CH3), 22.61 (CH2), 25.90 (CH2), 
28.96 (CH2), 28.99 (CH2), 31.76 (CH2), 68.72 (OCH2), 93.11 (CH), 98.62 (CH), 105.59 
(CH), 105.87 (C), 126.28 (2', CH), 126.28 (6’, CH), 129.08 (3' CH), 129.28 (5’, CH), 131.40 
Chemical formula: C22H24O4 
Molecular Weight: 352.42 g/mol
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(4', CH), 131.79 (1’, CH), 157.81 (C-O), 162.14 (C-O), 163.91 (C-OH), 165.24 (C-O), 
182.47 (C=O);  IR 1161.22 cm-1 (C-O-C, large ring C-O stretch), 998.27 cm-1 and 1281.39 
cm-1 (C-O, phenolic), 1512.26 cm-1 (C=C aromatic), 1666.37 cm-1 (C=O, ketone), 2651.27 
cm-1 (C-H, alkane), 2937.24 cm-1 (C-H, alkane), 2946.41 cm-1 (C-H, alkane), 3021.03 cm-
1 (C-H, aromatic); MS (ESI) m/z: calculated for C22H24O4 [M+H]+ = 352.1674, found 352.17 
4.5.5 5-Hydroxy-7-(octyloxy)-3-phenyl-4H-chromen-4-one (C10) or 
7-O-Octyloxychrysin 
Using the method described in section 2.2.2, page 123, 5-hydroxy-7-(octyloxy)-3-phenyl-
4H-chromen-4-one (C10) was made using potassium carbonate (2.00 eq, 0.26 g, 4.2 
mmol), 5,7-dihydroxyflavone (0.12 g, 0.47 mmol) and 1-bromoocane (2 eq, 142.6 μl, 9.4 
mmol).  5-hydroxy-7-(octyloxy)-3-phenyl-4H-chromen-4-one was obtained as a pale-
yellow powder with the following spectroscopic data:  
 
Structure 4.10 – Compound C10 
 
Yield (0.228 g, 75.0 %); m.p. 77 - 80 °C; Rf = 0.67 (Silica 60 Å, 2:1 ethyl acetate: petroleum 
ether, v/v; 1H NMR (400 MHz, CDCl3, δ ppm) 0.92 (3H, t, J = 7.0 Hz), 1.29-1.43 (8H, 
quint, J = 7.1, 7.0 Hz), 1.50 (2H, quint, J = 7.5, 7.1 Hz), 1.82 (2H, quint, J = 7.8, 7.3, 1.5, 
0.4 Hz), 4.05 (2H, t, J = 7.5 Hz), 6.40 (1H, d, J = 2.2 Hz), 6.52 (1H, d, J = 2.2 Hz), 6.70 
(1H, s), 7.58 (3H, dddd, J = 7.8, 7.3, 1.5, 0.4 Hz), 7.92 (2H, dtd, J = 7.8, 1.4, 0.4 Hz), 
12.78 (1H, s, 5-OH); 13C NMR (100 MHz, CDCl3, δ ppm) 14.11 (CH3), 22.64 (CH2), 25.94 
(CH2), 28.96 (CH2), 29.22 (CH2), 29.22 (CH2), 31.81 (CH2), 68.73 (OCH2), 93.10 (CH), 
98.63 (CH), 105.57 (CH), 105.83 (C), 126.27 (2', CH), 126.27 (6', CH), 129.08 (3', CH), 
129.08 (5', CH), 131.37 (4', CH), 131.80 (1’, C), 157.80 (C-O), 162.13 (C-O),  163.91 (C-
OH), 165.24 (C-O),  182.47 (C=O);  m/z [M+H]+ =; IR 1169.51 cm-1 (C-O-C, large ring C-
O stretch), 1033.91 cm-1 and 1272.96 cm-1 (C-O, phenolic), 1587.89 cm-1 (C=C aromatic), 
1607.79 cm-1 (C=O, ketone), 2643.39 cm-1 (C-H, alkane), 2918.76 cm-1 (C-H, alkane), 
3023.26 (C-H, aromatic); MS (ESI) m/z: calculated for C23H26O4 [M+H]+ = 366.1909, found 
366.1899 
Chemical formula: C23H26O4 
Molecular Weight: 366.45 g/mol
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4.5.6  5-Hydroxy-7-(nonyloxy)-3-phenyl-4H-chromen-4-one (C11) 
or 7-O-Nonylchrysin – novel 
Using the method described in section 2.2.2, page 123, with some modifications, 5-
hydroxy-7-(nonyloxy)-3-phenyl-4H-chromen-4-one (C 11) was made using potassium 
carbonate (2.00 eq, 0.26 g, 4.2 mmol), 5,7-dihydroxyflavone (0.12 g, 0.47 mmol) and 1-
Bromononane (2 eq 195 μl, 9.45 mmol). This was stirred for 48 hours at room 
temperature. On completion of the reaction, the contents were transferred immediately 
into -80 °C refrigerator and allowed for 5 minutes. This was transferred into a -25 ºC 
refrigerator and stored for 48 h. 5-Hydroxy-7-(nonyloxy)-3-phenyl-4H-chromen-4-one was 
obtained as a bright yellow semi-powder:  
 
Structure 4.11 – Compound C11 
Yield (0.221 g, 66.5 %); m.p. 73 - 76 °C; Rf = 0.63 (Silica 60 Å, 2:1 ethyl acetate: petroleum 
ether, v/v; 1H NMR (400 MHz, CDCl3, δ ppm) 0.92 (3H, t, J = 7.0 Hz), 1.25-1.43 (10H, 
quint, J = 7.0 Hz), 1.49 (2H, quint, J = 7.5, 7.0 Hz), 1.83 (2H, quint, J = 7.5 Hz), 4.05 (2H, 
t, J = 7.5 Hz), 6.40 (1H, d, J = 2.2 Hz), 6.52 (1H, d, J = 2.2 Hz), 6.70 (1H, s), 7.58 (3H, 
7.47 m, J = 7.8, 7.3, 1.5, 0.4 Hz), 7.92 (2H, dtd, J = 7.8, 1.4, 0.4 Hz), 12.78 (1H, s, 5-OH); 
13C NMR (100 MHz, CDCl3, δ ppm) 14.12 (CH3), 22.67 (CH2), 25.93 (CH2), 28.95 (CH2), 
29.25 (CH2), 29.32 (CH2), 29.51 (CH2), 31.87 (CH2), 68.72 (OCH2), 93.12 (CH), 98.61 
(CH), 105.58 (CH), 105.87 (C), 126.28 (2', CH), 126.28 (6', CH) 129.08 (3' CH), 129.08 
(5' CH), 131.40 (41, CH), 131.79 (1', C), 157.81 (C-O), 162.12 (C-O), 163.91 (C-OH), 
165.23 (C-O), 182.47 (C=O); IR 1169.51 cm-1 (C-O-C, large ring C-O stretch), 1033.91 
cm-1 and 1272.96 cm-1 (C-O, phenolic), 1505.20 cm-1 (C=C aromatic), 1660.79 cm-1 
(C=O, ketone), 2323.48 cm-1 (C-H, alkane), 2643.39 cm-1 (C-H, alkane), 2918.76 cm-1 (C-
H, alkane), 3018.56 cm-1 (C-H, aromatic); MS (ESI) m/z: calculated for C24H28O4 [M+H]+ 
= 380.2065, found 380.2057 
4.5.7  7-(Decyloxy)-5-hydroxy-3-phenyl-4H-chromen-4-one (C12) - 
or 7-O-Decylchrysin – novel compound 
Using the method described in section 2.2.2, page 123, 7-(decyloxy)-5-hydroxy-3-phenyl-
4H-chromen-4-one (C12), was made using potassium carbonate (2.00 eq, 0.26 g, 4.2 
Chemical formula: C24H28O4 
Molecular Weight: 380.47 g/mol
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mmol), 5,7-dihydroxyflavone (0.12 g, 0.47 mmol) and 1-bromodecane (2 eq 235.3 μl, 9.8 
mmol). 7-(Decyloxy)-5-hydroxy-3-phenyl-4H-chromen-4-one was obtained as a bright 
yellow semi-solid compound: 
 
Structure 4.12 – Compound C12 
Yield (0.231 g, 65.2 %); m.p. 74 - 76 °C; Rf = 0.54 (Silica 60 Å, 2:1 ethyl acetate: petroleum 
ether, v/v; 1H NMR (400 MHz, CDCl3, δ ppm) 0.92 (3H, t, J = 7.0 Hz), 1.24-1.42 (12H, 
1.28 (m, J = 7.0, 6.6 Hz), 1.50 (2H, m, J = 7.5, 7.0 Hz), 1.83 (2H, quint, J = 7.5 Hz), 4.05 
(2H, t, J = 7.5 Hz), 6.40 (1H, d, J = 2.2 Hz), 6.52 (1H, d, J = 2.2 Hz), 6.70 (1H, s), 7.58 
(3H, m, J = 7.8, 7.3, 1.5, 0.4 Hz), 7.92 (2H, dtd, J = 7.8, 1.4, 0.4 Hz), 12.78 (1H, s, 5-OH); 
13C NMR (100 MHz, CDCl3, δ ppm) 14.13 (CH3), 22.69 (CH2), 25.94 (CH2), 28.96 (CH2), 
29.33 (CH2), 29.33 (CH2), 29.56 (CH2), 29.56 (CH2), 31.90 (CH2), 68.72 (OCH2), 93.10 
(CH), 98.62 (CH), 105.58 (CH), 105.85 (C), 126.27 (2', CH), 126.27 (6’, CH), 129.08 (3', 
CH), 129.08 (5’, CH), 131.38 (4’, CH), 131.79 (1', C), 157.80 (C-O), 162.13 (C-O), 163.88 
(C-OH), 165.23 (C-O), 182.46 (C=O); m/z [M+H]+ = 394.2208; IR 1169.51 cm-1 (C-O-C, 
large ring C-O stretch), 1026.75 cm-1 and 1283.27 cm-1 (C-O, phenolic), 1512.15 cm-1 
(C=C aromatic), 1663.49 cm-1 (C=O, ketone), 2286.36 cm-1 (C-H, alkane), 2323.33 cm-1 
(C-H, alkane), 2645.76 cm-1 (C-H, alkane), 3014.51 cm-1 (C-H, aromatic); MS (ESI) m/z: 
calculated for C25H30O4 [M+H]+ = 394.2222, found 394.2208 
 
4.6  7-O-Bromoalkane-derivatives of Chrysin 
 
One of the aims of this project was to make 7-O-bromoalkylchrysin derivatives. The first 
compound made was 7-(3-bromopropoxy)-5-hydroxy-3-phenyl-4H-chromen-4-one. The 






The dibromoalkane used for synthesis of C13 is 1,3-dibromopropane (93 μl, 4.72 mmol). 
The yield and spectral data obtained is presented below. 
Chemical formula: C25H30O4 




Structure 4.13 – Compound C13 
 
Yield (0.245 g, 80.2 %); m.p. 142 - 143 °C; Rf = 0.47 (Silica 60 Å, 1:2 ethyl acetate: 
petroleum ether, v/v; 1H NMR (400 MHz, CDCl3, δ ppm) 2.39 (2H, tt, J = 7.5, 6.5 Hz), 3.65 
(2H, t, J = 6.5 Hz), 4.24 (2H, t, J = 7.5 Hz), 6.42 (1H, d, J = 2.2 Hz), 6.54 (1H, d, J = 2.2 
Hz), 6.70 (1H, s), 7.55 (3H, m J = 7.8, 7.3, 1.5, 0.4 Hz), 7.92 (2H, dtd, J = 7.8, 1.4, 0.4 
Hz), 12.78 (1H, s, 5-OH); 13C NMR (100 MHz, CDCl3, δ ppm) 30.94 (CH2), 31.48 (CH2-
Br), 66.29 (OCH2), 93.24 (CH), 98.54 (CH), 105.03 (CH), 105.34 (C), 126.45 (2', CH), 
126.45 (6’, CH), 129.13 (3', CH), 129.13 (5’, CH), 130.56 (4’, CH), 132.16 (1', C), 157.36 
(C-O), 161.15 (C-O), 163.49 (C-OH), 164.37 (C-O), 182.08 (C=O); IR 692.00 cm-1 (C-Br), 
1100.16 cm-1 (C-O-C, large ring C-O stretch), 1032 cm-1 and 1244.19 cm-1 (C-O, 
phenolic), 1607.29 cm-1 (C=C aromatic), 1651.28 cm-1 (C=O, ketone), 285.08 cm-1 (C-H, 
alkane), 2917.41 cm-1 (C-H, aromatic); MS (ESI) m/z: calculated for C18H15BrO4 [M+H]+ 





Structure 4.14 – Compound C14 
 
The dibromoalkane used for synthesis of C14 is 1,4-dibromobutane (1 eq 102 μl, 4.72 
mmol). The yield and spectral data obtained is presented below. 
Yield (0.284 g, 93.3 %); m.p. 143 – 144 °C; Rf = 0.62 (Silica 60 Å, 2:1 ethyl acetate: 
petroleum ether, v/v; 1H NMR (400 MHz, CDCl3, δ ppm) 1.98-2.18 (4H, 2.05 (quint, J = 
7.5 Hz), 2.10 (tt, J = 7.5, 6.9 Hz)), 3.54 (2H, t, J = 6.9 Hz), 4.12 (2H, t, J = 7.5 Hz), 6.42 
(1H, d, J = 2.2 Hz), 6.54 (1H, d, J = 2.2 Hz), 6.70 (1H, s), 7.57 (3H, m, J = 7.8, 7.3, 1.5, 
0.4 Hz), 7.92 (2H, dtd, J = 7.8, 1.4, 0.4 Hz), 12.78 (1H, s, 5-OH); 13C NMR (100 MHz, 
CDCl3, δ ppm) 27.62 (CH2), 29.82 (CH2), 33.20 (CH2-Br), 67.54 (OCH2), 93.09 (CH), 
98.56 (CH), 105.75 (CH), 105.90 (C), 126.29 (1', CH), 126.29 (6', CH), 129.10 (3', CH), 
Chemical formula: C18H15BrO4 
Molecular Weight: 375.21 g/mol
Chemical formula: C19H17BrO4 
Molecular Weight: 389.24 g/mol
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129.10 (3', CH), 131.33 (4', CH), 131.86 (C), 157.80 (C-O), 162.21 (C-O), 164.00 (C-OH), 
164.84 (C-O), 182.47 (C=O); IR 685.38 cm-1 (C-Br), 1160.46 cm-1 (C-O-C, large ring C-
O stretch), 1038 cm-1 and 1252.36 cm-1 (C-O, phenolic), 1609.38 cm-1 (C=C aromatic), 
1643.54 cm-1 (C=O, ketone), 2894.36 cm-1 (C-H, alkane), 3089.23 cm-1 (C-H, aromatic); 
MS (ESI) m/z: calculated for C19H17BrO4 [M+H]+ = 388.0310, found 388.03 
 
4.6.3  7-((5-Bromopentyl)oxy)-5-hydroxy-3-phenyl-4H-chromen-4-one 
(C15) 
The dibromoalkane used for synthesis of C15 is 1,5-dibromopentane (1 eq 108 μl, 4.72 
mmol). The yield and spectral data obtained is presented below. 
 
Structure 4.15 – Compound C15 
 
Yield (0.286 g, 94.0 %); m.p. 120 – 122 °C; Rf = 0.72 (Silica 60 Å, 2:1 ethyl acetate): 
petroleum ether, v/v; 1H NMR (400 MHz, CDCl3, δ ppm) 1.68 (2H, quint, J = 7.5 Hz), 1.85-
2.05 (4H, 1.82 (quint, J = 7.5, 6.9 Hz), 3.65 (2H, t, J = 6.9 Hz), 4.24 (2H, t, J = 7.5 Hz), 
6.42 (1H, d, J = 2.2 Hz), 6.54 (1H, d, J = 2.2 Hz), 6.70 (1H, s), 7.58 (dddd, J = 7.8, 7.3, 
1.5, 0.4 Hz), 7.92 (2H, dtd, J = 7.8, 1.4, 0.4 Hz), 12.78 (1H, s, 5-OH); 13C NMR (100 MHz, 
CDCl3, δ ppm) 24.73 (CH2), 28.15 (CH2), 32.37 (CH2), 33.48 (CH2-Br), 68.26 (OCH2), 
93.10 (CH), 98.57 (CH), 105.67 (CH), 105.87 (C), 126.28 (1’, CH), 126.28 (6’, CH),  
129.09 (3' CH), 129.09 (5' CH), 131.34 (4’, CH), 131.83 (1', C), 157.79 (C-O), 162.17 (C-
O), 163.95 (C-OH), 164.99 (C-O), 182.47 (C=O);  IR 673.50 cm-1 (C-Br), 1160.48 cm-1 
(C-O-C, large ring C-O stretch), 1035.84 cm-1 and 1251.54 cm-1 (C-O, phenolic), 1585.17 
cm-1 (C=C aromatic), 1605.89 cm-1 (C=O, ketone), 2851.36 cm-1 (C-H, alkane), 2925.09 
cm-1 (C-H, alkane), 2949.90 cm-1 (C-H, alkane), 3058.38 cm-1 (C-H, aromatic); MS (ESI) 
m/z: calculated for C20H19BrO4 [M+H]+ = 402.0466, found 402.05 
4.6.4  7-((4-Bromopentyl)oxy)-5-hydroxy-3-phenyl-4H-chromen-4-
one or 7-O-2-Bromopentylchrysin (C16) - novel 
The dibromoalkane used for synthesis of C16 is 1,4-dibromopentane (1 eq 108 μl, 4.72 
mmol). The yield and spectral data obtained is presented below. 
Chemical formula: C20H19BrO4 




Structure 4.16 – Compound C16 
Yield (0.286 g, 94.0 %); m.p. 123 – 124 °C; Rf = 0.74 (Silica 60 Å, 2:1 ethyl acetate): 
petroleum ether, v/v; 1H NMR (400 MHz, CDCl3, δ ppm) 1.78 (3H, d, J = 6.8 Hz), 1.88-
2.16 (4H, 1.99 (td, J = 7.4, 6.8 Hz), 2.04 (td, J = 7.4, 6.8 Hz), 2.07 (tt, J = 7.5, 7.4 Hz), 
2.11 (tt, J = 7.5, 7.4 Hz)), 4.10 (2H, t, J = 7.5 Hz), 4.25 (1H, h, J = 6.8 Hz), 6.38 (1H, d, J = 
1.9 Hz), 6.50 (1H, d, J = 1.9 Hz), 6.70 (1H, s), 7.56 (3H, dd, J = 7.8, 7.3 Hz), 7.93 (2H, 
dtd, J = 7.8, 1.4, 0.4 Hz) 12.78 (1H, s, 5-OH); 13C NMR (100 MHz, CDCl3, δ ppm) 26.58 
(CH3), 27.41 (CH2), 37.51 (CH2), 50.94 (CH2-Br), 67.76 (OCH2), 93.07 (CH), 98.57 (CH), 
105.73 (CH), 105.89 (C), 126.29 (2', CH), 126.29 (2', CH), 129.10 (3', CH), 129.10 (3', 
CH), 131.33 (4’, CH), 131.85 (1', C), 157.79 (C-O), 162.19 (C-O), 163.07 (C-OH), 164.89 
(C-O), 182.47 (C=O); IR 765.53 cm-1 (C-Br), 1172.08 cm-1 (C-O-C, large ring C-O stretch), 
1101.61 cm-1 and 1270.95 cm-1 (C-O, phenolic), 1603.28 cm-1 (C=C aromatic), 1621.23 
cm-1 (C=O, ketone), 2854.31 cm-1 (C-H, alkane), 2943.23 cm-1 (C-H, alkane), 2965.54 
cm-1 (C-H, alkane), 3068.12 cm-1 (C-H, aromatic); MS (ESI) m/z: calculated for 
C20H19BrO4 [M+H]+ = 402.0466, found 404.0521 
 
4.6.5  7-((12-Bromododecyl)oxy)-5-hydroxy-3-phenyl-4H-
chromen-4-one (C17)  
The dibromoalkane used for synthesis of C17 is 1,4-dibromopentane (0.17 g, 4.75 mmol).  
The yield and spectral data obtained is presented below. 
 
Structure 4.17 – Compound C17 
Yield (0.258 g, 89.0 %); m.p. 91 – 92 °C; Rf = 0.65 (Silica 60 Å, 2:1 ethyl acetate: 
petroleum ether, v/v); 1H NMR (400 MHz, DMSO-d6, δ ppm) 1.28-1.53 (16H, 1.35 (tt, J = 
7.0, 6.6 Hz), 1.42 (tt, J = 7.5, 7.0 Hz), 1.44 (tt, J = 7.0, 6.6 Hz), 1.46 (quint, J = 7.0 Hz), 
1.48 (tt, J = 7.0, 6.6 Hz), 1.76-1.86 (4H, 1.80 (tt, J = 7.5, 6.9 Hz), 1.82 (quint, J = 7.5 Hz)), 
Chemical formula: C20H19BrO4 
Molecular Weight: 404.27 g/mol
Chemical formula: C27H33BrO4 
Molecular Weight: 501.45 g/mol
174 
 
4.10 (2H, t, J = 6.9 Hz), 4.25 (2H, t, J = 7.5 Hz), 6.38 (1H, d, J = 2.2 Hz), 6.50 (1H, d, J = 
2.2 Hz), 6.70 (1H, s), 7.55 (3H, dddd, J = 7.8, 7.3, 1.5, 0.4 Hz), 7.92 (2H, dtd, J = 7.8, 1.4, 
0.4 Hz), 12.78 (1H, s, 5-OH); 13C NMR (100 MHz, CDCl3, δ ppm) 14.11 (CH2),  26.15 
(CH3), 28.18 (CH2), 28.77 (CH2), 28.95 (CH2), 29.31 (CH2), 29.43 (CH2), 29.52 (CH2), 
29.67 (CH2), 32.83 (CH2), 34.08 (CH2-Br), 68.71 (OCH2), 93.10 (CH), 98.62 (CH), 105.58 
(CH), 105.85 (C), 126.28 (1', CH), 126.28 (6', CH), 129.08 (3', CH), 129.08 (5', CH), 
131.38 (4', CH), 131.80 (1', C), 157.80 (CH), 162.13 (C-O), 163.90 (C-OH), 165.22 (C), 
182.82 (C=O); IR 684.90 cm-1 (C-Br), 1118.35 cm-1 (C-O-C, large ring C-O stretch), 
1166.82 cm-1 and 1300.67 cm-1 (C-O, phenolic), 1584.66 cm-1 (C=C aromatic), 1611.43 
cm-1 (C=O, ketone), 2851.08 cm-1 (C-H, alkane), 2917.41 cm-1, 3071.03 cm-1 (C-H, 
aromatic); MS (ESI) m/z: calculated for C20H19BrO4 [M+H]+ = 500.1562, found 500.16  
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Name / Properties 
























yl)oxy)butyl acetate or 7-O-chrysinbutylacetate 
Chemical formula: C21H20O6 
Exact Mass: 368.1330 















Chemical formula: C24H22O4 
Exact Mass: 372.1433 

















Chemical formula: C22H16N2O8 
Exact Mass: 420.0661 
















Chemical formula: C18H16O4 
Exact Mass: 296.10 
















Chemical formula: C19H18O4 
Exact Mass: 310.1278 

















4H-chromen-4-one or 7-O-butylchrysin 
Chemical formula: C19H18O4 
Exact Mass: 310.12 















Chemical formula: C20H20O4 
Exact Mass: 324.13 
Molecular Weight: 324.37 g/mol 
A – 46.4 
B – 88.1 













Chemical formula: C21H22O4 
Exact Mass: 338.15 
Molecular Weight: 338.40 g/mol 
A – 58.2 
B – 81.2 














Chemical formula: C22H24O4 
Exact Mass: 352.17 
Molecular Weight: 352.42 g/mol 
A – 46.1 
B – 81.4 













Chemical formula: C23H26O4 
Exact Mass: 366.1899 
Molecular Weight: 366.45 g/mol 
A – 49.3 














Chemical formula: C24H28O4 
Exact Mass: 380.2057 
Molecular Weight: 380.47 g/mol 
A – 47.0 
B – 66.5 













Chemical formula: C25H30O4 
Exact Mass: 394.2208 
Molecular Weight: 394.50 g/mol 
A – 56.2 
B – 65.2 
C – 66.7 
 
 











chromen-4-one or 7-O-bromopropylchrysin 
Chemical formula: C18H15BrO4 
Exact Mass: 374.02 













4-one or 4-bromobutylchrysin 
Chemical formula: C19H17BrO4 
Exact Mass: 388.03 













chromen-4-one, or 7-O-bromopentylchrysin 
Chemical formula: C20H19BrO4 
Exact Mass: 402.05 













chromen-4-one or 4-bromopentylchrysin 
Chemical formula: C20H19BrO4 
Exact Mass: 404.0521 















chromen-4-one, or 12-bromododecylchrysin 
Chemical formula: C27H33BrO4 
Exact Mass: 500.16 





 91 – 
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A  - Yield reported for method A used in synthesis of the compound. Method A is synthesis via the microwave reactor. 
B - Yield reported for method B used in synthesis of the compound. Method B involves stirring the reaction mixture under controlled 
conditions of temperature and other reaction conditions. 
C   - Yield reported for method C. 
N/A   - Not applicable 
R1   - Chrysin molecule without hydrogen proton at 7-OH  
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The synthesis of these compounds was approached from different perspectives in order to 
provide the highest yield and atom economy with the fewest possible steps. This study has 
been able to achieve this via the use of a microwave reactor which offered a shorter period 
(≤ 10 minutes) for the synthesis of these compounds compared to a period of 24 – 48 hours 
using the conventional method of stirring the reaction mixture. The use of a microwave 
reactor in driving the quick synthesis of these compounds implies that a large-scale 
production of these compounds within a short time period is possible and feasible via the 
methods developed in this study. Although some 7-O-bromoalkyl, 7-O-alkyl and 7-O-
chrysin derivatives have been previously made (Cheng et al., 2014; Valdez-Calderón et al., 
2016), this is the first time a microwave reactor has been used in the synthesis of these 
compounds. This is also the first time the antimicrobial and anticancer activities of these 
compounds have been reported. It is also the first time 7-O-bromoalkylchrysin derivatives 
with carbon atoms ≥ 7, and aliphatic 7-O-chrysin derivatives (7-O-bromododecylchrysin and 
7-O-4-bromopentylchrysin) have been reported. 
The 7-O-chrysin derivatives synthesised are divided into three series for this study: 
Series 1: 7-O-chrysin derivatives (C1 – C3). 
Series 2: 7-O-alkylchrysin derivatives comprising of C4 – C12. 
Series 3:  7-O-bromoalkylchrysin derivatives comprising of C13 – C17. 
 
The names of these compounds are listed in Table 4.2 below. 
 
Table 4.2: name and series of compounds synthesised in this study. 
Compound Name of Compound Series name 
C1 7-O-chrysinbutyl acetate                        
Series 1 C2 7-O-chrysin-3,5-dimethylbenzene  
C3 7-O-chysin-2,4-dinitrobenzene 

























Chrysin 5,7-dihydroxyflavone Parent compound 
CPZ Chlorpromazine hydrochloride   Positive control drug 
 
Series 1 compounds made in this study are 7-O-chrysinbutyl acetate (C1), 7-O-chrysin-
3,5-dimethylbenzene (C2) and 7-O-chrysin-2,4-dinitrobenzene (C3). These are novel 
compounds. 
Series 2 compounds synthesised in this study are classified into 2:  
Group A: methylated series-2 compounds – 7-O-Isopropylchrysin (C4) and 7-O-2-
Methylpropylchrysin (C5) – novel compound. 
Group B: Non-methylated series-2 compounds – 7-O-butylchrysin (C6), 7-O-pentylchrysin 
(C7), 7-O-hexylchrysin (C8), 7-O-heptylchrysin (C9), 7-O-octylchrysin (C10), 7-O-
nonylchrysin (C11), 7-O-decylchrysin (C12). Compounds synthesised using method B were 
used for biological studies. 
Series 2 compounds were made via three methods: method A, involving irradiation of the 
reactants in a microwave reactor using acetonitrile as the reaction solvent. Method B 
involves irradiation of the reactants in a microwave reactor using dimethylformamide 
(DMF). Unlike method A, tetrabutylammonium bromide (0.04 mmol) was added to the 
reactants. Method C involves stirring of the reactants for 24 – 48 hours. 
The yields recorded for these compounds was higher with method B (yields > 75 %, except 
for C12) compared to method A (< 60 %) and method C (< 70 %). This increase in yield 
may be attributed to the quaternary ammonium salt (tetrabutylammonium bromide) added 
to the reactants, whose bromide counter-ion may have acted as a phase transfer catalyst, 
thus the increase yield recorded with method B. 
In the 1H NMR, the singlet proton with δ 12.61, corresponds to the 5-OH of chrysin, and a 
triplet with δ 4.05, corresponding to 2-protons (OCH2, J = 7.1), at the point of attachment of 
the various reactants. Unusual differences in melting point was observed for these 
compounds: the methylated series 2 adducts (C4 and C5) recorded higher melting points 
(m.p.) of 145 – 146 °C and 143 – 145 °C. The m.p. of C4 was slightly higher than C5 which 
had an increased chain length (-CH3). Similarly, the m.p. pattern observed for the non-
methylated series 2 compounds showed a decreasing m.p. as the number of carbon chain 
180 
 
increases. C6 with 4-carbon chain indicated m.p. of 138 – 139 °C, C7 with 5-carbon chain 
(m.p. 138 – 140 °C), C8 with 6-carbon chain (136 – 137 °C), C9 with 7-carbon chain (118 
– 120 °C), C10 with 8-carbon chain (77 – 80 °C), C11 with 9-carbon chain (73 – 76 °C) and 
C10 (74 – 76 °C). 
This suggests that increasing the chain length (methylation) of chrysin at 7-OH, reduces 
the melting point of chrysin. It also suggests that the attachment of a branched aliphatic 
chain (as in C4) near the 7-OH of chrysin, increases the melting point, and if further apart 
(as in C5), the melting point tends to decrease. The m.p. of series 2 compounds decreased 
drastically for C11 and C12 (having 9 and 10 carbon atoms). 
It was difficult to precipitate out C11 and C12 using the conventional methods developed in 
this study as these compounds were semi-liquids. After some unsuccessful attempts to 
precipitate C11 and C12, the reaction conditions were modified such that the reaction was 
made to progress at room temperature for 48 h and not at 80 °C. After 48 hours, the reaction 
was transferred immediately into a -80 °C refrigerator for 5 minutes, and then into a -25 °C 
refrigerator where it was stored for 48 h. The solution was not frozen as acetonitrile freezes 
at -45 °C. This enabled the precipitation of C11 and C12 respectively. C11 was partly oily. 
C12 was partly oily and translucent on the filter paper used. To precipitate C12, very cold 
water was used to filter C12. 
C4 (Comte et al., 2001), C6, C7 and C8 have been previously made (Cheng et al., 2014). 
In this study, in addition to C4, C6, C7 and C8 (which have been previously made), we 
synthesised novel 7-O-chrysin adducts: 7-O-octylchrysin (C9), 7-O-nonylchrysin (C10) and 
7-O-decylchrysin (C12). Although the spectral data of C7 and C9 have been reported on 
PubMed, no biological investigation has been reported by any author. 
Series 3 compounds includes the bromoalkane-derivatives of chrysin. Five (5) compounds 
which include: 7-O-bromopropylchrysin, 7-O-bromobutylchrysin, 7-O-5-
bromopentylchrysin, 7-O-4-bromopentylchrysin (novel compound) were synthesised in this 
group. Compounds synthesised using method B were used for biological studies. It is 
believed that the methyl, halogen, acetate and nitrite groups attached at some points in the 
molecules of chrysin derivatives could influence the biological activities of the newly 
synthesised compounds, and the biological activities of these new molecules could then be 
investigated. Compounds synthesised in this study were made using two or three different 
methods; by radiating the reactants in a microwave reactor, by stirring the reactants for a 
certain period or. The spectral data of chrysin is presented in the appendix. The first 
derivatives of chrysin that was synthesised were the series 1 compounds (C1, C2 and C3). 
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All series 1 compounds made in this study are novel 7-O-chrysin derivatives. Compounds 
synthesised using method B were used for biological studies. 
The first chrysin adduct that was made is 7-O-chrysinbutyl acetate (C1) – page 154. In the 
1H NMR spectrum of the chrysin adduct (C 1), proton 12-H and 15-H, have chemical shift 
of 3.98 – 4.15 ppm (O-CH2). This corresponds to the attachment of the 4-bromobutyl 
acetate to the 7-OH position of chrysin. Attachment of 4-bromobutyl acetate at the 5-OH is 
difficult without a strong base like NaOH due to the development of hydrogen bond between 
the hydrogen atom at C-5 and the carbonyl oxygen at C-3 of chrysin. This hydrogen bond 
therefore tends to prevent the interaction of chemical groups with the –OH group at C-5 of 
chrysin, allowing interaction with the –OH group at C-7 of chrysin. This assumption was 
confirmed in a research by Zheng et al., (2016) and Lapkin et al. (2014), who exploited the 
effect of hydrogen bonding in chrysin and galangin. They concluded that a strong hydrogen 
bond and interaction exist in chrysin molecule, which prevents the interaction of the 
hydrogen atom at position C-5 of chrysin. The stronger this hydrogen bond, interaction with 
other molecules becomes difficult giving rise to a strong covalent and electrostatic 
interaction at the hydroxyl group at the C-5 position of chrysin. Spectroscopic data: 1D (1H, 
13C, C-APT) and 2D (COSY, gHMBC) and IR support the findings that the 7-OH position 
is where the reaction occurred. Additionally, in the 1H NMR spectrum of the chrysin adduct 
(C1), the chemical shift at 12.61 (1 H, s, 5-OH) corresponds to the 5-OH hydroxyl atom. 
In order to investigate the effect of the hydrogen bond at the 5-OH position of the chrysin 
molecule, the concentration of 4-bromobutyl acetate and potassium carbonate were 
increased to 10 eq respectively and the product obtained monitored on a TLC plate. There 
was no evidence of formation of chrysin adduct at 5-OH of chrysin as confirmed by 
spectroscopic data. This is a confirmation of previous observation of the existence of 
hydrogen bond at 5-OH of chrysin (Lapkin et al., 2014; Zheng et al., 2016) which limits the 
reactivity of chrysin at the 5-OH position. This noted, other chrysin adducts made showed 
a similar pattern with a 1H NMR spectrum of the chrysin adducts corresponding to –OH 
group at C-5 seen around 12.61 – 13.01 ppm. 
Although a colour change (brown precipitate) was observed between the C1 obtained using 
method A (synthesis using the microwave reactor) and method B (ivory white precipitate), 
the NMR spectrum of both compounds was identical. The yield obtained using the 
microwave extractor (method A) – 80.20 % was significantly higher than the yield obtained 
using method B (68.0 %). The reason for these colour changes is not certain but may have 
resulted from the heating effect of the reaction mixture in the microwave reactor at a higher 
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temperature (120 °C) and power of 900 W. To investigate the effect of increased 
temperature on the colour change observed, the temperature of the microwave reactor was 
reduced to 100 °C (other variables remaining constant). This time, an ivory white precipitate 
was obtained but the yield declined from 80.2 % obtained previously to 72.85 % (result 
obtained after taking an average of 3 reactions). This suggests that the colour change 
observed was due to the increased temperature and the environment at the microwave 
reactor. This finding also suggests that at high reaction temperatures, the yield of C1 
increases using the microwave reactor (Jensen et al., 2017).  
The second chrysin derivative synthesised was 7-O-chrysin-3,5-dimethylbenzene (C2). 
The ease with which this reaction occurred with acetonitrile but not acetone or methanol 
may be attributed to the nucleophilic addition of the nitrile giving rise to intermediates which 
undergo further reactions with the –OH to form the product. The structure of the solvent 
can influence the outcome of the reaction especially when ionic liquids such as acetonitrile 
are used due to the entropy changes occurring in the reaction medium. In a study by 
Keaveney et al., (2016) and Keaveney et al., (2017), the role of ionic solvents was 
investigated, and it was concluded that ionic liquids increase the effective concentration of 
reactants, allowing interaction between reactants especially those containing short chain 
alkyl groups as non-polar ionic domains are created in these molecules, allowing an 
increase in the rate constants for ionic liquids. The positioning of the methyl groups at the 
meta positions (3, 5) in the benzene ring may have allowed the rapid progression of the 
reaction, allowing for the electrophilic substitution of the bromine atom, and the formation 
of (C 2). It was difficult to increase the yield of C2 when reaction temperature was ≥ 70 ºC. 
C2 was made at room temperature while C1 and C3 were made at temperatures ≥ 60 ºC. 
These findings suggest that the microwave reactor degrades the benzene ring due to the 
polarization effect of microwave which oxidizes the benzene rings in C2 and C3 (Zhang et 
al., 2012). This was visible in the impurities spotted on the TLC plate when C2 and C3 (from 
the microwave reactor) were eluted on TLC plates. These impurities were absent on C1. 
These impurities were also absent in C2 and C3 synthesised via method B (stirring). 
Series 2 compounds include the 7-O-alkylchrysin derivatives (C4 -12). In the 1H NMR 
spectrum, these compounds indicated similar spectra at δ (ppm) ranging from 7.47 – 7.50 
(2 H, H-3’ and H-5’); 7.91 - 7.92 corresponding (2H, H-2’ and H-6’); and 12.64 – 13.01 
corresponding to (1 H, s, 5-OH). These corresponds to 1H NMR spectra reported by Cheng 
et al., (2014) and Kingkaew et al., (2018). In this study, series 2 compounds were 
synthesised using acetonitrile as reaction medium and not acetone as previously 
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synthesised (Cheng et al., 2014; Kingkaew et al., 2018). Acetonitrile (as a reaction medium) 
offered better yield of 7-O-butylchrysin (C6) – 78.86 % compared to previous study using 
acetone (74.5 %) (Cheng et al., 2014), and a better yield of 7-O-hexylchrysin (C8) (88.12 
%), compared to the yield reported by Comte et al., (2001) using acetone (59.1%). 
Nevertheless, the yield reported by Cheng et al., (2014) for C8 using acetone (89.7 %) is 
comparable to that reported in this study.   
Similarly, a higher yield of 7-O-isopropylchrysin (C4) synthesised via the microwave 
reactor, was recorded in this study using acetonitrile as a reaction medium, 62.7 % yield 
was recorded in this study. This yield is comparable to that reported by Comte et al., (2001) 
and Pan et al., 2015 (65.8 %). The increased yield of series 2 chrysin derivatives recorded 
in this study could be attributed to the use of dry ice / ice-cold water in rapidly cooling and 
washing the products. This process is hypothesised to favour the equilibrium towards the 
yield of products, converting reactants to products. Other reports did not cool the reaction 
medium rapidly, and the researchers did not wash / store their products in ice-cold water. 
To confirm this hypothesis, the same reaction conditions were employed, and the products 
allowed to cool to room temperature and then washed with water at 25 ºC. 50 – 82 % yields 
(compared to the yields recorded when the products were rapidly cooled in dry-ice / ice-
cold water) was recorded. The increased yield recorded in this study using acetonitrile, 
compared to those reported by other researchers using acetone could be attributed to the 
fact that that acetonitrile is an ionic liquid (Keaveney et al., 2016). Ionic liquids increase the 
effective concentration of reactants, allowing interaction between reactants especially those 
containing short chain alkyl groups as non-polar ionic domains are created in these 
molecules, allowing an increase in the rate constants for ionic liquids (Keaveney et al., 
2016; Keaveney et al., 2017). To compare the role of acetonitrile and acetone in the yield 
of chrysin derivatives, acetone was used as a reaction medium (with other variables 
remaining constant); it was observed that the yields recorded for acetonitrile was higher 
than the yields recorded for acetone (as reaction solvents). 
Although some series-3 chrysin adducts made in this study have been previously made, 
this is the first time the antibacterial and anticancer activities of these compounds have 
been reported. Experimental data obtained in this study also compares to data previously 
reported Valdez-Calderón et al. (2016) has previously made three series 3 compounds 
synthesised in this study – 7-O-bromopropylchrysin, 7-O-bromobutylchrysin and 7-O-5-
bromopentylchrysin and studied the anthelminthic activities of these compounds but not 
their antibacterial and anticancer activities. Cheng et al. (2014), has previously made some 
series 2 compounds (7-O-butylchrysin and 7-O-hexylchrysin), studying their inhibitory 
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activity against α-glucosidase, an enzyme implicated in diabetes. The 7-O-bromoalkane-
derivatives of chrysin offered a better yield compared to other chrysin adducts. 
One of the aims of this study was to make 7-O-chrysin adducts such that chrysin adducts 
synthesised were attached to the 7-OH of chrysin. This noted, an attempt was made to 
synthesise 7-O-chloro-chrysin adducts like the 7-O-bromoalkylchrysin adducts of series 1 
using 1-chlorobutane and 1-chlorohexane (using the methods described for the synthesis 
of 7-O-bromoalkylchrysin adducts). Unlike the chrysin adducts reported above, little 
precipitates were formed for these compounds. The microwave reactor was used for the 
synthesis of these chloro-chrysin adducts as well but little no precipitates were formed. One 
reason ice cold water was used in precipitating the Chrysin derivativesmade was to ensure 
the products were stabilised before extraction as the bromoalkane and alkanes used for 
the synthesis of these chrysin adducts had relatively low melting points (−112.5 °C for 1-
bromobutane). Ice cold water was used to stabilise the chloro-adducts of chrysin, little 
precipitate was formed. Precipitates formed were poured unto crushed ice and left for 24 
hours at –80 °C; little precipitates were formed. Precipitates formed were filtered as 
described for the synthesis of 7-O-bromoalkylchrysin adducts using ice cold water. The 
precipitate formed dissolved in water. This is because chlorine is water soluble in most 
instances. The reason water was used in washing the precipitate is because unreacted 
chrysin was easily washed off the precipitate during filtration using the vacuum pump. 
Another reason water was used is because potassium carbonate dissolves easily in water 
but not in other solvents. This implies a pure compound of interest can be obtained even 
without subjecting the product to further purification using column chromatography. We 
attempted to purify the chloro-chrysin adducts using different purification techniques 
(except HPLC) but we obtained very poor yield (≤ 10 %). The yield obtained was impure 
when checked using the TLC plate as minor impurities were present. Nevertheless, on TLC 
plate, the impurities were not chrysin as the retardation factor (Rf) values for these 
impurities were different from the Rf value of chrysin. It was reasoned that these impurities 
could be 5-O-chrysin adducts and both 5-O- and 7-O-chrysin adducts in combination with 
the 7-O-chrysin adducts which were of interest to us in this study. Because no literature 
has been published for aliphatic chloro-chrysin adducts, this finding is worthy of note for 
future researchers who should seek to synthesize and purify aliphatic chloro-chrysin 
adducts with the aim of studying their biological activities. This is important because the 
magnitude of anticancer activities observed against MCF 7 and HCT 116 cell lines was 
interesting compared to those indicated by chrysin, and the Rf values suggests these 
impurities were not chrysin. 
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The 13C NMR spectra for series 1 compound indicated fifteen signals of chrysin and their 
chemical shifts do not differ from each compound’s chemical shift by more than 1.8 ppm 
technically. A characteristic similar to all compounds in series were δC 105.8 ppm (with 
minor differences ≤ 0.1 ppm). Oxygen bearing vinyl or aromatic carbon atoms was observed 
at δC 159 – 162 ppm (C7), 105.72 ppm (C2), 162 – 164 ppm (C5), 157.77 – 158.35 ppm 
(C9). For ring B carbon atoms, signals were detected at δC 131.33 – 131.39 ppm (1’), 
129.60 – 129.99 ppm (C4’), 129.09 – 130.44 ppm (3’, 5’), 126.27 – 126.38 ppm (C2’ and 
C6’). For C3 and C10 aromatic carbons, overlapping signals between δC 182.45 – 182.53 
ppm (C3) and 67.76 – 67.91 ppm (C10). Oxygen bearing aliphatic carbon (O-CH2) was 
detected at δC 66.20 – 68.21 ppm. Signals for bromine bearing atoms (Br-CH2) were seen 
at δC 29.35 – 32.63 ppm. All other aliphatic carbon atoms were observed between δC 25.35 
– 33.87 ppm. Proton and carbon atom assignments were corroborated by gHMBC and 
gHSQC experiments and HMBC correlation supported the O-alkylation of Chrysin 
derivatives at C7. These corresponds to signals previously reported (Comte et al., 2001; 
Cheng et al., 2014; Valdez-Caldron et al., 2016). NMR data matched the mass 
spectroscopy (MS) data for all synthesised chrysin derivatives. MS data for novel 
compounds are presented in appendix I. 
Previously, some chrysin adducts have been made and their biological activities evaluated. 
Among the chrysin adducts made include the geranylated, prenylated, O-benzylated, C-
benzylated, isopropylated and methylated chrysin derivatives by targeting positions 6, 7 
and 8 of the chrysin molecule (Comte et al, 2001). Comte et al., (2001) reported a lower 
KD value (a quantitative measurement of antibody affinity), which was 500 folds lower than 
that of chrysin and concluded that alkylation of the chrysin molecule strengthens the 
interaction of chrysin at the modulatory site which binds hydrophobic compounds, and this 
methylation also inhibited the efflux of daunomycin from the cell domain, thus an increased 
activity of these methylated chrysin adducts. In this study, we synthesised novel methylated 
chrysin adducts (C5 and C16), which are structural isomers of C4 and C15. The boiling 
points of methylated chrysin adducts was slightly higher than those of the isomers without 
a methyl group with an increase ≥ 2 ˚ C. The methylated chrysin adducts also had a flaky 
powdery appearance (fine powders) compared to chrysin and other chrysin adducts. 
Chrysin adducts were soluble in chloroform unlike chrysin which was partially soluble in 
chloroform but very soluble in DMSO. The only chrysin adduct which was partially soluble 
in chloroform is C3 (lacks an alkyl group). Interestingly, like C3, C2 also had a phenyl 
substitution at position 7 (phenyl-7-O-chrysin) of the chrysin molecule but unlike the NO2 
groups in C3, C2 has dimethyl groups attached to positions 3 and 5 of the phenyl ring, and 
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a methyl group separating the benzyl ring from the chrysin molecule at the 7-OH position. 
Thus, C2 was soluble in chloroform, C3 was partially soluble. This suggests that 
methylation of the chrysin molecule increases its solubility in chloroform and this finding 
agrees with those of Comte et al., (2001) 
4.6.6  Hydrophilicity of Chrysin Derivatives 
The solubility of chrysin derivatives synthesised in this work in polar solvents was 
determined as stated in section 2.25, page 128 and the results presented below. 
Table 4.3: Hydrophilic index of synthesised chrysin derivatives in comparison to chrysin 
















C1 0.75 1.07 0.75 1.15 0.75 1.25 7-O-chrysinbutyl acetate 
C2 0.70 1.00 0.70 1.08 0.70 1.17 7-O-chrysin-3,5-
dimethylbenzene 
C3 0.25 0.36 0.45 0.69 0.55 0.92 7-O-chysin-2,4-dinitrobenzene 
C4 0.25 0.36 0.30 0.46 0.30 0.50 7-O-isopropylchrysin 
C5 0.30 0.43 0.30 0.46 0.35 0.58 7-O-chrysin-2-methylpropane 
C6 0.15 0.21 0.25 0.38 0.25 0.42 7-O-butylchrysin 
C7 0.15 0.21 0.20 0.31 0.30 0.50 7-O-pentylchrysin 
C8 0.15 0.21 0.20 0.31 0.35 0.58 7-O-hexylchrysin 
C9 0.15 0.21 0.25 0.38 0.20 0.33 7-O-heptylchrysin 
C10 0.10 0.14 0.20 0.31 0.30 0.50 7-O-octylchrysin 
C11 0.10 0.14 0.20 0.31 0.30 0.50 7-O-nonylchrysin 
C12 0.15 0.21 0.30 0.46 0.35 0.58 7-O-decylchrysin 
C13 0.70 1.00  0.65 1.00 0.70 1.17 7-O-3-bromopropylchrysin 
C14 0.50 0.71 0.55 0.85 0.50 0.83 7-O-4-bomobutylchrysin 
C15 0.45 0.64 0.50 0.77 0.40 0.67 7-O-5-bromopentylchrysin 
C16 0.35 0.50 0.45 0.69 0.45 0.75 7-O-4-bromopentylchrysin 
C17 0.20 0.29 0.20 0.31 0.20 0.33 7-O-12-bromododecylchrysin 
Chrysin 0.70 1.00 0.65 1.00 0.60 1.00 5,7-dihydroxyflavone 
 
Rf = Rf value (ratio of the distance moved by the solute to the distance moved by the solvent); RfX = hydrophilic 
index; DMF = dimethylformamide; THF = tetrahydrofuran; HC= hydrophilic index. The hydrophilic index is a 
measure of the potential ability of a molecule to dissolve in polar solvents. Hydrophilic compounds tend to be 
better candidates for pharmaceutical agents. C1, C2 and C13 indicated better hydrophilicity to chrysin.  
From the Rf values of chrysin derivatives recorded using the thin-layer chromatography 
(TLC) plates, hydrophilicity indices – ability of chrysin derivatives to dissolve in polar 
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solvents (75 % v/v polar solvent in water) of these compounds (chrysin derivatives) was 
calculated using the equation: 
 
The Rf values reported per chrysin derivative is an average of at least two independent 
experiments. The HC data indicates that the solubility of chrysin derivatives in the mixture 
of methanol, DMF or THF and water increases as from methanol to THF. This implies that 
chrysin derivatives dissolves better in 75 % v/v THF than DMF and methanol. From results 
obtained from Table 4.3, the solubility values of chrysin derivatives are at least 1.1 to 2.2 
times more soluble in 75 % v/v DMF than in 75 % v/v methanol and 1.1 to 3.2 times more 
soluble in in 75 % v/v THF than in 75 % v/v methanol. Comparing the solubility of chrysin 
derivatives between THF and DMF (75 % v/v), it is observed that these compounds are 
about 1.0 to 2.0 times more soluble in THF than in DMF. It could therefore be inferred that 
the solubility of chrysin derivatives in the solvents investigated follows the order: THF > 
DMF > methanol. The HC of these compounds was calculated such that chrysin is a 
constant with numerical value 1.0. It could be hypothesised that chrysin derivatives with HC 
values greater than 1.0 are more lipophilic (soluble in polar solvents) than chrysin. Chrysin 
derivatives with HC 0.8 to 1.0 could be hypothesised to indicate similar lipophilicity to 
chrysin and those with HC ≤ 0.8 could be said to be less hydrophilic, compared to chrysin. 
Results presented on table 4.3 indicate that 7-O-chrysinbutyl acetate (C1) is more lipophilic 
than chrysin in all solvents used. 7-O-3-bromopropylchrysin (C13) is also more lipophilic 
than chrysin in 75 % v/v THF. C13 also indicated similar lipophilicity in 75 % v/v methanol 
and DMF respectively. 7-O-chrysin-3,5-dimethylbenzene (C3) also showed similar 
lipophilicity in THF to chrysin. Although the 7-O-bromoalkyl chrysin derivatives were more 
hydrophobic (less lipophilic) than chrysin, an interesting finding is observed. 7-O-
bromoalkyl chrysin derivatives are more lipophilic than their 7-O-alkylchrysin derivatives 
(Table 4.3). This behaviour could be due to the similarity of chrysin polarity to these 
solvents. The aromatic ring present in the chrysin molecule makes chrysin less polar. 
Unfortunately, no work on the solubility of chrysin derivatives synthesised in this work in 
aqueous mixtures of THF, DMF and methanol (75 % v/v) has been reported in the literature 
for comparison. However, Zhou et al., (2014) has previously reported the mole fraction 
solubility values of chrysin in pure water at 250 °C to be 1.86 × 10− 5 moldm-3. The better 
lipophilicity indicated by 7-O-bromoalkyl derivatives of chrysin compared to their 7-O-
alkylchrysin derivatives could be because of the influence of the bromide attached to these 
compounds.  
The role of the bromine atom in improving solubility of compounds in organic solvents have 
been previously reported (Christov, 2012; Królikowska & Hofman, 2019).  
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Chapter 5  Results / Discussion: Biological Activities and Selectivity 
of Sesquiterpene Lactone Extracts and Synthesised 
Chrysin Derivatives 
Biological activities investigated in this project are divided into two: antibacterial activities 
and anticancer activities. This project has been divided into two distinct sections (see the 
project aims). The results for the antibacterial and anticancer activities of sesquiterpene 
lactones isolated in this study, and the results for the antibacterial and anticancer 
activities of synthetic chrysin derivatives are presented below. 
5.1 Results / Discussion for Antibacterial Activities of 
Isolates from Inula helenium 
   
Dried Inula helenium extracts obtained from Soxhlet extraction (SE), microwave-assisted 
extraction (MAE) and ultrasound-assisted extraction (UAE), fractionated using different 
solvents (methanol, ethyl acetate and hexane) were tested against the microbial species 
used in this study and the respective zone of inhibition is reported in Table 5.1 below. 






















(10 µg /mL) 
ZOI (mm) ZOI (mm) ZOI (mm) ZOI (mm) 
M E H M E H M E H DMSO 
Escherichia coli NCTC 
13353 




- 4 16 2 - 13 3 2 18 27 
Bacillus cereus ATCC 
10876 
6 3 21 - 3 15 2 3 21 25 
Staphylococcus aureus 
ATCC 25923  
5 5 19 4 4 15 2 4 21 24 
MRSA ATCC 252 
NCIMB 13280 
- - 5 - - 5 - 3 7 20 
Enterococcus faecalis 
NCIMB 13280 
3 4 10 - - 13 - 2 12 24 
Pseudomonas flores-
cens ATCC 13525 
2 4 11 3 - 7 2 2 14 25 
Klebsiella pneumoniae 
NCTC 13439 
- 4 5 - 2 6 - 2 5 26 
Candida albicans MTCC 
227 
2 2 4 2 3 4 2 2 5 - 
M – Methanol; E – Ethyl acetate; H – Hexane; – means no activity observed. 
NCTC   - National Collection of Type Culture 
NCIMB   - National Collection of Industrial Food and Marine Bacteria 
ATCC  - American Type Culture Collection 
MTCC  - Microbial Type Culture Collection 




Extracts indicating inhibition zones ≥ 8 mm were isolated (because one of the aims of this 
work are to isolate bioactive compounds) and purified via high-performance liquid 
chromatography (HPLC) to obtain three pure bioactive sesquiterpene lactones – 
alantolactone (D1), isoalantolactone (D2) and costunolide (D3). These pure compounds 
were tested to determine the minimum inhibitory concentration (MIC) against these 
microbial strains. Disc diffusion assay was not done for these compounds (D1, D2 and D3) 
because they were the predominant compounds present in the hexane fraction isolated 
from Inula helenium (accounting for over 89 % of total compounds isolated from the hexane 
fraction). The result for the bactericidal inhibition indicated by these sesquiterpene lactones 
is presented in Table 5.2 below. 















Escherichia coli NCTC 
13353 
500 / ND 500 / ND - / ND       4 / ND 
Pseudomonas aeruginosa 
NCTC 13437 
- / ND - / ND - / ND       8 / ND 
Bacillus cereus ATCC 
10876 
50 / 100 50 / 100 125 / 250       8 / ND 
Staphylococcus aureus 
ATCC 25923  
65 / 130 65 / 130 125 / 125       4 / ND 
MRSA ATCC 252 NCIMB 
13280 
- / ND - / ND - / ND      16 / ND 
Enterococcus faecalis 
NCIMB 13280 
250 / ND 250 / ND    500       8 / ND 
Pseudomonas florescens 
ATCC 13525 
250 / ND 500 / ND - / ND       8 / ND 
Klebsiella pneumoniae 
NCTC 13439 
- / ND - / ND - ND     16 / ND 
Candida albicans MTCC 
227 
> 500 > 500 / ND 250 / ND     150 / ND 
AL  - Alantolactone 
IAL - Isoalantolactone 
CST - Costunolide 
-  - No activity observed at MIC ≥ 500 µg /mL. 
ND - Not done 
 
The result presented for (Agar diffusion assay) – Table 5.1, indicates that the isolates from 
Inula helenium elicited antibacterial activities. The best antibacterial activity was recorded 
with hexane fraction obtained by ultrasound-assisted extraction (UAE) followed by hexane 
fraction from the Soxhlet extractor. Compounds isolated from ethyl acetate and methanol 
fraction indicated weak antimicrobial activity for all the extraction methods used. From the 
results presented in Table 5.1, only the hexane fractions (from SE, MAE and UAE) were 
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further purified and three bioactive sesquiterpene lactones were purified by HPLC from the 
hexane fractions of Inula helenium – alantolactone (D1), isoalantolactone (D2) and 
costunolide (D3). These fractions were combined because the analysis on TLC plate 
suggests they contain similar spots and an assumption was made that they contained 
similar compounds. 
Compounds isolated from UAE (hexane fraction) showed inhibition zones of 27 mm on 
ESBL producing E. coli NCTC 13353 and P. aeruginosa NCTC 13437, 26 mm on K. 
pneumonia NCTC 13439, 25 mm on B. cereus ATCC 10876 and P. florescence ATCC 
13525, 24 mm on S. aureus ATCC 25923 and E. faecalis NCIMB 1328 and 20 mm on 
MRSA ATCC 252. Activities indicated by hexane fractions from MAE and UAE were 
comparable with those from the UAE. Poor inhibition (inhibition > 125 μg/ml) was recorded 
for fractions from methanol and ethyl acetate in all extraction methods used Table 5.1. 
The compounds isolated and purified from the hexane fraction of Inula helenium – 
alantolactone, isoalantolactone and costunolide were tested against bacteria and fungus 
species using the micro broth dilution method. 
The sesquiterpene lactones isolated inhibited the bacterial species tested except P. 
aeruginosa and K. pneumonia. The compound alantolactone elicited good inhibitory action 
against B. cereus (MIC 50 μg/ml) and S. aureus (MIC 65 μg/ml). Alantolactone also 
indicated moderate inhibition of E. faecalis and P. florescens (MIC 250 μg/ml) and poor 
inhibitory action against E. coli (500 μg/ml). MRSA, K. pneumonia and P. aeruginosa were 
not sensitive to inhibition by alantolactone at doses ≤ 1000 μg/ml. The compound 
isoalantolactone elicited a good antibacterial action, similar to that indicated by 
alantolactone on B. cereus (MIC 50 μg/ml), S. aureus (MIC 65 μg/ml); moderate inhibition 
(MIC 250 μg/ml) against E. faecalis and poor inhibitory actions (500 μg/ml) against P. 
florescence and E. coli, and like alantolactone, MRSA, K. pneumonia and P. aeruginosa 
were not sensitive to inhibition by isoalantolactone. Costunolide indicated moderate 
inhibition against B. cereus and S. aureus (MIC 125 μg/ml), poor inhibitory action against 
E. faecalis and no inhibition against E. coli, P. aeruginosa, MRSA and P. pneumonia. 
Alantolactone and isoalantolactone indicated similar antibacterial activity while costunolide 
indicated moderate to weak antibacterial activities against all bacterial strains tested. 
The bioactive compounds isolated from Inula helenium belongs to a group of compounds 
known as sesquiterpene lactones and do have diverse chemical structures and a wide 
spectrum of biological activities such as cytotoxic, antibacterial, antifungal, constituent of 
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plant growth regulating hormone, insect anti-feedant, antitussive, anti-tumourigenic and 
anti-protozoal activities (Seca et al., 2014). This study reports the isolation and antibacterial 
activities of alantolactone, isoalantolactone and costunolide isolated from the roots of Inula 
helenium. Disc diffusion assay with hexane fraction from SE, UAE and MAE all indicated 
good zone of inhibition (ZOI) against all bacteria tested (MIC 15 – 27 mm) except MRSA 
(ZOI 5 – 6 mm). Kunduhoglu et al., (2011) reported that ethanol extracts contained the 
bioactive components of Inula helenium. Conversely, Stanojević et al., (2010) reported 
activity for aqueous extracts. Talib & Mahasneh, (2010) reported a good inhibitory action 
for methanol extracts against MRSA but in our findings, methanol and ethanol fractions did 
not indicate antibacterial activity against MRSA; only the hexane fraction did. Methanol and 
ethyl acetate extracts indicated poor activities with ZOI (2 – 6 mm) on all bacteria tested. In 
this study, water extracts initially tested for antimicrobial activity indicated no ZOI against 
bacterial species and for this reason, it was discontinued (data not shown). The 
sesquiterpene lactones were responsible for the antibacterial activity reported in this study. 
Sesquiterpene lactones were fractionated from the hexane fraction; an indication that they 
are soluble in non-polar solvents (hexane) and poorly soluble in polar solvents (such as 
water and methanol). Since water is more polar than methanol, this could account for the 
lack of ZOI recorded for the water fraction. 
Diguţă et al. (2014) has previously reported the antimicrobial activity of Inula specie against 
some bacterial strains using agar disk diffusion method. Comparison of antimicrobial 
activities of ethanolic extracts of powdered roots of Inula helenium using 30%, 50% and 
70% ethanol. The 70% ethanolic extract showed high inhibitory activity against E. coli, the 
50% ethanolic extract showed moderate inhibitory activity against E. coli, whereas low 
inhibitory activity was recorded for the 30% extract. Although the researcher did not indicate 
the concentrations used, these findings agrees with our findings, and indicates that 
hydrophobicity of extraction solvents alone is not enough in the extraction of compounds 
from Inula helenium. Our report also indicates that as polarity of solvents increased, the 
antimicrobial activities of the plants extracts also increased. For instance, compounds 
fractionated using hexane indicated better inhibitory activities against bacterial strains. 
These activities were better than those indicated by methanol – a polar solvent, and ethyl 
acetate, a less polar solvent, indicated minimal inhibition against bacterial strains. It could 
therefore be suggested that polarity of solvents is responsible for extraction of active 
compounds from Inula helenium. 
Diguţă et al. (2014) also reported similar trend for S. aureus and E. faecalis. No inhibitory 
activity was reported in the case of 30% ethanolic extract against S. aureus and E. faecalis 
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whereas the 70% ethanolic extract indicated moderate inhibitory activities against S. aureus 
and E. faecalis. These findings are similar to the findings in this study. For instance, good 
and significant activities were recorded against E. coli, S. aureus and E. faecalis using the 
hexane fraction. These activities were poor in the extracts obtained from polar solvents – 
methanol and ethyl-acetate. 
Qiu et al., (2011) and Zhao et al., (2010) reported antibacterial activities of alantolactone 
and isoalantolactone against Gram-negative bacteria with isoalantolactone also acting as 
an inhibitor of α-toxin, (which confers virulence to bacteria), preventing its expression. The 
differences in inhibitory activities of these isomeric sesquiterpene lactones could be 
attributed to their conformational orientations at the carbonyl moiety and the stearic 
hindrances at the axial methyl groups of these compounds (Blagojevic & Radulovic, 2012). 
Compounds isolated from Inula helenium – alantolactone, isoalantolactone and costunolide 
indicated poor inhibitory activities against Gram-negative bacteria tested – E. coli, P. 
aeruginosa, K. pneumonia and P. florescens with MIC ≥ 250 µg /mL. These results were 
comparable to those reported by Jiang et al., (2011), except for E. coli. Jiang et al., (2011) 
reported an MIC of 125 µg /mL for alantolactone against E. coli. The poor antibacterial 
activity of these compounds could be attributed to the outer membrane in Gram-negative 
bacteria which prevents influx of these compounds into the bacterial cell. Most bacteria also 
develop enzymes such as β-lactamase, which inactivates drugs (Kapoor et al., 2017; 
Mandal & Das, 2015). 
Antibacterial activity of ethanolic extracts of Saussurea lappa (MIC 0.5 µg /mL) against 
Streptococcus mutans was reported by Yu et al., (2007). There are sketchy data on the 
antibacterial activity of costunolide. In this work, costunolide indicated moderate bacterial 
inhibition against B. cereus and S. aureus at MIC 125 µg /mL) but no inhibition against all 
bacterial strains tested at MIC < 500 µg /mL. The poor bacterial inhibition shown by 
costunolide (compared to alantolactone and isoalantolactone) may be because of the 
orientation (annulation) of the γ-lactone ring (Ludwiczuk et al., 2017). Alantolactone and 
isoalantolactone are classified as eudesmanolide sesquiterpene lactones (Seca et al., 
2014) and are orientated in the 8,12-olides annulation (Ludwiczuk et al., 2017) whereas 
costunolide, a germacronolide sesquiterpene lactone (Seca et al., 2014) is oriented in the 
6,12 annulation (Ludwiczuk et al., 2017). The role of annulation (Ludwiczuk et al., 2017) 
and the type of functional chains attached to sesquiterpene lactones as the reason for the 
diverse antibacterial activity of these compounds has been reported (Bachelier, 2006). 
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The compounds isolated also inhibited the pathogenic fungus tested. Costunolide inhibited 
the growth of the fungus C. albicans at a dose of 250 µg /mL better than alantolactone and 
isoalantolactone which indicated inhibition at doses > 500 µg / mL. Ahmed & Abdelgaleil, 
(2005) reported the antifungal activity of costunolide isolated from the bark of Magnolia 
grandiflora against pathogenic fungi with costunolide showing a better antifungal activity 
compared to the reference drug - Fluconazole. In this study, costunolide inhibited the 
growth of C. albicans better than alantolactone, isoalantolactone and the control drug – 
Fluconazole (MIC 150 µg / mL). 
Isoalantolactone and alantolactone exist mainly in the "U"-shape conformations and the 
carbonyl moiety is hindered sterically by the axial methyl groups, whereas costunolide can 
exist in any of the four (UU, UD, DU and DD) conformations, giving it the ability to lyse the 
cell membrane of the pathogenic fungus - C. albicans. Faraldos et al., (2007) reported the 
conformational structure of costunolide. The ability of costunolide to exist in the four 
conformational states gives it advantage over alantolactone and isoalantolactone which 
exist only in the “U” conformation and thus, a better antifungal activity than alantolactone 
and isoalantolactone against C. albicans. 
The ability of these sesquiterpene lactones to dissolve in hexane, a low polar solvent, 
indicates sesquiterpene lactones isolated in this study have smaller pore sizes. This gives 
them the ability to pass through the cell wall of C. albicans, eliciting their action against this 
fungus. It should be noted that the sesquiterpene lactones isolated from Inula helenium and 
as purified by HPLC presented different appearances; alantolactone was isolated as a white 
powdery compound, isoalantolactone was isolated as a needle-like white precipitate 
whereas costunolide was isolated as a semi-transparent white compound. Costunolide can 
easily pass through the cell wall of C. albicans compared to other compounds isolated in 
this study. Barrero et al., (2000) reported that low polarity is a molecular requirement for 
antifungal activities of compounds. Barrero et al., (2000) reported in his findings that 
lactones with higher polarities were better antifungal agents. Thus, the sesquiterpene 
lactones - costunolide and dehydrocostus lactone (with low polarities) indicated better 
antifungal activities than salonitenolide and cnicin. For compounds to be effective antifungal 
agents, they must possess the ability to pass through the cell membrane and the 
sesquiterpene lactones isolated in this project meets this criterion. This explains why 
alantolactone, isoalantolactone and costunolide elicited weak antifungal activity against C. 
albicans. In addition to polarity, it has also been established that the α-methylene-γ-lactone 
moiety is responsible for biological activities of sesquiterpene lactones (Lawrence et al., 
2001; Seca et al., 2014); it therefore implies that polarity, the conformation of the 
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sesquiterpene lactone, the small size of the molecule and the α-methylene-γ-lactone moiety 
are responsible for the antifungal activities indicated by the sesquiterpene lactones isolated 
in this study. 
An important finding was made when comparing the ZOI of the fractions reported in Table 
5.1 against P. aeruginosa, the hexane fraction indicated ZOI of 16 mm for Soxhlet extraction 
(SE), 13 mm for microwave-assisted extraction (MAE) and 18 mm for ultrasound-assisted 
extraction (UAE).  MIC investigation of purified compounds isolated from the hexane 
fractions indicated no bacterial inhibition against P. aeruginosa. A look at the HPLC 
chromatogram (Figure 3.2) indicates the presence of traces of compounds which were 
biologically inactive against the bacteria tested. There is a possibility that the ZOI observed 
against P. aeruginosa may be attributed to: 
i)  One or more compounds eluted from 5 – 30 minutes. 
ii)  The potentiating effect of two or more sesquiterpene lactones isolated in this study. 
iii) A potentiating effect of all compounds in the hexane fraction. 
 
Spiridonov et al., (2005) has previously reported the potentiating effect of helenin – a 
combination of alantolactone (40 %) and isolantolactone (60 %), which indicated a better 
bioactivity compared to the positive control drug used in a certain study. The potentiating 
effect of compounds isolated from Inula helenium was not done in this study. It is therefore 
hypothesised that the good antibacterial activity (ZOI) recorded by the hexane fraction 
against P. aeruginosa is as a result of the hypothesis highlighted above. 
5.2 Results for Antibacterial Activities of Synthesised Chrysin 
Derivatives 
 
7-O-chrysin adducts made in this study were screened against the microbial species tested 
in this study and the zone of inhibition reported in Table 5.3. These results (Agar diffusion 
assay) indicates that the chrysin analogues made in this study, elicited antibacterial 
activities against both Gram-negative and Gram-positive bacteria. The best antibacterial 
activity was recorded for the Gram-positive bacteria with compounds C1, C2, C3, C6, C8 
and C16 indicating zone of inhibition ranging from 12 – 19 mm on S. aureus with C1, C3, 
C2, C8 and C16 indicating inhibitory zones of 19, 17, 16, 16 and 15 mm respectively. On 
E. coli, C3, C2, C1, C5 and C16 indicated inhibitory zones of 16, 15, 13, 12 and 12 mm 
respectively. Compounds C7, C9 – C15 indicated inhibitory zones ≤ 2 mm and for this 
reason were not diluted via the micro broth dilution method to determine their MIC. 
Compounds indicating zone of inhibition ≥ 4 mm were diluted further via micro broth dilution 
method to determine their MIC (Table 5.4). 
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Name of the  
compound used 
C1 16 18 15 7-O-chrysinbutyl acetate 
C2 15 16 8 
7-O-chrysin-
3,5dimethylbenzene 
C3 17 17 14 
7-O-chrysin-2,4- 
dinitrobenzene 
C4 10 8 5 7-O-isopropylchrysin 
C5 12 8 12 7-O-2-methylpropylchrysin 
C6 - 12 5 7-O-butylchrysin 
C8 8 16 7 7-O-hexylchrysin 
C16 12 15 9 4-bromopentylchrysin 
C17 - 9 - 12-bromododecylchrysin 
Chrysin 6 6 9 5,7-dihydroxyflavone 
Gentamycin/ 
Fluconazole 
24 26 12 Gentamycin / Fluconazole 
–  - No activity 
One Gram-positive bacterium (S. aureus) and one Gram-negative bacterium (E. coli) were used for disc 
diffusion assay prior to MIC assay. In order to study the activity in more detail, strains from representative 
Gram-positive and Gram-negative species were chosen for further testing. Following a review of the literature, 
it was found that S. aureus and E. coli are among the most commonly used species when testing novel 
antimicrobials. Compounds not stated above did not show any noticeable inhibition of bacterial growth at 
doses ≥ 500 µg/mL. C6 and C17 showed inhibition against Gram-positive bacteria only. 
 
In order to determine the antimicrobial activities of chrysin analogues using the broth 
microdilution method, compounds synthesised from chrysin have been classified into three 
series according to their functional groups, aromaticity or aliphatic nature. 
Series 1: Compounds C1, C2 and C3. 
Series 2: Alkyl derivatives of chrysin (C4 – C12). 
Series 3: Bromoalkylchrysin derivatives (C13 – C17). 
 
For Series 3 compound, C13 – C15 were inactive against the bacterial species tested. 
Interestingly, C16 (a novel compound and an isomer of compound 15) indicated good 






Table 5.4: MIC / MBC of Chrysin adducts against Bacteria and Parasitic Fungus – Candida albicans 
 
Bacterial species tested 
























E. faecalis  
NCIMB 
13280 









C1 50.0 / 
100.0 














C2 100 / 
200 














C3 12.5 / 
25 
















C4 200.0 - - - - - 200.0 Nt 800.0 7-O-isopropylchrysin 
C5 100.0 200.0 250.0 125.0 - - 100.0 Nt 100.0 7-O-2-
methylpropylchrysin 
C6 - 400.0 - 250.0 - - 200.0 Nt 800.0 7-O-butylchrysin 




Nt 400.0 7-O-hexylchrysin 
C16 100.0 - - - 125.0 100.0 50.0 Nt 200.0 7-O-4-
bromopentylchrysin 
C17 - - 250.0 - - 200.0 100.0 Nt - 7-O-
bromododecylchrysin 
Chrysin 250.0 - - 500.0 - 250.0 125.0 125.0 200.0 5,7-dihydroxyflavone 
Gentamicin 
Fluconazol 
8.0 16.0 16.0 16.0 32.0 8.0 8.0 8.0 125.0 - 
ESBL – Extended Spectrum Producing β-lactamases 
Nt  - Not tested. 
-   - No observed inhibition at doses ≥ 500 µg / mL for bacteria and 800 µg / mL for the fungus – C. albicans. 
C3 indicated bacterial inhibition against all bacteria tested at MIC values ≤ 62.5 µg/mL. C3 showed interesting inhibition against S. aureus, B. cereus, E. 
faecalis and E. coli were at MIC value of 12.5 µg/mL. C1 inhibited S. aureus at MIC value 12.5 µg/mL. C3 also inhibited P. aeruginosa at MIC value of 25.0 
µg/mL. C1, C2 and C3 showed inhibition against all bacteria tested at MIC values ≤ 250 µg/mL.
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C17 indicated good antibacterial activity (MIC 100 µg /mL) against S. aureus and moderate 
inhibition against E. faecalis (200 µg /mL and K. pneumonia (250 µg /mL) (Table 5.4). P. 
aeruginosa and E. faecalis were not inhibited by compounds in this series. For series 2 
compounds, C7, C9 – C15 were inactive against the bacterial strains tested. However, C4, 
C5, C6 and C8 elicited inhibition against bacteria tested with MIC values ranging from 50 
– 400 µg /mL. C8 showed a wide spectrum of activity against bacteria exerting good activity 
against S. aureus and E. faecalis – (MIC 50 and 100 µg /mL), C8 is the only member of 
this series which inhibited the growth of the antibiotic resistant bacteria MRSA (MIC 250 
µg /mL) and E. faecalis (Table 5.4). C8 also inhibited the growth of P. aeruginosa at a dose 
of 200 µg /mL. With exception of C4 (MIC 400 µg /mL), other compounds in this series – 
C5, C6 and C8 showed good antibacterial inhibition against S. aureus (MIC 100, 100 and 
50 µg /mL). P. aeruginosa was susceptible to compounds (C4, C5, C6 and C8) in this 
series with MIC 100, 200, 400 and 200 µg /mL respectively (Table 5.4). C4 and C5 also 
showed good inhibition (MIC 100 and 50 µg /mL) against E. coli, while C6 indicated no 
inhibition against E. coli at doses ≤ 1000 µg /mL. K. Pneumoniae was not inhibited by 
compounds in this series except C5 which indicated moderate inhibition (MIC 250 µg /mL). 
Series 1 compounds indicated a wide spectrum of good antibacterial activities against 
bacteria tested. C1 and C3 indicated a good antibacterial activity on all bacterial strains 
tested with MIC values ranging from 12.5 – 125 µg /mL). C3 showed a broad spectrum of 
inhibition against all bacterial strains tested with MIC values ranging from 50 – 250 µg /mL. 
C1 indicated a similar antibacterial activity to C3, inhibiting all bacterial strains tested with 
S. aureus (MIC 25 µg /mL), E. coli, E. faecalis and B. cereus (MIC 50 µg /mL) being the 
most susceptible bacteria to inhibition by C1 which also indicated good antimicrobial 
activity against the antibiotic resistant bacteria – MRSA and E. faecalis at MIC of 100 µg 
/mL. C1 also indicated moderate inhibition against K. pneumonia (MIC 125 µg /mL) which 
was the least susceptible bacterium to inhibition by C1. 
C2 also indicated a broad spectrum of antibacterial activities against all bacteria tested 
with Staphylococcus aureus (MIC 50 µg /mL), Bacillus cereus, E-coli and E. faecalis (100 
µg /mL) indicating good susceptibility to C2.  C2 also showed moderate inhibition against 
MRSA, P. aeruginosa and K. pneumonia (MIC 250, 200 and 250 µg /mL respectively). 
The main source of chrysin is from propolis. Previous reports have indicated antibacterial 
activity of ethanolic extracts from propolis against S. aureus at MIC ranging from 10 – 20 
μg/ml and MBC of 20 μg/ml (Chen, et al., 2018). Propolin C characterised from propolis 
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indicated MIC values ranging from 1.25 to 10 μg/ml against S. aureus, MIC ≤ 2 μg/ml for 
MRSA. Sousa et al., (2016) also reported MIC values of 7.5, 10 and 10 μg/ml against S. 
aureus, E. coli and P. aeruginosa treated with methanolic extracts of propolis. Chrysin has 
been purified as the main constituent of propolis and has been reported to inhibit bacterial 
growth at MIC value ranging from 100 – 250 μg/ml (Li et al., 2009). This value is 
comparable to the findings reported in this study (MIC values of 125 μg/ml for S. aureus 
and B. cereus; 250 μg/ml for E. coli and E. faecalis). The novel chrysin derivatives C1, C2 
and C3 showed interesting antibacterial activity against Gram-positive and Gram-negative 
bacteria with the former being the most susceptible bacteria to inhibition by these 
compounds. The significant antibacterial activity reported in this study for synthetic chrysin 
derivatives – C1, C2 and C3 against Gram positive bacteria may be attributed to the 
absence of outer cell membrane found in Gram-negative bacteria (Ramírez-Guízar et al., 
2017). The absence of the outer membrane allows easy penetration of small molecules 
across the periplasmic space, into the bacteria (Miller et al., 1986). Li et al, (2009) had 
previously synthesised chrysin derivatives containing 3-carbon spacers attached to 
different positions of the chrysin molecule. An investigation of antibacterial activities of 
these compounds showed that heterocyclic compounds attached at the 7-OH position of 
chrysin were more effective compared to those whose attachments were elsewhere with 
MIC values ranging from 3.13 to 50 μg/ml against S. aureus and E. coli respectively. These 
findings are in agreement with our findings in this work. Furthermore, we report that 
heterocyclic chrysin-derivatives indicated better antibacterial activities ranging from 12.5 
μg/ml for C3 against B. cereus¸S. aureus, E. faecalis and E. coli; 25.0 μg/ml against P. 
aeruginosa and 31.3 μg/ml against P. florescens. MRSA and K. pneumoniae were inhibited 
at 62.5 μg/ml. Antibacterial activity of heterocyclic compounds were better than those 
indicated by aliphatic compounds. Our finding correspond with those of Li et al, (2009) who 
also reported similar findings. Aliphatic derivatives of chrysin containing 3-carbon spacers 
indicated weak antibacterial inhibition compared to heterocyclic compounds (Li et al., 
2009). The good inhibition shown by heterocyclic chrysin derivatives (C1, C2 and C3) might 
be connected with the hydrophobicity of these molecules (Comte et al., 2001). Comte et 
al., (2001) reported that the hydrophobicity of synthetic 7-O-Chrysin derivatives enable 
them to bind to P-glycoprotein, and allows for influx of drugs into the cell thus an increase 
intracellular drug accumulation which is necessary for bacterial inhibition and death. Long 
chain 7-O-chrysin derivatives synthesised in this work are less hydrophobic than their 
heterocyclic counterpart. This might be responsible for their reduced ability to accumulate 
in the bacterial cell. 
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Antibacterial activities indicated by C1, C2 and C3 were better than those of other chrysin 
derivatives. Chrysin contains two hydroxyl functional groups at position 5 and 7. The 
hydroxyl bond at position-5 of chrysin creates hydrogen-bonding in the chrysin molecule 
(Zheng et al., 2016; Lapkin et al. 2014). The hydroxyl-bond at position-7 of chrysin 
molecule increases its hydrophilicity. Because chrysin is more hydrophilic than synthesised 
chrysin derivatives made in this study (Comte et al., 2001), chrysin might lack the ability to 
penetrate the bacterial cell compared to C1, C2 and C3 that are mainly hydrophobic in 
nature. 
Chrysin derivatives made in this study were most potent against Gram-positive bacteria 
(with exception of C3 that significantly inhibited the growth of both Gram-positive and 
Gram-negative bacteria). 
5.3 Antifungus Activity of Synthesised Chrysin Derivatives 
 
7-O-chrysin adducts made in this study were screened against the fungus C. albicans and 
results presented in Table 5.4 (Agar disk diffusion assay) and Table 5.4 (MIC) above.  C1 
(ZOI 15 mm), C2 (ZOI 14 mm) and C4 (ZOI 11 mm) indicated ZOI greater than 10 mm. 
C7, C9 – C15 and C17 did not inhibit the growth of the C. albicans fungus at doses ≤ 800 
µg / mL. Other Chrysin derivativesshowed a ZOI ranging from 5-9 mm; C16 (ZOI 9 mm), 
C2 (ZOI 8 mm), C8 (ZOI 7 mm), C4 and C5 (5 mm). Compounds indicating ZOI against 
the C. albicans fungus were diluted further to determine their MIC. 
C1 and C3 indicated an MIC of 50 µg / mL, C5 (100 µg / mL), C16 (200 µg / mL). Other 
compounds (C2, C4, C6 and C8) indicated ZOI ≥ 400 µg / mL. 
C1 and C3 showed better ZOI compared to the positive control drug – Fluconazole (ZOI 
12 mm). ZOI indicated by C5 (12 mm) is comparable to that indicated by Fluconazole (12 
mm). C1, C2 (MIC 50 µg / mL) and C5 (MIC 100 µg / mL) also indicated better MIC values 
compared to Fluconazole (125 µg / mL) – Table 5.4. 
Chrysin is the major flavonoid present in propolis (honey), accounting for 62 – 80 % of total 
flavonoids (Koo et al., 2002; Uzel et al., 2005). Antifungal activity of propolis has previously 
been reported against C. albicans, C. tropicalis and C. krusei at MIC 32, 32 and 16 µg / 
mL (Uzel et al., 2005). Salomão et al. (2004) and Kujumgiev et al. (1999) have previously 
reported the antifungal activity of propolis at ZOI 18 mm and 22 mm respectively. Antifungal 
activities reported were due to the presence of flavonoids – chrysin, galangin and flavonol 
(Koo et al., 2002). Interestingly, most authors have reported antifungal activities of propolis 
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without mentioning the antifungal activities of chrysin. In this work, chrysin, inhibited C. 
albicans at 200 µg / mL. There are sketchy literatures (data) on the antifungal activity of 
chrysin as most authors only reported the antifungal activities of propolis obtained from 
different locations (Koo et al., 2002; Salamão et al., 2004; Uzel et al., 2005). Uzel et al., 
(2005) characterised apigenin, galangine, quercetin, naringenin and pinocembrin as the 
flavonoids present in propolis. It could therefore be inferred that the MIC of 4 µg / mL 
against C. albicans ATCC 10231 reported by Uzel et al., (2005) might be due to the 
presence of not just chrysin but other flavonoids. C. albicans ATCC 10231 is also known 
as a susceptible strain which shows least resistance against fungicidal agents such as 
fluconazole and it is often used as a positive control strain (Maebashi et al., 2001) whereas 
the strain used in this work (C. albicans MTCC 227) is known for indicate resistance to 
fluconazole and most other antifungal agents. These factors may be responsible for the 
poor antifungal activity recorded by chrysin in this study. Unlike chrysin, synthesised 
chrysin-derivatives (C1, C3 and C5) indicated better activities than chrysin and the positive 
control drug – fluconazole against the C. albicans fungus. Elevated levels of CDR1 and 
CDR2 mRNA encoding putative ATP binding cassette (ABC) transporters have been 
reported as being responsible for C. albicans MTCC 227 resistance (Maebashi et al., 
2001). C1, C3 and C5 might have accumulated intracellularly within the fungus whose 
expression of CDR1 and CDR2 involved in the fluconazole resistance may be absent. This 
process is energy-dependent (Maebashi et al., 2001) and tends to reduce the lipophilicity 
of fluconazole across the fungal membrane as azole (in fluconazole) are less lipophilic than 
flavonoids (as in chrysin-derivatives) (Sheehan et al., 1999). Lipophilicity is an important 
criterion which allows drugs to pass through cell membranes into the intercellular space of 
organisms (Sheehan et al., 1999). Another mechanism of antifungal action involves the 
inhibition of ergosterol, an important component of fungal plasma membrane is via 
inhibition of the cytochrome P-450-dependent enzyme lanosterol demethylase (Hargrove 
et al., 2017). 
5.4  Results for Anticancer Activities of Sesquiterpene Lactones 
isolated from Inula helenium. 
 
Fractions from Inula helenium extracts (methanol, ethyl acetate and hexane) were tested 
against leukaemia cell lines (K562 and Molt-4), and colorectal cancer cell line (Caco-2). 
Results obtained are presented in Table 5.5 below. The hexane fraction indicated good 
cytotoxic inhibition (0.8 – 36.68 µg/mL) against the cancer cell lines tested. Due to poor 
cytotoxic inhibition shown by the methanol and ethyl acetate fractions, they were not 
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purified further by HPLC and the cytotoxicity of pure compounds from these fractions were 
not investigated. This is because the aim of this project is to discover new bioactive 
compounds. 
Table 5.5: IC50 values for K562, Molt-4 and Caco-2 cell lines treated with fractions (methanol, 
ethyl acetate and hexane fractions) obtained from Inula helenium root extracts 
Extraction 
solvent 
Cancer Cell line / IC50 (µg/mL) 
K 562 Molt 4 Caco 2 
24 h 48 h 72 h 24 h 48 h 72 h 24 h 48 h 72 h 
Methanol 
fraction 
- - 38.02 
± 4.25 
- - - - - - 
Ethyl acetate 
fraction 




- - - - - - 




































- -  No cytotoxic inhibition at IC50 ≤ 100 µg/mL 
h        -   hours 
 
The anticancer activities of sesquiterpene lactones isolated from Inula helenium in this 
study has previously been reported and documented against some cell lines used in this 
study (see section 1.4).  
 
Table 5.6: IC50 values for sesquiterpene lactones – alantolactone, isoalantolactone and 
costunolide against K562 cell line 
K562 Cancer Cell line treated for 24, 48 and 72 hours 
 IC50 (µM) 
Compound 24 hours 48 hours  72 hours 
Alantolactone (D1) 24.86 ± 4.16 13.48 ± 1.07   4.95 ± 0.68 
Isoalantolactone (D2) 28.44 ± 3.88 21.38 ± 5.25   7.38 ± 2.01 
Costunolide (D3)   6.68 ± 1.17 11.72 ± 3.02 10.98 ± 3.64 
Chlorpromazine 
hydrochloride (CPZ) 
13.66 ± 0.52   9.92 ± 1.62   4.53 ± 0.87 
 
Table 5.7: IC50 values for sesquiterpene lactones – alantolactone, isoalantolactone and 
costunolide against Molt-4 cell line 
Molt-4 Cancer Cell line treated for 24, 48 and 72 hours 
 IC50 (µM) 
Compound 24 hours 48 hours 72 hours  
Alantolactone (D1) - - - 
Isoalantolactone (D2) - - - 
Costunolide (D3) 30.66 ± 4.72 46.26 ± 7.21 - 
Chlorpromazine 
hydrochloride (CPZ) 
8.21 ± 1.01 5.85 ± 0.36 6.43 ± 0.78 
- - No bioactivity at doses ≤ 100 µM. 
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However, there are sketchy data on the anticancer activities of these compounds (D1, 
D2 and D3) against the leukaemia cell lines (Molt-4) and the colon cancer cell line 
(Caco-2). The anticancer activity of D1, D2 and D3 were also investigated against the 
leukaemia cell lines (K562 and Molt-4) and colorectal cancer cell line (Caco-2). The 
results are presented in Table 5.6 - Table 5.8. 
Table 5.8: IC50 values for sesquiterpene lactones – alantolactone, isoalantolactone and 
costunolide against Caco-2 cell line 
Caco-2 Cancer Cell line treated for 24, 48 and 72 hours 
 IC50 (µM) 
Compound 24 hours 48 hours  72 hours  
Alantolactone (D1) - 54.84 ± 6.37 33.81 ± 4.68 
Isoalantolactone (D2) 28.34 ± 4.39 37.59 ± 8.48 46.56 ± 6.86 
Costunolide (D3)  44.65 ± 12.75 34.72 ± 7.34 22.36 ± 4.76 
Chlorpromazine 
hydrochloride (CPZ) 
 6.38 ± 0.72  5.93 ± 0.42   6.73 ± 0.62 
- - No bioactivity at doses ≤ 100 µM. 
 
Results of cytotoxicity of alantolactone (ALA), isoalantolactone (ISL) and costunolide (CST) 
against the leukaemia cell line (K562) are presented in Table 5.6. Cytotoxicity of ALA and 
ISL increased from 24 to 72 hours. After treatment of cell, 24 hours later, ALA and ISL 
indicated cytotoxic inhibition at doses of 24.86 µM and 28.44 µM. This cytotoxic inhibition 
(IC50) against K562 cell line increased to 13.48 µM for ALA and 21.38 µM for ISL after 48 
hours treatment (a decrease in IC50 value indicates better cytotoxicity against cancer cell 
line). The best cytotoxic inhibition was observed after 72 h treatment with ALA (IC50 4.95 
µM) and ISL (IC50 7.38 µM). In contrast to the results obtained for ALA and ISL, CST 
indicated the best cytotoxic inhibition against K562 cell line after 24 hours treatment – IC50 
6.68 µM (Table 5.6). The cytotoxic inhibition elicited by costunolide decreased after 72 
hours treatment (IC50 10.98 µM). Cytotoxic inhibition elicited by ALA and ISO were 
comparable to those of the positive control – CPZ (IC50 4.53 µM) after 72 h treatment. ALA 
indicated the best cytotoxicity against K562 cell line among the sesquiterpene lactones 
tested. 
Results of cytotoxicity of alantolactone (ALA), isoalantolactone (ISL) and costunolide (CST) 
against the leukaemia cell line (molt-4) are presented in Table 5.7. Unlike the cytotoxicity 
of ALA and ISL on K562 cell line, these compounds were inactive against the molt-4 cell 
line at doses ≤ 100 µM. CST indicated cytotoxic inhibition of molt-4 cell line after 24 hours 
treatment (IC50 30.66 µM). This inhibition decreased after 48 h treatment (IC50 46.26 µM). 
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This cytotoxic response (inhibition) against molt-4 cell line was lost after 72 hours treatment 
at doses ≤ 100 µM. 
Results of cytotoxicity of alantolactone (ALA), isoalantolactone (ISL) and costunolide (CST) 
against the colorectal cancer cell line (Caco-2) are presented in Table 5.8. ALA, ISL and 
CST indicated cytotoxic inhibition against Caco-2 cell line at IC50 ranging from 22.36 – 
54.84 µM with CST indicating the best cytotoxicity (IC50 22.36 µM). Interestingly, ALA did 
not inhibit the growth of Caco-2 cell line after 24 hours treatment at doses ≤ 100 µM. It is 
also observed that ISL indicated good early cytotoxicity against Caco-2 cell line (IC50 28.34 
µM) after 24 hours treatment which could not be sustained after 72 hours treatment (IC50 
46.56 µM). 
ALA, ISL and CST indicated very good cytotoxicity against the K562 cell lines. Since there 
are sketchy data on the anticancer activities of these compounds (ALA, ISL and CST) on 
leukaemia cell lines (K562) in hypoxia and normoxia (during hyperglycaemia and 
hypoglycaemia), this activity (anticancer activities of ALA, ISL and CST) was investigated 
in hypoxic and hyperglycaemic conditions and results presented in Table 5.9.  
Results presented in Table 5.6 (cytotoxic inhibition in normal glucose concentrations - 
normoglycaemia) and Table 5.9 [cytotoxic inhibition in hypoglycaemia (low glucose) and 
hyperglycaemia (high glucose) concentrations] indicates some interesting observations; in 
normoglycaemia, the IC50 values were higher (4.95 – 10.98 µM) than those observed 
during hypoglycaemia (IC50 0.58 – 6.72 µM) and hyperglycaemia (IC50 0.8 – 7.15 µM). 
Table 5.9: anticancer activity of sesquiterpene lactones on K562 cell line exposed to high glucose 
and low glucose concentrations during hypoxia and normoxia 






Hypoxia (72 hours) Normoxia (72 hours)  
low glucose high glucose low glucose high glucose 
IC50 SD IC50 SD IC50 SD IC50 SD 
Alantolactone (D1) 0.58 0.05 0.80 0.03 1.80 0.09 2.60 0.24 
Isoalantolactone (D2) 0.66 0.08 1.18 0.1 1.90 0.12 3.29 0.15 
Costunolide (D3) 3.07 0.38 4.77 0.98 6.72 0.6 7.15 0.96 
CPZ 33.55 2.74 42.88 2.82 9.36 0.56 16.21 0.39 
 
In hypoxia, cytotoxic inhibition of K562 cell line by alantolactone (D1) and isoalantolactone (D2) were better 
than inhibition indicated by costunolide (D3). D3 indicated better cytotoxic inhibition in low glucose 
concentration compared to inhibition at high glucose concentration.  Similar observation is recorded for D1 
and D2 in normoxia. Cytotoxicity indicated by D3 in normoxia during low glucose and high glucose 
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concentrations was negligible. CPZ was less cytotoxic in hypoxia. Cytotoxicity elicited by D1, D2 and D3 was 
better than that of CPZ. 
 
The anticancer activities of sesquiterpene lactones isolated from Inula helenium against 
cancer and normal cell lines during hypoxia and hyperglycaemia, were investigated and 
results presented in Table 5.9. In hypoxia under low glucose (LG) levels, alantolactone and 
isoalantolactone elicited similar cytotoxic inhibitions against K562 cell line at IC50 values of 
0.58 and 0.66 µM respectively. Costunolide elicited cytotoxic inhibition against K562 cell 
line at IC50 value of 3.07 µM.  
In hypoxia under high glucose (HG) levels, alantolactone and isoalantolactone elicited 
similar cytotoxic inhibition against K562 cell line (IC50 0.8 and 1.18 respectively). 
Costunolide elicited cytotoxic inhibition against K562 cell line at IC50 value of 4.77 µM - 
Table 5.9. 
In normoxia under low glucose concentration, alantolactone (D1), isoalantolactone (D2) 
and costunolide (D3) elicited cytotoxicity against K562 cell line at IC50 values 1.8, 1.9 and 
2.8 µM. Under high glucose concentration in normoxia, alantolactone, isoalantolactone and 
costunolide elicited cytotoxicity against K562 cell line at IC50 values 2.6, 3.29 and 6.72 µM. 
Cytotoxicity elicited by these compounds was 10 – 50-fold better than that of the standard 
drug – CPZ (Table 5.9). 
Alantolactone, isoalantolactone and costunolide elicited similar cytotoxic trend against 
K562 cell line exposed to similar treatment and conditions. In hypoxic conditions, 
alantolactone (D1), isoalantolactone (D2) and costunolide (D3) indicated the best cytotoxic 
inhibition against K562. When K562 cell line was exposed to treatment with high glucose 
concentration, cytotoxic inhibition of D1, D2 and D3 against K562 decreased. In similar 
hypoxic conditions (low glucose and high glucose), very interesting observations were 
made; CPZ which indicated IC50 value of 9.36 and 16.21 µM in normal oxygen 
concentration (in low glucose and high glucose respectively) was ineffective against the 
K562 cancer cell line at concentrations ≤ 33 µM (table 5.9). This observation is an indication 
that in hypoxia, cancer cells develop resistance to most chemotherapeutic agents (Vaupel 
& Mayer, 2007). Resistance to CPZ by K562 in hypoxia is best observed in hyperglycaemic 
(high glucose) conditions (table 5.9); CPZ elicited weak cytotoxicity (IC50 42.88 µM) against 
the K562 cancer cell line. As the glucose concentration decreased (under hypoxic 
condition), the cytotoxicity elicited by CPZ increased (IC50 33.55). Please note; a low IC50 
value implies good cytotoxic (killing activities) inhibition of the cancer cells. This finding 
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further confirms that cancer cells proliferates faster in hyperglycaemia than in 
hypoglycaemia (Li et al., 2018). 
In normoxia, when K562 was expose to low glucose concentration, the resistant of K562 
to cytotoxic inhibition by these compounds (D1, D2 and D3) increased compared to 
cytotoxic resistance of K562 to D1, D2 and D3 in hypoxic conditions. This was different for 
CPZ whose cytotoxicity against K562 decreased under normal oxygen concentrations 
compared to hypoxic conditions. When K562 was exposed to high glucose concentrations, 
there is further increased in resistance of K562 to cytotoxicity from D1, D2 and D3. 
Although resistance of K562 to cytotoxic inhibition by CPZ is observed as glucose 
concentration increases under normal oxygen concentrations, there is no significant 
decrease in K562 resistance to CPZ induced cytotoxicity under high glucose 
concentrations (Table 5.6). 
Cytotoxicity induced by D1, D2 and D3 was superior under hypoxia than in normoxia. 
Similarly, cytotoxicity indicated by D1, D2 and D3 was superior in low glucose 
concentration than in high glucose concentration. This suggests that these sesquiterpene 
lactones D1, D2 and D3 killed K562 cancer cell better during hypoxia and have the potential 
to kill K562 cells best when exposed to low glucose concentrations. This observation was 
different for CPZ which elicited better cytotoxicity against K562 in hypoxia than in normoxia. 
Interestingly, there is no significant difference in cytotoxicity induced by CPZ when glucose 
concentration changes. This suggests cytotoxicity elicited by CPZ is not dependent on 
glucose concentration. This is the case with D1, D2 and D3. Their cytotoxic inhibition 
against K562 is glucose and oxygen dependent. 
Inula helenium has been conventionally used in Ayurveda for treatment of numerous 
ailments such as dysentery, fever etc. and its antibacterial and anticancer activities has 
been documented (Huo et al., 2010; Seca et al., 2014). One of the aims of this study was 
to investigate the anticancer activities of extracts and purified compounds isolated from 
Inula helenium against a range of cancer cell lines of different origins. In carcinogenesis, 
the interaction of factors affecting transcription factors, intracellular signal transduction and 
aberration in gene expression have been implicated for tumourigenesis (Rahman et al., 
2012). The extracts of Inula helenium have been reported to elicit in vitro anticancer 
activities (Koc et al., 2018; Seca et al., 2014). 
The compounds in the roots of Inula helenium were extracted with solvents of different 
polarity and the best anticancer activity was recorded for the hexane fraction (IC50 0.8 
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μg/mL), better than the cytotoxicity indicated by Chlorpromazine hydrochloride (CPZ) – 
IC50 2.17 μg/mL. This is consistent with results obtained from previous studies (Lawrence 
et al., 2001). Previous reports only investigated the cytotoxicity of extracts from Inula 
helenium after 72-hour administration (Lawrence et al., 2001; Huo et al., 2010). This study 
also reports the antiproliferative effect of the hexane extracts against cancer cell lines after 
24 and 48-hour administration with IC50 values ranging from 1.74 – 2.08 μg/mL against the 
K562 cell line; an activity better than those shown by CPZ. Merghoub et al., (2009) reported 
anticancer activities on the methanolic leaves extracts of Inula viscoa against HeLa and 
SiHa cell lines at higher (low cytotoxicity) IC50 values (54 – 60 μg/mL). In this study, the 
methanolic extract indicated a better antiproliferative activity against K562 cell line (IC50 
38.02 μg/mL) while the ethyl acetate fraction indicated a cytotoxic inhibition at a dose of 
24.36 μg/mL). The difference in cytotoxic inhibition reported in this work is because 
different cell lines (K562) was used in this work whereas Meghoub et al., (2009) used HeLa 
and SiHa cell lines. Different species of Inula (Inula viscosa) was used by Meghoub et al., 
(2009). The difference in cytotoxicity reported in this work to that reported by Meghoub et 
al., (2009) is because the phytochemical composition of Inula helenium used in this study 
differs from those present in Inula viscosa (Kheyar-Kraouche et al., 2018). Our findings in 
this research is consistent with those of Pal et al., (2010) who reported a better cytotoxic 
activity from the hexane extract (IC50 10.25 to 17.89 µg/mL). 
The difference in the cytotoxic effect of the most responsive cell line (K562) compared to 
the least responsive cell line (Molt-4) suggests induction of molecular and cellular apoptotic 
mechanisms based on the common genotoxic transformation of cancer cells (Park et al., 
2014). 
Inula specie constitutes a variety of bioactive secondary metabolites especially the 
sesquiterpene lactones that possesses anticancer activities (Huo et al., 2008, Réthy et al., 
2007, Park and Kim, 1998). Most compounds isolated from Inula species have been tested 
on over twenty cancer cell lines with HL-60, HepG-2, A-549, MCF-7 and HeLa being the 
most frequently cited (Seca et al., 2014). However, most of these compounds are inactive 
or indicates an IC50 value higher than 10 μg/mL or 20 μM. These values are much higher 
than values reported for conventional cytotoxic drugs like daunorubicin (IC50 values ranging 
from 1 – 10 μM) (Seca et al., 2014). In this work, the hexane fraction met this criterion and 
was purified further to obtain three bioactive compounds which were investigated against 
the K562, Molt-4 and Caco-2 cell lines. 
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The anticancer activities of sesquiterpene lactones isolated from Inula helenium in this 
study – alantolactone (ALA), isoalantolactone (ISL) and costunolide (CST) against most 
cancer cell lines used in this work has previously been reported (Lawrence et al., 2001; 
Huo et al., 2010; Hu et al., 2011; Seca et al., 2014; Lin et al., 2015) except for the Molt-4 
and Caco-2 cell lines. The second aspect of this work investigated the anticancer activities 
of ALA, ISL and CST against the leukaemia cell lines (K562 and Molt-4) and the colorectal 
cancer cell line Caco-2). The anticancer activities (IC50) of ALA and ISL against K562 cell 
line after 72 hours treatment was 4.95 µM and 7.38 µM respectively. Lawrence et al., 
(2001) reported lower IC50 values for ALA (0.7 μM) and ISL (1.2 μM) against K562 cell 
lines.  Sun et al., (2003) reported an IC50 of 3.5 μg/mL. These activities were reported after 
72-hour treatment with compounds. In this work, we also report the cytotoxicity of these 
compound after 24- and 48-hours treatment. ALA and ISL showed weak inhibition after 24 
(24.86 and 28.44 µM) hours treatment. After 72 hours treatment, more cancer cells were 
inhibited by ALA (IC50 4.95 μM) and ISL (IC50 7.38 μM) – (Table 5.5, page 196). This is an 
indication that ALA and ISL are able to inhibit the proliferation of cancer cell lines, 
preventing the further growth and multiplication cells after prolong treatment with drug (Liu 
et al., 2018). An important criterion for a potentially good anticancer therapy is its ability to 
inhibit cancer cells proliferation after prolonged treatment (Liu et al., 2018). Conversely, 
CST indicated good early cytotoxic inhibition against the K562 cell line (IC50 6.68 μM). This 
inhibition could not be maintained after 48- and 72-hours treatment (IC50 11.72 and 10.98 
μM) – Table 5.5. Looking at Table 5.5, an explanation to the seemingly stable inhibition of 
the K562 cell line from 24 hours, to 48- and 72-hours treatment is because the K562 cell 
line continued to proliferate. Unlike ALA and ISL, the K562 cell line may have developed 
some resistance against CST (Barua et al., 2018; Vadde et al., 2017). A similar trend was 
observed for the treatment of Molt-4 cell line with CST (Table 5.6, page 196). After 
treatment for 72 hours, CST lost the ability to inhibit the proliferation of Molt-4 cell line. This 
is the first time the anticancer activity of CST against Molt-4 cell line has been reported 
although this inhibition was lost after 72 hours treatment. The loss of cytotoxicity inhibition 
after 72 hours could be attributed to the development of resistance mechanisms by the 
K562 cancer cell line (Barua et al., 2018; Vadde et al., 2017). 
CST also indicated moderate cytotoxic inhibition against Caco-2 cell line after 72 hours 
treatment (Table 5.8, page 197), but poor inhibition (no inhibition at doses ≤ 100 μM for 
ALA) after 24 h treatment. Moreover, ISL lost its cytotoxicity against Caco-2 cell at IC50 ≤ 
46 μM. ALA and CST may therefore be beneficial agents (anticancer agents) against Caco-
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2 cell line due to their ability to inhibit the proliferation of Caco-2 cell line in the long run (72 
hours, compared to ISL which lost its cytotoxicity after 72 hours of treatment). 
The third aspect involved a novel study into the cytotoxicity of ALA, ISL and CST against 
K562, Molt-4 and Caco-2 cell lines in hypoxia and normoxia, and in hyperglycaemia and 
hypoglycaemia (Tables 5.6 – 5.8). Maintenance of oxygen homeostasis is critical for 
organism’s survival and solid tumours have been associated with 50–60% of solid tumours 
consisting of hypoxic tissue areas (Vaupel et al., 2004). During hypoxia, tissues are not 
oxygenated adequately due to insufficient concentrations of oxygen in blood thereby 
initiating changes which alters the oncogenic genes in the microenvironment (Harris, 
2002). Metabolism is also altered, giving rise to non-functional blood vessels and a 
consequent metastasis (Harris, 2002). Unlike in normal cells where oxygen supply is 
required for metabolism, neoplastic cells requires 2 to 10-fold oxygen supply (which is 
limited in supply), leading to a more hypoxic microenvironment around the cancerous cells 
(Vaupal et al., 2004). The cancer cells are then able to generate pseudo-blood vessels 
within the cancerous niche to supply the excess oxygen requirements of the tumour cells 
(Suda et al., 2011). This characteristic of tumour cells promotes carcinogenesis and drug 
resistance (Vaupel & Mayer, 2007). In this study, hypoxia increased the antiproliferative 
effect of sesquiterpene lactones tested with ALA and ISL indicating cytotoxicity (IC50) at a 
dose of 0.58 and 0.66 µM compared to cytotoxicity (IC50) at a dose 1.80 and 1.90 µM during 
normal oxygen concentration. Many cancer therapies cannot treat cancers due to the 
inability of these drugs to penetrate the tumour micro-environment. Cancer cells become 
resistant due to the hypoxic microenvironment within the tumour cells (Vaupel et al., 2004). 
Compounds isolated in this study indicated better antiproliferative inhibition in hypoxia than 
in normoxia indicating these compounds may be inhibiting the expression of hypoxia-
inducible factor (HIF1α) gene (Fiegl & Spiekermann, 2011) which is associated with the 
development of resistance to drug in hypoxic conditions (Velasco-Hernandez et al., 2014). 
The antiproliferative activities of compounds isolated in this work was better than that of 
the positive control drug (CPZ). 
Attempts have been made previously to increase the antiproliferation of the cancer stem 
cells in hypoxia by introduction of cytokines with no success at clinical trials in Germany 
(Büchner et al., 2006). In another clinical trial in Dutch, little (but not significant) success 
was reported (Löwenberg et al., 2003). The reason for this failure is that cytokines cannot 
be recruited effectively against hypoxic cells (Drolle et al., 2015). A promising approach 
may involve inhibition of specific pathways by combining small molecules that inhibit 
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different pathways such as inhibition of the apoptotic machinery / PI3K/Akt-pathways or 
the use of chemotherapy – as compounds isolated in this work indicated promising 
antiproliferative activities against K562 cell line in hypoxic conditions in-vitro. The role of 
the PI3K/Akt-pathway has been demonstrated to increase the anti-leukemic efficacy of 
ABT-737 cell line (a BH3 mimetic) thus interfering with apoptosis in a hypoxic AML model 
(Jin et al., 2013). 
Hypoxia as a component of the leukaemic microenvironment encourages the proliferation 
of leukaemia cancer cells. This affects susceptibility of the leukaemia cells towards 
chemotherapy. In this work, we isolated bioactive sesquiterpene lactones – alantolactone, 
isoalantolactone and costunolide which indicated significant antiproliferative activity 
against the K562 (leukaemia) cell line at IC50 values better than that indicated by the 
positive control – CPZ. Further investigation especially the impact of hypoxia on certain 
genetically defined leukaemia sub-types and on the stem-cells might be a promising 
therapeutic approach in the future as the role of hypoxia (a condition of insufficient tissue 
oxygenation) in maintaining stemness in cancers and cancer stem cells (CSC) have been 
reported and has been associated with malignancy and tumourigenesis. CSC are involved 
in cancer degeneration and resistance especially in the leukaemia and colorectal cancers 
(Vadde et al., 2017). 
Furthermore, the anticancer activities of sesquiterpene lactones isolated in this study were 
investigated against the K562 cell line in hyperglycaemic and hypoglycaemic conditions. 
There are reports of increased cancer incidences and mortality in patients with diabetes 
compared to non-diabetic patients (Barua et al., 2018; Simon & Balkau, 2010), an 
indication that hyperglycaemia promotes the development of cancer as cancer cells 
proliferate rapidly during hyperglycaemia (Li et al., 2018). It therefore implies that as cells 
proliferate rapidly, they are difficult to treat (Li et al., 2018). In this study, ALA, ISL and CST 
inhibited the proliferation of K562 cell lines in hyperglycaemic and hypoglycaemic 
conditions with IC50 values ranging from 0.80 – 7.15 µM. A comparison of cytotoxic 
inhibition in hyperglycaemia and in hypoglycaemia indicates that the antiproliferative 
activity of ALA, ISL and CST was at its best during hypoglycaemia. The difference between 
cytotoxic inhibition in hypoglycaemia and in hyperglycaemia is not significant. This finding 
suggests that hyperglycaemia increases cell proliferation (Li et al., 2018) and as cell 
proliferates rapidly, the drug concentration tends to deplete as new cells are constantly 
being formed. An IC50 value of 1.80 and 1.90 µM was observed in low glucose (during 
normoxia) for cells treated with ALA and ISL. This value almost doubled in hyperglycaemia. 
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This data supports previous findings that cancer cells rapidly proliferates during 
hyperglycaemia (Barua et al., 2018; Li et al., 2018; Simon & Balkau, 2010). 
There is a link between hyperglycaemia, hypoglycaemia and hypoxia in cancer progression 
(Li et al., 2018). In this work, the cytotoxic effect of ALA, ISL and CST were better in hypoxia 
and hypoglycaemia combined. In hyperglycaemia and normoxia (combined), there was a 
5-6-fold loss of cytotoxicity by these compounds (ALA, ISL and CST) against the K562 cell 
line. This supports the previous findings that rapidly proliferating cells (during 
hyperglycaemia) are difficult to treat compared to slowly proliferating cells (Barua et al., 
2018; Drolle et al., 2015; Fiegl & Spiekermann, 2011; Harris, 2002; Li et al., 2018; Simon 
& Balkau, 2010; Vaupel & Mayer, 2007). This is the first time this finding has been reported 
in K562 cell lines. The efficiency associated with cytotoxic inhibition of cancer growth in 
hypoxia and hypoglycaemia (combined) may be attributed to induction of cell cycle arrest 
at G0/G1 phase of the cell cycle (Drolle et al., 2015) as cells could not transit to the S 
phase of the cell cycle. Drolle et al., (2015) investigated the decrease cell number observed 
in a study involving leukaemia cell line and reported a significant reduction of cells in S-
phase after exposure to hypoxia for 48 hours treatment and reported a 50.5 % reduction 
of cells in the S phase from 42.5 % to 21.0 % and traced this significant reduction of cells 
in the S phase of the cell cycle to the upregulation of the p27Kip1 regulatory protein. Drolle 
et al., (2015) confirmed this observation on noticing a similar blockade of transition of cell 
cycle at the G0/G1 phase in NB4 cell line. 
Lawrence et al., (2001) reported that ALA and ISL acts as alkylating agents, blocking the 
G2/M and S phase of the cell cycle. This may account for the continued cytotoxic effect 
elicited by ALA and ISL even in hyperglycaemic conditions in rapidly proliferating cells as 
alkylating agents acts best in rapidly proliferating cells (Scholar, 2007). Alkylating agents 
have been reported to significantly inhibit leukaemia and colorectal cancers even at the 
stem cell levels (Scholar, 2007). 
Acute myeloid leukaemia treatment (AML) is associated with poor outcomes of treatment 
due to leukaemia stem cells (LSCs) which are difficult to eliminate with conventional 
therapy. These LSCs lead to cancer relapse in AML (Ding et al., 2016). Findings in this 
report suggest that sesquiterpene lactones – D1, D2 and D3 may be able to destroy LSCs 
even in hypoxic and hyperglycaemic conditions. Only very few small molecules have been 
reported to show anti-LSCs activity including D1 and D2 reported in this study (Lawrence 
et al., 2001).  
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5.5 Anticancer Activities of Synthesised Chrysin Derivatives 
5.5.1 Treatment of Colorectal Cancers with Synthesised Chrysin 
Derivatives 
5.5.1.1 HCT 116 Cell Line 
 
The cytotoxic activity of chrysin adducts made in this study was tested on HCT 116 cell 
line after 24, 48 and 72 hours respectively and their cytotoxic concentration (IC50): 
concentration required to kill 50 % of cancer cells presented in Table 5.10. IC50 is also 
represented as EC50. 
Table 5.10: IC50 values for Chrysin derivatives against HCT 116 Cancer Cell Line  
HCT 116 cancer cell line treated for 24, 48 and 48 hours 
 IC50 (µM)  
Compound 24 hours 48 hours 72 hours Name of compound 
C1 3.21 ± 0.11 3.11 ± 0.41 1.99 ± 0.24 7-O-chrysinbutyl acetate 
C2 3.74 ± 0.14 3.92 ± 0.11 2.17 ± 0.19 
7-O-chrysin-3,5-
dimethylbenzene 
C3 2.61 ± 0.08 1.96 ± 0.53 1.45 ± 1.71 7-O-chysin-2,4-dinitrobenzene 
C4 42.43 ± 3.65 40.51 ± 2.25 29.59 ± 3.25 7-O-isopropylchrysin 
C5 68.52 ± 6.21 65.82 ± 4.46 54.76 ± 2.77 7-O-chrysin-2-methylpropane 
C6 31.93 ± 4.76 25.96 ± 4.26 21.63 ± 1.88 7-O-butylchrysin 
C7 24.32 ± 5.28 21.98 ± 5.87 17.75 ± 1.53 7-O-pentylchrysin 
C8 41.79 ± 6.22 41.87 ± 5.86 30.37 ± 3.81 7-O-hexylchrysin 
C9 39.07 ± 2.36 36.85 ± 1.44 30.56 ± 2.04 7-O-heptylchrysin 
C10 23.56 ± 4.46 24.45 ± 3.74 16.40 ± 1.18 7-O-octylchrysin 
C11 26.32 ± 2.27 24.04 ± 8.22 17.53 ± 2.32 7-O-nonylchrysin 
C12 23.03 ± 1.64 22.69 ± 3.64 18.91 ± 2.95 7-O-decylchrysin 
C13 40.73 ± 5.63 37.16 ± 2.16 30.97 ± 4.17 7-O-3-bromopropylchrysin 
C14 52.96 ± 5.37 53.04 ± 4.21 44.20 ± 2.73 7-O-4-bomobutylchrysin 
C15 121.23±12.45 115.52± 3.76 96.27 ± 22.23 7-O-5-bromopentylchrysin 
C16 83.86 ± 9.67 83.72 ± 3.22 69.77 ± 27.92 7-O-4-bromopentylchrysin 
C17 32.91 ± 3.98 32.60 ± 1.75 27.17 ± 4.35 7-O-12-bromododecylchrysin 
Chrysin 7.33 ± 0.68 6.54 ± 0.54 4.07 ± 0.49 5,7-dihydroxyflavone 
CPZ 9.43 ± 0.76 8.23 ± 0.63 5.90 ± 0.54 Chlorpromazine hydrochloride   
- - No activity at doses ≤ 200 µM 
Chrysin derivatives synthesised in this study are classified into three series: 
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Series 1: Chrysin derivativesC1 to C3. 
Series 2: 7-O-alkylchrysin derivatives (C4 to C16). 
Series 3: 7-O-bromochrysin derivatives (C13 to C17) are the same compounds as 7-O-
bromoalkylchrysin derivatives. 
All compounds tested against HCT cell line elicited some level of inhibition against the 
HCT 116 cell line. 
Series 3 compounds (7-O-bromoalkylchrysin derivatives) indicated inhibitory responses 
against the HCT 116 cell line with IC50 values ranging from 27.17 – 96.27 µM. 7-O-12-
bromododecylchrysin and 7-O-3-bromopropylchrysin elicited good anticancer activity 
against HCT 116 cell line at IC50 values of 27.17 and 30.97 µM (Table 5.10) when the HCT 
cell line was treated for 72 hours. At 24 and 48 hours, these compounds indicated weak 
inhibition against HCT 116 cell line (Table 5.10). 
The highest level of inhibition indicated by Series 3 compound is achieved after 72 hours; 
a characteristic also observed in chrysin and CPZ. The least inhibition was observed after 
24 hours of treatment (Table 5.10). 
Series 2: series 2 compounds (7-O-alkylchrysin derivatives) indicated inhibitory responses 
against the HCT 116 cell line better than Series 3 compounds with IC50 values ranging 
from 27.17 – 96.27 µM (Table 5.10) with IC50 values ranging from 17.75 to 54.76 µM. Like 
Series 3 compound, series 2 compounds elicited the highest level of inhibition against at 
72 hours after administration of test compounds and least inhibition after 24 hours of 
administration of test compounds. However, 7-O-octylchrysin (C10) elicited quick cytotoxic 
activities against HCT 116 cell line after 24 hours of administration of C10 (IC50 23.56 µM) 
which decreased slightly (IC50 23.56 µM). 
An interesting observation is the significant decrease in IC50 values for all series 2 
compounds after 72 hours of administration of these compounds compared to the 
differences observed between administration for 24 and 48 hours. 
C10, C11, C7 and C12 indicated significant cytotoxicity against HCT 116 cell lines after 72 
hours at IC50 values 16.40 µM (C10), 17.53 µM (C11), C7 (17.75 µM) and C12 18.91 µM 
(C12). 
Results obtained in this study suggests that long chain series 2 compounds (with carbon 
atoms ≥ 7) are more cytotoxic compared to short chain series 2 compounds. 
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Series 1: The most cytotoxic Chrysin derivatives synthesise in this study are the Series 1 
compounds. Series 1 compounds indicated very interesting cytotoxicity against HCT 116 
cell lines better than the parent compound – chrysin and much more significant than that 
of the positive control (CPZ) after administration at 24 h, 48 hours and 72 hours 
respectively (Table 5.10). 
 
Figure 5.1: Dose response (µM) – IC50 plot of the most cytotoxic series 1 compound – 7-O-chrysin-2,4-
dinitrobenzene (C3) against HCT 116 cell line after 72 hours treatment. 
Error bars represent standard error (see the box on Figures 5.1 – 5.20 for details) 
7-O-Chysin-2,4-dinitrobenzene (C3) indicated the best cytotoxicity (IC50) against HCT 116 
cell line at 24 hours (2.61 µM), 48 hours (1.96 µM) and 1.70 µM (72 h). C3 elicited its best 
inhibition against HCT 116 after 72 hours of administration. Cytotoxicity indicated by C3 
after 72 hours was very significant compared to those indicated after 24 and 48 hours as 
the IC50 value at 72 hours (1.70 µM) doubled those indicated after 24 hours (1.96 µM) and 
48 hours (2.61 µM) (Table 5.10). Inhibitory response against HCT 116 indicated by C3 was 
better than those of chrysin (17.33 µM at 24 h, 16.54 µM at 48 hours and 14.07 at 72 h) 
and CPZ (9.43 µM at 24 h, 8.23 µM at 48 hours and 5.90 at 72 h). The cytotoxicity (IC50) 
plot for the most cytotoxic Series 1 compounds (7-O-chrysin-2,4-dinitrobenzene) after 72 
hours treatment indicates an IC80 of 3.4 µM (Figure 5.1). The interesting thing with the 
Origin 9.1 software is its ability to define several other variables such as the inhibitory 
concentration required to kill 80% cancer cells (IC80) as well as the inhibitory concentration 
required to kill 20 % cancer cell line. For C3, the IC80 suggests over 80 % of HCT 116 
: Compound C3 (µM) 
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cancer cell line were killed at a concentration of 3.4 µM by C3 after 72 hours of treatment 
(Figure 5.1 above). 
  
 
 Figure 5.2: Dose response – IC50 plot (µM) of Series 1 compounds – 7-O-chrysinbutyl acetate (C1) 
against HCT 116 cell line after 72 hours treatment. 
7-O-chrysinbutyl acetate (C1) indicated significant cytotoxicity comparable to that indicated 
by C3, against HCT 116 cell line at 24 hours (3.21 µM), 48 hours (3.11 µM) and 1.99 µM 
(72 h). C1 elicited its best inhibition against HCT 116 after 72 hours of administration. 
Cytotoxicity indicated by C1 after 72 hours was significant compared to those indicated 
after 24 and 48 hours as the IC50 value at 72 hours (1.99 µM) doubled those indicated after 
24 hours (3.11 µM) and 48 hours (3.21 µM) (Table 5.9). Inhibitory response against HCT 
116 indicated by C3 was better than those of chrysin and CPZ. 
Cytotoxicity indicated by C2 – 3.21 µM at 24 h, 3.11 µM at 48 hours and 1.99 at 72 hours 
was better than those indicated by chrysin and CPZ at 24 h, 48 h and at 72 h. The best 
inhibitory response of C1 against HCT 116 cell line was recorded after 72 hours of 
administration of C1 (Table 5.10). 
C2 also significantly inhibited the growth of HCT 116 cell line at IC50 concentrations of 3.74, 
3.92 and 2.17 µM after 24 h, 48 hours and 72 hours respectively. IC50 indicated by C2 were 
better than those indicated for chrysin. The best inhibitory response of C2 against HCT 116 
cell line was recorded after 72 hours of administration of C2 (Table 5.10 above). 
 





Figure 5.3: Dose response – IC50 plot (µM) of 7-O-chrysin-3,5-dimethylbenzene against HCT 116 cell line 
after 72 hours treatment. 
In this study, Series 1 compounds elicited significant cytotoxicity better than the parent 
compound – chrysin and the positive control drug – Chlorpromazine hydrochloride (CPZ) 
(Table 5.10). 
A summary of graphical representation of the IC50 of chrysin derivatives used in this study 
(Table 5.10) is presented in Figure 5.4 below. 
 




                                      Figure 5.4: Graphical representation of IC50 (µM) of all Chrysin derivativessynthesised (C1 to C17) against HCT 116 cell line 
An interesting observation was that all Chrysin derivativesmade in this study indicated some degree of inhibition against HCT 116 cancer 
cell line with Series 1 compounds indicating the most cytotoxic activity against HCT 116 cell line. All Series 1 compounds used in this 
study are novel compounds.
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5.5.1.2  Results for Caco-2 Cancer Cell Line 
 
Chrysin derivatives made in this study indicated significant cytotoxic activities against 
Caco-2 cancer cell lines Table 5.11. Unlike the HCT 116 cell lines, IC50 values were 
determined after 72 hours of treatment with test compounds. IC50 values are presented in 
Table 5.11. 
 
Table 5.11: IC50 values of Chrysin derivatives against Caco-2 cancer cell line 
Caco-2 cell line treated for 72 hours 
Compound IC50 (µM)  Name of chrysin adduct 
C1 5.89 ± 0.41 7-O-chrysinbutyl acetate 
C2 4.53 ± 0.79 7-O-chrysin-3,5-dimethylbenzene 
C3 4.83 ± 0.37 7-O-chysin-2,4-dinitrobenzene 
C4 35.20 ± 3.66 7-O-isopropylchrysin 
C5 95.54 ± 4.72 7-O-chrysin-2-methylpropane 
C6 36.75 ± 3.51 7-O-butylchrysin 
C7 - 7-O-pentylchrysin 
C8 - 7-O-hexylchrysin 
C9 - 7-O-heptylchrysin 
C10 15.27 ± 1.22 7-O-octylchrysin 
C11 13.05 ± 1.01 7-O-nonylchrysin 
C12 18.91 ± 2.95 7-O-decylchrysin 
C13 19.25 ± 3.79 7-O-3-bromopropylchrysin 
C14 16.77 ± 1.45 7-O-4-bomobutylchrysin 
C15 22.06 ± 3.84 7-O-5-bromopentylchrysin 
C16 21.26 ± 2.21 7-O-4-bromopentylchrysin 
C17 17.60 ± 6.30 7-O-12-bromododecylchrysin 
Chrysin 4.84 ± 0.19 5,7-dihydroxyflavone 
CPZ 5.17 ± 0.64 Chlorpromazine hydrochloride   
 
 - - No activity at doses ≤ 200 µM 
Chrysin derivatives made in this study indicate significant cytotoxic activities against Caco-
2 cancer cell lines (Table 5.11). Unlike the HCT 116 cell lines, IC50 values were determined 
after 72 hours of treatment with test compounds. 
Series 3: The bromoalkylchrysin derivatives – C13 to C17 of chrysin adducts made in this 
study were tested against Caco-2 cell cancer cell line. IC50 values ranging from 16.77 to 
218 
 
22.06 µM were recorded with C14 indicating the lowest IC50 value (16.77 µM) – Table 5.11. 
All bioactive series 2 compounds recorded similar cytotoxicity against Caco-2 cell line. 
 
Figure 5.5: Dose response – IC50 plot (µM) for Caco-2 cell line treated with 4-bromobutylchrysin for 72 hours 
Series 2: The series 2 chrysin adducts (C4 to C12) indicated inhibition against Caco-2 cell 
line with IC50 values ranging from 13.05 to 95.54 µM.  
  
Figure 5.6: Dose response – IC50 plot (µM) for Caco-2 treated with 7-O-nonylchrysin for 72 hours 
 
: Compound C16 (µM) 
: Compound C11 (µM) 
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The most cytotoxic chrysin adducts in this series are 7-O-nonylchrysin – C11 (IC50 13.05 
µM) and 7-O-octylchrysin – C10 (IC50 15.27 µM). 7-O-decylchrysin – C12 also indicated 
significant cytotoxicity against Caco-2 cell line. 
C4 and C6 indicated weak cytotoxicity while C5, C7, C8 and C9 where inactive against 
Caco-2 cells (Table 5.11). 
Results obtained for series 2 compounds suggests long chain alkyl-chrysin adducts are 
cytotoxic against Caco-2 cell line whereas short chain 7-O-alkylchrysin derivatives of 
chrysin are inactive against Caco-2 cell line at concentrations ≤ 30 µM. 
Series 1: Series 1 compounds (C1, C2 and C3) elicited significant cytotoxicity against 
Caco-2 cell line with IC50 values 5.89 µM, 4.53 µM and 4.83 µM (Table 5.11) when treated 
with these compounds. Cytotoxicity elicited by Series 1 compounds are better than 
cytotoxicity indicated by chrysin and CPZ. 
 
Figure 5.7: Dose response – IC50 plot (µM) of 7-O-Chrysinbutyl acetate against Caco-2 cell line after 72 
hours treatment. 
 
Cancer growth inhibition of C1, C2 and C3 indicates better IC50 values than those indicated 
by the positive control drug – CPZ. However, the difference in cytotoxicity between chrysin 
and CPZ was not significant. The dose response curve (Figure 5.7) indicates an IC80 of 
17.63 µM suggesting that 80 % of Caco-2 cell line is susceptible to cytotoxic inhibition from 
C1. 
: Compound C1 (µM) 
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The dose response curve in (Figure 5.8) indicates an IC80 of 12.67 µM suggesting that 80 
% of Caco-2 cell line was is susceptible to cytotoxic inhibition from C2. The dose response 
curve in (Figure 5.9) indicates an IC80 of 11.68 µM suggesting that 80 % of Caco-2 cell line 
was is susceptible to cytotoxic inhibition from C3. The IC80 values indicated by Series 1 
compounds is more significant than that indicated by chrysin against Caco-2 cell line. 
 




Figure 5.9: Dose response – IC50 plot (µM) of Caco-2 cell line treated with chrysin-2,4-dinitrobenzene for 72 
hours  
: Compound C2 (µM) 
: Compound C3 (µM) 
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5.5.2  Results for Treatment of Leukaemia Cancers with 
Synthesised Chrysin Derivatives  
5.5.2.1 Results for Molt-4 Cancer Cell Line 
 
Chrysin derivatives made in this study were evaluated against Molt-4 cancer cell lines 
(Table 5.12). Unlike the HCT 116 cell lines, IC50 values were determined after 72 hours of 
treatment with test compounds. This is because any compound which cannot inhibit the 
growth of cancer cells after 72 hours treatment is considered inactive even if they indicate 
cytotoxicity within 24 – 48 hours treatment. 
 
Table 5.12: IC50 values of Chrysin derivatives against Molt-4 cancer cell Line  
Molt-4 cell line treated for 72 hours 
Compounds IC50 (µM) Molt-4 Name of chrysin adduct 
C1 7.05 ± 0.47 7-O-chrysinbutyl acetate 
C2 13.87 ± 3.00 
7-O-chrysin-3,5-
dimethylbenzene 
C3 5.41 ± 0.53 7-O-chysin-2,4-dinitrobenzene 
C4 97.71 ± 70.88 7-O-isopropylchrysin 
C5 17.40 ± 3.50 7-O-chrysin-2-methylpropane 
C6 - 7-O-butylchrysin 
C7 51.21 ± 9.23 7-O-pentylchrysin 
C8 39.49 ± 3.29 7-O-hexylchrysin 
C9 35.14 ± 2.38 7-O-heptylchrysin 
C10 - 7-O-octylchrysin 
C11 - 7-O-nonylchrysin 
C12 44.74 ± 3.14 7-O-decylchrysin 
C13 59.41 ± 29.05 7-O-3-bromopropylchrysin 
C14 73.82 ± 65.75 7-O-4-bomobutylchrysin 
C15 23.58 ± 1.67 7-O-5-bromopentylchrysin 
C16 13.28 ± 2.34 7-O-4-bromopentylchrysin 
C17 5.35 ± 0.47 7-O-12-bromododecylchrysin 
Chrysin 5.23 ± 0.96 5,7-dihydroxyflavone 
CPZ 7.05 ± 0.47 Chlorpromazine hydrochloride   
 - - No activity at doses ≤ 200 µM 
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Chrysin derivatives made in this study indicates significant cytotoxic activities against Molt-
4 cancer cell lines Table 5.12. 
Series 3: The bromoalkylchrysin derivatives – C13 to C17 of chrysin adducts were tested 
against Molt-4 cancer cell line. IC50 values ranging from 13.28 to 73.83 µM were recorded 
with C17 indicating the lowest (best) cytotoxicity (IC50 13.28 µM) – Figure 5.10. The novel 
Series 3 compounds synthesised in this study (C17 and C16) were the only compounds 
indicating significant (IC50 13.28 µM for C17) and moderate (IC50 23.58 µM for C16). C13, 
C14 and C15 indicated cytotoxicity above 40 µM. Cytotoxicity elicited by C17 is comparable 
to that of CPZ. 
 
Figure 5.10: IC50 plot (µM) for Molt-4 cell line treated with 7-O-bromododecylchrysin for 72 hours 
 
Series 2 compounds (C4 to C12) indicated weak cytotoxicity against Molt-4 cell line except 
7-O-chrysinmethylpropane – C5 (Table 5.12), which indicated significant cytotoxicity 
against the molt-4 cell line. Other compounds in this group (C4, C5, C7, C8 and C9) 
indicated cytotoxicity (IC50) at doses above 50 µM. C6, C10, C11 and C12 did not elicit 
cytotoxicity against Molt-4 cell line at concentration < 100 µM. Cytotoxicity indicated by C5 
was comparable to that of C2 – a Series 3 compound. 
Series 1 compounds indicated significant cytotoxic inhibition against Molt-4 cell line. C1 
(IC50 7.05 µM) and C3 (IC50 5.41 µM) indicated better cytotoxicity compared to those of 
chrysin  and CPZ  (Table 5.12). C2 also indicated cytotoxicity (13.87 µM) comparable to 
: Compound C17 (µM) 
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that of chrysin. The graphical presentation of cytotoxicity elicited by chrysin derivatives is 
presented in Figure 5.11 below. 
 
Figure 5.11: IC50 (µM) values of chrysin derivatives against Molt-4 cell line. 
Series 3 compound (C13 to C17) indicated weak cytotoxicity (except C16 and C17), series 2 
compounds (C4 to C12) indicated weak cytotoxicity except C5 which indicated significant 






5.5.2.2  Results for K562 Cancer Cell Line 
 
Dose response (IC50 data) for chrysin adducts tested against K562 cancer cell line is 
presented in Table 5.13. 
Table 5.13: Table showing IC50 values of chrysin adducts against K562 Cell Line 
K562 cell line treated for 72 h 
Compound IC50 (µM) Name of chrysin adduct 
C1 7.27 ± 0.71 7-O-chrysinbutyl acetate 
C2 5.58 ± 0.29 7-O-chrysin-3,5-dimethylbenzene 
C3 8.69 ± 2.05 7-O-chysin-2,4-dinitrobenzene 
C4 - 7-O-isopropylchrysin 
C5 - 7-O-chrysin-2-methylpropane 
C6 - 7-O-butylchrysin 
C7 - 7-O-pentylchrysin 
C8 - 7-O-hexylchrysin 
C9 - 7-O-heptylchrysin 
C10 - 7-O-octylchrysin 
C11 - 7-O-nonylchrysin 
C12 15.08 ± 0.21 7-O-decylchrysin 
C13 18.72 ± 2.68 7-O-3-bromopropylchrysin 
C14 17.52 ± 1.60 7-O-4-bomobutylchrysin 
C15 15.31 ± 2.08 7-O-5-bromopentylchrysin 
C16 15.23 ± 0.15 7-O-4-bromopentylchrysin 
C17 3.14 ± 0.22 7-O-12-bromododecylchrysin 
Chrysin 7.38 ± 1.56 5,7-dihydroxyflavone 
CPZ 7.27 ± 0.71 Chlorpromazine hydrochloride   
 - - No activity at doses ≤ 200 µM 
 
Series 3 compound (C13 to C17) elicited cytotoxic inhibition against Molt-4 cell line at IC50 
ranging from 15.31 – 36.72 with C16 and C17 indicating cytotoxicity at concentrations ≤ 23 




Figure 5.12: IC50 (µM) graph for cytotoxic activity of C1 against K562 cell line treated for 72 hours 
 
Series 2 compounds were inactive against K562 cell lines at doses ≤ 100 µM. 
 
 
Figure 5.13: IC50 (µM) graph for cytotoxic activity of C2 against K562 cell line treated for 72 hours 
Series 1 compounds (C1 and C2) elicited better cytotoxicity against K562 cell line 
compared to those of chrysin (IC50 7.38 µM) and CPZ (IC50 7.27 µM). C1 indicated an IC50 
of 7.27 µM; C2 (IC50 5.58 µM) and C3 (IC50 8.69 µM) (Table 5.13). Cytotoxic inhibition 
elicited by C2 is comparable to that indicated by CPZ. 
: Compound C1 (µM) 
: Compound C2 (µM) 
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A graphical illustration of cytotoxicity elicited by bioactive chrysin derivatives is presented 
in Figure 5.14 below. 
 
Figure 5.14: Comparison of IC50 (µM) values of Series 1, 2 and 3 Chrysin derivatives against K562 cell line. 
Series 3 compounds elicited cytotoxicity comparable to those indicated by chrysin and CPZ. Series 
1 compounds were inactive against K562 cell line. 
 
The bromoalkylchrysin derivatives (Series 3 compound) were superior cytotoxic inhibitors 
of K562 cell line compared to the aliphatic 7-O-Chrysin derivatives which indicated no 
cytotoxic inhibition against K562 cell line. Cytotoxic response indicated by Series 3 
compound was comparable to that of C3 – a Series 1 compound. Generally, Series 1 
compounds were the most cytotoxic inhibitors of K562 cell lines compared to all other 
groups. The result suggests 7-O-bromochrysin derivatives are more cytotoxic than 7-O-





5.5.3  Results for Treatment of Breast Cancers with Synthesised 
Chrysin Derivatives  
5.5.3.1 Results for MCF 7 Cancer Cell Line 
 
Cytotoxic activity of 7-O-chrysin derivatives against MCF 7 cell line was investigated. 
Results are presented in Table 5.14. 
Table 5.14: Table showing IC50 values of chrysin adducts against MCF 7 Cell Line 
MCF 7 cell line treated for 72 h 
Compounds IC50 (µM) Name of Chrysin analogue 
C1 17.6 ± 1.08 7-O-chrysinbutyl acetate 
C2 - 7-O-chrysin-3,5-dimethylbenzene 
C3 26.18 ± 3.34 7-O-chysin-2,4-dinitrobenzene 
C4 - 7-O-isopropylchrysin 
C5 46.53 ± 11.45 7-O-chrysin-2-methylpropane 
C6 - 7-O-butylchrysin 
C7 - 7-O-pentylchrysin 
C8 - 7-O-hexylchrysin 
C9 - 7-O-heptylchrysin 
C10 - 7-O-octylchrysin 
C11 - 7-O-nonylchrysin 
C12 - 7-O-decylchrysin 
C13 66.73 ± 25.61 7-O-3-bromopropylchrysin 
C14 63.03 ± 7.21 7-O-4-bomobutylchrysin 
C15 37.75 ± 0.14 7-O-5-bromopentylchrysin 
C16 27.32 ± 4.48 7-O-4-bromopentylchrysin 
C17 22.92 ± 1.89 7-O-12-bromododecylchrysin 
Chrysin 4.20 ± 1.70 5,7-dihydroxyflavone 
CPZ 2.17 ± 0.10 Chlorpromazine hydrochloride   
  - - No activity at doses ≤ 200 µM 
Series 3 (C13 to C17) compound elicited weak anticancer activity against MCF 7 with IC50 
values ranging from 22.92 to 66.73 µM. 7-O-12-Bromododecylchrysin (C17) and 7-O-4-
Bromopentylchrysin (C16) elicited the best cytotoxicity against MCF 7 cell line (Table 5.14 
above). Interestingly a decrease in cytotoxic activity is observed in Series 3 compounds – 
as the carbon atoms increased (Table 5.14). This result suggests longer chains 




Series 2 compounds (C4 to C12) were inactive against MCF 7 cell line except the 7-O-2-
methylchrysin adducts which indicated a weak cytotoxicity (IC50 46.53 µM) – (Table 3.12), 
an indication that methylation increases the cytotoxic activity of propylchrysin adduct. 
Series 1 compounds (C1, C2 and C3): The only Series 1 compound with good cytotoxic 
activity against MCF 7 is 7-O-chrysinbutyl acetate (C1). C2 was inactive against MCF 7 





5.5.3.2  Results for MDA-MB 468 Cancer Cell Line 
 
Cytotoxic activity of 7-O-chrysin derivatives against MDA-MB 468 cell line was 
investigated. Results are presented in Table 5.15. 
 
Table 5.15: Table showing IC50 values of chrysin adducts against MDA-MB 468 cell line 
MDA-MB 468 cell line treated for 72 hours 
Compounds IC50 (µM) Name of Chrysin analogue 
C1 7.49 ± 0.61 7-O-chrysinbutyl acetate 
C2 25.41 ± 1.36 7-O-chrysin-3,5-dimethylbenzene 
C3 16.59 ± 1.33 7-O-chysin-2,4-dinitrobenzene 
C4 - 7-O-isopropylchrysin 
C5 - 7-O-chrysin-2-methylpropane 
C6 - 7-O-butylchrysin 
C7 - 7-O-pentylchrysin 
C8 6.06 ± 3.43 7-O-hexylchrysin 
C9  7-O-heptylchrysin 
C10 38.80 ± 22.90 7-O-octylchrysin 
C11 - 7-O-nonylchrysin 
C12 - 7-O-decylchrysin 
C13 - 7-O-3-bromopropylchrysin 
C14 - 7-O-4-bomobutylchrysin 
C15 - 7-O-5-bromopentylchrysin 
C16 8.17 ± 0.36 7-O-4-bromopentylchrysin 
C17 18.24 ± 2.44 7-O-12-bromododecylchrysin 
Chrysin 5.84 ± 0.67 5,7-dihydroxyflavone 
CPZ 5.83 ± 0.51 Chlorpromazine hydrochloride   
  - - No activity at doses ≤ 200 µM 
 
Series 3 compounds (C13 to C17) shows that short carbon chain Series 3 compounds 
(C13 to C15) were inactive against MDA-MB 468 cell line. As the carbon chain increases 
(C17), 7-O-bromododecylchrysin (C17) elicited significant anticancer activity against the 
breast cancer cell line – MDA-MB 468 at IC50 18.24 µM. This activity is comparable to that 
indicated by the positive control drug – CPZ and better than that indicated by chrysin (table 
5.15). Another interesting finding is the significant cytotoxicity demonstrated by the 
methylated 7-O-bromochrysin compound – 7-O-4-bromopentylchrysin (C16) which 
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indicates a superior cytotoxic effect on MDA-MB 468 (IC50 8.17 µM) compared to 7-O-
bromochrysin compounds without the methyl group – (Table 5.15). This novel compound 
indicated better anticancer activity against the triple-negative breast cancer cell line (MDA-
MB 468) compared to chrysin (IC50 5.84 µM) and CPZ (IC50 5.83 µM). The dose response 
(IC50 plot) for C16 is presented in Figure 5.15. 
 
 
Figure 5.15: IC50 (µM) of 4-bromopentylchrysin against MDA-MB 468 cell line treated for 72 hours 
Series 2 compounds (C4 to C12): 7-O-hexylchrysin (C7) elicited significant cytotoxic 
effect (IC50 6.0 µM) against MDA-MB 468.  
 
Figure 5.16: Dose response (IC50 plot) of C7 against MDA-MB 468 cell line after treatment for 72 hours 
 
: Compound C16 (µM) 
: Compound C8 (µM) 
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7-O-Hexylchrysin (C7) indicated weak cytotoxicity against MDA-MB 468 (IC50 38.80 µM). 
Other compounds in this group were inactive against MDA-MB 468 cell line. The cytotoxic 
concentration (IC50) of C7 is presented in Figure 5.16 above. 
Series 1 compounds (C1 to C3): 7-O-chrysinbutyl acetate (C1) indicated significant 
cytotoxic effect against MDA-MB 468 cell line – IC50 7.49 µM (Table 5.15 above). C2 and 
C3 were inactive against this cell line. The cytotoxicity (IC50) plot for C1 against MDA-MD 
468 is presented in Figure 5.17.   
 
Figure 5.17: IC50 (µM) of C1 against MDA-MB 468 cell line 
 
C2 elicited weak cytotoxicity (IC50 25.41 µM), C3 indicated significant cytotoxicity (16.59 
µM) against MDA-MB 468 cell line. A comparison of cytotoxic inhibition elicited by these 
compounds indicates a comparable cytotoxic inhibition between C8, CPZ, chrysin, C1 and 
C16 against MDA-MB 468 cell line (Figure 5.17 above). 
 
  
: Compound C1 (µM) 
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5.5.4 Results for Treatment of Liver (Hepatocellular carcinoma) 
Cancer Cell Line with Synthesised Chrysin Derivatives  
5.5.4.1 Results for HepG2 Cancer Cell Line 
 
Cytotoxic activity of 7-O-chrysin derivatives against HepG2 cell line was investigated. 
Results are presented in Table 5.16.  
 
Table 5.16: Table showing IC50 values of chrysin adducts against HepG2 Cell Line 
HepG2 cell line treated for 72 hours 
Compounds IC50 (µM) Name of Chrysin adduct 
C1 17.53 ± 1.01 7-O-chrysinbutyl acetate 
C2 34.82 ± 1.01 7-O-chrysin-3,5-dimethylbenzene 
C3 4.93 ± 0.35 7-O-chysin-2,4-dinitrobenzene 
C4 - 7-O-isopropylchrysin 
C5 - 7-O-chrysin-2-methylpropane 
C6 - 7-O-butylchrysin 
C7 - 7-O-pentylchrysin 
C8 25.98 ± 3.19 7-O-hexylchrysin 
C9 - 7-O-heptylchrysin 
C10 - 7-O-octylchrysin 
C11 - 7-O-nonylchrysin 
C12 - 7-O-decylchrysin 
C13 - 7-O-3-bromopropylchrysin 
C14 - 7-O-4-bomobutylchrysin 
C15 - 7-O-5-bromopentylchrysin 
C16 - 7-O-4-bromopentylchrysin 
C17 - 7-O-12-bromododecylchrysin 
Chrysin 10.69 ± 0.94 5,7-dihydroxyflavone 
CPZ 5.62 ± 0.83 Chlorpromazine hydrochloride   
  - - No activity at doses ≤ 200 µM 
HepG2 cell were resistant to Series 3 (C4 to C12) and series 2 (C13 to C17) compounds 
except 7-O-hexylchrysin (C6) which indicated good cytotoxic inhibition against HepG2 cell 
line. Cancer cells inhibition shown by C6 was better than that of C2 Table 5.16. 
Series 1 compounds: investigation of cytotoxic inhibition of Series 1 compounds against 
HepG2 cell line indicates that 7-O-chysin-2,4-dinitrobenzene was the most Cytotoxic with 
IC50 4.93 µM, which is better than those showed by chrysin (10.69 µM) and CPZ (5.62 µM). 
C1 also showed good anticancer inhibition of HepG2 cells. This activity is comparable to 
that indicated by chrysin.  
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5.5.5  Results for Treatment of Lung Cancer Cell Line with 
Synthesised Chrysin Derivatives  
5.5.5.1 Results for A549 Cancer Cell Line 
 
Cytotoxic activity of 7-O-chrysin derivatives against A549 cell line was investigated. 
Results are presented in Table 5.17. 
 
Table 5.17: Table showing IC50 values of chrysin adducts against A549 Cell Line 
A549 cell line treated for 72 hours 
Compounds IC50 (µM) Name of Chrysin analogue 
C1 20.01 ± 0.78 7-O-chrysinbutyl acetate 
C2 - 7-O-chrysin-3,5-dimethylbenzene 
C3 33.13 ± 2.19 7-O-chysin-2,4-dinitrobenzene 
C4 - 7-O-isopropylchrysin 
C5 - 7-O-chrysin-2-methylpropane 
C6 - 7-O-butylchrysin 
C7 - 7-O-pentylchrysin 
C8 - 7-O-hexylchrysin 
C9 - 7-O-heptylchrysin 
C10 - 7-O-octylchrysin 
C11 - 7-O-nonylchrysin 
C12 - 7-O-decylchrysin 
C13 - 7-O-3-bromopropylchrysin 
C14 - 7-O-4-bomobutylchrysin 
C15 - 7-O-5-bromopentylchrysin 
C16 16.79 ± 1.73 7-O-4-bromopentylchrysin 
C17 - 7-O-12-bromododecylchrysin 
Chrysin 14.64 ± 1.36 5,7-dihydroxyflavone 
CPZ 8.75 ± 1.24 Chlorpromazine hydrochloride   
  - - No activity at doses ≤ 200 µM 
Most chrysin adducts made in this study were inactive against A549 cell line. For Series 3 
(C13 to C17) compounds, 7-O-4-bromopentylchrysin (C16) elicited significant cytotoxic 
inhibition against A549 (IC50 16.79 µM) (Figure 5.18) comparable to that presented by 
chrysin (IC5014.64 µM) (Table 5.17). 
Series 2 (C4 to C12) compounds were inactive against A549 cell line at IC50 ≤ 100 µM. 
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For Series 1 (C1 to C3) compounds, C1 inhibited the growth of A549 cell line at IC50 20.01 
µM. C2 was inactive against A549. C3 showed weak inhibition against A549 cell line (IC50 
33.13 µM). Nevertheless, cytotoxic inhibition indicated by C1 and C16 were comparable to 
those showed by the conventional drug – CPZ (IC50 8.75 µM), and comparable to that 
indicated by chrysin (IC50 14.64 µM). 
 
Figure 5.18: Dose response – IC50 (µM) plot of the most cytotoxic chrysin adduct (C16) against A549 
 
C16 also indicated a significant IC20 (8.22 µM) against A549 cell line (Figure 5.18).  
  
Drug concentration (Log): Compound C16 (µM) 
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5.5.6  Results for Treatment of Skin Cancer (Keratinocyte) Cell Line 
with Synthesised Chrysin Derivatives  
5.5.6.1 Results for HacaT Cancer Cell Line 
 
Cytotoxic activity of 7-O-chrysin derivatives against HacaT cell line was investigated. 
Results are presented in Table 5.18. 
 
Table 5.18: Table showing IC50 values of chrysin adducts against HacaT Cell Line 
HacaT cell line treated for 72 hours 
Compounds IC50 (µM) Name of Chrysin analogue 
C1 37.76 ± 14.56 7-O-chrysinbutyl acetate 
C2 - 7-O-chrysin-3,5-dimethylbenzene 
C3 - 7-O-chysin-2,4-dinitrobenzene 
C4 - 7-O-isopropylchrysin 
C5 21.84 ± 3.36 7-O-chrysin-2-methylpropane 
C6 6.38 ± 1.09 7-O-butylchrysin 
C7 26.37 ± 1.21 7-O-pentylchrysin 
C8 12.81 ± 1.63 7-O-hexylchrysin 
C9 12.29 ± 2.38 7-O-heptylchrysin 
C10 9.62 ± 0.69 7-O-octylchrysin 
C11 25.67 ± 0.12 7-O-nonylchrysin 
C12 28.4 ± 1.35 7-O-decylchrysin 
C13 - 7-O-3-bromopropylchrysin 
C14 - 7-O-4-bomobutylchrysin 
C15 - 7-O-5-bromopentylchrysin 
C16 - 7-O-4-bromopentylchrysin 
C17 - 7-O-12-bromododecylchrysin 
Chrysin 9.8 ± 1.00 5,7-dihydroxyflavone 
CPZ 12.69 ± 1.26 Chlorpromazine hydrochloride   
 - - No activity at doses ≤ 200 µM 
Series 2: all Series 3 compound (C4 to C12) tested showed interesting cytotoxic inhibition 
against HacaT cell line. 7-O-butylchrysin (C6) – IC50 6.38 µM (Table 5.18) and 7-O-
octylchrysin (C10) – IC50 9.62 µM showed very interesting cytotoxicity against HacaT cell 
line with C6 inducing a superior cytotoxicity compared to chrysin and CPZ. 7-O-
heptylchrysin (IC50 12.28 µM) and 7-O-hexylchrysin – IC50 12.81 µM also elicited significant 
cytotoxicity against HacaT cell line. Cytotoxic inhibition elicited by C8 and C9 were better 
than those indicated by chrysin and CPZ. 
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Series 3 compounds (C13 to C17) were inactive against HacaT cell line. 
 
 
Figure 5.19: IC50 (µM) of 7-O-chrysinbutane against HacaT cell line treated for 72 hours 
 
For Series 1 compounds, only 7-O- 7-O-chrysinbutyl acetate indicated weak cytotoxicity 
against HacaT cell line. C2 and C3 were inactive against HacaT cell line. 
 
 




: Compound C6 (µM) 
: Compound C10 (µM) 
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5.5.7  Results for Treatment of Mesothelioma cell line with 
Synthesised Chrysin Derivatives  
5.5.7.1 Result for Mero-14 Cancer Cell Line  
 
Cytotoxic activity of 7-O-chrysin derivatives against Mero cell line was investigated. Results 
are presented in Table 5.19. It should be noted that CPZ and standard anticancer drugs 
are relatively inactive against the Mero-14 cell line (Mujoomdar et al., 2010). For this 
reason, drug repurposing and the use of chlorpromazine hydrochloride – CPZ; (a drug 
used in treating psychotic disorders such as schizophrenia) in cancer therapy has been 
reported (Mello et al., 2016; Shenoy, Biaglow, Varnes, & Daniel, 1982; Yang et al., 2019). 
 
Table 5.19: Table showing IC50 values of chrysin adducts against Mero 14 Cell line 
Mero-14 cell line treated for 72 hours 
Compounds IC50 (µM) Name of Chrysin analogue 
C1 7.65 ± 0.53 7-O-chrysinbutyl acetate 
C2 26.31 ± 4.09 7-O-chrysin-3,5-dimethylbenzene 
C3 8.71 ± 0.85 7-O-chysin-2,4-dinitrobenzene 
C4 26.71 ± 1.47 7-O-isopropylchrysin 
C5 - 7-O-chrysin-2-methylpropane 
C6 - 7-O-butylchrysin 
C7 - 7-O-pentylchrysin 
C8 122.51 ± 8.96 7-O-hexylchrysin 
C9 - 7-O-heptylchrysin 
C10 - 7-O-octylchrysin 
C11 - 7-O-nonylchrysin 
C12 - 7-O-decylchrysin 
C13 - 7-O-3-bromopropylchrysin 
C14 46.13 ± 2.63 7-O-4-bomobutylchrysin 
C15 32.34 ± 3.44 7-O-5-bromopentylchrysin 
C16 9.56 ± 0.82 7-O-4-bromopentylchrysin 
C17 25.46 ± 4.12 7-O-12-bromododecylchrysin 
Chrysin 45.99 ± 3.08 5,7-dihydroxyflavone 
CPZ 3.42 ± 2.87 - 
 - - No activity at doses ≤ 200 µM   
The results presented above indicates the 7-O-bromochrysin derivatives (C13 to C17) 
inhibited the growth of Mero-14 cell line. 7-O-4-bromopentylchrysin (C16) which was the 
most cytotoxic bromoalkylchrysin derivative (IC50 9.56 µM) indicated a significant cytotoxic 
inhibition against the Mero-14 cancer cell line. Other than C16, other bromoalkylchrysin 
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derivatives showed weak cytotoxic inhibition (25.46 µM – C17, 32.32 µM –C15 and 46.13 
µM – C14) - Table 5.19. 
Most 7-O-alkylchrysin derivatives were inactive against Mero-14 cell lines. The only 
compound in this group which indicated significant cytotoxic inhibition against Mero 14 is 
7-O-isopropylchrysin (C4) at IC50 concentration of 26.71 µM. 
Series 1 compounds (C1 to C3) elicited significant cytotoxic inhibition against Mero14 cell 
line: C1 (IC50 7.55 µM), C1 (IC50 26.31 µM), C3 (IC50 26.71 µM). 
Methylation of Series 3 (7-O-bromochrysin derivatives) and 2 compounds (7-O-alkylchrysin 
derivatives) increased the cytotoxic activity of these chrysin adducts as observed in the 
methylated 7-O-isopropylchrysin (C4) and 7-O-4-bromopentylchrysin (C16). Despite the 
increased cytotoxic activity observed by the addition of a methyl group to C4 and C16, it is 
observed that C16 (with a bromine atom) indicated a 3-fold increase in cytotoxicity against 
Mero-14 cell line when compared to 7-O-isopropylchrysin (C4) without a bromine atom. 
The effect of increased cytotoxicity of methylated aliphatic 7-O-Chrysin adducts against 
Mero 14 cell line is also observed in aromatic chrysin adduct (7-O-chrysin-3,5-
dimethylbenzene (C2) - Table 5.19. 
Methylation of C2 also increased its cytotoxicity compared to its aliphatic counterpart – C4. 
However, the cytotoxic effect of C16 surpassed those of C2 and C4 three folds – an 
indication that methylation and bromination of 7-O-Chrysin adducts increases their 
cytotoxicity. 
An interesting observation was seen in Series 1 compound (C1 to C3). C1 and C2 showed 
significant and interesting cytotoxicity against Mero 14 cell line (IC50 7.65 and 8.71 µM). 
The cytotoxic activities of C1 and C3 were three times better than that of C2 (IC50 26.31 
µM). It therefore suggests the electron-withdrawing –NO2 group in C3 and the ketone group 
(oxygen atoms in these groups) are responsible for the cytotoxicity of these compounds 
against Mero 14 cell line. 
Another interesting observation is that bioactive cytotoxic adducts synthesised in this study 
were more cytotoxic against Mero 14 cell line than the parent compound – chrysin. C1, C3 




5.5.8 Results for Treatment of Normal Bronchial Epithelium Cell 
Line (BEAS-2B) with Synthesised Chrysin Derivatives  
 
To investigate if the 7-O-chrysin adducts made in this study are cytotoxic against normal 
cells, we investigated the cytotoxicity of these chrysin adducts against the adherent, 
epithelial-like, normal human bronchial epithelial cell (BEAS-2B). The results are reported 
in Table 5.20. 
 
Table 5.20: Cytotoxicity of 7-O-chrysin adducts on normal Cell Line (BEAS-2B) 
BEAS-2B cell line (normal cell line) treated for 72 hours 
Compounds IC50 (µM) Name of Chrysin analogue 
C1 143.22 ± 15.67 7-O-chrysinbutyl acetate 
C2 59.66 ± 7.81 7-O-chrysin-3,5-dimethylbenzene 
C3 112.23 ± 25.78 7-O-chysin-2,4-dinitrobenzene 
C4 - 7-O-isopropylchrysin 
C5 - 7-O-chrysin-2-methylpropane 
C6 - 7-O-butylchrysin 
C7 - 7-O-pentylchrysin 





C10 - 7-O-octylchrysin 
C11 156.64 ± 3.65 7-O-nonylchrysin 
C12 - 7-O-decylchrysin 
C13 - 7-O-3-bromopropylchrysin 
C14 - 7-O-4-bomobutylchrysin 
C15 - 7-O-5-bromopentylchrysin 
C16 153.66 ± 45.72 7-O-4-bromopentylchrysin 
C17 157.46 ± 3.74 7-O-12-bromododecylchrysin 
Chrysin 45.64 ± 10.06 5,7-dihydroxyflavone 
CPZ 22.36 ± 6.40 Chlorpromazine hydrochloride   
- - No activity at doses ≤ 400 µM 
For comparison and easy understanding of the cytotoxicity reported in this study, a 
summary of results indicating a comprehensive cytotoxic inhibition of 7-O-chrysin adducts 





Table 5.21: A comprehensive overview of cytotoxicity IC50 (µM) indicated by chrysin derivatives against cancer cell lines and normal cell line (BEAS-2B) after 
72 h of treatment with drugs Table 5.22: A comprehensive overview of cytotoxicity IC50 (µM) indicated by chrysin derivatives against cancer cell 
lines and normal cell line (BEAS-2B) after 72 h of treatment with drugs 
IC50 (x ± SD) µM* 
Comp. HCT 116 Molt-4 K562 MCF 7 HepG2 A549 HaCaT Caco-2 Mero-14 BEAS-2B 
MDA-MB 
 468 
1 1.99 ± 0.24 7.05 ± 0.47 7.27 ± 0.71 17.6 ± 1.08 17.53 ± 1.01 20.01 ± 0.78 37.76 ± 14.56 5.89 ± 0.41 7.65 ± 0.53 143.22 ± 15.67 7.49 ± 0.61 
2 2.17 ± 0.19 13.87 ± 3.00 5.58 ± 0.29 - 34.82 ± 1.01 - - 4.53 ± 0.79 26.31 ± 4.09 59.66 ± 7.81 25.41 ± 1.36 
3 1.45 ± 1.71 5.41 ± 0.53 8.69 ± 2.05 26.18 ± 3.34 4.93 ± 0.35 33.13 ± 2.19 - 4.83 ± 0.37 8.71 ± 0.85 112.23 ± 25.78 16.59 ± 1.33 
4 29.59 ± 3.25 97.71 ± 70.88 - - - - - 25.20 ± 2.66 26.71 ± 1.47 - - 
5 54.76 ± 2.77 17.40 ± 3.50 - 
46.53 ± 
11.45 
- - 21.84 ± 3.36 95.54 ± 4.72 - - - 
6 21.63 ± 1.88 - - - - - 6.38 ± 1.09 36.75 ± 3.51 - - - 
7 17.75 ± 1.53 51.21 ± 9.23 - - - - 26.37 ± 1.21 - -  - - 
8 30.37 ± 3.81 39.49 ± 3.29 - - 25.98 ± 3.19 - 12.81 ± 1.63 - 24.03 ± 0.85 122.51 ± 2.13 6.06 ± 3.43 
9 30.56 ± 2.04 35.14 ± 2.38 - - - - 12.29 ± 2.38 - - 285.67 ± 121.67  
10 16.40 ± 1.18 - - - - - 9.62 ± 0.69 15.27 ± 1.22 - - 
38.80 ± 
22.90 
11 17.53 ± 2.32 - - - - - 25.67 ± 0.12 13.05 ± 1.01 - 156.64 ± 3.65 - 
12 18.91 ± 2.95 44.74 ± 3.14 15.08 ± 0.21 - - - 28.4 ± 2.86 18.91 ± 1.28 - - - 
13 30.97 ± 4.17 44.74 ± 3.14 15.08 ± 0.21 
66.73 ± 
25.61 
- - - 19.25 ± 3.79 - - - 








23.58 ± 1.67 15.31 ± 2.08 27.32 ± 4.48 - 16.79 ± 1.73 - 21.26 ± 2.21 9.56 ± 0.82 153.66 ± 45.72 8.17 ± 0.36 
17 27.17 ± 4.35 13.28 ± 2.34 15.23 ± 0.15 22.92 ± 1.89 - - - 17.60 ± 6.30 25.46 ± 4.12 157.46 ± 3.74 18.24 ± 2.44 
Chrys
in 
4.07 ± 0.29 5.35 ± 0.47 3.14 ± 0.22 4.20 ± 1.70 10.69 ± 0.94 14.64 ± 1.36 9.8 ± 1.00 4.84 ± 0.19 45.99 ± 3.08 45.64 ± 10.06 5.84 ± 0.67 
CPZ 5.9 ± 0.54 5.23 ± 0.96 7.38 ± 1.56 2.17 ± 0.10 5.62 ± 0.83 8.75 ± 1.24 12.69 ± 1.26 5.17 ± 0.64 13.42 ± 3.50 22.36 ± 6.40 5.83 ± 0.51 
- - No bioactivity at doses ≤ 200 µM for cancer cell lines and 400 for BEAS-2B 
* - IC50 values are expressed as a mean value ± SD from two independent experiments performed in triplicate. CPZ: chlorpromazine, positive control
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Multidrug resistance is associated with cancer cells due to the adaptation of cancer cells 
to the killing actions of chemotherapeutics (Pajak & Orzechowski, 2006). On a molecular 
level, those adaptations are exemplified by the overexpression of detoxifying enzymes 
(Moscow & Cowan, 1988), immune escape mechanisms (Begley & Ribas, 2008) or the 
expression of ABC-transporters which promotes the outward-transport of most commonly 
used cancer drugs in spite of their different chemical structures and thereby prevents the 
achievement of effective drug concentrations in the target cells (Lee, 2010). This causes 
an immense clinical problem and consequently there has been intense search for 
compounds which can act to kill cancer cells even after 24 – 48 hours of treatment (Lee, 
2010). Amongst those compounds, many flavonoids appear to serve as substrates of 
BCRP, MRP-2 and P-gp (components of ABC-transporters) by competitively inhibiting 
these targets (Álvarez et al., 2009). Previous studies have shown that flavonoids increase 
the expression of P-gp in vitro and in vivo (Lohner et al., 2007). In a study by Álvarez et al. 
(2009) using the colorectal cancer – Caco-2, chrysin demonstrated inhibition to three apical 
components of the ABC-transporter – BCRP, MRP-2 and P-gp. These transporters 
extruded the chemotherapeutics topotecan out of HCT 116 and Caco-2 cells. The effect 
elicited by chrysin is similar to those reported by chrysin and its derivatives in this study 
against the colorectal cancer – HCT 116 and Caco-2 cell line. 
At 25, 50 and 100 µM concentrations, none of the series 2 compounds (C4 – C12) 
containing alkyl-groups elicited inhibitory activities against the lung cancer cell line (A549). 
A similar observation was recorded for the liver cancer cell line (HepG2). It was also 
observed that most of the series 2 compounds could not inhibit the growth of leukaemia 
cancer cells (Molt-4 and K562), mesothelioma cancer cell (Mero-14) and the breast cancer 
cell lines – MCF-7 (oestrogen-receptor positive breast cancer cell line) and the MDA-MB 
468 (triple-negative breast cancer cell line) at concentrations ≤ 50 µM. The failure of these 
compounds to elicit cytotoxicity is an indication that the series-2 compounds may be poor 
competitors for the enzyme active sites in the cancer cells. Furthermore, it is an indication 
that absence of the hydroxyl group at position-7 of the parent compound (chrysin) may 
have caused a conformational change in the molecule, making the cancer cell lines 
resistant to the 7-O-alkylchrysin derivatives synthesised in this experiment. It is an 
indication that the hydroxy group(s) on the chrysin molecule might be essential for their 
inhibitory activities and therefore we sought to synthesise brominated 7-O-chrysin adducts 
(7-O-bromoalkyl adducts) and to investigate whether the bromide ion could change the 
dynamics of the molecules (increasing its anticancer activities). The role of the hydroxyl 
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groups in the chrysin molecule in eliciting cytotoxicity against cancer cells has previously 
been reported (Che et al., 2011; Fonseca et al., 2017; Mehdi et al., 2018; Sun et al., 2012). 
We reasoned that brominated chrysin adducts may possess chemical dynamics similar to 
the chrysin molecules as alkylated derivatives failed to indicate good cytotoxicity against 
the cancer cell lines stated above. Solubility analysis of the series 2 compounds (7-O-
alkylchrysin derivatives of chrysin) indicates that these compounds have poor solubilities 
compared to chrysin. It could be inferred therefore that the poor solubilities of these 
compounds may have prevented them from reaching and / or binding to the active sites of 
the enzymes that would have elicited cytotoxicity against these cancer cells. 
Interestingly, brominated chrysin adducts (7-O-bromochrysin derivatives) indicated better 
cytotoxicities (as expected) against the leukaemia cancer cell lines (Molt-4 and K562), 
breast cancer cell line (MCF-7) and the mesothelioma cancer cell line (Mero-14). 
Surprisingly, the MDA-MB-468 breast cancer cell line was resistant to the cancer inhibitory 
activities of the brominated 7-O-chrysin derivatives (series-3 compounds). It is believed 
that the oestrogen receptor in the MCF-7 breast cancer cell line (the oestrogen receptor is 
lacking in the MDA-MB 468 breast cancer cell line) may play an active role in cytotoxicity 
of the brominated chrysin derivatives. The oestrogen receptor may therefore be the active 
site for the binding of the brominated 7-O-chrysin derivatives. The role of the oestrogen 
receptor in promoting breast cancer has been described previously (Gross & Yee, 2002). 
Interruption of oestrogen receptor (ER)-α function is therefore an effective strategy in 
breast cancer treatment. Of interest is the good anticancer activity recorded for C16 (a 
brominated 7-O-chrysin derivative). C16 is an isomer of C15. Despite being isomers, C15 
indicated weak inhibition against the cancer cell lines stated above compared to C16. 
Taking a look at these compounds, it will be observed that C15 is a straight-chain 
compounds whereas C16 is a branched chain compound (methylated compound). It could 
therefore be inferred that the methyl group in addition to the bromine ion may have acted 
synergistically in bringing about the good anticancer activity recorded for C16 because the 
brominated isomer (C15) which is lacking the methyl group indicated weaker anticancer 
activity. The methyl group and the bromine atom may have changed the orientation of the 
molecule (C16), enabling it to bind to the active site that would elicit cytotoxic inhibition 
against cancer cell lines. It should be noted that C16 is the only series 2 compound that 
inhibited (significant cytotoxic activity) the growth of A549. The reason for this is unknown 




C17, a brominated 7-O-chrysin adduct (series 3 compounds) indicated very interesting 
cytotoxic inhibition against the cancer cells stated above. Cytotoxicities elicited by C17 was 
better than those indicated by other brominated 7-O-chrysin derivatives and comparable 
to C16 and chrysin. A look at the series 3 compounds shows that there all contain short 
chain carbons (n ≤ 5). However, C17 is a long chain 7-O-brominated chrysin adduct 
containing 12 carbon atoms attached to the 7-O-position of chrysin. The long aliphatic 
chain could provide a large degree of flexibility to the compound (C17) and its structure. It 
should be noted that the 12-carbon chain of C17 is nearly the size of the chrysin molecule 
and double the size of the A-ring of chrysin. The long aliphatic chain could bind to a 
hydrophobic region of the active site of an enzyme, giving rise to the cytotoxic activities of 
C17. The role of long chain brominated compounds has previously been investigated by 
Liu, (2003) when he demonstrated that long-chain theophylline derivatives elicited better 
anticancer activities compared to short-chain theophylline derivatives. 
Series 2 (7-O-alkylchrysin derivatives) compounds and series 3 (7-O-bromoalkylchrysin 
derivatives) compounds were surprisingly inactive against the liver cancer cell line (HepG2) 
at concentration ≤ 100 µM. Surprisingly, C8 (a six-carbon series 2 compound) is about as 
cytotoxic as chrysin and much more potent than C2 – a series 1 compound. The anticancer 
activities of series 1 compounds shall be discussed shortly. We wondered why series 2 
and series 3 compounds (C4 – C17) failed to inhibit the growth of the HepG2 cancer cell 
line and why C8 was able to inhibit the growth of this cancer cell line. Feng et al., (2017) 
studied the proliferation of the HepG2 cancer cell (hepatic carcinoma) using MTT assay in 
comparison with other cancer cell lines. They observed a significant rise in the optical 
density value of the HepG2 culture medium compared to the control. They also reported 
the presence of endothelial EA.hy926 cells in the culture medium. They concluded that the 
tumour microenvironment enables the HepG2 cells to proliferate and migrate faster than 
other cell lines and also stated that the HepG2 cells are associated with the vascular 
endothelial cells. This implies that wherever there is an HepG2 cell, vascular endothelial 
cells are also present. The failure of series 2 and series 3 compounds to inhibit the growth 
of the HepG2 cancer cells may be attributed to the rapid proliferation and migration of the 
HepG2 cells which sucked-up the compounds (C4 – C17), preventing these compounds 
from eliciting cytotoxic activity against them. Results obtained from the MTT-assay in this 
study supports the findings of Feng et al., (2017). An unusual increase in optical density 
was observed when culturing, growing and treating the HepG2 cancer cell lines (see 
appendix). It is also possible that the enzymes active sites were masked from the series 2 
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and series 3 compounds thus their failure to elicit anticancer activities. C8 may exhibit its 
cytotoxic inhibition via a different mechanism and this needs further investigation. 
The series 2 compounds (C4 – C12) were surprisingly active against the aneuploid 
immortal keratinocyte cells – skin cancer cell line (HacaT cells); eliciting significant 
inhibition against the proliferation of the HacaT cells at concentrations better than the 
activities elicited by chrysin and the conventional drug – CPZ. Surprisingly, the series 2 
compounds were the only class of 7-O-chrysin derivatives indicating significant 
antiproliferative activities against the skin cancer cell line. The positive control – CPZ and 
the parent compound – chrysin were inactive against HacaT cell line at concentrations ≤ 
30 µM. This observation needs further investigation. 
Studies on the anticancer activities of chrysin against different cancer types have been 
previously reported (Che et al., 2011; Fonseca et al., 2017; Patel et al., 2016). Similarly, 
the series 1 compounds (C1, C2 and C3) indicated better antiproliferative activity (better 
than those elicited by chrysin and the standard anticancer agent – CPZ) against HCT 116, 
Molt-4, K562, Caco-2 and Mero-14 cell line after 72 hours treatment. This suggests that 
like chrysin, synthetic chrysin derivatives made in this study could block the expression of 
ABC-transporters thus preventing the efflux of these compounds out of the cancer cell. A 
similar trend was also observed with all synthetic chrysin derivatives made in this study. 
They expressed better cytotoxic effects after treatment of these cancer cell lines for 72 
hours. An indication that a chemotherapy agent efflux out of the cell is seen when the 
anticancer agent demonstrates good cytotoxic inhibition at 24 hours treatment but fail to 
maintain this inhibition after 48 or 72-hours treatment (Lee, 2010). Lee et al., (2010) also 
reported that chrysin also blocked the efflux of topotecan in HCT 116 and Caco-2 cell line, 
leading to accumulation of topotecan in cells thus meeting the criteria of an effective MDR-
reversing agent by efficient blockade of topotecan efflux. The results in this study suggests 
C1, C2 and C3 could also inhibit their efflux out of the cancer cells by blocking the ABC-
transporters. This hypothesis needs to be verified. 
The good cytotoxic activities showed by the series 1 compounds (C1, C2 and C3) against 
different cancer cell lines (colorectal – HCT 116 and Caco-2, leukaemia – K562 and Molt-
4, breast –MDA-MB 468, liver – HepG2, lung – A549 and mesothelioma – Mero-14) might 
be linked to the effect of substituted functional groups attached to these molecules 
(Fonseca et al., 2017; Lohner et al., 2007; Patel et al., 2016). The functional groups 
attached to chrysin may have changed the chemical dynamics of the series 1 compounds, 
making them more potent than the series 2 and series 3 counterparts. Thus, the significant 
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cytotoxicity indicated by C1 may be linked to the methoxy-group in C1. Previous studies 
on the enhanced cytotoxicity of methoxy groups in the selenium moiety of chrysin has 
previously been reported against Ehrlich ascetic tumour cells (Liu et al., 1992). Wen et al., 
(2016) reported antiproliferative activities of a series of 3-(3′-hydroxy-4′-
methoxyphenyl)selenyl-5,6,7-trimethoxy-1H-indoles against three cancer cell lines – HT-
29, SGC-7901 and A549 cell lines. In another study, the cytotoxic effect of methoxy groups 
in colorectal cancers was reported (Reddy et al., 2016). These studies support the findings 
in this study for the significant cytotoxicity elicited by C1 due to the presence of the methoxy 
moiety. The 4-carbon bridge between the 7-OH position of chrysin and the methoxy group 
in C1 may have been responsible for the better solubility of this compound compared to 
chrysin. One of the aims of this project is to synthesise chrysin derivatives with better 
bioactivities and solubilities compared to the parent compound – chrysin. This hypothesis 
may be true because compound C7 (also having a 4-carbon spacer between the 7-OH 
group of chrysin and the terminal carbon) indicated poor solubility and poor bioactivities 
against all cancer cell lines investigated. Similarly, compound C14 (also having a 4-carbon 
spacer between the 7-OH group of chrysin and the terminal bromine) also indicated poor 
solubility and poor bioactivities against cancer cell lines tested. This suggests the methoxy 
group is responsible for the better solubility and bioactivity of C1. C1 elicited cytotoxic 
inhibition against all cancer cell lines investigated. 
C2 with a phenyl-group attached at 7-OH also showed significant cytotoxic inhibition 
against colorectal cancers (HCT 116 and Caco-2 cell lines), leukaemia cancers (K562 and 
molt-4 cell lines) and interestingly the mesothelioma cell line – Mero-14 which is resistant 
to most therapies (Sleire et al., 2017). The anticancer activities of C2 was better than those 
indicated by chrysin against the colorectal cancer cell lines (HCT 116 and Caco-2), 
leukaemia cancer cell lines (Molt-4 and K562) and the mesothelioma cancer cell line (Mero-
14). C2 also indicated better cytotoxicity against HCT 116, K562, Caco-2 and Mero-14 
cancer cell line compared to CPZ. C2 was also more soluble than chrysin in polar solvents. 
The anticancer activities of 5,7-dihydroxy-2-phenyl-6,8-bis((4-fluorophenyl)selanyl)-4H-
chromen-4-one), a chrysin derivative containing a phenyl-ring has previously been 
reported with an IC50 of 19.9 μM (Fonseca et al., 2017). In another experiment by Patel et 
al., (2016), they investigated the anticancer activities of a series of chrysin-piperazine 
conjugates and reported the anticancer activities of all phenylated chrysin-piperazine 
conjugates against ovarian (SK-OV-3), cervical (CaSki and HeLa cell lines) at IC50 values 
5.04 – 8.21 μg/mL. Patel et al (2016) also reported that 4-carbon spacers attached at 7-
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OH did not indicate an improved cytotoxicity of chrysin derivatives. These are in 
agreements with our findings in this work for C2. 
The role of nitrogenated organic compounds in engaging in a wide variety of intermolecular 
interactions such as hydrophobic forces, van der Walls interaction, metal-coordination 
bonding and hydrogen-bonding has been described previously (Hosseinzadeh et al., 
2018). This allows them to equally match the diverse range of structural enzymes binding 
pockets in cancer cells. Because many enzymes have been reported to have affinity for, 
and interact with nitrogenated compounds, causing them to disrupt biological pathways in 
cancer cells (Hosseinzadeh et al., 2018), we synthesised compound C3 and investigated 
its effect against cancer cell lines. C3 significantly inhibited the growth of all cancer cell 
lines investigated (except the skin cancer cells – HacaT) at concentrations better than 
those of chrysin and CPZ against HCT 116, Molt-4, K562, HepG2, Caco-2 and Mero-14 
cancer cell lines. 
The significant cytotoxicity indicated by C3 may be associated with the role played by the 
nitrogen atom on a benzene ring. Patel et al., (2016) demonstrated potentiating effect of 
nitrogenated chrysin-piperazine conjugates with IC50 ranging from 5.09 to 8.05 μg/mL. The 
significant cytotoxicity demonstrated by C3 might also be because of the electron donating 
ability of nitrogen, which donates its lone pair of electrons. By donating its electrons, it may 
act as an alkylating agent, killing the cancer cells (Patel et al., 2016). 
Although series 1 compounds indicated significant cytotoxicity against cancer cell lines, C2 
did not indicate cytotoxic inhibition against breast cancer (MCF 7), lung cancer (A549) and 
HacaT cell lines at IC50 ≤ 100 µM. A look at the positioning of atoms on C2 and C3 at the 
point of attachment of the phenyl ring to 7-OH of chrysin indicates an ortho-bonding of the 
dimethyl-groups attached to the benzene ring of C2. For C3, an ortho and para 
conformation is seen. The role of ortho, meta and para-bonds on the cytotoxicity of chrysin 
derivatives has been previously demonstrated by Patel et al., (2016). Patel et al., (2016) 
demonstrated that para-substitution at the 7-OH groups increased the cytotoxicity of 
chrysin derivatives better than ortho or para-substitutions. This explains why C3 (with one 
ortho and one para-substitution) indicated better cytotoxicity than C2. Our findings suggest 
that an ortho and para-substitution is important for optimal bioactivity for phenylated chrysin 
derivatives as the para position increases the polarity and electronic density of the 
compounds (Fonseca et al., 2017). 
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Apart from series 1 compounds (C1, C2 and C3) which demonstrated significant 
cytotoxicity against cancer cell lines, series 2 compounds (brominated 7-O-alkyl chrysin 
derivatives) – C13 to C17 also indicated good to moderate cytotoxicity against cancer cell 
lines. Structure-activity data from experiments indicates that compounds having one 
halogen (bromine, fluorine or chlorine) are more cytotoxic against cancer cell lines 
including the lung cancer cell line – A549 (Reddy et al., 2015). This explains why 
brominated 7-O-chrysin derivatives were more cytotoxic compared to non-brominated 7-
O-chrysin derivatives made in this study. 
An interesting finding in this work is the role played by methyl-groups and halogens in 
cytotoxicity of molecule(s) made in this study. For instance, the novel compound made in 
this study – C16 which has both the methyl and halogen functional groups maintained its 
cytotoxicity against eight cancer cell lines (HCT 116, Caco-2, Molt -4, K562, MCF 7, MDA-
MB 468, A549 and Mero-14) with IC50 values ranging from 9.56 – 27.32 µM), except for 
HCT 116 cell line (IC50 69.77 µM). This cytotoxic potential was reduced in C4 and C5 (novel 
compound) with only the methyl functional group. C4 and C5 indicated moderate 
cytotoxicity against four cancer cell lines – HCT 116, Caco-2, Molt-4, Mero 14 (for C4) and 
(MCF 7 for C5) with IC50 values ranging from 17.4 – 97.71 µM. These findings demonstrate 
that methylation in addition to halogenation of chrysin derivatives increases their 
cytotoxicity better than compounds with just only a methyl or a halogen group. The role of 
the methyl group in increasing the cytotoxicity of chrysin-selenium derivatives has been 
reported (Barreiros et al., 2006). The effect of methylation was expressed significantly in 
the treatment of the lung cancer cell line – A549 with synthesised chrysin derivatives. 
Except for C1, only methylated derivatives – C3 and C16 inhibited the proliferation of the 
lung cancer cell line. 
The increase in cytotoxic effect of halogenation of 7-O-alkylchrysin is best expressed on 
the K562 cell line. Series 3 compounds (C13 to C17) showed cytotoxic inhibition against 
K562. Series 2 compounds (which are similar to series 3 compounds except for the 
absence of the bromine atom) did not indicate cytotoxicity against the K562 level at 
concentrations ≤ 100 µM. This further confirms the role of the terminal bromine atom in 
increasing cytotoxicity of the 7-O-bromoalkylchrysin compounds (Reddy et al., 2015). 
Beyond apoptosis, another crucial parameter which has been shown to be diminished in 
cancer cells exposed to an effective chemotherapeutics is diminished differentiation of 
cancer cells (van der Flier & Clevers, 2009). In this study, untreated cancer cells indicated 
23 – 48 % increase in concentration (from readings made using the spectrophotometer) 
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compared to treated cancer cells. This finding is an indication that chrysin derivatives (C1, 
C2 and C3) made in this study effectively inhibited the differentiation of HCT 116 and Caco-
2 cell line in the early (24 hours), mid (48 hours) and later (72 hours) stages. 
The apoptotic effect of chrysin derivatives (C1, C2 and C3) might be due to inhibition of 
expression of ABC-transporters. In a study by Tainton et al. (2004) where mutant cells 
were transfected into cells, there was a reduction in caspase activities in the transport 
deficient P-gp. Multidrug-resistant tumour cell lines expresses high levels of P-gp, which 
inhibits caspase-activation mediated by ligation of Fas (Smyth et al., 1998). It therefore 
suggests that inhibition of P-gp leads to a better drug performance (Lohner et al., 2007). 
The role of chrysin derivatives made in this study against p-gp should be investigated in 
future research. 
The differences observed in the cytotoxicity shown by chrysin derivatives synthesised in 
this work is an indication that large biochemical differences that exist between cancer cell 
lines which influences their level of interaction with chemotherapeutic agents. It is also an 






5.6  Selectivity Index (SI)  
 
Selectivity index (SI) is defined as the inhibitory concentration of the drug required to kill 
50 % of normal cells (BEAS-2B) compared to the inhibitory concentration required to kill 
50 % cancer cells (Seca et al., 2014). 
 
 
BEAS-2B was the normal cell line used in this study. The selectivity index for the various 
cancer cell lines was evaluated and the results stated below. Seca et al., (2014) noted that 
many interesting literatures fail to investigate / evaluate the SI index of novel compounds 
reported in their literature thus making it difficult to evaluate the safety index of a promising 
novel anticancer agents. A higher SI is a pointer that a potential anticancer agent will kill 
cancer cells and not normal cell and vice versa. The selectivity index of sesquiterpene 
lactones isolated from Inula helenium has previously been reported against leukaemia 
cancer cell line (Ding et al., 2016; Seca et al., 2014). This section therefore focuses on 
investigating the selectivity indices of synthetic chrysin-derivatives. 
 
5.6.1  Selectivity Index (SI) of Chrysin-Derivatives on Breast Cancer 
The SI of 7-O-chrysin adducts was evaluated against breast cancer cell lines (MCF 7). 
Results are presented in Table 5.22 below. C2 was not cytotoxic against MCF 7 and for 
this reason; no SI was evaluated for C2. 
C2 indicated a very narrow selectivity index against MDA-MB 468 (SI = 2) - Table 5.22. 
This implies that although C2 indicated good cytotoxicity against MDA-MB 468 (IC50 25.41 
µM), its safety may need be monitored due to the slim SI indicated by C2. 7-O-4-
bromopentylchrysin (C16) was highly selective cytotoxic against MDA-MB 468 with SI = 19 
despites eliciting significant cytotoxic inhibition against this cell line (IC50 8.17 µM).  
Chrysin indicated selective cytotoxicity against MCF 7 but marginal selectivity against 
MDA-MB 468. Both chrysin and CPZ indicated a slim SI against MDA-MB 468. With 
exception of cytotoxicity shown by C2 against MDA-MB 468, these results suggest 7-O-
chrysin adducts synthesised in this study selectively elicited cytotoxicity against breast 




Table 5.23: Selectivity index (SI) of chrysin adducts on breast cancer cell lines. BEAS-2B is the normal cell line used in this study. 
Selectivity Index (SI) for normal cell line and Breast Cancer Cell Lines 





SI (MCF 7) MDA-MB 468 SI (MDA-
MD 468) 
Name of compound 
C1 143.22± 5.67 17.6 ± 1.08 8 7.49 ± 0.61 19 7-O-chrysinbutyl acetate 
 








C3 112.23 ± 25.78 26.18 ± 3.34 4 16.59 ± 1.33 7 7-O-chysin-2,4-dinitrobenzene 
C4 
- - 
NT - NT 7-O-isopropylchrysin 
C5 - 46.53 ± 11.45 NT - NT 7-O-chrysin-2-methylpropane 
C6 - - NT - NT 7-O-butylchrysin 
C7 - - NT - NT 7-O-pentylchrysin 
C8 122.51 ± 2.13 - NT 6.06 ± 3.43 20 7-O-hexylchrysin 
C9 285.67± 121.67 - NT  NT 7-O-heptylchrysin 
C10 - - NT 38.80 ± 22.90 NT 7-O-octylchrysin 
C11 156.64 ± 3.65 - NT - NT 7-O-nonylchrysin 
C12 - 66.73 ± 25.61 NT - NT 7-O-decylchrysin 
C13 - 63.03 ± 7.21 NT - NT 7-O-3-bromopropylchrysin 
C14 - 37.75 ± 0.14 NT - NT 7-O-4-bomobutylchrysin 
C15 - 27.32 ± 4.48 NT 8.17 ± 0.36 NT 7-O-5-bromopentylchrysin 
C16 153.66 ± 45.72 22.92 ± 1.89 7 18.24 ± 2.44 8 7-O-4-bromopentylchrysin 
C17 157.46 ± 3.74 4.20 ± 1.70 37 5.84 ± 0.67 27 7-O-12-bromododecylchrysin 
Chrysin 45.64 ± 10.06 2.17 ± 0.10 21 5.83 ± 0.51 8 5,7-dihydroxyflavone 
CPZ 22.36 ± 6.40 17.6 ± 1.08 1 7.49 ± 0.61 3 Chlorpromazine hydrochloride   
NT - Not evaluated 
–   - No activity 
The lower the selectivity index, the more toxic the compound is on normal cell lines. 
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5.6.2  Colorectal Cancer Cells 
 
The SI of 7-O-chrysin adducts was evaluated against breast cancer cell lines. Results are 
presented Table 5.23 below. Colorectal cancer cell lines were the most susceptible to 
cytotoxic inhibition by 7-O-chrysin adducts synthesised in this study. The SI presented 
indicates that most 7-O-alkylchrysin adducts - series 2 compounds (C4 to C12) were 
inactive against BEAS-2B cell line (Table 5.23). Their SI was therefore not evaluated.  
Despite significant cytotoxicity elicited by Series 1 compounds, they were relatively inactive 
against BEAS-2B cell lines. C1 indicated SI of 72 and 24 against HCT 116 and Caco-2 cell 
lines. C2 indicated SI of 27 and 13 against HCT 116 and Caco-2 cell lines. C3 indicated SI 
of 77 and 23 against HCT and Caco-2 cell lines. Chrysin indicated SI of 3 and 3 against 
HCT and Caco-2 cell lines. 
CPZ indicated SI of 1 and 2 against HCT and Caco-2 cell lines. Although the standard drug 
– CPZ indicated significant cytotoxicity against K562 cell line, its SI was low compared to 
those of chrysin and Chrysin derivatives made in this study. 
These results (Table 5.23) suggest suggests 7-O-chrysin adducts made in this research, 







Table 5.24: SI of chrysin adducts on colorectal cancer cell lines 
Selectivity index for normal cell line and breast colorectal cell lines 











Name of compound 
C1 143.22 ± 15.67 1.99 ± 0.24 72 5.89 ± 0.41 24 7-O-chrysinbutyl acetate 
C2 59.66 ± 7.81 2.17 ± 0.19 27 4.53 ± 0.79 13 7-O-chrysin-3,5-dimethylbenzene 
C3 112.23 ± 25.78 1.45 ± 1.71 77 4.83 ± 0.37 23 7-O-chysin-2,4-dinitrobenzene 
C4 - 29.59 ± 3.25 NT 25.20 ± 2.66 NT 7-O-isopropylchrysin 
C5 - 54.76 ± 2.77 NT 95.54 ± 4.72 NT 7-O-chrysin-2-methylpropane 
C6 - 21.63 ± 1.88 NT 36.75 ± 3.51 NT 7-O-butylchrysin 
C7 - 17.75 ± 1.53 NT - NT 7-O-pentylchrysin 
C8 122.51 ± 2.13 30.37 ± 3.81 4 - NT 7-O-hexylchrysin 
C9 285.67 ± 121.67 30.56 ± 2.04 9 - NT 7-O-heptylchrysin 
C10 - 16.40 ± 1.18 NT 15.27 ± 1.22 NT 7-O-octylchrysin 
C11 156.64 ± 3.65 17.53 ± 2.32 9 13.05 ± 1.01 12 7-O-nonylchrysin 
C12 - 30.97 ± 4.17 NT 19.25 ± 3.79 NT 7-O-decylchrysin 
C13 - 44.20 ± 2.73 NT 16.77 ± 1.45 NT 7-O-3-bromopropylchrysin 
C14 - 96.27 ± 22.23 NT 22.06 ± 3.84 NT 7-O-4-bomobutylchrysin 
C15 - 69.77 ± 27.92 NT 21.26 ± 2.21 NT 7-O-5-bromopentylchrysin 
C16 153.66 ± 45.72 27.17 ± 4.35 6 17.60 ± 6.30 9 7-O-4-bromopentylchrysin 
C17 157.46 ± 3.74 4.07 ± 0.29 37 4.84 ± 0.19 33 7-O-12-bromododecylchrysin 
Chrysin 45.64 ± 10.06 5.9 ± 0.54 8 5.17 ± 0.64 9 5,7-dihydroxyflavone 
CPZ 22.36 ±  6.40 1.99 ± 0.24 11 5.89 ± 0.41 4 Chlorpromazine hydrochloride   
NT - Not evaluated 
–   - No activity  
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5.6.3  Leukaemia Cell Lines 
 
The SI of 7-O-chrysin adducts was evaluated against leukaemia cell and results presented 
in Table 5.24 below. 7-O-bromochrysin derivatives of chrysin indicated SI – 10 and 7 (C16 
and 17 respectively) against K562 cell line, and 7 and 12 (C16 and C17) against Molt-4 
cell line. 7-O-alkylchrysin derivatives (C4 to C12) were inactive against BEAS-2B, thus no 
SI for these compounds was evaluated. C1 selectively killed leukaemia cells (K562 and 
Molt-4) at SI 20 respectively. C2 was selective against K562 (SI = 11) but indicated a 
narrow SI (4) margin for Molt-4. C3 also selectively inhibited the leukaemia cancer cells 
growth in K562 (SI = 13) and Molt-4 (SI = 21). Chrysin selectively killed leukaemia cell line 
(SI = 4 and 3 for K562 and Molt-4 respectively) whereas CPZ indicated a slim SI margin 
against K562 and Molt-4 cell lines (3 and 2). Chrysin adducts synthesised in this study 
selectively inhibited the growth of K562 and Molt-4 while the standard drug – CPZ 




Table 5.25: SI of chrysin adducts on leukaemia cell lines 
Selectivity index for normal cell line and leukaemia cancer cell lines 









Name of compound 
C1 143.22 ± 15.67 7.27 ± 0.71 20 7.05 ± 0.47 20 7-O-chrysinbutyl acetate 
C2 59.66 ± 7.81 5.58 ± 0.29 11 13.87 ± 3.00 4 7-O-chrysin-3,5-dimethylbenzene 
C3 112.23 ± 25.78 8.69 ± 2.05 13 5.41 ± 0.53 21 7-O-chysin-2,4-dinitrobenzene 
C4 
-  - 
NT 97.71 ± 70.88 NT 7-O-isopropylchrysin 
C5 - - NT 17.40 ± 3.50 NT 7-O-chrysin-2-methylpropane 
C6 - - NT - NT 7-O-butylchrysin 
C7 - - NT 51.21 ± 9.23 NT 7-O-pentylchrysin 
C8 122.51 ± 2.13 - NT 39.49 ± 3.29 3 7-O-hexylchrysin 
C9 285.67 ± 121.67 - NT 35.14 ± 2.38 8 7-O-heptylchrysin 
C10 - - NT - NT 7-O-octylchrysin 
C11 156.64 ± 3.65 - NT - NT 7-O-nonylchrysin 
C12 - 15.08 ± 0.21 NT 44.74 ± 3.14 NT 7-O-decylchrysin 
C13 - 18.72 ± 2.68 NT 59.41 ± 29.05 NT 7-O-3-bromopropylchrysin 
C14 -  17.52 ± 1.60 NT 73.82 ± 65.75 NT 7-O-4-bomobutylchrysin 
C15 -  15.31 ± 2.08 NT 23.58 ± 1.67 NT 7-O-5-bromopentylchrysin 
C16 153.66 ± 45.72 15.23 ± 0.15 10 13.28 ± 2.34 7 7-O-4-bromopentylchrysin 
C17 157.46 ± 3.74 3.14 ± 0.22 50 5.35 ± 0.47 12 7-O-12-bromododecylchrysin 
Chrysin 45.64 ± 10.06 7.38 ± 1.56 6 5.23 ± 0.96 3 5,7-dihydroxyflavone 
CPZ 22.36 ± 6.40 7.27 ± 0.71 3 7.05 ± 0.47 2 Chlorpromazine hydrochloride   
NT - Not evaluated 
–   - No activity
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5.6.4  Liver Cancer – HepG2 Cell Line 
 
The selectivity index of chrysin adducts on HepG2 cells was investigated and reported in 
Table 5.25 below. 
 
Table 5.26: SI of chrysin adducts on HepG2 







SI (HepG2) Name of compound 
C1 143.22 ± 15.67 17.53 ± 1.01 8 7-O-chrysinbutyl acetate 
 
C2 




C3 112.23 ± 25.78 4.93 ± 0.35 23 7-O-chysin-2,4-dinitrobenzene 
C4 - - NT 7-O-isopropylchrysin 
C5 - - NT 7-O-chrysin-2-methylpropane 
C6 - - NT 7-O-butylchrysin 
C7 - - NT 7-O-pentylchrysin 
C8 122.51 ± 2.13 25.98 ± 3.19 5 7-O-hexylchrysin 
C9 285.67 ± 121.67 - NT 7-O-heptylchrysin 
C10 - - NT 7-O-octylchrysin 
C11 156.64 ± 3.65 - NT 7-O-nonylchrysin 
C12 - - NT 7-O-decylchrysin 
C13 - - NT 7-O-3-bromopropylchrysin 
C14 - - NT 7-O-4-bomobutylchrysin 
C15 - - NT 7-O-5-bromopentylchrysin 
C16 153.66 ± 45.72 - NT 7-O-4-bromopentylchrysin 
C17 157.46 ± 3.74 10.69 ± 0.94 NT 7-O-12-bromododecylchrysin 
Chrysin 45.64 ± 10.06 5.62 ± 0.83 4 5,7-dihydroxyflavone 
CPZ 22.36 ± 6.40 17.53 ± 1.01 3 Chlorpromazine hydrochloride   
NT - Not evaluated 
–   - No activity 
 
C3 indicated a good SI on HepG2 cell (23). Other bioactive compounds indicated narrow 
SI (8, 2, and 5) for C1, C2 and C8. 




5.6.5  A549 Cell Line 
 
The selectivity index of chrysin adducts on A549 cells was investigated and reported in 
Table 5.26 below. 
Table 5.27: SI of chrysin adduct on A549 Cell Line 








Name of compound 
C1 143.22 ± 15.67 20.01 ± 0.78 7 7-O-Chrysinbutyl acetate 
 
C2 




C3 112.23 ± 25.78 33.13 ± 2.19 3 7-O-Chysin-2,4-dinitrobenzene 
C4 - - NT 7-O-Isopropylchrysin 
C5 - - NT 7-O-Chrysin-2-methylpropane 
C6 - - NT 7-O-Butylchrysin 
C7 - - NT 7-O-Pentylchrysin 
C8 122.51 ± 2.13 - 7 7-O-Hexylchrysin 
C9 285.67 ± 121.67 - NT 7-O-Heptylchrysin 
C10 - - NT 7-O-Octylchrysin 
C11 156.64 ± 3.65 - NT 7-O-Nonylchrysin 
C12 - - NT 7-O-Decylchrysin 
C13 - - NT 7-O-3-Bromopropylchrysin 
C14 - - NT 7-O-4-Bomobutylchrysin 
C15 - 16.79 ± 1.73 NT 7-O-5-Bromopentylchrysin 
C16 153.66 ± 45.72 - 9 7-O-4-Bromopentylchrysin 
C17 157.46 ± 3.74 14.64 ± 1.36 11 7-O-12-Bromododecylchrysin 
Chrysin 45.64 ± 10.06 8.75 ± 1.24 5 5,7-dihydroxyflavone 
CPZ 22.36 ± 6.40 20.01 ± 0.78 1 Chlorpromazine hydrochloride   
NT - Not evaluated 
–   - No activity 
 
The SI of chrysin adducts on A549 was marginal. C1 and C16 showed a SI of 7 and 9; C3, 
chrysin indicated a very narrow SI of 5 whereas the SI on A549 indicates it is lethal. 
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5.6.6  HacaT Cell Line 
 
The selectivity index of chrysin adducts on HacaT cells line was investigated and reported 
in Table 5.27 below. 
Table 5.28: SI of chrysin adduct on HacaT Cell Line 








Name of compound 
C1 143.22 ± 15.67 37.76 ± 14.56 4 7-O-chrysinbutyl acetate 
C2 59.66 ± 7.81 - NT 7-O-chrysin-3,5-dimethylbenzene 
C3 112.23 ± 25.78 - NT 7-O-chysin-2,4-dinitrobenzene 
C4 - - NT 7-O-isopropylchrysin 
C5 - 21.84 ± 3.36 NT 7-O-chrysin-2-methylpropane 
C6 - 6.38 ± 1.09 NT 7-O-butylchrysin 
C7 - 26.37 ± 1.21 NT 7-O-pentylchrysin 
C8 122.51 ± 2.13 12.81 ± 1.63 10 7-O-hexylchrysin 
C9 285.67 ± 121.67 12.29 ± 2.38 23 7-O-heptylchrysin 
C10 - 9.62 ± 0.69 NT 7-O-octylchrysin 
C11 156.64 ± 3.65 25.67 ± 0.12 6 7-O-nonylchrysin 
C12 - - NT 7-O-decylchrysin 
C13 - - NT 7-O-3-bromopropylchrysin 
C14 - - NT 7-O-4-bomobutylchrysin 
C15 - - NT 7-O-5-bromopentylchrysin 
C16 153.66 ± 45.72 - NT 7-O-4-bromopentylchrysin 
C17 157.46 ± 3.74 9.8 ± 1.00 16 7-O-12-bromododecylchrysin 
Chrysin 45.64 ± 10.06 12.69 ± 1.26 5 5,7-dihydroxyflavone 
CPZ 22.36 ± 6.40 37.76 ± 14.56 1 Chlorpromazine hydrochloride   
NT - Not evaluated 
–   - No activity 
 
The selectivity index of chrysin adducts on HacaT cells line was investigated.  
The 7-O-bromoalkylchrysin adducts were inactive against BEAS-2B cell lines thus no SI 
was evaluated for the 7-O-bromochrysin compounds against HacaT cell line. The 7-O-
alkylchrysin adducts indicated good SI ≥ 6. C1 indicated a SI of 4, chrysin 5. CPZ indicated 
a lethal SI (1) against HacaT cell line.  
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5.6.7  Mero 14 Cell Line 
 
The selectivity index of chrysin adducts on Mero 14 cells line was investigated and reported 
in Table 5.28 below. 
Table 5.29: SI of chrysin adduct on Mero 14 Cell Line 








Name of compound 
C1 143.22± 15.67 7.65 ± 0.53 19 7-O-Chrysinbutyl acetate 
C2 59.66 ± 7.81 26.31 ± 4.09 2 7-O-Chrysin-3,5-dimethylbenzene 
C3 112.23 ± 25.78 8.71 ± 0.85 13 7-O-Chysin-2,4-dinitrobenzene 
C4 - 26.71 ± 1.47 - 7-O-Isopropylchrysin 
C5 - - - 7-O-Chrysin-2-methylpropane 
C6 - - - 7-O-Butylchrysin 
C7 - -  - 7-O-Pentylchrysin 
C8 122.51 ± 2.13 24.03 ± 0.85 10 7-O-Hexylchrysin 
C9 285.67 ± 121.67 - - 7-O-Heptylchrysin 
C10 - - - 7-O-Octylchrysin 
C11 156.64 ± 3.65 - - 7-O-Nonylchrysin 
C12 - - - 7-O-Decylchrysin 
C13 - 46.13 ± 2.63 - 7-O-3-Bromopropylchrysin 
C14 - 32.34 ± 3.44 - 7-O-4-Bomobutylchrysin 
C15 - 9.56 ± 0.82 - 7-O-5-Bromopentylchrysin 
C16 153.66 ± 45.72 25.46 ± 4.12 6 7-O-4-Bromopentylchrysin 
C17 157.46 ± 3.74 45.99 ± 3.08 3 7-O-12-Bromododecylchrysin 
Chrysin 45.64 ± 10.06 13.42 ± 3.50 3 5,7-dihydroxyflavone 
CPZ 22.36 ± 6.40 7.65 ± 0.53 3 Chlorpromazine hydrochloride   
NT  –  Not tested 
-   -  No activity 
 
C1, C3 and C16 indicated good SI (19, 13 and 16) Mero 14 cell line. C2 and C8 indicate 
very narrow SI (2 and 1). Chrysin indicated a lethal SI (1). CPZ indicated a narrow SI of 2. 
Interestingly, the chrysin adducts synthesised in this study – C1 and C3 indicated good 
safety index against Mero 14 while chrysin, the parent compound from were these 
compounds were made indicated a lethal safety index. CPZ also indicated a narrow safety 
index (sensitivity index).  
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Chapter 6   General Discussion / Conclusion 
This work was divided into two distinct sections that explored the antibacterial and 
anticancer activities of bioactive sesquiterpene lactones isolated from the root extracts of 
Inula helenium and, investigation of the antibacterial and anticancer activities of 
synthesised chrysin derivatives. 
Natural products, such as plants extracts (either as crude extracts, standardised products 
or as pure compounds), provide unlimited opportunities for novel drug discoveries because 
of the presence of numerous phytochemicals in them which can be used to treat diseases 
(Catalano et al., 2013; Croteau et al., 2000; Seca et al., 2014). The World Health 
Organisation estimates that about 80% of the world population depends on ethnomedicine 
for their healthcare needs (Catalano et al., 2013). The first crucial and outcome 
determining step in drug discovery is extraction. Extraction is important because further 
separation and characterisation depends on good extraction of desired and targeted 
molecules. In this work, several basic operations were done including steps such as 
grinding and drying of homogenised roots of Inula helenium, extraction of bioactive 
components using three extraction methods – Soxhlet extraction, microwave-assisted 
extraction (MAE) and ultrasound-assisted extraction (UAE) using methanol. Three 
solvents were used in fractionation of extracted components – methanol, ethyl-acetate and 
hexane. Although methanol offered the highest yield of extracted compounds, followed by 
ethyl-acetate, bioactive compounds were isolated mainly from the hexane fractions. This 
finding is consistent with those of Sassi et al., (2008), Afifi-Yazar et al. (2011) and Talib 
and Mahasneh (2010). Other authors have reported that the highest yield of bioactive 
components was isolated from petroleum ether and / or acetone fractions (Al-Dissi et al., 
2001; Sassi et al., 2008). This is still consistent with the findings in this work as the polarity 
index of petroleum ether (0.1) is the same as that of hexane (Al-Dissi et al., 2001). UAE 
offered the best extraction method for bioactive components of Inula helenium. This is 
consistent with the findings of Wang et al., (2013). Abu-Lafi et al., (2018) and Lawrence et 
al., (2001) used maceration technique in extraction of compounds from Inula helenium. 
They reported poor yield (5 – 28.2 %) compared to the yield obtained in this work (15.6 – 
44.1%) of fractionated sample. This is an indication that maceration technique is less 
efficient compared to the techniques used in this study. In addition to alantolactone and 
isoalantolactone – which have been previously isolated from Inula helenium (Konishi et al., 
2002; Lawrence et al., 2001; Seca et al., 2014), costunolide, a known sesquiterpene 
lactone – first isolated from Costus speciosus (Eliza et al, 2010), was also isolated from 
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Inula helenium. This is the first time this compound has been isolated from Inula helenium. 
A careful search of the literature reveals that authors used different extraction and isolation 
methods, but none centrifuged the extracted compounds. Centrifugation involves the 
application of centrifugal force to separate particles from a solution according to their 
densities, shapes, sizes and viscosities of the medium and rotor speed. This forces light / 
floating molecules unto the base of the centrifuged. Costunolide was isolated in minute 
quantity (1.48 %) compared to alantolactone (36.3 %) and isoalantolactone (32.14 %) from 
fractionated extracts. This minute quantity of costunolide was detected because the 
extraction and isolation procedures were optimised such that the hexane fractions which 
contained the bioactive components were freeze-dried and purified using an automated 
high-performance liquid chromatography (HPLC) containing an auto-sampler and an auto-
sample collector. Other authors used crude methods of extraction, followed by column 
chromatography (Moghadam et al., 2012; Cheng et al., 2012; Lawrence et al., 2001). One 
can therefore infer that the use of optimised extraction, isolation and purification techniques 
is necessary in the isolation of novel compounds. Alantolactone, isoalantolactone and 
costunolide showed moderate to weak antibacterial activities against Gram-positive 
bacteria. A significant observation in this work is the significant antibacterial activity 
recorded by the hexane fraction of Inula helenium extracts against ESBL producing Gram-
negative bacteria: E. coli (NCTC 13353) and P. aeruginosa NCTC 13437, and Gram-
positive bacteria: S. aureus ATCC 25923 and B. cereus ATCC 10876 when susceptibility 
assay (disc diffusion assay) was done. This activity was not observed when the hexane 
fraction of Inula helenium were purified. This might be because alantolactone, 
isoalantolactone and costunolide acted in a synergistic or additive manner against the 
bacterial strains tested. The synergistic effect of helenin (a combination of 40% 
alantolactone and 60% isoalantolactone) has been reported previously as eliciting better 
bioactivity against the Raji lymphoblastoid cells (Spiridonov et al., 2005; Seca et al., 2014). 
The HPLC chromatograms also reveals there are some minute compounds which did not 
indicate any antibacterial activity individually. These compounds might play a role in the 
better antibacterial activity seen in disc diffusion assay. The preliminary data obtained by 
Liu et al., (2001) are consistent with the findings above. However, they observed that 
isoalantolactone is a poor inhibitor of bacterial growth (E. coli, P. aeruginosa and B. 
subtilis). Their result also suggests a stronger anti-fungus activity of isoalantolactone. This 
is consistent with findings in this research.  
Alantolactone, isoalantolactone and costunolide also indicated significant anticancer 
activities against the leukaemia cell line – K562 in hypoxia and hyperglycaemic conditions. 
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The anticancer activity of alantolactone, isoalantolactone and costunolide has previously 
been reported (Eliza et al., 2009; Eliza et al., 2010; Hu et al., 2018; Lawrence et al., 2001; 
Seca et al., 2014). Our findings suggest that sesquiterpene lactones isolated from Inula 
helenium (alantolactone, isoalantolactone and costunolide) could potentially be useful for 
the development of therapeutic agents for the treatment of leukaemia cancer. This is the 
first-time the anticancer activities of these sesquiterpene lactones against leukaemia cells 
have been reported in hypoxia and hyperglycaemia. This finding is important because 
hypoxia influences leukaemic cells differentiation, proliferation, and resistance to 
chemotherapy (Deynoux et al., 2016). Resistance of the K562 cancer cell line to the 
conventional anticancer therapy – CPZ in hypoxia was recorded in this study. A significant 
discovery in this research is the fact that the sesquiterpene lactones isolated in this 
research inhibited the growth of the leukaemia cancer cell line (K562) in a 10 – 50-fold 
manner (increased activity). It could be inferred that the sesquiterpene lactones (D1, D2 
and D3) might be acting by inhibiting angiogenesis. Angiogenesis increases the resistance 
of cancer cells to chemotherapeutics (George et al., 2018). Amyloid leukaemia is the most 
common myeloid leukaemia in adults. Several strategies have been applied in clinical 
treatments for adults younger than 30 years. However, increasing the cure and survival 
rate for older patients (above 60 years) has increasingly become challenging due to drug-
resistance and recurrence after treatment (Estey, 2014). Finding novel amyloid leukaemia 
therapies is presently an active area for clinical trials (Medina, 2018). Despite some 
improvements in leukaemia cancer treatment, cancer cell relapse after treatment has 
significantly increased (Deynoux et al., 2016). It has been hypothesised that by selectively 
targeting leukaemia stem cells, drug-resistance and tumour relapse without damage done 
to normal cells could be achieved (Ding et al., 2016). This therapeutic limitation may be 
overcome by potential treatment with alantolactone, isoalantolactone and costunolide. 
Alantolactone selectively ablates acute myeloid leukaemia progenitor and stem cells (Ding 
et al., 2016). The significant cytotoxic inhibition of the K562 leukaemia cells observed in 
this work indicates that these cancer cells may not be resistant to these sesquiterpene 
lactones. Alantolactone, isoalantolactone and costunolide have been studied as potential 
anticancer agents in several cancer cell lines (Eliza et al., 2010; He et al., 2018; Lawrence 
et al., 2011; Seca et al., 2014). Costunolide elicits its anticancer activitiy via activation of 
p53 and inhibition of proliferation of cancer cells (Hu et al., 2018), binding to thioredoxin 
reductase-1 (Zhuge et al., 2018), inhibition of NF-κB etc. The mechanism of action of 
alantolactone and isoalantolactone has been hypothesised to include induction of 
apoptosis and improvement of chemosensitivity of cancer cells by improving the activities 
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of the autophagy-lysosome pathway (He et al., 2018), suppression of STAT 3 (transcription 
factor that is a potent regulator of tumorigenesis) activity (Chun et al., 2015), inhibition of 
the cell cycle at the G2/M and S phase; thus, they act as alkylating agents (Lawrence et 
al., 2001; Nandakumar et al., 2017). In this study, it could be hypothesised that 
alantolactone, isoalantolactone and costunolide elicits cytotoxic inhibition against the K562 
cell line via inhibition of angiogenesis because a 10-50-fold increase in anticancer activities 
was recorded for these compounds in hypoxia; a characteristic absent when the cancer 
cells (K562) were treated with CPZ. Alantolactone inhibits the expression of P-glycoprotein 
in drug-resistant leukaemia cell line – K562 (that showed resistance to Adriamycin) (Yang 
et al., 2013) and idarubicin (Liu et al., 2013). The observations in this work (Table 5.6, 
page 196) indicates that K562 cell line is less resistant to cytotoxic inhibition by 
alantolactone and isoalantolactone as the IC50 value was observed to decrease (a 
decrease in IC50 value signifies better cytotoxicity of a compound) from 24.66 µM after 24 
h treatment to 4.96 µM after 72 h treatment with alantolactone. Similarly, there was a 
significant decrease in IC50 values from 28.44 µM to 7.38 µM after treatment for 24 h and 
48 h with isoalantolactone. With costunolide, the observation was different; there was a 
noticeable mild resistance of the K562 cancer cell line after treatment for 72 h (Table 5.6 
page 196). The observations with alantolactone and isoalantolactone are consistent with 
those of Ding et al., (2016) and it shows that K562 cancer cell line is less-resistant to 
cytotoxic inhibition by these compounds. These compounds (alantolactone and 
isoalantolactone) also indicated better cytotoxicity compare to the positive control drug – 
CPZ. The α-methylene-γ-butyrolactone moiety of sesquiterpene lactone isolated in this 
work is responsible for the cytotoxicity of these compounds (Lawrence et al., 2001; Seca 
et al., 2014; Yan et al., 2013).  
The second aspect of this work explored the antibacterial and anticancer activities of 
derivatives of a known flavonoid – chrysin. Chrysin is a small molecule containing two-
hydroxyl (-OH) functional groups at positions-5 and -7 of the chrysin molecule (Cheng et 
al., 2014). Authors have reported that synthesis of chrysin derivatives at the 5-OH position 
will result in a strong hydrogen-bonding that will prevent interaction of the chrysin-
derivative with the cellular components (Cai et al. 2017; Walle et al., 2001). Others have 
reported that the 5-OH position of chrysin is the active site of this molecule (Zhou et al., 
2012), implying that synthesizing derivatives at the 5-OH position will eliminate the 
biological activities of this molecule. This research work therefore focussed on synthesizing 
chrysin-derivatives at the 7-OH position with better biological activities. The synthesis of 
chrysin derivatives at other positions has previously been reported (Che et al., 2011; Chen 
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et al., 2014; Fonseca et al., 2017). Different methods including the use of a microwave-
reactor, stirring of reaction mixture under regulated conditions of temperature and / or 
enzymatic reaction were used. Microwave-irradiation was time-saving as the reaction 
conditions were optimised to bring forth the reaction yield in less than 15 minutes. The 
yield recorded was low compared to the yield recorded when the reaction mixture was 
stirred under regulated reaction conditions. This synthesis is an important milestone as 
there is little literature on the synthesis of flavonoids derivatives using microwave 
irradiation. This methodology can be included within the concept of green chemistry 
because the strong absorption of microwave irradiation led to shorter reaction times and 
improved energy efficiency. In this work, eight novel chrysin derivatives were synthesised. 
7-O-chrysinbutyl acetate (C1), 7-O-chrysin-3,5-dimethylbenzene (C2) and 7-O-chysin-2,4-
dinitrobenzene (C3) (novel compounds) indicated significant to moderate antimicrobial 
activity against the microbial strains tested especially the Gram-positive bacteria and the 
pathogenic fungus C. albicans. In addition to C1, C2 and C3, 7-O-butylchrysin (C6 - novel) 
and 7-O-4-bromopentylchrysin (C16 - novel) also showed significant to moderate inhibition 
against the extended spectrum β-lactamase (ESBL) producing E. coli NCTC 13353. This 
is the first time the antibacterial activity of these compounds has been reported. The 
straight chain 7-O-alkylchrysin derivatives (C7 to C12) indicated weak to no activity against 
the microbial strains tested. This finding (weak / no activity of 7-O-alkylchrysin derivatives) 
is consistent with previous findings (Li et al., 2009; Li et al., 2017). With exception of C6 
(7-O-alkylchrysin derivative), these observations indicate that 7-O-alkylchrysin derivatives 
are weak antimicrobial agents. Similarly, straight chain 7-O-bromoalkylchrysin derivatives 
are weak antimicrobial agents. It should be noted that C16 is a branched-chain 7-O-
bromoalkylchrysin derivatives. Although only one branched-chain 7-O-bromoalkylchrysin 
derivatives was synthesised in this work, more synthetic branched-chain 7-O-
bromoalkylchrysin derivatives should be synthesised in future research, and their 
antimicrobial activity investigated. This will enable an inference / conclusion to be made 
regarding the potency of the branched-chain 7-O-bromoalkylchrysin derivatives as 
potential antimicrobial agents. The site and number of hydroxyl and carbonyl or O-alkyl 
groups on the phenol ring of compounds are thought to be responsible for their toxicity to 
micro-organisms (Lawrence et al., 2009). This might account for the significant 
antibacterial toxicity of C1 which contains a hydroxyl-group and an O-alkyl functional 
group. Phenolics (phenol-ring containing compounds) also elicit bactericidal toxicity by 
disrupting cell membranes and denaturing proteins (Lawrence et al., 2009). This could 
account for the significant toxicity of C2 and C3 that contains additional phenolic rings 
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attached to the 7-OH position of chrysin. The role of phenolic nitrites in disrupting cell 
membranes and denaturing proteins have previously been described (Dykhuizen et al., 
1996). C3, a nitrite analogue of chrysin synthesised in this study indicated a broad 
spectrum of significant to moderate antibacterial activity against all bacteria strains tested. 
C3 indicated the overall best antibacterial inhibition. This role of nitrite, in addition to the 
hydroxyl group and the phenol rings might be acting to disrupt the cell wall and denaturing 
proteins. C3 could be acting at multiple sites and there might be numerous possible targets 
for inhibition in the bacterial cells, including inhibition of metalloproteins, iron–sulphur 
proteins and the respiratory chain (Lawrence et al., 2009). Phenolic compounds containing 
nitrites are also thought to inhibit the enzymatic activity of the micro-organisms (Duke et 
al., 1992) and inhibit glucose uptake and ATP production in the resting cells of bacteria 
(Weir et al., 2004). 
ESBL are a group of rapidly evolving β-lactamases which can hydrolyse certain drugs such 
as the third generation aztreonam and cephalosporins. β-lactam antibiotics are susceptible 
to hydrolysis by these enzymes (Paterson and Bonono 2005). It is difficult to treat ESBL 
producing bacteria using most antibiotics such as the penicillin, cephalosporins etc. 
However, compound which significantly inhibited the growth of ESBL producing bacteria 
at concentrations ≤ 50 µg / mL were synthesised in this research. Interestingly, chrysin 
failed to inhibit the growth of all bacteria tested especially the ESBL producing bacteria at 
concentrations < 250 µg / mL. The reason for this failure of chrysin to inhibit the growth of 
these bacteria could be because these bacteria may have hydrolysed the hydroxyl group 
at the 7-OH position of chrysin. C1, C2 and C3 may have elicited their inhibitory activities 
due to the present of functional groups (attached to the 7-OH position of chrysin) which 
prevented hydrolysis of these compounds. For instance, the nitrites attached to the 
benzene ring in C3, the methoxy group in C1 and the dimethyl groups attached to the 
benzene ring in C2 are relatively stable compounds compared to the hydroxyl groups in 
chrysin and these compounds (nitrites, methoxy, alkylated benzene rings) are known to be 
inhibitors of bacterial growth (Duke et al., 1992; Dykhuizen et al., 1996; Lawrence et al., 
2009). 
Similarly, the anticancer activity of novel 7-O-chrysin-derivatives synthesised in this work 
were investigated in vitro against ten cancer cell lines and one normal cell line (BEAS-2B). 
C1, C2 and C3 indicated significant to moderate anticancer activity against the cancer cell 
lines investigated. Other synthetic chrysin derivatives such as the 7-O-bromochrysin 
adducts C13 to C17 (showed significant anticancer activity against leukaemia cell line – 
265 
 
K562), 7-O-chrysin-2-methylpropane– C5 (novel compound), 7-O-4-bromopentylchrysin – 
C16 (novel compound) and 7-O-bromododecylchrysin (C12) indicated significant to weak 
anticancer activities against cancer cell lines. It is also worthy to note that 7-O-hexylchrysin 
also indicated significant anticancer activity against the lung cancer cell line – A549 
whereas the 7-O-alkylchrysin compounds – C5 to C12 showed significant to moderate 
anticancer activities against skin cancer cell line (HacaT cell line) – the only class of 
compounds that indicated anticancer activities against HacaT cell line (with exception of 
C1). 7-O-butylchrysin (C6) and 7-O-hexylchrysin (C8) stands out in this class of 
synthesised chrysin derivatives (7-O-alkylchrysin) with anticancer activity better than those 
indicated by chrysin and CPZ against hacaT cell line (C6) and the breast cancer cell line 
– MDA-MB 468 (C8). The anticancer activities indicated by these compounds (especially 
C1, C2, C3, C6, C8 and C16) were comparable to those indicated by chrysin and CPZ and 
in some cases, better than those indicated by chrysin and CPZ. Interestingly, synthesised 
chrysin derivatives showed a high degree of selectivity towards human normal lung cell 
line (BEAS-2B) compared to CPZ which indicated marginal selectivity. The high degree of 
selectivity and sensitivity indicated by these compounds enhances their possibility and 
potentials as prospective pharmacological agents. Zheng et al., (2003) synthesised a 
series of chrysin-derivatives prepared by trifluoromethylation, acetylation, methylation, 
nitration, halogenation and alkylation. Of these compounds, only nitrated chrysin 
derivatives (8-nitrochrysin) and 8-iodomethoxychrysin indicated cytotoxicity against 
colorectal adenocarcinoma cell line (HT-29) and human gastric adenocarcinoma cell line 
(SGC-7901). As observed in this work, halogenated, acetylated and alkylated chrysin 
derivatives indicated weak / no cytotoxicity against the cell lines investigated. This agrees 
with the findings of Zheng et al., (2003). Other synthetic chrysin derivatives made at 
positions 6 and 8 of the chrysin molecule were inactive against cancer cell lines at IC50 < 
50 µM (Zheng et al., 2003). Liu et al., (2018) also reported that aliphatic chrysin derivatives 
indicated no cytotoxicity against cancer cell lines at IC50 < 50 µM. Nevertheless, 
methylated chrysin derivatives synthesised at the 7-OH position indicated cytotoxic 
inhibition against cancer cell lines at IC50 ranging from 24 – 40 µM. This result agrees with 
the findings in this work as methylated 7-O-chrysin derivative (C6) and brominated-
methylated 7-O-chrysin derivative (C16) indicated similar cytotoxicity against cancer cell 
lines. C1, an O-alkylated compound, indicated significant cytotoxic inhibition against cell 
lines tested in this work. Methoxylated compounds synthesised by other authors also 
indicated good cytotoxicity against cancer cell lines (Fonseca et al., 2017; Liu et al., 2018; 
Zheng et al., 2003). However, the cytotoxic inhibition of C1 reported in this work was better 
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than those reported by Fonseca et al., (2017). This discrepancy might be as a result of the 
development of hydrogen bonding at positions 5-OH and 7-OH of the chrysin molecule 
because they synthesised chrysin derivatives at positions other than the 5-OH and 7-OH 
positions. Patel et al., (2016) has previously reported good cytotoxicity of chrysin-
piperazine conjugates synthesised at the 7-OH position of the chrysin molecule. The effect 
of hydrogen-bonding in limiting the bioactivity of the chrysin molecule has been described 
previously (Lapkin et al., 2014; Zheng et al., 2016). It could therefore be hypothesised that 
nitrated, oxygenated and methylated 7-O-chrysin-derivatives tend to elicit better cytotoxic 
inhibition against cancer cell lines compared to halogenated or alkylated compounds. 
One of the aims of this project was to isolate novel bioactive compounds from Inula 
helenium. Costunolide, a sesquiterpene lactone first isolated from Costus speciosus was 
isolated for the first time from Inula helenium in addition to alantolactone and 
isoalantolactone which have been previously isolated from this plant. These compounds 
elicited moderate antibacterial activity against B. cereus ATCC 10876 and S. aureus ATCC 
25923. Extracts from Inula helenium indicated significant synergistic activity against a wide 
spectrum of microbial agents tested, including the pathogenic fungus – C. albicans. 
Sesquiterpene lactones isolated from Inula helenium also showed significant cytotoxicity 
against the leukaemia cell line K562 in hypoxia, normoxia, hyperglycaemia and 
hypoglycaemic conditions In-vitro. Likewise, synthesised chrysin derivatives (especially 
C1, C2 and C3) also indicated promising anticancer activity against most cancer cell lines 
used in this study. Cytotoxicity of synthesised chrysin derivatives was selective against 
normal bronchial cell line – BEAS-2B. Other aim(s) of this project was to synthesise chrysin 
derivatives with better bioactivities and solubilities compared to chrysin. C1 and C3 (potent 
bioactive compounds synthesised in this study), indicated better bioactivities and 
solubilities than chrysin. Similarly, C13 showed comparable lipophilicity to chrysin. 
Likewise, synthesised 7-O-chrysin derivatives C1, C2 and C3, indicated significant to 
moderate antibacterial activity against bacteria tested with C1 and C3 showing very 
promising bacterial inhibition against ESBL producing E. coli, and other bacteria, including 
inhibition of the pathogenic fungus – Candida albicans MTCC 227. Bioactivities indicated 
by synthesised chrysin derivatives were better than those shown by chrysin and in some 
cases, comparable to those shown by conventional therapies / drugs used as positive 
controls. Although the biological activity of chrysin derivatives was not investigated in-vivo 
to determine the bioavailability of these compounds, the hydrophilic index indicates that 
C1, a novel chrysin derivative was more soluble in polar solvents than chrysin. Similarly, 
C3 and C13 indicated similar solubility in polar solvents to chrysin. A better lipophilic index 
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is an indication that a compound is likely to make it into the cellular components, thus a 
better bioactivity in-vivo (Bae et al., 2012; Beretta et al., 2012). Nevertheless, hydrophobic 
compounds could also be important anticancer agents individually, or in combination with 
other anticancer agents where their role could be in increasing internal concentration of 
anticancer agents via inhibition of the P-glycoprotein (Pgp), thus preventing drug-efflux 
from cells (Abdallah et al., 2015; Mohana et al., 2016). The use of nanoparticles in 
delivering hydrophobic agents to targeted cells could also overcome this challenge. Also, 
some hydrophobic drugs effectively bind to targets in-vivo, thus they could still elicit 
significant bioactivity against their targets (Amin, 2013; Mason et al., 2008). The calculated 
masses of all novel chrysin derivatives was similar to the actual masses recorded. 
In this project, a novel compound (costunolide) was isolated from Inula helenium. Novel 
chrysin derivatives which elicited a broad spectrum of antibacterial activities against Gram-
positive and Gram-negative bacteria (including ESBL producing bacteria) were 
synthesised. These compounds also elicited better anticancer activities than chrysin and 
the conventional anticancer drug – Chlorpromazine hydrochloride. Some synthesised 
chrysin derivatives were also more soluble than chrysin. 
The present study has given some insight into the interaction of novel 7-O-chrysin 
derivatives with cancer cells. However, further work is necessary to determine the 
mechanism of action of these compounds. 
In the first instance, several new analogues will have to be synthesised in other to carry 
out more detailed structure-activity relationship. The synthetic route developed in this 
synthesis is suitable for the generation of these analogues. These structures should 
include branched and shorter chain analogues targeting the 7-OH position of chrysin: 7-
O-bromoalkylchrysin and 7-O-alkylchrysin analogues with N = 1 and 2, 7-O-
bromoalkylchrysin with N = 6, 7, 8, 9, 10 and 11, 7-O-alkylchrysin analogues with N = 11 
and 12. Branched chain analogues may also be made. Apart from 7-O-bromoalkylchrysin 
analogues, 7-O-chloroalkyl, 7-O-Fluoroalkyl and 7-O-iodoalkyl chrysin derivatives should 
also be made and their cytotoxicity investigated. 
A significant omission from this thesis was data that will prove that 7-O-chloroalkyl 
derivatives may indicate a better anticancer activity compared to their 7-O-
bromoalkylchrysin counterparts. This will likely be achieved by the synthesis and 
purification of 7-O-chloroalkyl derivatives of chrysin as 7-O-chloroalkyl chrysin derivatives 
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made in this study were impure; and their bioactivities investigations were discontinued 
during biological studies. 
Further studies could also include synthesis and examining 5-O-bromoalkyl, and 5-O-alkyl 
derivatives of chrysin; comparing their cytotoxicity to those of their 7-O-counterparts. 
An interesting further study could include the synthesis of 7-O-thioalkyl chrysin derivatives 
as the sulphur ion can completely change the dynamics and activity of molecules. 
The lipophilic nature of some chrysin adducts made in this study might present difficulty in 
drug delivery to patients; however, rapid advances in phospholipid vesicles (liposomes) 
based delivery systems should provide adequate formulations of the drugs. This is highly 
recommended for synthesised chrysin derivatives that indicated significant biological 
activities compared to chrysin and/or the positive control agents used in this study. 
In the disc diffusion assay study involving the antibacterial activities of hexane fraction of 
Inula helenium on bacteria, the data suggests a significant inhibition of the growth of P. 
aeruginosa. This was not replicated during the minimum inhibitory concentration (MIC) 
studies. From the HPLC chromatograms, the hexane fraction contained other compounds 
(in addition to alantolactone, isoalantolactone and costunolide) that were inactive (when 
tested individually) against bacteria tested at MIC ≤ 500 µg/mL. It is possible that the 
inhibitory response might be associated with the activities of two or more compounds in 
the hexane fraction. It might also be that a combination of two or more bioactive 
sesquiterpene lactones isolated in this study (alantolactone, isoalantolactone and 
costunolide) were responsible for this activity observed in the disc diffusion assay. The 
potentiating effect of these compounds should therefore be investigated in the future. 
Minimum doubling time / growth curve (MDT) and antimicrobial synergy testing / 
checkerboard assay should be done using compounds C1, C2, C3, D1, D2 and D3 on 
bacterial species that are susceptible to inhibition by these compounds. MDT testing is 
used in determining the doubling time of the bacteria population. This assay shows the 
effect of antibacterial agents on bacterial growth by comparing growth in broth culture with 
and without the antimicrobial compound. Optical density (OD) values are recorded at 
multiple timepoints and calculated by comparing the OD at different timepoints in 
exponential phase of growth (Gibson et al., 2018). Synergy testing evaluates the 
interaction of two antimicrobial agents when used in combination. MIC and MBC values of 
test compounds alone and in combination against each bacterial strain being evaluated is 
used to calculate the antagonistic, synergistic or additive effect of compounds isolated / 
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synthesised in this work. The promising antibacterial and antifungus activity of C1 and C3 
warrants in-vivo investigation in mouse or albino Wistar rat model infected with bacterial 
or fungal species. Other bacterial species which are susceptible to antibacterial inhibition 
should also be investigated. 
In-vitro and in-vivo studies involving the anticancer activities of sesquiterpene lactones 
isolated in this work against the leukaemia cell line (K562) and their mechanism of action 
should be investigated. This should include activities on hypoxia-inducible factor-1α and 
the relationship between inhibition of cancer in hypoxia by these compounds 
(alantolactone, isoalantolactone and costunolide). 
The mechanism of action of synthesised chrysin derivatives that indicated cytotoxicity ≤ 20 
µM should be investigated. This might include the free radical scavenging activity, cell 
cycle analysis, histone deacetylase (HDAC) activity, Western Blotting, Real Time 
Quantitative polymerase-chain-reaction (PCR) analysis and in-vivo analysis using 
xenograft model (such as albino Wister rats or nude mice). These analyses will aid in the 
understanding of the mechanism of action of these compounds. 
Molecular docking of bioactive chrysin derivatives synthesised in this study, especially 
those of C1, C2, C3, C4, C5, C8 and C16 with the aim of determining the domain of binding 
fitness of these molecules and how these molecules could form complex on protein 
receptors should be investigated. The role of hydrogen-bonding as postulated by some 
authors could also be investigated by investigating the binding affinity of these molecules 
with amino acids. Molecular docking will reveal the structure-activity relationship between 
compounds and the receptor proteins. An investigation should be done to ascertain the 
active site of the chrysin molecules by synthesising chrysin-derivatives at the 5-OH position 
and then synthesising chrysin derivatives at the aromatic ring as well. Zhou et al., (2012) 
have postulated that the 5-OH position of chrysin is the active site, whereas Babu et al., 
(2006) have postulated that the aromatic ring is the active site of this molecule. This is 
confusing, and verification is needed as this will aid future synthesis of useful bioactive 
chrysin derivative. A synthetic plan could include synthesis of compounds at the 5-OH 
position of the chrysin molecule while allowing the 7-OH position and the aromatic ring to 
be vacant. Another approach could include synthesising chrysin derivatives at the aromatic 
ring while allowing the 5-OH and 7-OH positions to be vacant. Another approach could be 
synthesising derivatives at both the 5-OH positions and at the aromatic ring and their 
anticancer activity investigated. A loss of activity when 5-OH is occupied, or when the 
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aromatic ring is occupied and vice versa will give an insight into the actual active site of 
the chrysin molecule especially if such investigation is followed by molecular docking. 
7-O-bromoalkyl chrysin derivatives synthesised in this study indicated weak anticancer 
activity. This trend could change if chlorinated and fluorinated chrysin derivatives are 
synthesised at the 7-OH position of the chrysin molecule as highly electronegative atoms 
such as chlorine and fluorine could change the thermodynamics of molecules. Also 
recommended for further studies include; the free radical scavenging activity, cell cycle 
analysis, histone deacetylase (HDAC) activity, Western Blotting, Real Time Quantitative 
polymerase-chain-reaction (PCR) analysis and in-vivo analysis using xenograft model 
(such as albino Wister rats or nude mice). These analyses will aid in the understanding of 
the mechanism of action of synthesised chrysin derivatives. The histone deacetylases 
(HDACs) catalyse deacetylation of the ε-amino group of lysine in the N-terminal tails of 
histones. Histone deacetylation and acetylation plays crucial roles in gene expression in 
eukaryotic cells, causing chromatin remodelling (Hadnagy et al., 2008). Imbalance in 
histone acetylation can cause changes in chromatin conformation, leading to dysregulation 
of genes involved in apoptosis, cell differentiation and cell cycle progression (McLaughlin 
& La Thangue, 2004). 
Western blot is a procedure used to separate and identify proteins from a mixture of 
proteins base on the molecular weight and size of these proteins, using gel electrophoresis 
(Mahmood & Yang, 2012). The results obtained are then transferred to a membrane 
producing a band. These membranes are then incubated with labels antibodies specific to 
the protein of interest. Unbound antibodies are washed off, leaving only the antibodies of 
interest bound on these membranes (Mahmood & Yang, 2012). A film of the bound 
antibodies is then developed, and the bound antibodies detected. Antibodies only bind to 
proteins of interest and this is highly specific. Thus, only one band should be visible per 
protein of interest. The thickness of the band corresponds to the amount of protein present; 
thus, doing a standard can indicate the amount of protein present (Mahmood & Yang, 
2012). 
the antitumor activity of chrysin derivatives in a nude mice or albino Wistar rat xenograft 
model implanted with cancer cells used in this study (especially those with increase 
susceptibility to treatment by compounds made in this study) should be investigated to 
determine the interaction of these compounds (synthesised chrysin derivatives) with other 
cellular components. Despite the promising anticancer activity of the chrysin molecule, the 
literature review indicates that the absorption and bioavailability of this molecule is very 
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poor and less than 5% has been found in the serum (Mani & Natesan, 2018; Sabzichi et 
al., 2017). This is also an indication of poor solubility of this compound within biological 
systems. One of the aims of this project was to synthesise chrysin derivatives with 
improved solubility and bioavailability in biological systems. In-vivo anticancer activity 
using xenograft model will ascertain the bioavailability of bioactive chrysin derivatives 
synthesised in this work. 
The relationship between hypoxia, hyperglycaemia and cancer should be investigated by 
studying the anticancer activities of synthetic chrysin derivatives – C1, C2 and C3 against 
leukaemia cancer cell line (K562) and other cell lines in hypoxia and hyperglycaemia. This 
is necessary because chrysin derivatives indicated good antiproliferative activity against 
the K562 cell line. Chrysin derivatives synthesised in this work could be studied in addition 
to a standard investigation of the mechanism of action of chrysin derivatives against Pgp 
in K562 cell line. This could offer new insight on a possible relationship between cancer 
and disease. 
Multidrug resistance (MDR) of tumour cells is associated with overexpression of P-
glycoprotein (Pgp). Pgp are responsible for the efflux of chemotherapeutic drugs out of the 
cells using ATP hydrolysis as an energetic source (Amin, 2013). Many cancer cells are 
resistant to anticancer agents including epipodophyllotoxins, taxanes, vinca alkaloids and 
anthracyclines (Amin, 2013). Pgp is able to efflux drugs out of the cells due to its ability to 
bind most compounds, transporting them out of the cell such as corticosterone, 
dexamethasone etc (Amin, 2013). Interestingly, more hydrophobic compounds such as 
antiprogestin RU 486 and progesterone acts as efficient modulators of cellular MDR. This 
is because these compounds are hydrophobic in nature (Mason et al., 2008). They 
therefore inhibit the efflux of anticancer drugs because they act as efficient modulators of 
cellular MDR (Amin., 2013; Mason et al., 2008). However, antiprogestin RU 486 and 
progesterone cannot be used at therapeutic levels because of the negative effect 
associated with using excessive hormones (Amin., 2013). Findings in this project indicates 
that chrysin and most of its derivatives are hydrophobic agents. The role of flavonoids as 
modulators of Pgp have previously been reported (Abdallah et al., 2015; Mohana et al., 
2016). Future research should focus on investigating the role of chrysin and its derivatives 
(synthesised in this project), as potential Pgp modulators in tumour cells in-vitro and in-
vivo in leukaemia cancer cell (K562) as well as other cancer cells. Characterisation of the 
inhibitory flavonoid-binding site on Pgp at the cellular and molecular levels will enhance 
the development of more potent Pgp inhibitors. The success of such research could 
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revolutionize cancer treatment because the discovery of Pgp inhibitors implies that 
anticancer agents can accumulate in cancer cells, killing them thus overcoming the 
challenge associated with MDR. 
In summary, in the extraction and isolation work, costunolide – a novel isolate from Inula 
helenium, was isolated. This was possible via the method developed in this study which 
include centrifugation of supernatants in order to obtain minute quantity of bioactive 
compounds such as costunolide. On the synthetic work we developed a rapid method 
(microwave irradiation) for the synthesis of chrysin derivatives in less than 12 minutes. 
Conventionally, it takes between 24 - 48 hours or more to synthesise similar molecules. 
Novel biologically active small molecules that significantly inhibited the growth of cancer 
cells and pathogens were also synthesised. Some compounds were specific (i.e. inhibited 
the growth of either Gram-positive or Gram-negative bacteria) only. Some compounds 
indicated broad-spectrum antibacterial inhibition of both Gram-positive and Gram-negative 
bacteria including the extended-spectrum beta-lactamases (ESBL) producing bacteria as 
well as the multi-drug resistant (MDR) such as the ESBL producing Escherichia coli, 
Pseudomonas aeruginosa and Klebsiella pneumoniae. The MDR Gram-negative bacteria 
as well as the MDR Gram-Positive bacteria (MRSA) are serious health concerns in 
hospitals, clinics and the society. As their names suggest, there are difficult to treat 
because they have developed resistance to almost all drugs currently in the market. 
Compounds synthesised in this work significantly inhibited the growth of the MDR 
pathogens. Antibacterial activities of synthesised chrysin derivatives were better than 
those of chrysin. Antifungal activity of synthesised chrysin derivatives (C1 and C3 were 
better than those of chrysin and the standard antifungal drugs – fluconazole. We also 
reported the cytotoxic inhibition of the K562 cancer cell by sesquiterpene lactones isolated 
from Inula helenium in and in hyperglycaemia. We also reported the anticancer activities 
of novel chrysin derivatives against a range of cancer cell lines. The anticancer activities 
of novel chrysin derivatives was selective; killing only the cancer cells but not normal cells. 
Additional work on the mechanism of action of these compounds (chrysin derivatives) 
where undertaken such as apoptosis studies and growth inhibition studies. Additional work 
done is reported in the appendix. 
Novel chrysin derivatives synthesised in this study especially compounds C1, C2, C3, C8 
and C16 are potential antimicrobial and anticancer drug candidates; likewise, the 






The spectral data of novel compounds are presented below: 
Appendix I: Spectral data (high resolution mass spectrometry data) of novel compounds. 
Appendix II: Spectral data (high resolution mass spectrometry data) of novel compounds. 
 
APPENDIX I 
Appendix I-A: TOF MS ES of C1 (7-O- Chrysinbutyl acetate). 
Appendix I-B: TOF MS ES of C2 (7-O-Chrysin-3,5-dimethylbenzene). 
Appendix I-C: TOF MS ES of C3 (7-O-Chysin-2,4-dinitrobenzene). 
Appendix I-D: TOF MS ES of C5 (7-O-Chrysin-2-methylpropane). 
Appendix I-E: TOF MS ES of C10 (7-O-Octylchrysin). 
Appendix I-F: TOF MS ES of C11(7-O-Nonylchrysin). 
Appendix I-G: TOF MS ES of C12 (7-O-Decylchrysin). 
Appendix I-H: TOF MS ES of C16 (7-O-4-Bromopentylchrysin). 
Appendix I-I: TOF MS ES of D3 Costunolide. 
 
APPENDIX II 
Appendix II-A: 1H NMR assignment of C1 (7-O- Chrysinbutyl acetate). 
Appendix II-B: 1H NMR assignment of C2 (7-O-Chrysin-3,5-dimethylbenzene). 
Appendix II-C: 1H NMR assignment of C3 (7-O-Chysin-2,4-dinitrobenzene). 
Appendix II-D: 1H NMR assignment of C5 (7-O-Chrysin-2-methylpropane). 
Appendix II-E: 1H NMR assignment of C10 (7-O-Octylchrysin). 
Appendix II-F: 1H NMR assignment of C11 (7-O-Nonylchrysin). 
Appendix II-G: 1H NMR assignment of C12 (7-O-Decylchrysin). 
Appendix II-H: 1H NMR assignment of C16 (7-O-4-Bromopentylchrysin). 
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